US20020182675A1 - Novel genes encoding proteins having diagnostic, preventive, therapeutic and other uses - Google Patents
Novel genes encoding proteins having diagnostic, preventive, therapeutic and other uses Download PDFInfo
- Publication number
- US20020182675A1 US20020182675A1 US10/042,431 US4243101A US2002182675A1 US 20020182675 A1 US20020182675 A1 US 20020182675A1 US 4243101 A US4243101 A US 4243101A US 2002182675 A1 US2002182675 A1 US 2002182675A1
- Authority
- US
- United States
- Prior art keywords
- tango
- protein
- amino acid
- polypeptide
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 560
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 530
- 230000001225 therapeutic effect Effects 0.000 title abstract description 4
- 230000003449 preventive effect Effects 0.000 title abstract description 3
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 151
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 146
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 146
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 138
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 131
- 229920001184 polypeptide Polymers 0.000 claims abstract description 130
- 241000282414 Homo sapiens Species 0.000 claims abstract description 94
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 39
- 238000012216 screening Methods 0.000 claims abstract description 7
- 238000005400 testing for adjacent nuclei with gyration operator Methods 0.000 claims description 438
- 125000000539 amino acid group Chemical group 0.000 claims description 208
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 132
- 208000035475 disorder Diseases 0.000 claims description 128
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 102
- 239000002299 complementary DNA Substances 0.000 claims description 99
- 230000014509 gene expression Effects 0.000 claims description 87
- 238000000034 method Methods 0.000 claims description 86
- 125000003729 nucleotide group Chemical group 0.000 claims description 86
- 210000001519 tissue Anatomy 0.000 claims description 81
- 230000000694 effects Effects 0.000 claims description 77
- 239000002773 nucleotide Substances 0.000 claims description 66
- 206010028980 Neoplasm Diseases 0.000 claims description 56
- 102000004882 Lipase Human genes 0.000 claims description 47
- 108090001060 Lipase Proteins 0.000 claims description 47
- 150000001875 compounds Chemical class 0.000 claims description 46
- 208000029742 colonic neoplasm Diseases 0.000 claims description 33
- 238000012360 testing method Methods 0.000 claims description 33
- 239000000523 sample Substances 0.000 claims description 32
- 230000027455 binding Effects 0.000 claims description 31
- 150000001413 amino acids Chemical class 0.000 claims description 28
- 239000012634 fragment Substances 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- 230000000295 complement effect Effects 0.000 claims description 22
- 239000004367 Lipase Substances 0.000 claims description 20
- 235000019421 lipase Nutrition 0.000 claims description 20
- 210000002966 serum Anatomy 0.000 claims description 17
- 239000013068 control sample Substances 0.000 claims description 16
- 230000004060 metabolic process Effects 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 16
- 229940040461 lipase Drugs 0.000 claims description 15
- 230000003511 endothelial effect Effects 0.000 claims description 14
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 11
- 238000010521 absorption reaction Methods 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 9
- 208000027866 inflammatory disease Diseases 0.000 claims description 9
- 108020004999 messenger RNA Proteins 0.000 claims description 9
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 8
- 102100031416 Gastric triacylglycerol lipase Human genes 0.000 claims description 8
- 208000008589 Obesity Diseases 0.000 claims description 8
- 230000017531 blood circulation Effects 0.000 claims description 8
- 108010091264 gastric triacylglycerol lipase Proteins 0.000 claims description 8
- 208000026278 immune system disease Diseases 0.000 claims description 8
- 235000020824 obesity Nutrition 0.000 claims description 8
- 230000035939 shock Effects 0.000 claims description 8
- 208000027796 Blood pressure disease Diseases 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 208000037841 lung tumor Diseases 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 102000019280 Pancreatic lipases Human genes 0.000 claims description 6
- 108050006759 Pancreatic lipases Proteins 0.000 claims description 6
- 206010033645 Pancreatitis Diseases 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 6
- 208000007536 Thrombosis Diseases 0.000 claims description 6
- 230000007423 decrease Effects 0.000 claims description 6
- 230000003247 decreasing effect Effects 0.000 claims description 6
- 201000007089 exocrine pancreatic insufficiency Diseases 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 230000002757 inflammatory effect Effects 0.000 claims description 6
- 235000019626 lipase activity Nutrition 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 208000010125 myocardial infarction Diseases 0.000 claims description 6
- 229940116369 pancreatic lipase Drugs 0.000 claims description 6
- 208000007882 Gastritis Diseases 0.000 claims description 5
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 5
- 206010031127 Orthostatic hypotension Diseases 0.000 claims description 5
- 201000003099 Renovascular Hypertension Diseases 0.000 claims description 5
- 208000037849 arterial hypertension Diseases 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 206010009887 colitis Diseases 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 239000012678 infectious agent Substances 0.000 claims description 5
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 5
- 208000023958 prostate neoplasm Diseases 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 206010042772 syncope Diseases 0.000 claims description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 5
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 208000031220 Hemophilia Diseases 0.000 claims description 4
- 208000009292 Hemophilia A Diseases 0.000 claims description 4
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 206010022489 Insulin Resistance Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 208000026935 allergic disease Diseases 0.000 claims description 4
- 230000007815 allergy Effects 0.000 claims description 4
- 208000029078 coronary artery disease Diseases 0.000 claims description 4
- 201000005917 gastric ulcer Diseases 0.000 claims description 4
- 230000001965 increasing effect Effects 0.000 claims description 4
- 206010028417 myasthenia gravis Diseases 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 3
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 239000013598 vector Substances 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000003306 harvesting Methods 0.000 claims description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims 3
- 239000002853 nucleic acid probe Substances 0.000 claims 3
- 238000000159 protein binding assay Methods 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 11
- 239000000203 mixture Substances 0.000 abstract description 6
- 230000001105 regulatory effect Effects 0.000 abstract description 5
- 230000033077 cellular process Effects 0.000 abstract description 4
- 239000013604 expression vector Substances 0.000 abstract description 4
- 230000000692 anti-sense effect Effects 0.000 abstract description 3
- 230000009261 transgenic effect Effects 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 525
- 101000837854 Homo sapiens Transport and Golgi organization protein 1 homolog Proteins 0.000 description 414
- 102100028569 Transport and Golgi organization protein 1 homolog Human genes 0.000 description 414
- 101000793115 Homo sapiens Aryl hydrocarbon receptor nuclear translocator Proteins 0.000 description 115
- 102000049150 human ARNT Human genes 0.000 description 115
- 108010076504 Protein Sorting Signals Proteins 0.000 description 91
- 241001529936 Murinae Species 0.000 description 83
- 210000004027 cell Anatomy 0.000 description 68
- 229940024606 amino acid Drugs 0.000 description 43
- 210000001072 colon Anatomy 0.000 description 36
- 230000002209 hydrophobic effect Effects 0.000 description 36
- 235000001014 amino acid Nutrition 0.000 description 35
- 230000001086 cytosolic effect Effects 0.000 description 32
- 108700026244 Open Reading Frames Proteins 0.000 description 27
- 230000004048 modification Effects 0.000 description 25
- 238000012986 modification Methods 0.000 description 25
- 230000035790 physiological processes and functions Effects 0.000 description 24
- 230000035755 proliferation Effects 0.000 description 22
- 230000000875 corresponding effect Effects 0.000 description 20
- 230000012010 growth Effects 0.000 description 20
- 230000018109 developmental process Effects 0.000 description 18
- 230000026731 phosphorylation Effects 0.000 description 18
- 238000006366 phosphorylation reaction Methods 0.000 description 18
- 230000004069 differentiation Effects 0.000 description 17
- 238000003776 cleavage reaction Methods 0.000 description 16
- 210000004072 lung Anatomy 0.000 description 16
- 230000007017 scission Effects 0.000 description 16
- 208000022362 bacterial infectious disease Diseases 0.000 description 15
- 102000052586 bactericidal permeability increasing protein Human genes 0.000 description 15
- 108010032816 bactericidal permeability increasing protein Proteins 0.000 description 15
- 238000011161 development Methods 0.000 description 15
- 230000001605 fetal effect Effects 0.000 description 15
- 150000002632 lipids Chemical class 0.000 description 15
- 230000004481 post-translational protein modification Effects 0.000 description 15
- 230000004083 survival effect Effects 0.000 description 15
- 208000035143 Bacterial infection Diseases 0.000 description 14
- 102000014105 Semaphorin Human genes 0.000 description 14
- 108050003978 Semaphorin Proteins 0.000 description 14
- 210000000481 breast Anatomy 0.000 description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 239000002158 endotoxin Substances 0.000 description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 13
- 239000003925 fat Substances 0.000 description 12
- 235000019197 fats Nutrition 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 12
- 102000035160 transmembrane proteins Human genes 0.000 description 12
- 108091005703 transmembrane proteins Proteins 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 102000000395 SH3 domains Human genes 0.000 description 11
- 108050008861 SH3 domains Proteins 0.000 description 11
- 150000002066 eicosanoids Chemical class 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 239000011159 matrix material Substances 0.000 description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 10
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 10
- 230000001594 aberrant effect Effects 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 10
- 230000004576 lipid-binding Effects 0.000 description 10
- 210000004379 membrane Anatomy 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 10
- 102000052052 Casein Kinase II Human genes 0.000 description 9
- 108010010919 Casein Kinase II Proteins 0.000 description 9
- 102000003886 Glycoproteins Human genes 0.000 description 9
- 108090000288 Glycoproteins Proteins 0.000 description 9
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 9
- 206010027476 Metastases Diseases 0.000 description 9
- 230000004988 N-glycosylation Effects 0.000 description 9
- 102000000185 SRCR domains Human genes 0.000 description 9
- 108050008568 SRCR domains Proteins 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 230000001413 cellular effect Effects 0.000 description 9
- SLPJGDQJLTYWCI-UHFFFAOYSA-N dimethyl-(4,5,6,7-tetrabromo-1h-benzoimidazol-2-yl)-amine Chemical compound BrC1=C(Br)C(Br)=C2NC(N(C)C)=NC2=C1Br SLPJGDQJLTYWCI-UHFFFAOYSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 210000000987 immune system Anatomy 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 208000024172 Cardiovascular disease Diseases 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 8
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 8
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 8
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 8
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 8
- 239000000232 Lipid Bilayer Substances 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 102000009203 Sema domains Human genes 0.000 description 8
- 108050000099 Sema domains Proteins 0.000 description 8
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 8
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 8
- 235000004279 alanine Nutrition 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 230000033228 biological regulation Effects 0.000 description 8
- 230000002759 chromosomal effect Effects 0.000 description 8
- 125000001165 hydrophobic group Chemical group 0.000 description 8
- 230000002163 immunogen Effects 0.000 description 8
- 235000005772 leucine Nutrition 0.000 description 8
- 210000000496 pancreas Anatomy 0.000 description 8
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 8
- 235000008729 phenylalanine Nutrition 0.000 description 8
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 8
- 235000002374 tyrosine Nutrition 0.000 description 8
- 239000004474 valine Substances 0.000 description 8
- 230000002792 vascular Effects 0.000 description 8
- 201000001320 Atherosclerosis Diseases 0.000 description 7
- 241000283690 Bos taurus Species 0.000 description 7
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 7
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 7
- 102000003923 Protein Kinase C Human genes 0.000 description 7
- 108090000315 Protein Kinase C Proteins 0.000 description 7
- 238000012300 Sequence Analysis Methods 0.000 description 7
- 208000036142 Viral infection Diseases 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- 210000000988 bone and bone Anatomy 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 208000019423 liver disease Diseases 0.000 description 7
- 230000009401 metastasis Effects 0.000 description 7
- 230000001537 neural effect Effects 0.000 description 7
- 230000001766 physiological effect Effects 0.000 description 7
- 210000002307 prostate Anatomy 0.000 description 7
- 238000012916 structural analysis Methods 0.000 description 7
- 230000009385 viral infection Effects 0.000 description 7
- 206010009944 Colon cancer Diseases 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 230000036523 atherogenesis Effects 0.000 description 6
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 6
- 230000008827 biological function Effects 0.000 description 6
- 210000000981 epithelium Anatomy 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 6
- 229960000310 isoleucine Drugs 0.000 description 6
- 238000013507 mapping Methods 0.000 description 6
- -1 myristoylases Proteins 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 108091060211 Expressed sequence tag Proteins 0.000 description 5
- 102000018697 Membrane Proteins Human genes 0.000 description 5
- 108010052285 Membrane Proteins Proteins 0.000 description 5
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 5
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 5
- 201000009267 bronchiectasis Diseases 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 230000000112 colonic effect Effects 0.000 description 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 230000002538 fungal effect Effects 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 210000000440 neutrophil Anatomy 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000002688 persistence Effects 0.000 description 5
- 239000013615 primer Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108091005725 scavenger receptor cysteine-rich superfamily Proteins 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- NURUARRJQOZSIF-DXIBHZBQSA-N (3s)-3-[[(2s)-2-[(2-aminoacetyl)amino]-3-phenylpropanoyl]amino]-4-[[(2s)-1-[[(2s)-4-amino-1-[[2-[[2-[[2-[[(2s)-1-(carboxymethylamino)-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl Chemical compound OC(=O)CNC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 NURUARRJQOZSIF-DXIBHZBQSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
- 208000003200 Adenoma Diseases 0.000 description 4
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 description 4
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 description 4
- 206010012559 Developmental delay Diseases 0.000 description 4
- 108010058643 Fungal Proteins Proteins 0.000 description 4
- 206010017533 Fungal infection Diseases 0.000 description 4
- 101001004953 Homo sapiens Lysosomal acid lipase/cholesteryl ester hydrolase Proteins 0.000 description 4
- 102000004157 Hydrolases Human genes 0.000 description 4
- 108090000604 Hydrolases Proteins 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 description 4
- 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 4
- 208000031888 Mycoses Diseases 0.000 description 4
- 102000004722 NADPH Oxidases Human genes 0.000 description 4
- 108010002998 NADPH Oxidases Proteins 0.000 description 4
- 102000003867 Phospholipid Transfer Proteins Human genes 0.000 description 4
- 108090000216 Phospholipid Transfer Proteins Proteins 0.000 description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 239000004599 antimicrobial Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 102000048394 human LIPA Human genes 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 201000006370 kidney failure Diseases 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000000926 neurological effect Effects 0.000 description 4
- 210000000963 osteoblast Anatomy 0.000 description 4
- 210000002826 placenta Anatomy 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 208000019553 vascular disease Diseases 0.000 description 4
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 3
- 101710115734 CUB domain-containing protein Proteins 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 108091035707 Consensus sequence Proteins 0.000 description 3
- 102000044668 Cytoplasmic protein NCK Human genes 0.000 description 3
- 108700036620 Cytoplasmic protein NCK Proteins 0.000 description 3
- 241000257465 Echinoidea Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102100029620 Immunoglobulin lambda constant 2 Human genes 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 102000002151 Microfilament Proteins Human genes 0.000 description 3
- 208000019022 Mood disease Diseases 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- 241000282849 Ruminantia Species 0.000 description 3
- 108010058778 Schizosaccharomyces pombe Proteins Proteins 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 101800004925 Speract Proteins 0.000 description 3
- 206010047115 Vasculitis Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000009435 amidation Effects 0.000 description 3
- 238000007112 amidation reaction Methods 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 210000003050 axon Anatomy 0.000 description 3
- 230000003376 axonal effect Effects 0.000 description 3
- 230000031018 biological processes and functions Effects 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 230000012202 endocytosis Effects 0.000 description 3
- 210000004954 endothelial membrane Anatomy 0.000 description 3
- 208000027096 gram-negative bacterial infections Diseases 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 208000014951 hematologic disease Diseases 0.000 description 3
- 238000007901 in situ hybridization Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 102000027450 oncoproteins Human genes 0.000 description 3
- 108091008819 oncoproteins Proteins 0.000 description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 201000007094 prostatitis Diseases 0.000 description 3
- 230000002797 proteolythic effect Effects 0.000 description 3
- 210000001147 pulmonary artery Anatomy 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000021014 regulation of cell growth Effects 0.000 description 3
- 230000025053 regulation of cell proliferation Effects 0.000 description 3
- 230000019254 respiratory burst Effects 0.000 description 3
- 230000008054 signal transmission Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 206010043554 thrombocytopenia Diseases 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 229910052720 vanadium Inorganic materials 0.000 description 3
- CMSGUKVDXXTJDQ-UHFFFAOYSA-N 4-(2-naphthalen-1-ylethylamino)-4-oxobutanoic acid Chemical compound C1=CC=C2C(CCNC(=O)CCC(=O)O)=CC=CC2=C1 CMSGUKVDXXTJDQ-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- VGNYHOBZJKWRGI-UHFFFAOYSA-N 6-amino-2-[[4-amino-2-[(2-amino-3-hydroxypropanoyl)amino]-4-oxobutanoyl]amino]hexanoic acid Chemical compound NCCCCC(C(O)=O)NC(=O)C(CC(N)=O)NC(=O)C(N)CO VGNYHOBZJKWRGI-UHFFFAOYSA-N 0.000 description 2
- 208000017194 Affective disease Diseases 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 208000031729 Bacteremia Diseases 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- 102100037084 C4b-binding protein alpha chain Human genes 0.000 description 2
- 101150071146 COX2 gene Proteins 0.000 description 2
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 2
- 101100202502 Caenorhabditis elegans scd-2 gene Proteins 0.000 description 2
- 101100149252 Caenorhabditis elegans sem-5 gene Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 208000018152 Cerebral disease Diseases 0.000 description 2
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- 208000035984 Colonic Polyps Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 208000026372 Congenital cystic kidney disease Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 201000008163 Dentatorubral pallidoluysian atrophy Diseases 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 102100030012 Deoxyribonuclease-1 Human genes 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 108700019745 Disks Large Homolog 4 Proteins 0.000 description 2
- 102000047174 Disks Large Homolog 4 Human genes 0.000 description 2
- 102100024099 Disks large homolog 1 Human genes 0.000 description 2
- 102100024117 Disks large homolog 2 Human genes 0.000 description 2
- 101710185758 Disks large homolog 2 Proteins 0.000 description 2
- 108700042352 Drosophila drk Proteins 0.000 description 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 2
- 208000037487 Endotoxemia Diseases 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010080865 Factor XII Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 description 2
- 102100033067 Growth factor receptor-bound protein 2 Human genes 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 101000871017 Homo sapiens Growth factor receptor-bound protein 2 Proteins 0.000 description 2
- 101001106794 Homo sapiens Putative protein RFPL3S Proteins 0.000 description 2
- 101000689199 Homo sapiens Src-like-adapter Proteins 0.000 description 2
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 108010004020 Immunoglobulin lambda-Chains Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 208000016604 Lyme disease Diseases 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- 206010027457 Metastases to liver Diseases 0.000 description 2
- 108010040897 Microfilament Proteins Proteins 0.000 description 2
- 108010085220 Multiprotein Complexes Proteins 0.000 description 2
- 102000007474 Multiprotein Complexes Human genes 0.000 description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 2
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 2
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 2
- 101150000187 PTGS2 gene Proteins 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102100036598 Peroxisomal targeting signal 1 receptor Human genes 0.000 description 2
- 108010032441 Peroxisome-Targeting Signal 1 Receptor Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 101710136733 Proline-rich protein Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 206010037423 Pulmonary oedema Diseases 0.000 description 2
- 102100021328 Putative protein RFPL3S Human genes 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 102100023320 Ral guanine nucleotide dissociation stimulator Human genes 0.000 description 2
- 101001064310 Rattus norvegicus Gastric triacylglycerol lipase Proteins 0.000 description 2
- 102100035528 Ret finger protein-like 3 Human genes 0.000 description 2
- 101710183525 Ret finger protein-like 3 Proteins 0.000 description 2
- BYIROAKULFFTEK-CIUDSAMLSA-N Ser-Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CO BYIROAKULFFTEK-CIUDSAMLSA-N 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 102100024519 Src-like-adapter Human genes 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 108010055297 Sterol Esterase Proteins 0.000 description 2
- 102000000019 Sterol Esterase Human genes 0.000 description 2
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 208000037884 allergic airway inflammation Diseases 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000014670 detection of bacterium Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 108010043837 egg surface sperm receptor Proteins 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000004955 epithelial membrane Anatomy 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 201000011066 hemangioma Diseases 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000003284 homeostatic effect Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 208000003906 hydrocephalus Diseases 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000002390 hyperplastic effect Effects 0.000 description 2
- 201000009939 hypertensive encephalopathy Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000003099 inflammatory bowel disease 2 Diseases 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- 208000005264 motor neuron disease Diseases 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 210000002741 palatine tonsil Anatomy 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 230000006461 physiological response Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 201000011461 pre-eclampsia Diseases 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 208000017497 prostate disease Diseases 0.000 description 2
- 208000005333 pulmonary edema Diseases 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000002940 repellent Effects 0.000 description 2
- 239000005871 repellent Substances 0.000 description 2
- 230000012488 skeletal system development Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 150000003595 thromboxanes Chemical class 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 description 1
- XKQYCEFPFNDDSJ-UHFFFAOYSA-N 1-[3-[2-[(4-azido-2-hydroxybenzoyl)amino]ethyldisulfanyl]propanoyloxy]-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound OC1=CC(N=[N+]=[N-])=CC=C1C(=O)NCCSSCCC(=O)ON1C(=O)C(S(O)(=O)=O)CC1=O XKQYCEFPFNDDSJ-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 208000017612 Acute Hemorrhagic Pancreatitis Diseases 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 1
- 206010066728 Acute interstitial pneumonitis Diseases 0.000 description 1
- 208000002016 Adenosine monophosphate deaminase deficiency Diseases 0.000 description 1
- 208000006888 Agnosia Diseases 0.000 description 1
- 241001047040 Agnosia Species 0.000 description 1
- 206010001881 Alveolar proteinosis Diseases 0.000 description 1
- 102100039160 Amiloride-sensitive amine oxidase [copper-containing] Human genes 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002412 Angiocentric lymphomas Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000003017 Aortic Valve Stenosis Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 206010003062 Apraxia Diseases 0.000 description 1
- 208000006740 Aseptic Meningitis Diseases 0.000 description 1
- 206010003598 Atelectasis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 1
- 206010061000 Benign pancreatic neoplasm Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 206010004659 Biliary cirrhosis Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010006126 Brain herniation Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 1
- 208000007257 Budd-Chiari syndrome Diseases 0.000 description 1
- 208000029402 Bulbospinal muscular atrophy Diseases 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 101100063957 Caenorhabditis elegans doxa-1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 208000014912 Central Nervous System Infections Diseases 0.000 description 1
- 208000015374 Central core disease Diseases 0.000 description 1
- 201000003728 Centronuclear myopathy Diseases 0.000 description 1
- 208000023442 Cephalocele Diseases 0.000 description 1
- 206010057854 Cerebral Toxoplasmosis Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000005595 Chronic Idiopathic Jaundice Diseases 0.000 description 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 102100030556 Coagulation factor XII Human genes 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010062328 Congenital cyst Diseases 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 102000010958 Cortactin Human genes 0.000 description 1
- 108010037663 Cortactin Proteins 0.000 description 1
- 108091029523 CpG island Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012373 Depressed level of consciousness Diseases 0.000 description 1
- 108700043208 Dimauro disease Proteins 0.000 description 1
- 101710185746 Disks large homolog 1 Proteins 0.000 description 1
- 102100022263 Disks large homolog 3 Human genes 0.000 description 1
- 101710185762 Disks large homolog 3 Proteins 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 101710167313 Drebrin-like protein Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010072268 Drug-induced liver injury Diseases 0.000 description 1
- 201000004943 Dubin-Johnson syndrome Diseases 0.000 description 1
- 108700034637 EC 3.2.-.- Proteins 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 101710184989 Embryonic protein UVS.2 Proteins 0.000 description 1
- 102100034239 Emerin Human genes 0.000 description 1
- 201000009344 Emery-Dreifuss muscular dystrophy Diseases 0.000 description 1
- 208000002403 Encephalocele Diseases 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 208000037149 Facioscapulohumeral dystrophy Diseases 0.000 description 1
- 102000000429 Factor XII Human genes 0.000 description 1
- 208000001951 Fetal Death Diseases 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 1
- 108091006094 GTPase-accelerating proteins Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000009139 Gilbert Disease Diseases 0.000 description 1
- 208000022412 Gilbert syndrome Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 208000022461 Glomerular disease Diseases 0.000 description 1
- 206010018366 Glomerulonephritis acute Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 206010018404 Glucagonoma Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 102100034294 Glutathione synthetase Human genes 0.000 description 1
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 1
- 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 1
- 108020004202 Guanylate Kinase Proteins 0.000 description 1
- 108010043026 HGF activator Proteins 0.000 description 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
- 208000002927 Hamartoma Diseases 0.000 description 1
- 208000031071 Hamman-Rich Syndrome Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019713 Hepatic vein thrombosis Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 102100031465 Hepatocyte growth factor activator Human genes 0.000 description 1
- 101000924727 Homo sapiens Alternative prion protein Proteins 0.000 description 1
- 101000779845 Homo sapiens Amphiphysin Proteins 0.000 description 1
- 101001053984 Homo sapiens Disks large homolog 1 Proteins 0.000 description 1
- 101000951365 Homo sapiens Disks large-associated protein 5 Proteins 0.000 description 1
- 101001069973 Homo sapiens Glutathione synthetase Proteins 0.000 description 1
- 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 description 1
- 101000624643 Homo sapiens M-phase inducer phosphatase 3 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101001061518 Homo sapiens RNA-binding protein FUS Proteins 0.000 description 1
- 101000829980 Homo sapiens Ral guanine nucleotide dissociation stimulator Proteins 0.000 description 1
- 101000580039 Homo sapiens Ras-specific guanine nucleotide-releasing factor 1 Proteins 0.000 description 1
- 101000847156 Homo sapiens Tumor necrosis factor-inducible gene 6 protein Proteins 0.000 description 1
- 101000659267 Homo sapiens Tumor suppressor candidate 2 Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020586 Hypercalcaemic nephropathy Diseases 0.000 description 1
- 206010021030 Hypomania Diseases 0.000 description 1
- 208000029663 Hypophosphatemia Diseases 0.000 description 1
- 208000019468 Iatrogenic Disease Diseases 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 208000009995 Idiopathic pulmonary hemosiderosis Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 208000035478 Interatrial communication Diseases 0.000 description 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000027747 Kennedy disease Diseases 0.000 description 1
- 101710176178 Kidney androgen-regulated protein Proteins 0.000 description 1
- 102000004016 L-Type Calcium Channels Human genes 0.000 description 1
- 108090000420 L-Type Calcium Channels Proteins 0.000 description 1
- 108700006394 Lactate Dehydrogenase Deficiency Proteins 0.000 description 1
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 description 1
- 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101710099648 Lysosomal acid lipase/cholesteryl ester hydrolase Proteins 0.000 description 1
- 102100026001 Lysosomal acid lipase/cholesteryl ester hydrolase Human genes 0.000 description 1
- 102100026061 Mannan-binding lectin serine protease 1 Human genes 0.000 description 1
- 101710117390 Mannan-binding lectin serine protease 1 Proteins 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 208000015021 Meningeal Neoplasms Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027201 Meningitis aseptic Diseases 0.000 description 1
- 206010027202 Meningitis bacterial Diseases 0.000 description 1
- 206010027260 Meningitis viral Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 206010027527 Microangiopathic haemolytic anaemia Diseases 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 201000002169 Mitochondrial myopathy Diseases 0.000 description 1
- 208000003430 Mitral Valve Prolapse Diseases 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 206010028424 Myasthenic syndrome Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000021908 Myocardial disease Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 208000010316 Myotonia congenita Diseases 0.000 description 1
- 208000012905 Myotonic disease Diseases 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- 241001467460 Myxogastria Species 0.000 description 1
- 101710186414 N-succinylglutamate 5-semialdehyde dehydrogenase Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000034965 Nemaline Myopathies Diseases 0.000 description 1
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 102000002111 Neuropilin Human genes 0.000 description 1
- 108050009450 Neuropilin Proteins 0.000 description 1
- 102000004207 Neuropilin-1 Human genes 0.000 description 1
- 108090000772 Neuropilin-1 Proteins 0.000 description 1
- 102100023620 Neutrophil cytosol factor 1 Human genes 0.000 description 1
- 101710120102 Neutrophil cytosol factor 1 Proteins 0.000 description 1
- 102100023618 Neutrophil cytosol factor 2 Human genes 0.000 description 1
- 101710120095 Neutrophil cytosol factor 2 Proteins 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 201000009110 Oculopharyngeal muscular dystrophy Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102100030476 POU domain class 2-associating factor 1 Human genes 0.000 description 1
- 101710114665 POU domain class 2-associating factor 1 Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000000407 Pancreatic Cyst Diseases 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- 101100272680 Paracentrotus lividus BP10 gene Proteins 0.000 description 1
- 208000006199 Parasomnias Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 108700010203 Phosphoglycerate Kinase 1 Deficiency Proteins 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 208000019547 Placental disease Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035720 Pneumonia lipoid Diseases 0.000 description 1
- 206010036172 Porencephaly Diseases 0.000 description 1
- 206010058989 Portal vein occlusion Diseases 0.000 description 1
- 201000009454 Portal vein thrombosis Diseases 0.000 description 1
- 208000022214 Post-traumatic amnestic disease Diseases 0.000 description 1
- 102000019337 Prenyltransferases Human genes 0.000 description 1
- 108050006837 Prenyltransferases Proteins 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 208000025844 Prostatic disease Diseases 0.000 description 1
- 101710152606 Protein lin-2 Proteins 0.000 description 1
- 208000010362 Protozoan Infections Diseases 0.000 description 1
- 208000033522 Proximal spinal muscular atrophy type 2 Diseases 0.000 description 1
- 206010056658 Pseudocyst Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 206010037368 Pulmonary congestion Diseases 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102100028469 RNA-binding protein FUS Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 101150015043 Ralgds gene Proteins 0.000 description 1
- 102000003901 Ras GTPase-activating proteins Human genes 0.000 description 1
- 108090000231 Ras GTPase-activating proteins Proteins 0.000 description 1
- 102100027551 Ras-specific guanine nucleotide-releasing factor 1 Human genes 0.000 description 1
- 108090000244 Rat Proteins Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010038470 Renal infarct Diseases 0.000 description 1
- 206010038540 Renal tubular necrosis Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000020619 Rotor syndrome Diseases 0.000 description 1
- 101150034822 SDC25 gene Proteins 0.000 description 1
- 101150026794 SHO1 gene Proteins 0.000 description 1
- 101100381485 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) BBC1 gene Proteins 0.000 description 1
- 101100381532 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) BEM1 gene Proteins 0.000 description 1
- 101100165573 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) BOI2 gene Proteins 0.000 description 1
- 101000934623 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Protein BOB1 Proteins 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- XPVIVVLLLOFBRH-XIRDDKMYSA-N Ser-Trp-Lys Chemical compound NCCCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CO)C(O)=O XPVIVVLLLOFBRH-XIRDDKMYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 206010041329 Somatostatinoma Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 102000005890 Spectrin Human genes 0.000 description 1
- 101710090563 Spectrin alpha chain Proteins 0.000 description 1
- 102100031874 Spectrin alpha chain, non-erythrocytic 1 Human genes 0.000 description 1
- 101710157175 Spectrin alpha chain, non-erythrocytic 1 Proteins 0.000 description 1
- 201000010829 Spina bifida Diseases 0.000 description 1
- 208000006097 Spinal Dysraphism Diseases 0.000 description 1
- 101001072173 Streptomyces griseus Glutamyl endopeptidase 2 Proteins 0.000 description 1
- 208000032978 Structural Congenital Myopathies Diseases 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 101000588258 Taenia solium Paramyosin Proteins 0.000 description 1
- 208000035954 Thomsen and Becker disease Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102100034686 Tight junction protein ZO-1 Human genes 0.000 description 1
- 108050001370 Tight junction protein ZO-1 Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 208000005386 Transient Global Amnesia Diseases 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 1
- 102100032807 Tumor necrosis factor-inducible gene 6 protein Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 208000009443 Vascular Malformations Diseases 0.000 description 1
- 208000001910 Ventricular Heart Septal Defects Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 201000006035 X-linked dominant hypophosphatemic rickets Diseases 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 108091000387 actin binding proteins Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000004073 acute interstitial pneumonia Diseases 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 208000031112 adenoma of pancreas Diseases 0.000 description 1
- 201000006960 adult spinal muscular atrophy Diseases 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 206010002320 anencephaly Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 206010002906 aortic stenosis Diseases 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 208000013914 atrial heart septal defect Diseases 0.000 description 1
- 206010003664 atrial septal defect Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000037424 autonomic function Effects 0.000 description 1
- 230000004009 axon guidance Effects 0.000 description 1
- 201000009904 bacterial meningitis Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 210000000625 blastula Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 201000007303 central core myopathy Diseases 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- 208000025434 cerebellar degeneration Diseases 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000013507 chronic prostatitis Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 201000006815 congenital muscular dystrophy Diseases 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 230000001496 desquamative effect Effects 0.000 description 1
- 230000009025 developmental regulation Effects 0.000 description 1
- ZPTBLXKRQACLCR-XVFCMESISA-N dihydrouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)CC1 ZPTBLXKRQACLCR-XVFCMESISA-N 0.000 description 1
- 201000011304 dilated cardiomyopathy 1A Diseases 0.000 description 1
- 206010013461 dissociative amnesia Diseases 0.000 description 1
- 201000009338 distal myopathy Diseases 0.000 description 1
- 201000008865 drug-induced hepatitis Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 208000002296 eclampsia Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 208000028299 esophageal disease Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 208000008570 facioscapulohumeral muscular dystrophy Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 231100000479 fetal death Toxicity 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 229940098330 gamma linoleic acid Drugs 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- 102000011778 gamma-delta T-Cell Antigen Receptors Human genes 0.000 description 1
- 108010062214 gamma-delta T-Cell Antigen Receptors Proteins 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 231100000852 glomerular disease Toxicity 0.000 description 1
- 231100000853 glomerular lesion Toxicity 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 201000004502 glycogen storage disease II Diseases 0.000 description 1
- 201000009339 glycogen storage disease VII Diseases 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 208000020390 granulomatous prostatitis Diseases 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 102000006638 guanylate kinase Human genes 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 208000007000 hereditary hyperbilirubinemia Diseases 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 102000057421 human MET Human genes 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 201000009075 hydranencephaly Diseases 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 206010020765 hypersomnia Diseases 0.000 description 1
- 208000015210 hypertensive heart disease Diseases 0.000 description 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
- 230000000396 hypokalemic effect Effects 0.000 description 1
- 208000011111 hypophosphatemic rickets Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000008102 immune modulation Effects 0.000 description 1
- 230000034435 immune system development Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000010249 in-situ analysis Methods 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 201000006913 intermediate spinal muscular atrophy Diseases 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical group O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 208000007067 lipid pneumonia Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 208000006116 lymphomatoid granulomatosis Diseases 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 108091005485 macrophage scavenger receptors Proteins 0.000 description 1
- 102000049853 macrophage stimulating protein Human genes 0.000 description 1
- 108010053292 macrophage stimulating protein Proteins 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000009242 medullary sponge kidney Diseases 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 201000008806 mesenchymal cell neoplasm Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 230000002988 nephrogenic effect Effects 0.000 description 1
- 201000002648 nephronophthisis Diseases 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 210000004788 neurological cell Anatomy 0.000 description 1
- 230000003705 neurological process Effects 0.000 description 1
- 230000004751 neurological system process Effects 0.000 description 1
- 208000014500 neuronal tumor Diseases 0.000 description 1
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 210000001706 olfactory mucosa Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 208000027838 paramyotonia congenita of Von Eulenburg Diseases 0.000 description 1
- 208000003278 patent ductus arteriosus Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000029308 periodic paralysis Diseases 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 208000025934 placenta disease Diseases 0.000 description 1
- 206010035653 pneumoconiosis Diseases 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 201000008752 progressive muscular atrophy Diseases 0.000 description 1
- 201000008171 proliferative glomerulonephritis Diseases 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 208000029817 pulmonary adenocarcinoma in situ Diseases 0.000 description 1
- 201000003489 pulmonary alveolar proteinosis Diseases 0.000 description 1
- 201000009732 pulmonary eosinophilia Diseases 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 201000003456 pulmonary hemosiderosis Diseases 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 201000008158 rapidly progressive glomerulonephritis Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 201000010384 renal tubular acidosis Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000004189 reticular formation Anatomy 0.000 description 1
- 230000004141 reverse cholesterol transport Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 208000021569 rheumatoid lung disease Diseases 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 238000002416 scanning tunnelling spectroscopy Methods 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 208000022610 schizoaffective disease Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- FESBVLZDDCQLFY-UHFFFAOYSA-N sete Chemical compound [Te]=[Se] FESBVLZDDCQLFY-UHFFFAOYSA-N 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 238000002516 single-drop micro-extraction Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 208000011317 telomere syndrome Diseases 0.000 description 1
- 238000000123 temperature gradient gel electrophoresis Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 208000012175 toxemia of pregnancy Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012085 transcriptional profiling Methods 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 208000032349 type 2B vitamin D-dependent rickets Diseases 0.000 description 1
- 208000032521 type II spinal muscular atrophy Diseases 0.000 description 1
- 208000005606 type IV spinal muscular atrophy Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003741 urothelium Anatomy 0.000 description 1
- 230000025102 vascular smooth muscle contraction Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 201000003130 ventricular septal defect Diseases 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 201000010044 viral meningitis Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Definitions
- the present invention provides sequence information for polynucleotides derived from human and murine genes and for proteins encoded thereby, and thus enables the practitioner to assess, predict, and affect the physiological state of various human and murine tissues.
- the present invention is based, at least in part, on the discovery of a variety of human and murine cDNA molecules which encode proteins which are herein designated TANGO 202, TANGO 234, TANGO 265, TANGO 273, TANGO 286, TANGO 294, and INTERCEPT 296. These seven proteins, fragments thereof, derivatives thereof, and variants thereof are collectively referred to herein as the polypeptides of the invention or the proteins of the invention. Nucleic acid molecules encoding polypeptides of the invention are collectively referred to as nucleic acids of the invention.
- nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes. Accordingly, in one aspect, the present invention provides isolated nucleic acid molecules encoding a polypeptide of the invention or a biologically active portion thereof. The present invention also provides nucleic acid molecules which are suitable as primers or hybridization probes for the detection of nucleic acids encoding a polypeptide of the invention.
- the invention also features nucleic acid molecules which are at least 40% (or 50%, 60%, 70%, 80%, 90%, 95%, or 98%) identical to the nucleotide sequence of any of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73, the nucleotide sequence of a cDNA clone deposited with ATCC® as one of Accession numbers 207219, 207184, 207228, 207185, 207220, and 207221 (“a cDNA of a clone deposited as one of ATCC® 207219, 207184, 207228, 207185, 207220, and 207221”), or a complement thereof.
- the invention features nucleic acid molecules which include a fragment of at least 15 (25, 40, 60, 80, 100, 150, 200, 250, 300, 350, 400, 450, 550, 650, 700, 800, 900, 1000, 1200, 1400, 1600, 1800, 2000, 2200, 2400, 2600, 2800, 3000, 3500, 4000, 4500, or 4928) consecutive nucleotide residues of any of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73, the nucleotide sequence of a cDNA of a clone deposited as one of ATCC® 207219, 207184, 207228, 207185, 207220, and 207221, or a complement thereof.
- the invention also features nucleic acid molecules which include a nucleotide sequence encoding a protein having an amino acid sequence that is at least 50% (or 60%, 70%, 80%, 90%, 95%, or 98%) identical to the amino acid sequence of any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74, or the amino acid sequence encoded by a cDNA of a clone deposited as one of ATCC® 207219, 207184, 207228, 207185, 207220, and 207221, or a complement thereof.
- the nucleic acid molecules have the nucleotide sequence of any of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73, or the nucleotide sequence of a cDNA of a clone deposited as one of ATCC® 207219, 207184, 207228, 207185, 207220, and 207221.
- nucleic acid molecules which encode a fragment of a polypeptide having the amino acid sequence of any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74, or the amino acid sequence encoded by a cDNA of a clone deposited as one of ATCC® 207219, 207184, 207228, 207185, 207220, and 207221, the fragment including at least 8 (10, 15, 20, 25, 30, 40, 50, 75, 100, 125, 150, or 200) consecutive amino acids of any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74, or the amino acid sequence encoded by a cDNA of a clone deposited as one of ATCC® 207219, 207184, 207228, 207185, 207220, and 207221.
- the invention includes nucleic acid molecules which encode a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74, or the amino acid sequence encoded by a cDNA of a clone deposited as one of ATCC® 207219, 207184, 207228, 207185, 207220, and 207221, wherein the nucleic acid molecule hybridizes under stringent conditions to a nucleic acid molecule having a nucleic acid sequence encoding any of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73, the nucleotide sequence of a cDNA of a clone deposited as one of ATCC® 207219, 207184, 207228, 207185, 207220, and 207221
- isolated polypeptides or proteins having an amino acid sequence that is at least about 50%, preferably 60%, 75%, 90%, 95%, or 98% identical to the amino acid sequence of any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74.
- isolated polypeptides or proteins which are encoded by a nucleic acid molecule having a nucleotide sequence that is at least about 40%, preferably 50%, 75%, 85%, or 95% identical the nucleic acid sequence encoding any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74, and isolated polypeptides or proteins which are encoded by a nucleic acid molecule consisting of the nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule having the nucleotide sequence of any of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73.
- polypeptides which are naturally occurring allelic variants of a polypeptide that includes the amino acid sequence of any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74, or the amino acid sequence encoded by a cDNA of a clone deposited as one of ATCC® 207219, 207184, 207228, 207185, 207220, and 207221, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes under stringent conditions to a nucleic acid molecule having the nucleotide sequence of any of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73, or a complement thereof.
- the invention also features nucleic acid molecules that hybridize under stringent conditions to a nucleic acid molecule having the nucleotide sequence of any of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73, the nucleotide sequence of a cDNA of a clone deposited as one of ATCC® 207219, 207184, 207228, 207185, 207220, and 207221, or a complement thereof.
- the nucleic acid molecules are at least 15 (25, 40, 60, 80, 100, 150, 200, 250, 300, 350, 400, 450, 550, 650, 700, 800, 900, 1000, 1200, 1400, 1600, 1800, 2000, 2200, 2400, 2600, 2800, 3000, 3500, 4000, 4500, or 4928) nucleotides in length and hybridize under stringent conditions to a nucleic acid molecule having the nucleotide sequence of any of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73, the nucleotide sequence of a cDNA of a clone deposited as one of ATCC® 207219, 207184, 207228, 207185, 207220, and 207221, or a complement thereof.
- the isolated nucleic acid molecules encode a cytoplasmic, transmembrane, extracellular, or other domain of a polypeptide of the invention.
- the invention provides an isolated nucleic acid molecule which is antisense to the coding strand of a nucleic acid of the invention.
- Another aspect of the invention provides vectors, e.g., recombinant expression vectors, comprising a nucleic acid molecule of the invention.
- the invention provides isolated host cells, e.g., mammalian and non-mammalian cells, containing such a vector or a nucleic acid of the invention.
- the invention also provides methods for producing a polypeptide of the invention by culturing, in a suitable medium, a host cell of the invention containing a recombinant expression vector encoding a polypeptide of the invention such that the polypeptide of the invention is produced.
- Another aspect of this invention features isolated or recombinant proteins and polypeptides of the invention.
- Preferred proteins and polypeptides possess at least one biological activity possessed by the corresponding naturally-occurring human polypeptide.
- An activity, a biological activity, and a functional activity of a polypeptide of the invention refers to an activity exerted by a protein or polypeptide of the invention on a responsive cell as determined in vivo, or in vitro, according to standard techniques.
- Such activities can be a direct activity, such as an association with or an enzymatic activity on a second protein, or an indirect activity, such as a cellular process (e.g., signaling activity) mediated by interaction of the protein with a second protein.
- activities include, by way of example, formation of protein-protein interactions with proteins of one or more signaling pathways (e.g., with a protein with which the naturally-occurring polypeptide interacts); binding with a ligand of the naturally-occurring protein; and binding with an intracellular target of the naturally-occurring protein.
- Other activities include modulation of one or more of cellular proliferation, of cellular differentiation, of chemotaxis, of cellular migration, and of cell death (e.g., apoptosis).
- TANGO 202 exhibits the ability to affect growth, proliferation, survival, differentiation, and activity of human hematopoietic cells (e.g., bone marrow stromal cells) and fetal cells.
- TANGO 202 modulates cellular binding to one or more mediators, modulates proteolytic activity in vivo, modulates developmental processes, and modulates cell growth, proliferation, survival, differentiation, and activity.
- mediators e.g., bone marrow stromal cells
- TANGO 202 can be used to prevent, diagnose, or treat disorders relating to aberrant cellular protease activity, inappropriate interaction (or non-interaction) of cells with mediators, inappropriate development, and blood and hematopoietic cell-related disorders.
- Exemplary disorders for which TANGO 202 is useful include immune disorders, infectious diseases, auto-immune disorders, vascular and cardiovascular disorders, disorders related to mal-expression of growth factors, cancers, hematological disorders, various cancers, birth defects, developmental defects, and the like.
- TANGO 234 exhibits the ability to affect growth, proliferation, survival, differentiation, and activity of human lung, hematopoietic, and fetal cells and of (e.g., bacterial or fungal) cells and viruses which infect humans.
- TANGO 234 modulates growth, proliferation, survival, differentiation, and activity of gamma delta T cells, for example.
- TANGO 234 modulates cholesterol deposition on human arterial walls, and is involved in uptake and metabolism of low density lipoprotein and regulation of serum cholesterol levels.
- TANGO 234 can be used to affect development and persistence of atherogenesis and arteriosclerosis, as well as other vascular and cardiovascular disorders.
- Other exemplary disorders for which TANGO 234 is useful include immune development disorders and disorders involving generation and persistence of an immune response to bacterial, fungal, and viral infections.
- TANGO 265 modulates growth and regeneration of neuronal and epithelial tissues, and guides neuronal axon development.
- TANGO 265 is a transmembrane protein which mediates cellular interaction with cells, molecules and structures (e.g., extracellular matrix) in the extracellular environment.
- TANGO 265 is therefore involved in growth, organization, and adhesion of tissues and the cells which constitute those tissues.
- TANGO 265 modulates growth, proliferation, survival, differentiation, and activity of neuronal cells and immune system cells.
- TANGO 265 can be used, for example, to prevent, diagnose, or treat disorders characterized by aberrant organization or development of a tissue or organ, for guiding neural axon development, for modulating differentiation of cells of the immune system, for modulating cytokine production by cells of the immune system, for modulating reactivity of cells of the immune system toward cytokines, for modulating initiation and persistence of an inflammatory response, and for modulating proliferation of epithelial cells.
- TANGO 273 protein mediates one or more physiological responses of cells to bacterial infection, e.g., by mediating one or more of detection of bacteria in a tissue in which it is expressed, movement of cells with relation to sites of bacterial infection, production of biological molecules which inhibit bacterial infection, and production of biological molecules which alleviate cellular or other physiological damage wrought by bacterial infection.
- TANGO 273, a transmembrane protein is also involved in transmembrane signal transduction, and therefore mediates transmission of signals between the extracellular and intracellular environments of cells.
- TANGO 273 mediates regulation of cell growth and proliferation, endocytosis, activation of respiratory burst, and other physiological processes triggered by transmission of a signal via a protein with which TANGO 273 interacts.
- the compositions and methods of the invention can therefore be used to prevent, diagnose, and treat disorders involving one or more physiological activities mediated by TANGO 273 protein.
- disorders include, for example, various bone-related disorders such as metabolic, homeostatic, and developmental bone disorders (e.g., osteoporosis, various cancers, skeletal development disorders, bone fragility and the like), disorders caused by or related to bacterial infection, and disorders characterized by aberrant transmembrane signal transduction by TANGO 273.
- TANGO 286 protein is involved in lipid-binding physiological processes such as lipid transport, metabolism, serum lipid particle regulation, host anti-microbial defensive mechanisms, and the like.
- compositions and methods of the invention can therefore be used to prevent, diagnose, and treat disorders involving one or more physiological activities mediated by TANGO 286 protein.
- Such disorders include, for example, lipid transport disorders, lipid metabolism disorders, obesity, disorders of serum lipid particle regulation, disorders involving insufficient or inappropriate host anti-microbial defensive mechanisms, vasculitis, bronchiectasis, LPS-related disorders such as shock, disseminated intravascular coagulation, anemia, thrombocytopenia, adult respiratory distress syndrome, renal failure, liver disease, and disorders associated with Gram negative bacterial infections, such as bacteremia, endotoxemia, sepsis, and the like.
- TANGO 294 protein is involved in facilitating absorption and metabolism of fat.
- the compositions and methods of the invention can therefore be used to prevent, diagnose, and treat disorders involving one or more physiological activities mediated by TANGO 294 protein.
- disorders include, for example, inadequate expression of gastric/pancreatic lipase, cystic fibrosis, exocrine pancreatic insufficiency, medical treatments which alter fat absorption, obesity, and the like.
- INTERCEPT 296 protein is involved in physiological processes related to disorders of the human lung and esophagus.
- disorders include, for example, various cancers, bronchitis, cystic fibrosis, respiratory infections (e.g., influenza, bronchiolitis, pneumonia, and tuberculosis), asthma, emphysema, chronic bronchitis, bronchiectasis, pulmonary edema, pleural effusion, pulmonary embolus, adult and infant respiratory distress syndromes, heartburn, and gastric reflux esophageal disease.
- respiratory infections e.g., influenza, bronchiolitis, pneumonia, and tuberculosis
- asthma emphysema
- chronic bronchitis bronchiectasis
- pulmonary edema pleural effusion
- pulmonary embolus edema
- adult and infant respiratory distress syndromes e.g., pulmonary embolus, adult and infant respiratory distress syndromes, heart
- a polypeptide of the invention has an amino acid sequence sufficiently identical to an identified domain of a polypeptide of the invention.
- the term “sufficiently identical” refers to a first amino acid or nucleotide sequence which contains a sufficient or minimum number of identical or equivalent (e.g., with a similar side chain) amino acid residues or nucleotides to a second amino acid or nucleotide sequence such that the first and second amino acid or nucleotide sequences have a common structural domain and/or common functional activity.
- amino acid or nucleotide sequences which contain a common structural domain having about 65% identity, preferably 75% identity, more preferably 85%, 95%, or 98% identity are defined herein as sufficiently identical.
- the isolated polypeptide of the invention lacks both a transmembrane and a cytoplasmic domain. In another embodiment, the polypeptide lacks both a transmembrane domain and a cytoplasmic domain and is soluble under physiological conditions.
- polypeptides of the present invention can be operably linked to a heterologous amino acid sequence to form fusion proteins.
- the invention further features antibody substances that specifically bind a polypeptide of the invention such as monoclonal or polyclonal antibodies, antibody fragments, single-chain antibodies, and the like.
- the polypeptides of the invention or biologically active portions thereof can be incorporated into pharmaceutical compositions, which optionally include pharmaceutically acceptable carriers.
- These antibody substances can be made, for example, by providing the polypeptide of the invention to an immunocompetent vertebrate and thereafter harvesting blood or serum from the vertebrate.
- the present invention provides methods for detecting the presence of the activity or expression of a polypeptide of the invention in a biological sample by contacting the biological sample with an agent capable of detecting an indicator of activity such that the presence of activity is detected in the biological sample.
- the invention provides methods for modulating activity of a polypeptide of the invention comprising contacting a cell with an agent that modulates (inhibits or enhances) the activity or expression of a polypeptide of the invention such that activity or expression in the cell is modulated.
- the agent is an antibody that specifically binds to a polypeptide of the invention.
- the agent modulates expression of a polypeptide of the invention by modulating transcription, splicing, or translation of an mRNA encoding a polypeptide of the invention.
- the agent is a nucleic acid molecule having a nucleotide sequence that is antisense with respect to the coding strand of an mRNA encoding a polypeptide of the invention.
- the present invention also provides methods to treat a subject having a disorder characterized by aberrant activity of a polypeptide of the invention or aberrant expression of a nucleic acid of the invention by administering an agent which is a modulator of the activity of a polypeptide of the invention or a modulator of the expression of a nucleic acid of the invention to the subject.
- the modulator is a protein of the invention.
- the modulator is a nucleic acid of the invention.
- the modulator is a peptide, peptidominetic, or other small molecule (e.g., a small organic molecule).
- the present invention also provides diagnostic assays for identifying the presence or absence of a genetic lesion or mutation characterized by at least one of: (i) aberrant modification or mutation of a gene encoding a polypeptide of the invention, (ii) mis-regulation of a gene encoding a polypeptide of the invention, and (iii) aberrant post-translational modification of a polypeptide of the invention wherein a wild-type form of the gene encodes a polypeptide having the activity of the polypeptide of the invention.
- the invention provides a method for identifying a compound that binds to or modulates the activity of a polypeptide of the invention.
- such methods entail measuring a biological activity of the polypeptide in the presence and absence of a test compound and identifying those compounds which alter the activity of the polypeptide.
- the invention also features methods for identifying a compound which modulates the expression of a polypeptide or nucleic acid of the invention by measuring the expression of the polypeptide or nucleic acid in the presence and absence of the compound.
- the invention provides substantially purified antibodies or fragments thereof (i.e., antibody substances), including non-human antibodies or fragments thereof, which specifically bind with a polypeptide of the invention or with a portion thereof.
- these substantially purified antibodies/fragments can be human, non-human, chimeric, and/or humanized antibodies.
- Non-human antibodies included in the invention include, by way of example, goat, mouse, sheep, horse, chicken, rabbit, and rat antibodies.
- the antibodies of the invention can be polyclonal antibodies or monoclonal antibodies.
- the antibody substance of the invention specifically binds with an extracellular domain of one of TANGO 202, TANGO 234, TANGO 265, TANGO 273, TANGO 286, TANGO 294, and INTERCEPT 296.
- the extracellular domain with which the antibody substance binds has an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 6, 14, 22, 30, 37, 49, 50, and 56-58.
- any of the antibody substances of the invention can be conjugated with a therapeutic moiety or with a detectable substance.
- detectable substances include an enzyme, a prosthetic group, a fluorescent material (i.e., a fluorophore), a luminescent material, a bioluminescent material, and a radioactive material (e.g., a radionuclide or a substituent comprising a radionuclide).
- the invention also provides a kit containing an antibody substance of the invention conjugated with a detectable substance, and instructions for use.
- Still another aspect of the invention is a pharmaceutical composition comprising an antibody substance of the invention and a pharmaceutically acceptable carrier.
- the pharmaceutical composition contains an antibody substance of the invention, a therapeutic moiety (preferably conjugated with the antibody substance), and a pharmaceutically acceptable carrier.
- the invention includes a method of assessing whether a first human patient is afflicted with an epithelial or endothelial tumor (e.g., a colon, prostate, pancreatic, lung, or breast tumor). The method comprises comparing:
- a difference between the first sample and the control sample is an indication that the patient is afflicted with the tumor.
- the invention also includes a method of assessing whether a first human patient is afflicted with an epithelial or endothelial tumor. This method comprises comparing
- a difference between the first sample and the control sample is an indication that the patient is not afflicted with the tumor.
- the invention includes a method of screening for agents which decrease the activity of a TANGO-294-like lipase protein.
- the method comprises:
- Binding between the test compound and the TANGO 294-like lipase polypeptide is an indication that the test compound is an agent which decreases the activity of the TANGO 294-like lipase protein.
- a pharmaceutical composition can be made by identifying an agent according to this method and combining the agent and a pharmaceutically acceptable carrier to form the pharmaceutical composition.
- This pharmaceutical composition can be administered to a human afflicted with a disorder in order to modulate the activity of a TANGO 294-like lipase protein in the disorder.
- the disorder can, for example be a tumor, a disorder of fat absorption, a disorder of fat metabolism, a blood flow disorder, a blood pressure disorder, an inflammatory disorder, an immune disorder, a thrombotic disorder, or a disorder involving inappropriate platelet adherence.
- these disorders include tumors of endothelial or epithelial origin, colon tumors, pancreatic tumors, inadequate expression of gastric lipase, inadequate expression of pancreatic lipase, cystic fibrosis, exocrine pancreatic insufficiency, obesity, arterial hypertension, renovascular hypertension, syncope, orthostatic hypotension, shock, gastritis, gastric ulcer, colitis, irritable bowel syndrome, inflammatory bowel syndrome, dermatitis, pancreatitis, rheumatoid arthritis, psoriasis, myasthenia gravis, an allergy, insulin resistance, systemic lupus erythematosus, scleroderma, and autoimmune diabetes mellitus, an infection of a human by an infectious agent (e.g., human immunodeficiency virus), hemophilia, stroke, myocardial infarction, coronary artery disease, and atherosclerosis.
- infectious agent e.g., human immuno
- the invention includes a method of screening for agents which modulate the activity of a TANGO 294-like lipase protein. This method comprises:
- Increased TANGO 294-like lipase activity in the presence of the test compound is an indication that the test compound is an agent useful for increasing the activity of the TANGO 294-like lipase protein.
- Decreased TANGO 294-like lipase activity in the presence of the test compound is an indication that the test compound is an agent useful for decreasing the activity of the TANGO 294-like lipase protein.
- a pharmaceutical composition can be made by identifying an agent according to this method and combining the agent and a pharmaceutically acceptable carrier to form the pharmaceutical composition.
- This pharmaceutical composition can be administered to a human afflicted with a disorder in order to modulate the activity of a TANGO 294-like lipase protein in the disorder.
- the disorder can, for example be a tumor, a disorder of fat absorption, a disorder of fat metabolism, a blood flow disorder, a blood pressure disorder, an inflammatory disorder, an immune disorder, a thrombotic disorder, or a disorder involving inappropriate platelet adherence.
- these disorders include tumors of endothelial or epithelial origin, colon tumors, pancreatic tumors, inadequate expression of gastric lipase, inadequate expression of pancreatic lipase, cystic fibrosis, exocrine pancreatic insufficiency, obesity, arterial hypertension, renovascular hypertension, syncope, orthostatic hypotension, shock, gastritis, gastric ulcer, colitis, irritable bowel syndrome, inflammatory bowel syndrome, dermatitis, pancreatitis, rheumatoid arthritis, psoriasis, myasthenia gravis, an allergy, insulin resistance, systemic lupus erythematosus, scleroderna, and autoimmune diabetes mellitus, an infection of a human by an infectious agent (e.g., human immunodeficiency virus), hemophilia, stroke, myocardial infarction, coronary artery disease, and atherosclerosis.
- infectious agent e.g., human
- the invention includes a method of screening for agents which decrease the activity of a TANGO 294-like lipase protein. This method comprises:
- Binding between the test compound and the isolated nucleic acid molecule is an indication that the test compound is a agent useful for decreasing the activity of the TANGO 294-like lipase protein.
- a pharmaceutical composition can be made by identifying an agent according to this method and combining the agent and a pharmaceutically acceptable carrier to form the pharmaceutical composition.
- This pharmaceutical composition can be administered to a human afflicted with a disorder in order to modulate the activity of a TANGO 294-like lipase protein in the disorder.
- the disorder can, for example be a tumor, a disorder of fat absorption, a disorder of fat metabolism, a blood flow disorder, a blood pressure disorder, an inflammatory disorder, an immune disorder, a thrombotic disorder, or a disorder involving inappropriate platelet adherence.
- these disorders include tumors of endothelial or epithelial origin, colon tumors, pancreatic tumors, inadequate expression of gastric lipase, inadequate expression of pancreatic lipase, cystic fibrosis, exocrine pancreatic insufficiency, obesity, arterial hypertension, renovascular hypertension, syncope, orthostatic hypotension, shock, gastritis, gastric ulcer, colitis, irritable bowel syndrome, inflammatory bowel syndrome, dermatitis, pancreatitis, rheumatoid arthritis, psoriasis, myasthenia gravis, an allergy, insulin resistance, systemic lupus erythematosus, scleroderma, and autoimmune diabetes mellitus, an infection of a human by an infectious agent (e.g., human immunodeficiency virus), hemophilia, stroke, myocardial infarction, coronary artery disease, and atherosclerosis.
- infectious agent e.g., human immuno
- the invention also includes a method of reducing the activity of a TANGO 294-like lipase protein (i.e., TANGO 294, or a variant or alternative form thereof as disclosed herein) of a cell.
- the method comprises contacting the cell with a reagent which specifically binds with an isolated TANGO 294 nucleic acid molecule or with an isolated TANGO 294 polypeptide.
- FIG. 1 comprises FIGS. 1 A- 1 M.
- the nucleotide sequence (SEQ ID NO: 1) of a cDNA encoding the human TANGO 202 protein described herein is listed in FIGS 1 A- 1 D.
- the open reading frame (ORF; residues 34 to 1458; SEQ ID NO: 2) of the cDNA is indicated by nucleotide triplets, above which the amino acid sequence (SEQ ID NO: 3) of human TANGO 202 is listed.
- the nucleotide sequence (SEQ ID NO: 67) of a cDNA encoding the murine TANGO 202 protein described herein is listed in FIGS. 1 E- 1 I.
- the ORF (residues 81 to 1490; SEQ ID NO: 68) of the cDNA is indicated by nucleotide triplets, above which the amino acid sequence (SEQ ID NO: 69) of murine TANGO 202 is listed.
- An alignment of the amino acid sequences of human (“Hum.”; SEQ ID NO: 3) and murine (“Mur.”; SEQ ID NO: 69) TANGO 202 protein is shown in FIGS. 1J and 1K, wherein identical amino acid residues are indicated by “:” and similar amino acid residues are indicated by “.”.
- FIG. 1L is a hydrophilicity plot of human TANGO 202 protein, in which the locations of cysteine residues (“Cys”) and potential N-glycosylation sites (“Ngly”) are indicated by vertical bars and the predicted extracellular (“out”), intracellular (“ins”), or transmembrane (“TM”) locations of the protein backbone is indicated by a horizontal bar.
- Cys cysteine residues
- Ngly potential N-glycosylation sites
- TM transmembrane
- FIG. 1M is a hydrophilicity plot of murine TANGO 202 protein.
- FIG. 2 comprises FIGS. 2A to 2 Q- 17 .
- the nucleotide sequence (SEQ ID NO: 9) of a cDNA encoding the human TANGO 234 protein described herein is listed in FIGS. 2 A- 2 I.
- the ORF (residues 28 to 4386; SEQ ID NO: 10) of the cDNA is indicated by nucleotide triplets, above which the amino acid sequence (SEQ ID NO: 11) of human TANGO 234 is listed.
- FIG. 2J is a hydrophilicity plot of human TANGO 234 protein.
- An alignment of the amino acid sequences of human TANGO 234 (“Hum”; SEQ ID NO: 11) and bovine WC1 (“WC1”; SEQ ID NO: 78) proteins is shown in FIGS. 2 K- 2 P, wherein identical amino acid residues are indicated by “:” and similar amino acid residues are indicated by “.”.
- An alignment of the nucleotide sequences of an ORF encoding human TANGO 234 (“Hum”; SEQ ID NO: 10) and an ORF encoding bovine WC1 (“WC1”; SEQ ID NO: 79) proteins is shown in FIGS. 2 Q- 1 to 2 Q- 17 , wherein identical nucleotide residues are indicated by “:”.
- FIG. 3 comprises FIGS. 3 A- 3 U.
- the nucleotide sequence (SEQ ID NO: 17) of a cDNA encoding the human TANGO 265 protein described herein is listed in FIGS. 3 A- 3 E.
- the ORF (residues 32 to 2314; SEQ ID NO: 18) of the cDNA is indicated by nucleotide triplets, above which the amino acid sequence (SEQ ID NO: 19) of human TANGO 265 is listed.
- An alignment of the amino acid sequences of human TANGO 265 protein (“Hum.”; SEQ ID NO: 19) and murine semaphorin B protein (“Mur.”; SEQ ID NO: 70; GenBank Accession No. X85991) is shown in FIGS. 3 F- 3 H, wherein identical amino acid residues are indicated by “:” and similar amino acid residues are indicated by “.”.
- FIGS. 31 - 3 T an alignment of the nucleotide sequences of the cDNA encoding human TANGO 265 protein (“Hum.”; SEQ ID NO: 17) and the nucleotide sequences of the cDNA encoding murine semaphorin B protein (“Mur.”; SEQ ID NO: 71; GenBank Accession No. X85991) is shown.
- FIG. 3U is a hydrophilicity plot of TANGO 265 protein.
- FIG. 4 comprises FIGS. 4 A- 4 J.
- the nucleotide sequence (SEQ ID NO: 25) of a cDNA encoding the human TANGO 273 protein described herein is listed in FIGS. 4 A- 4 C.
- the ORF (residues 135 to 650; SEQ ID NO: 26) of the cDNA is indicated by nucleotide triplets, above which the amino acid sequence (SEQ ID NO: 27) of human TANGO 273 is listed.
- the nucleotide sequence (SEQ ID NO: 72) of a cDNA encoding the murine TANGO 273 protein described herein is listed in FIGS. 4 D- 4 G.
- the ORF (residues 137 to 652; SEQ ID NO: 73) of the cDNA is indicated by nucleotide triplets, above which the amino acid sequence (SEQ ID NO: 74) of murine TANGO 273 is listed.
- An alignment of the amino acid sequences of human (“Hum.”; SEQ ID NO: 27) and murine (“Mur.”; SEQ ID NO: 74) TANGO 273 protein is shown in FIG. 4H, wherein identical amino acid residues are indicated by “:” and similar amino acid residues are indicated by “.”.
- FIG. 4J is a hydrophilicity plot of human TANGO 273 protein
- FIG. 4J is a hydrophilicity plot of murine TANGO 273 protein.
- FIG. 5 comprises FIGS. 5 A- 5 I.
- the nucleotide sequence (SEQ ID NO: 33) of a cDNA encoding the human TANGO 286 protein described herein is listed in FIGS. 5 A- 5 D.
- the ORF (residues 133 to 1497; SEQ ID NO: 34) of the cDNA is indicated by nucleotide triplets, above which the amino acid sequence (SEQ ID NO: 35) of human TANGO 286 is listed.
- FIG. 5E is a hydrophilicity plot of TANGO 286 protein.
- An alignment of the amino acid sequences of human TANGO 286 (“286”; SEQ ID NO: 35) and BPI protein (“BPI”; SEQ ID NO: 38) protein is shown in FIGS. 5F and 5G, wherein identical amino acid residues are indicated by “:” and similar amino acid residues are indicated by “.”.
- An alignment of the amino acid sequences of human TANGO 286 (“286”; SEQ ID NO: 35) and RENP protein (“RENP”; SEQ ID NO: 39) is shown in FIGS. 5H and 5I, wherein identical amino acid residues are indicated by “:” and similar amino acid residues are indicated by “.”.
- FIG. 6 comprises FIGS. 6 A- 6 H.
- the nucleotide sequence (SEQ ID NO: 45) of a cDNA encoding the human TANGO 294 protein described herein is listed in FIGS. 6 A- 6 C.
- the ORF (residues 126 to 1394; SEQ ID NO: 46) of the cDNA is indicated by nucleotide triplets, above which the amino acid sequence (SEQ ID NO: 47) of human TANGO 294 is listed.
- An alignment of the amino acid sequences of human TANGO 294 protein (“294”; SEQ ID NO: 47) and a known human lipase protein (“HLP”; SEQ ID NO: 75; GenBank Accession No. NP — 004181) is shown in FIGS. 6D and 6E, wherein identical amino acid residues are indicated by “:” and similar amino acid residues are indicated by “.”.
- FIG. 6F is a hydrophilicity plot of TANGO 294 protein.
- An alignment of the amino acid sequences of human TANGO 294 protein (“294”; SEQ ID NO: 47) and a known human lysosomal acid lipase protein (“LAL”; SEQ ID NO: 41) is shown in FIGS. 6G and 6H, wherein identical amino acid residues are indicated by and similar amino acid residues are indicated by “.”
- FIG. 7 comprises FIGS. 7 A- 7 F.
- the nucleotide sequence (SEQ ID NO: 53) of a cDNA encoding the human INTERCEPT 296 protein described herein is listed in FIGS. 7 A- 7 C.
- the ORF (residues 70 to 1098; SEQ ID NO: 54) of the cDNA is indicated by nucleotide triplets, above which the amino acid sequence (SEQ ID NO: 55) of human INTERCEPT 296 protein is listed.
- FIG. 7D is a hydrophilicity plot of INTERCEPT 296 protein.
- An alignment of the amino acid sequences of human INTERCEPT 296 protein (“296”; SEQ ID NO: 55) and C. elegans C06E1.3 related protein (“CRP”; SEQ ID NO: 40) is shown in FIGS. 7E and 7F, wherein identical amino acid residues are indicated by “:” and similar amino acid residues are indicated by “.”.
- the present invention is based, at least in part, on the discovery of a variety of human and murine cDNA molecules which encode proteins which are herein designated TANGO 202, TANGO 234, TANGO 265, TANGO 273, TANGO 286, TANGO 294, and INTERCEPT 296. These proteins exhibit a variety of physiological activities, and are included in a single application for the sake of convenience. It is understood that the allowability or non-allowability of claims directed to one of these proteins has no bearing on the allowability of claims directed to the others. The characteristics of each of these proteins and the cDNAs encoding them are now described separately.
- a cDNA clone (designated jthke096b05) encoding at least a portion of human TANGO 202 protein was isolated from a human fetal skin cDNA library.
- the corresponding murine cDNA was isolated as a clone (designated jtmMa044f07) from a bone marrow stromal cell cDNA library.
- the human TANGO 202 protein is predicted by structural analysis to be a type I membrane protein, although it can exist in a secreted form as well.
- the murine TANGO 202 protein is predicted by structural analysis to be a secreted protein.
- the full length of the cDNA encoding human TANGO 202 protein (FIG. 1; SEQ ID NO: 1) is 1656 nucleotide residues.
- the open reading frame (ORF) of this cDNA nucleotide residues 34 to 1458 of SEQ ID NO: 1 (i.e., SEQ ID NO: 2), encodes a 475-amino acid transmembrane protein (FIG. 1; SEQ ID NO: 3).
- the invention thus includes purified human TANGO 202 protein, both in the form of the immature 475 amino acid residue protein (SEQ ID NO: 3) and in the form of the mature 456 amino acid residue protein (SEQ ID NO: 5).
- the invention also includes purified murine TANGO 202 protein, both in the form of the immature 470 amino acid residue protein (SEQ ID NO: 67) and in the form of the mature 451 amino acid residue protein (SEQ ID NO: 43).
- Mature human or murine TANGO 202 proteins can be synthesized without the signal sequence polypeptide at the amino terminus thereof, or they can be synthesized by generating immature TANGO 202 protein and cleaving the signal sequence therefrom.
- the invention includes fragments, derivatives, and variants of these TANGO 202 proteins, as described herein. These proteins, fragments, derivatives, and variants are collectively referred to herein as polypeptides of the invention or proteins of the invention.
- the invention also includes nucleic acid molecules which encode a polypeptide of the invention.
- nucleic acids include, for example, a DNA molecule having the nucleotide sequence listed in SEQ ID NO: 1 or some portion thereof or SEQ ID NO: 67 or some portion thereof, such as the portion which encodes mature human or murine TANGO 202 protein, immature human or murine TANGO 202 protein, or a domain of human or murine TANGO 202 protein.
- SEQ ID NO: 1 or some portion thereof or SEQ ID NO: 67 or some portion thereof such as the portion which encodes mature human or murine TANGO 202 protein, immature human or murine TANGO 202 protein, or a domain of human or murine TANGO 202 protein.
- These nucleic acids are collectively referred to as nucleic acids of the invention.
- TANGO 202 proteins and nucleic acid molecules encoding them comprise a family of molecules having certain conserved structural and functional features.
- family is intended to mean two or more proteins or nucleic acid molecules having a common or similar domain structure and having sufficient amino acid or nucleotide sequence identity as defined herein.
- Family members can be from either the same or different species (e.g., human and mouse, as described herein).
- a family can comprise two or more proteins of human origin, or can comprise one or more proteins of human origin and one or more of non-human origin.
- a common domain present in TANGO 202 proteins is a signal sequence.
- a signal sequence includes a peptide of at least about 10 amino acid residues in length which occurs at the amino terminus of membrane-bound and secreted proteins and which contains at least about 45% hydrophobic amino acid residues such as alanine, leucine, isoleucine, phenylalanine, proline, tyrosine, tryptophan, or valine.
- a signal sequence contains at least about 10 to 35 amino acid residues, preferably about 10 to 20 amino acid residues, and has at least about 35-60%, more preferably 40-50%, and more preferably at least about 45% hydrophobic residues.
- a signal sequence serves to direct a protein containing such a sequence to a lipid bilayer.
- a TANGO 202 protein contains a signal sequence corresponding to amino acid residues 1 to 19 of SEQ ID NO: 3 (SEQ ID NO: 4) or to amino acid residues 1 to 19 of SEQ ID NO: 69 (SEQ ID NO: 42). The signal sequence is cleaved during processing of the mature protein.
- TANGO 202 proteins can also include an extracellular domain.
- an “extracellular domain” refers to a portion of a protein which is localized to the non-cytoplasmic side of a lipid bilayer of a cell when a nucleic acid encoding the protein is expressed in the cell.
- the human TANGO 202 protein extracellular domain is located from about amino acid residue 20 to about amino acid residue 392 of SEQ ID NO: 3 in the non-secreted form, and from about amino acid residue 20 to amino acid residue 475 of SEQ ID NO: 3 (i.e., the entire mature human protein).
- the murine TANGO 202 protein extracellular domain is located from about amino acid residue 20 to amino acid residue 470 of SEQ ID NO: 69 (i.e., the entire mature murine protein).
- TANGO 202 proteins of the invention can also include a transmembrane domain.
- a “transmembrane domain” refers to an amino acid sequence having at least about 20 to 25 amino acid residues in length and which contains at least about 65-70% hydrophobic amino acid residues such as alanine, leucine, phenylalanine, protein, tyrosine, tryptophan, or valine.
- a transmembrane domain contains at least about 15 to 30 amino acid residues, preferably about 20-25 amino acid residues, and has at least about 60-80%, more preferably 65-75%, and more preferably at least about 70% hydrophobic residues.
- a TANGO 202 protein of the invention contains a transmembrane domain corresponding to about amino acid residues 393 to 415 of SEQ ID NO: 3 (SEQ ID NO: 7).
- TANGO 202 proteins of the invention can include a cytoplasmic domain, particularly including a carboxyl-terminal cytoplasmic domain.
- a “cytoplasmic domain” refers to a portion of a protein which is localized to the cytoplasmic side of a lipid bilayer of a cell when a nucleic acid encoding the protein is expressed in the cell.
- the cytoplasmic domain is located from about amino acid residue 416 to amino acid residue 475 of SEQ ID NO: 3 (SEQ ID NO: 8) in the non-secreted form of human TANGO 202 protein.
- TANGO 202 proteins typically comprise a variety of potential post-translational modification sites (often within an extracellular domain), such as those described herein in Tables I (for human TANGO 202) and II (for murine TANGO 202), as predicted by computerized sequence analysis of TANGO 202 proteins using amino acid sequence comparison software (comparing the amino acid sequence of TANGO 202 with the information in the PROSITE database ⁇ rel. 12.2; February, 1995 ⁇ and the Hidden Markov Models database ⁇ Rel. PFAM 3.3 ⁇ ).
- post-translational modification site refers to a protein domain that includes about 3 to 10 amino acid residues, more preferably about 3 to 6 amino acid residues wherein the domain has an amino acid sequence which comprises a consensus sequence which is recognized and modified by a protein-modifying enzyme.
- exemplary protein-modifying enzymes include amino acid glycosylases, cAMP- and cGMP-dependent protein kinases, protein kinase C, casein kinase II, myristoylases, and prenyl transferases.
- the protein of the invention has at least 1, 2, 4, 6, 10, 15, or 20 or more of the post-translational modification sites described herein in Tables I and II.
- Exemplary additional domains present in human and murine TANGO 202 protein include Kringle domains and CUB domains.
- the protein of the invention has at least one domain that is at least 55%, preferably at least about 65%, more preferably at least about 75%, yet more preferably at least about 85%, and most preferably at least about 95% identical to one of the domains described herein in Tables I and II.
- the protein of the invention has at least one Kringle domain and one CUB domain.
- Kringle domain has a characteristic profile that has been described in the art (Castellino and Beals (1987) J. Mol. Evol. 26:358-369; Patthy (1985) Cell 41:657-663; Ikeo et al. (1991) FEBS Lett. 287:146-148). Many, but not all, Kringle domains comprise a conserved hexapeptide signature sequence, namely
- the cysteine residue is involved in a disulfide bond.
- Kringle domains are triple-looped, disulfide cross-linked domains found in a varying number of copies in, for example, some serine proteases and plasma proteins. Kringle domains have a role in binding mediators (e.g., membranes, other proteins, or phospholipids) and in regulation of proteolytic activity. Kringle domains have been identified in the following proteins, for example: apolipoprotein A, blood coagulation factor XII (Hageman factor), hepatocyte growth factor (HGF), HGF-like protein (Friezner Degen et al., (1991) Biochemistry 30:9781-9791), HGF activator (Miyazawa et al., (1993) J.
- apolipoprotein A blood coagulation factor XII (Hageman factor), hepatocyte growth factor (HGF), HGF-like protein
- HGF activator Miyazawa et al., (1993) J.
- TANGO 202 is involved in one or more physiological processes in which these other Kringle domain-containing proteins are involved, has biological activity in common with one or more of these other Kringle domain-containing proteins, or both.
- CUB domains are extracellular domains of about 110 amino acid residues which occur in functionally diverse, mostly developmentally regulated proteins (Bork and Beckmann (1993) J. Mol. Biol. 231:539-545; Bork (1991) FEBS Lett. 282:9-12). Many CUB domains contain four conserved cysteine residues, although some, like that of TANGO 202, contain only two of the conserved cysteine residues. The structure of the CUB domain has been predicted to assume a beta-barrel configuration, similar to that of immunoglobulins.
- CUB domains include, for example, mammalian complement sub-components Cls and Clr, hamster serine protease Casp, mammalian complement activating component of Ra-reactive factor, vertebrate enteropeptidase, vertebrate bone morphogenic protein 1, sea urchin blastula proteins BP10 and SpAN, Caenorhabditis elegans hypothetical proteins F42A10.8 and R151.5, neuropilin (A5 antigen), sea urchin fibropellins I and III, mammalian hyaluronate-binding protein TSG-6 (PS4), mammalian spermadhesins, and Xenopus embryonic protein UVS.2.
- mammalian complement sub-components Cls and Clr hamster serine protease Casp
- mammalian complement activating component of Ra-reactive factor mammalian complement activating component of Ra-reactive factor
- vertebrate enteropeptidase vertebrate bone
- TANGO 202 is involved in one or more physiological processes in which these other CUB domain-containing proteins are involved, has biological activity in common with one or more of these other CUB domain-containing proteins, or both.
- the signal peptide prediction program SIGNALP (Nielsen et al. (1997) Protein Engineering 10:1-6) predicted that human TANGO 202 protein includes a 19 amino acid signal peptide (amino acid residues 1 to 19 of SEQ ID NO: 3; SEQ ID NO: 4) preceding the mature TANGO 202 protein (amino acid residues 20 to 475 of SEQ ID NO: 3; SEQ ID NO: 5).
- Human TANGO 202 protein includes an extracellular domain (amino acid residues 20 to 392 of SEQ ID NO: 3; SEQ ID NO: 6); a transmembrane domain (amino acid residues 393 to 415 of SEQ ID NO: 3; SEQ ID NO: 7); and a cytoplasmic domain (amino acid residues 416 to 475 of SEQ ID NO: 3; SEQ ID NO: 8).
- the murine homolog of TANGO 202 protein is predicted to be a secreted protein.
- human TANGO 202 can also exist in the form of a secreted protein, likely being translated from an alternatively spliced TANGO 202 mRNA.
- an extracellular portion of TANGO 202 protein (e.g., amino acid residues 20 to 392 of SEQ ID NO: 3) can be cleaved from the mature protein to generate a soluble fragment of TANGO 202.
- FIG. 1L depicts a hydrophilicity plot of human TANGO 202 protein. Relatively hydrophobic regions are above the dashed horizontal line, and relatively hydrophilic regions are below the dashed horizontal line.
- the hydrophobic region which corresponds to amino acid residues 1 to 19 of SEQ ID NO: 3 is the signal sequence of human TANGO 202 (SEQ ID NO: 4).
- the hydrophobic region which corresponds to amino acid residues 393 to 415 of SEQ ID NO: 3 is the transmembrane domain of human TANGO 202 (SEQ ID NO: 7).
- relatively hydrophilic regions are generally located at or near the surface of a protein, and are more frequently effective immunogenic epitopes than are relatively hydrophobic regions.
- the region of human TANGO 202 protein from about amino acid residue 61 to about amino acid residue 95 appears to be located at or near the surface of the protein, while the region from about amino acid residue 395 to about amino acid residue 420 appears not to be located at or near the surface.
- the predicted molecular weight of human TANGO 202 protein without modification and prior to cleavage of the signal sequence is about 51.9 kilodaltons.
- the predicted molecular weight of the mature human TANGO 202 protein without modification and after cleavage of the signal sequence is about 50.1 kilodaltons.
- the full length of the cDNA encoding murine TANGO 202 protein (FIG. 1; SEQ ID NO: 67) is 4928 nucleotide residues.
- the signal peptide prediction program SIGNALP (Nielsen et al. (1997) Protein Engineering 10:1-6) predicted that murine TANGO 202 protein includes a 19 amino acid signal peptide (amino acid residues 1 to 19 of SEQ ID NO: 69; SEQ ID NO: 42) preceding the mature TANGO 202 protein (amino acid residues 20 to 470 of SEQ ID NO: 69; SEQ ID NO: 43).
- Murine TANGO 202 protein is a secreted protein.
- FIG. 1M depicts a hydrophilicity plot of murine TANGO 202 protein. Relatively hydrophobic regions are above the dashed horizontal line, and relatively hydrophilic regions are below the dashed horizontal line.
- the hydrophobic region which corresponds to amino acid residues 1 to 19 of SEQ ID NO: 69 is the signal sequence of murine TANGO 202 (SEQ ID NO: 42).
- relatively hydrophilic regions are generally located at or near the surface of a protein, and are more frequently effective immunogenic epitopes than are relatively hydrophobic regions.
- the region of murine TANGO 202 protein from about amino acid residue 61 to about amino acid residue 95 appears to be located at or near the surface of the protein, while the region from about amino acid residue 295 to about amino acid residue 305 appears not to be located at or near the surface
- the predicted molecular weight of murine TANGO 202 protein without modification and prior to cleavage of the signal sequence is about 51.5 kilodaltons.
- the predicted molecular weight of the mature murine TANGO 202 protein without modification and after cleavage of the signal sequence is about 49.7 kilodaltons.
- FIGS. 1J and 1K depict an aligmnent of human and murine TANGO 202 amino acid sequences (SEQ ID NOs: 3 and 69, respectively).
- SEQ ID NOs: 3 and 69 depict an aligmnent of human and murine TANGO 202 amino acid sequences.
- the proteins are 76.5% identical.
- the human and murine ORFs encoding TANGO 202 are 87.4% identical, as assessed using the same software and parameters.
- TANGO 202 proteins are involved in disorders which affect both tissues in which they are normally expressed and tissues in which they are normally not expressed. Based on the observation that TANGO 202 is expressed in human fetal skin, ubiquitously in fetal mouse tissues, in adult murine bone marrow stromal cells, and in cells of adult murine bladder, renal glomeruli, brain, heart, liver, spleen and placenta, TANGO 202 protein is involved in one or more biological processes which occur in these tissues. In particular, TANGO 202 is involved in modulating growth, proliferation, survival, differentiation, and activity of cells of these tissues including, but not limited to, hematopoietic and fetal cells.
- TANGO 202 has a role in disorders which affect these cells and their growth, proliferation, survival, differentiation, and activity. Ubiquitous expression of TANGO 202 in fetal murine tissues, contrasted with limited expression in adult murine tissues further indicates that TANGO 202 is involved in disorders in which it is inappropriately expressed (e.g., disorders in which TANGO 202 is expressed in adult murine tissues other than bone marrow stromal cells and disorders in which TANGO 202 is not expressed in one or more developing fetal tissues).
- a Kringle domain in both the murine and human TANGO 202 proteins indicates that this protein is involved in modulating cellular binding to one or more mediators (e.g., proteins, phospholipids, intracellular organelles, or other cells), in modulating proteolytic activity, or both.
- mediators e.g., proteins, phospholipids, intracellular organelles, or other cells
- proteolytic activity e.g., proteolytic activity, or both.
- the presence of a Kringle domain in other proteins indicates activities that these proteins share with TANGO 202 protein (e.g., modulating cell dissociation and migration into and through extracellular matrices).
- TANGO 202 is involved in disorders relating to aberrant cellular protease activity, inappropriate interaction or non-interaction of cells with mediators, and in blood and hematopoietic cell-related disorders.
- disorders include, by way of example and not limitation, immune disorders, infectious diseases, auto-immune disorders, vascular and cardiovascular disorders, disorders related to mal-expression of growth factors, cancers, hematological disorders, and the like.
- the cDNA encoding TANGO 202 exhibits significant nucleotide sequence similarity with a polynucleotide encoding a kringle-domain-containing protein (designated HTHBZ47) described in the European Patent Application No. EP 0 911 399 A2 (published Apr. 28, 1999).
- HTHBZ47 a polynucleotide encoding a kringle-domain-containing protein
- the TANGO 202 protein can exhibit one or more of the activities exhibited by HTHBZ47, and can be used to prevent, inhibit, diagnose, and treat one or more disorders for which HTHBZ47 is useful.
- disorders include cancer, inflammation, autoimmune disorders, allergic disorders, asthma, rheumatoid arthritis, inflammation of central nervous system tissues, cerebellar degeneration, Alzheimer's disease, Parkinson's disease, multiple sclerosis, amylotrophic lateral sclerosis, head injury damage and other neurological abnormalities, septic shock, sepsis, stroke, osteoporosis, osteoarthritis, ischemic reperfusion injury, cardiovascular disease, kidney disease, liver disease, ischemic injury, myocardial infarction, hypotension, hypertension, AIDS, myelodysplastic syndromes and other hematologic abnormalities, aplastic anemia, male pattern baldness, and bacterial, fungal, protozoan, and viral infections.
- TANGO 202 protein has a role in disorders which involve inappropriate developmental processes (e.g., abnormally high proliferation or un-differentiation of a differentiated tissue or abnormally low differentiation or proliferation of a non-developed or non-differentiated tissue) and modulation of cell growth, proliferation, survival, differentiation, and activity.
- disorders include, by way of example and not limitation, various cancers and birth and developmental defects.
- proteins and nucleic acids of the invention which are identical to, similar to, or derived from human and murine TANGO 202 proteins and nucleic acids encoding them are useful for preventing, diagnosing, and treating, among others, vascular and cardiovascular disorders, hematological disorders, disorders related to mal-expression of growth factors, and cancer.
- Other uses for these proteins and nucleic acids of the invention relate to modulating cell growth (e.g., angiogenesis), proliferation (e.g., cancers), survival (e.g., apoptosis), differentiation (e.g., hematopoiesis), and activity (e.g., ligand-binding capacity).
- TANGO 202 proteins and nucleic acids encoding them are also useful for modulating cell dissociation and modulating migration of cells in extracellular matrices.
- a cDNA clone (designated jthsa104d11) encoding at least a portion of human TANGO 234 protein was isolated from a human fetal spleen cDNA library.
- the human TANGO 234 protein is predicted by structural analysis to be a transmembrane protein, although it can exist in a secreted form as well.
- the full length of the cDNA encoding human TANGO 234 protein (FIG. 2; SEQ ID NO: 9) is 4628 nucleotide residues.
- the invention thus includes purified human TANGO 234 protein, both in the form of the immature 1453 amino acid residue protein (SEQ ID NO: 11) and in the form of the mature 1413 amino acid residue protein (SEQ ID NO: 13).
- Mature human TANGO 234 protein can be synthesized without the signal sequence polypeptide at the amino terminus thereof, or it can be synthesized by generating immature TANGO 234 protein and cleaving the signal sequence therefrom.
- the invention includes fragments, derivatives, and variants of these TANGO 234 proteins, as described herein. These proteins, fragments, derivatives, and variants are collectively referred to herein as polypeptides of the invention or proteins of the invention.
- the invention also includes nucleic acid molecules which encode a polypeptide of the invention.
- nucleic acids include, for example, a DNA molecule having the nucleotide sequence listed in SEQ ID NO: 9 or some portion thereof, such as the portion which encodes mature TANGO 234 protein, immature TANGO 234 protein, or a domain of TANGO 234 protein. These nucleic acids are collectively referred to as nucleic acids of the invention.
- TANGO 234 proteins and nucleic acid molecules encoding them comprise a family of molecules having certain conserved structural and functional features, as indicated by the conservation of amino acid sequence between human TANGO 234 protein and bovine WC1 protein, as shown in FIGS. 2K through 2P, and the conservation of nucleotide sequence between the ORFs encoding human TANGO 234 protein and bovine WC1 protein, as shown in FIGS. 2 Q- 1 through 2 Q- 17 .
- a common domain present in TANGO 234 proteins is a signal sequence.
- a signal sequence includes a peptide of at least about 10 amino acid residues in length which occurs at the amino terminus of membrane-bound proteins and which contains at least about 45% hydrophobic amino acid residues such as alanine, leucine, isoleucine, phenylalanine, proline, tyrosine, tryptophan, or valine.
- a signal sequence contains at least about 10 to 35 amino acid residues, preferably about 10 to 20 amino acid residues, and has at least about 35-60%, more preferably 40-50%, and more preferably at least about 45% hydrophobic residues.
- a signal sequence serves to direct a protein containing such a sequence to a lipid bilayer.
- a TANGO 234 protein contains a signal sequence corresponding to amino acid residues 1 to 40 of SEQ ID NO: 11 (SEQ ID NO: 12). The signal sequence is cleaved during processing of the mature protein.
- TANGO 234 proteins can include an extracellular domain.
- the human TANGO 234 protein extracellular domain is located from about amino acid residue 41 to about amino acid residue 1359 of SEQ ID NO: 3.
- TANGO 234 can alternately exist in a secreted form, such as a mature protein having the amino acid sequence of amino acid residues 41 to 1453 or residues 41 to about 1359 of SEQ ID NO: 11.
- TANGO 234 include a transmembrane domain.
- a TANGO 234 protein of the invention contains a transmembrane domain corresponding to about amino acid residues 1360 to 1383 of SEQ ID NO: 11 (SEQ ID NO: 15).
- the present invention includes TANGO 234 proteins having a cytoplasmic domain, particularly including proteins having a carboxyl-terminal cytoplasmic domain.
- the human TANGO 234 cytoplasmic domain is located from about amino acid residue 1384 to amino acid residue 1453 of SEQ ID NO: 11 (SEQ ID NO: 16).
- TANGO 234 proteins typically comprise a variety of potential post-translational modification sites (often within an extracellular domain), such as those described herein in Table IV, as predicted by computerized sequence analysis of TANGO 234 proteins using amino acid sequence comparison software (comparing the amino acid sequence of TANGO 234 with the information in the PROSITE database ⁇ rel. 12.2; February, 1995 ⁇ and the Hidden Markov Models database ⁇ Rel. PFAM 3.3 ⁇ ).
- a protein of the invention has at least 1, 2, 4, 6, 10, 15, or 20 or more of the post-translational modification sites listed in Table IV.
- the protein of the invention has at least one domain that is at least 55%, preferably at least about 65%, more preferably at least about 75%, yet more preferably at least about 85%, and most preferably at least about 95% identical to one of these domains.
- the protein has at least two of the SRR and SRCR domains described herein in Table IV.
- the protein has at least one SRR domain and at least one SRCR domain.
- the SRR domain is named after a receptor domain identified in a sea urchin egg protein designated speract.
- the consensus sequence of this domain (using standard one-letter amino acid codes, wherein X is any amino acid residue) is as follows.
- Speract is a transmembrane glycoprotein of 500 amino acid residues (Dangott et al. (1989) Proc. Natl. Acad. Sci. USA 86:2128-2132). Structurally, this receptor consists of a large extracellular domain of 450 residues, followed by a transmembrane region and a small cytoplasmic domain of 12 amino acid residues. The extracellular domain contains four repeats of an approximately 115 amino acid domain. There are 17 amino acid residues that are perfectly conserved in the four repeats in speract, including six cysteine residues, six glycine residues, and two glutamate residues.
- TANGO 234 has five SRR domains, in which 16 of the 17 conserved speract residues are present of four of the SRR domains and 15 are present in the remaining SRR domain. This domain is designated the speract receptor repeated domain.
- the amino acid sequence of mammalian macrophage scavenger receptor type I (MSRI) exhibits such a domain (Freeman et al. (1990) Proc. Natl. Acad. Sci. USA 87:8810-8814).
- MSRI proteins are membrane glycoproteins implicated in the pathologic deposition of cholesterol in arterial walls during atherogenesis.
- TANGO 234 is involved in one or more physiological processes related to cholesterol deposition and atherogenesis, as well as other vascular and cardiovascular disorders.
- SRCR domains are disulfide rich extracellular domains which are present in certain cell surface and secreted proteins. Proteins having SRCR domains exhibit diverse ligand binding specificity. For example, in addition to modified lipoproteins, some of these proteins bind a variety of surface components of pathogenic microorganisms, and some of the proteins bind apoptotic cells. SRCR domains are also involved in mediating immune development and response.
- SRCR-containing proteins are involved in binding of modified lipoproteins (e.g., oxidized low density lipoprotein ⁇ LDL ⁇ ) by specialized macrophages, leading to the formation of macrophages filled with cholesteryl ester droplets (i.e., foam cells).
- TANGO 234 is involved in one or more physiological processes in which these other SRCR domain-containing proteins are involved, such as LDL uptake and metabolism, regulation of serum cholesterol level, atherogenesis, atherosclerosis, bacterial or viral infections, immune development, and generation and perseverance of immune responses.
- WC1 is a ruminant protein having an SRCR domain.
- WC1 and gamma delta T-cell receptor are the only known gamma delta T-cell specific antigens.
- Antibodies which bind specifically with WC1 induce growth arrest in IL-2-dependent gamma delta T-cell and augment proliferation of gamma delta T-cells in an autologous mixed lymphocyte reaction or in the presence of anti-CD2 or anti-CD5 antibodies. Injection of antibodies which bind specifically with WC1 into calves results in long-lasting depletion of gamma delta T-cells.
- antibodies which bind specifically with WC1 can be used to purify gamma delta T-cells.
- Gamma delta T-cells are involved in a variety of physiological processes. For example, these cells are potential mediators of allergic airway inflammation and lyme disease. Furthermore, these cells are involved in natural resistance to viral infections and can mediate autoimmune diseases. Elimination of gamma delta T-cells by injection of antibodies which bind specifically therewith can affect the outcomes of these disorders.
- TANGO 234 is likely the human orthologue of ruminant protein WC1, and thus is involved with the physiological processes described above in humans.
- An alignment of the amino acid sequences of (human) TANGO 234 and bovine WC1 protein is shown in FIGS. 2 K- 2 P. In this alignment (made using the ALIGN software ⁇ Myers and Miller (1989) CABIOS, ver. 2.0 ⁇ ; pam120.mat scoring matrix; gap penalties ⁇ 12/ ⁇ 4), the proteins are 40.4% identical.
- An alignment of the nucleotide sequences of the ORFs encoding (human) TANGO 234 and bovine WC1 protein is shown in FIGS. 2 Q- 1 to 2 Q- 17 . The two ORFs are 54.3% identical, as assessed using the same software and parameters.
- the signal peptide prediction program SIGNALP (Nielsen et al. (1997) Protein Engineering 10:1-6) predicted that human TANGO 234 protein includes a 40 amino acid signal peptide (amino acid residues 1 to 40 of SEQ ID NO: 11; SEQ ID NO: 12) preceding the mature TANGO 234 protein (amino acid residues 41 to 4386 of SEQ ID NO: 11; SEQ ID NO: 13).
- Human TANGO 234 protein includes an extracellular domain (amino acid residues 41 to 1359 of SEQ ID NO: 11; SEQ ID NO: 14); a transmembrane domain (amino acid residues 1360 to 1383 of SEQ ID NO: 11; SEQ ID NO: 15); and a cytoplasmic domain (amino acid residues 1384 to 1453 of SEQ ID NO: 11; SEQ ID NO: 16).
- FIG. 2J depicts a hydrophilicity plot of human TANGO 234 protein. Relatively hydrophobic regions are above the dashed horizontal line, and relatively hydrophilic regions are below the dashed horizontal line.
- the hydrophobic region which corresponds to amino acid residues 1 to 40 of SEQ ID NO: 11 is the signal sequence of human TANGO 234 (SEQ ID NO: 12).
- the hydrophobic region which corresponds to amino acid residues 1360 to 1383 of SEQ ID NO: 11 is the transmembrane domain of human TANGO 234 (SEQ ID NO: 15).
- relatively hydrophilic regions are generally located at or near the surface of a protein, and are more frequently effective immunogenic epitopes than are relatively hydrophobic regions.
- the region of human TANGO 234 protein from about amino acid residue 225 to about amino acid residue 250 appears to be located at or near the surface of the protein, while the region from about amino acid residue 990 to about amino acid residue 1000 appears not to be located at or near the surface.
- the predicted molecular weight of human TANGO 234 protein without modification and prior to cleavage of the signal sequence is about 159.3 kilodaltons.
- the predicted molecular weight of the mature human TANGO 234 protein without modification and after cleavage of the signal sequence is about 154.7 kilodaltons.
- Chromosomal mapping to identify the location of the gene encoding human TANGO 234 protein indicated that the gene was located at chromosomal location h12p13 (with synteny to mo6). Flanking chromosomal markers include WI-6980 and GATA8A09.43. Nearby human loci include IBD2 (inflammatory bowel disease 2), FPF (familial periodic fever), and HPDR2 (hypophosphatemia vitamin D resistant rickets 2). Nearby genes are KLRC (killer cell receptor cluster), DRPLA (dentatorubro-pallidoluysian atrophy), GAPD (glyceraldehyde-3-phosphate) dehydrogenase, and PXR1 (peroxisome receptor 1).
- Murine chromosomal mapping indicated that the murine orthologue is located near the scr (scruffy) locus.
- Nearby mouse genes include drpla (dentatorubral phillidoluysian atrophy), prp (proline rich protein), and kap (kidney androgen regulated protein).
- TANGO 234 proteins are involved in disorders which affect both tissues in which they are normally expressed and tissues in which they are normally not expressed. Based on the observation that TANGO 234 is expressed in human fetal lung, spleen, and, to a lesser extent in adult lung and thymus tissue, TANGO 234 protein is involved in one or more biological processes which occur in these tissues. In particular, TANGO 234 is involved in modulating growth, proliferation, survival, differentiation, and activity of cells including, but not limited to, lung, spleen, thymus bone marrow, hematopoietic, peripheral blood leukocytes, and fetal cells of the animal in which it is normally expressed.
- TANGO 234 has a role in disorders which affect these cells and their growth, proliferation, survival, differentiation, and activity. Expression of TANGO 234 in an animal is also involved in modulating growth, proliferation, survival, differentiation, and activity of cells and viruses which are foreign to the host (i.e., bacterial, fungal, and viral infections).
- TANGO 234 Homology of human TANGO 234 with bovine WC1 protein indicates that TANGO 234 has physiological functions in humans analogous to the functions of WC1 in ruminants.
- TANGO 234 is involved in modulating growth, proliferation, survival, differentiation, and activity of gamma delta T cells.
- TANGO 234 affects the ability of gamma delta T cells to interact with chemokines such as interleukin-2.
- TANGO 234 therefore is involved in the physiological processes associated with allergic airway inflammation, lyme arthritis, resistance to viral infection, auto-immune diseases, and the like.
- TANGO 234 is involved in physiological functions identical or analogous to the functions performed by other proteins having such domains.
- SRR domain-containing proteins TANGO 234 modulates cholesterol deposition in arterial walls, and is thus involved in development and persistence of atherogenesis and arteriosclerosis, as well as other vascular and cardiovascular disorders.
- TANGO 234 is involved in uptake and metabolism of LDL, regulation of serum cholesterol level, and can modulate these processes as well as the processes of atherogenesis, arteriosclerosis, immune development, and generation and perseverance of immune responses to bacterial, fungal, and viral infections.
- a cDNA clone (designated jthsa079g01) encoding at least a portion of human TANGO 265 protein was isolated from a human fetal spleen cDNA library.
- the human TANGO 265 protein is predicted by structural analysis to be a transmembrane membrane protein, although it can exist in a secreted form as well.
- the full length of the cDNA encoding human TANGO 265 protein (FIG. 3; SEQ ID NO: 17) is 3104 nucleotide residues.
- the invention thus includes purified TANGO 265 protein, both in the form of the immature 761 amino acid residue protein (SEQ ID NO: 19) and in the form of the mature 730 amino acid residue protein (SEQ ID NO: 21).
- Mature TANGO 265 protein can be synthesized without the signal sequence polypeptide at the amino terminus thereof, or it can be synthesized by generating immature TANGO 265 protein and cleaving the signal sequence therefrom.
- the invention includes fragments, derivatives, and variants of TANGO 265 protein, as described herein. These proteins, fragments, derivatives, and variants are collectively referred to herein as polypeptides of the invention or proteins of the invention.
- the invention also includes nucleic acid molecules which encode a polypeptide of the invention.
- nucleic acids include, for example, a DNA molecule having the nucleotide sequence listed in SEQ ID NO: 17 or some portion thereof, such as the portion which encodes mature TANGO 265 protein, immature TANGO 265 protein, or a domain of TANGO 265 protein. These nucleic acids are collectively referred to as nucleic acids of the invention.
- TANGO 265 proteins and nucleic acid molecules encoding them comprise a family of molecules having certain conserved structural and functional features.
- a common domain present in TANGO 265 proteins is a signal sequence.
- a signal sequence includes a peptide of at least about 10 amino acid residues in length which occurs at the amino terminus of membrane-bound proteins and which contains at least about 45% hydrophobic amino acid residues such as alanine, leucine, isoleucine, phenylalanine, proline, tyrosine, tryptophan, or valine.
- a signal sequence contains at least about 10 to 35 amino acid residues, preferably about 10 to 20 amino acid residues, and has at least about 35-60%, more preferably 40-50%, and more preferably at least about 45% hydrophobic residues.
- a signal sequence serves to direct a protein containing such a sequence to a lipid bilayer.
- a TANGO 265 protein contains a signal sequence corresponding to amino acid residues 1 to 31 of SEQ ID NO: 19 (SEQ ID NO: 20). The signal sequence is cleaved during processing of the mature protein
- TANGO 265 proteins can also include an extracellular domain.
- the human TANGO 265 protein extracellular domain is located from about amino acid residue 32 to about amino acid residue 683 of SEQ ID NO: 17.
- TANGO 265 can alternately exist in a secreted form, such as a mature protein having the amino acid sequence of amino acid residues 32 to 761 or residues 32 to about 683 of SEQ ID NO: 19.
- TANGO 265 proteins can also include a transmembrane domain.
- a TANGO 265 protein of the invention contains a transmembrane domain corresponding to about amino acid residues 684 to 704 of SEQ ID NO: 19 (SEQ ID NO: 23).
- TANGO 265 proteins include a cytoplasmic domain, particularly including proteins having a carboxyl-terminal cytoplasmic domain.
- the human TANGO 265 cytoplasmic domain is located from about amino acid residue 705 to amino acid residue 761 of SEQ ID NO: 19 (SEQ ID NO: 24).
- TANGO 265 proteins typically comprise a variety of potential post-translational modification sites (often within an extracellular domain), such as those described herein in Table VI, as predicted by computerized sequence analysis of TANGO 265 proteins using amino acid sequence comparison software (comparing the amino acid sequence of TANGO 265 with the information in the PROSITE database ⁇ rel. 12.2; February, 1995 ⁇ and the Hidden Markov Models database ⁇ Rel. PFAM 3.3 ⁇ ).
- a protein of the invention has at least 1, 2, 4, 6, 10, 15, or 20 or more of the post-translational modification sites listed in Table VI.
- an exemplary domains which occurs in TANGO 265 proteins is a sema domain.
- the protein of the invention has at least one domain that is at least 55%, preferably at least about 65%, more preferably at least about 75%, yet more preferably at least about 85%, and most preferably at least about 95% identical to one of the sema domains described herein in Table VI.
- Sema domains occur in semaphorin proteins. Semaphorins are a large family of secreted and transmembrane proteins, some of which function as repellent signals during neural axon guidance. The sema domain and a variety of semaphorin proteins in which it occurs are described, for example, in Winberg et al. (1998 Cell 95:903-916). Sema domains also occur in human hepatocyte growth factor receptor (Swissprot Accession no. P08581) and the similar neuronal and epithelial transmembrane receptor protein (Swissprot Accession no. P51805).
- TANGO 265 is involved in one or more physiological processes in which the semaphorins are involved, has biological activity in common with one or more of the semaphorins, or both.
- FIGS. 3 F- 3 H depict an alignment of the amino acid sequences of human TANGO 265 protein (SEQ ID NO: 19) and murine semaphorin B protein (SEQ ID NO: 76). In this alignment (pam120.mat scoring matrix, gap penalties ⁇ 12/ ⁇ 4), the amino acid sequences of the proteins are 82.3% identical.
- FIGS. 3 F- 3 H depict an alignment of the amino acid sequences of human TANGO 265 protein (SEQ ID NO: 19) and murine semaphorin B protein (SEQ ID NO: 76). In this alignment (pam120.mat scoring matrix, gap penalties ⁇ 12/ ⁇ 4), the amino acid sequences of the proteins are 82.3% identical.
- FIG. 31 through 3T depict an alignment of the nucleotide sequences of cDNA encoding human TANGO 265 protein (SEQ ID NO: 17) and murine cDNA encoding semaphorin B protein (SEQ ID NO: 77).
- this alignment (Pam120.mat scoring matrix, gap penalties ⁇ 12/ ⁇ 4), the nucleic acid sequences of the cDNAs are 76.2% identical.
- TANGO 265 is the human orthologue of murine semaphorin B and shares functional similarities to that protein.
- semaphorins are bi-functional, capable of functioning either as attractive axonal guidance proteins or as repellent axonal guidance proteins (Wong et al. (1997) Development 124:3597-3607). Furthermore, semaphorins bind with neuronal cell surface proteins designated plexins, which are expressed on both neuronal cells and cells of the immune system (Comeau et al. (1998) Immunity 8:473-482; Jin and Strittmatter (1997) J. Neurosci. 17:6256-6263).
- the signal peptide prediction program SIGNALP (Nielsen et al. (1997) Protein Engineering 10:1-6) predicted that human TANGO 265 protein includes a 31 amino acid signal peptide (amino acid residues 1 to 31 of SEQ ID NO: 19; SEQ ID NO: 20) preceding the mature TANGO 265 protein (amino acid residues 32 to 761 of SEQ ID NO: 19; SEQ ID NO: 21).
- Human TANGO 265 protein includes an extracellular domain (amino acid residues 32 to 683 of SEQ ID NO: 19; SEQ ID NO: 22); a transmembrane domain (amino acid residues 684 to 704 of SEQ ID NO: 19; SEQ ID NO: 23); and a cytoplasmic domain (amino acid residues 705 to 761 of SEQ ID NO: 19; SEQ ID NO: 24).
- FIG. 3U depicts a hydrophilicity plot of human TANGO 265 protein. Relatively hydrophobic regions are above the dashed horizontal line, and relatively hydrophilic regions are below the dashed horizontal line.
- the hydrophobic region which corresponds to amino acid residues 1 to 31 of SEQ ID NO: 19 is the signal sequence of human TANGO 265 (SEQ ID NO: 20).
- the hydrophobic region which corresponds to amino acid residues 684 to 704 of SEQ ID NO: 19 is the transmembrane domain of human TANGO 265 (SEQ ID NO: 23).
- relatively hydrophilic regions are generally located at or near the surface of a protein, and are more frequently effective immunogenic epitopes than are relatively hydrophobic regions.
- the region of human TANGO 265 protein from about amino acid residue 350 to about amino acid residue 375 appears to be located at or near the surface of the protein, while the region from about amino acid residue 230 to about amino acid residue 250 appears not to be located at or near the surface.
- the predicted molecular weight of human TANGO 265 protein without modification and prior to cleavage of the signal sequence is about 83.6 kilodaltons.
- the predicted molecular weight of the mature human TANGO 265 protein without modification and after cleavage of the signal sequence is about 80.2 kilodaltons.
- Chromosomal mapping was performed by computerized comparison of TANGO 265 cDNA sequences against a chromosomal mapping database in order to identify the approximate location of the gene encoding human TANGO 265 protein. This analysis indicated that the gene was located on chromosome 1 between markers D1S305 and D1S2635.
- TANGO 265 proteins are involved in disorders which affect both tissues in which they are normally expressed and tissues in which they are normally not expressed. Based on the observation that TANGO 265 is expressed in human fetal spleen, involvement of TANGO 202 protein in immune system development and modulation is indicated.
- TANGO 265 The presence of the sema domain in TANGO 265 indicates that this protein is involved in development of neuronal and epithelial tissues and also functions as a repellant protein which guides axonal development. TANGO 265 modulates nerve growth and regeneration and also modulates growth and regeneration of other epithelial tissues.
- TANGO 265 shares significant identity with murine semaphorin B suggests that it has activity identical or analogous to the activity of this protein. These observations indicate that TANGO 265 modulates growth, proliferation, survival, differentiation, and activity of neuronal cells and immune system cells.
- TANGO 265 protein is useful, for example, for guiding neural axon development, for modulating differentiation of cells of the immune system, for modulating cytokine production by cells of the immune system, for modulating reactivity of cells of the immune system toward cytokines, for modulating initiation and persistence of an inflammatory response, and for modulating proliferation of epithelial cells.
- a cDNA clone (designated jthoc028g06) encoding at least a portion of human TANGO 273 protein was isolated from a lipopolysaccharide-(LPS-)stimulated human osteoblast cDNA library.
- the corresponding murine cDNA clone (designated jtmoa001c04) was isolated from an LPS-stimulated murine osteoblast cDNA library.
- the human and murine TANGO 273 proteins are predicted by structural analysis to be transmembrane proteins.
- the full length of the cDNA encoding human TANGO 273 protein (FIG. 4; SEQ ID NO: 25) is 2964 nucleotide residues.
- the invention thus includes purified human TANGO 273 protein, both in the form of the immature 172 amino acid residue protein (SEQ ID NO: 27) and in the form of the mature 150 amino acid residue protein (SEQ ID NO: 29).
- the invention also includes purified murine TANGO 273 protein, both in the form of the immature 172 amino acid residue protein (SEQ ID NO: 74) and in the form of the mature 150 amino acid residue protein (SEQ ID NO: 44).
- Mature human or murine TANGO 273 proteins can be synthesized without the signal sequence polypeptide at the amino terminus thereof, or they can be synthesized by generating immature TANGO 273 protein and cleaving the signal sequence therefrom.
- the invention includes fragments, derivatives, and variants of these TANGO 273 proteins, as described herein. These proteins, fragments, derivatives, and variants are collectively referred to herein as polypeptides of the invention or proteins of the invention.
- the invention also includes nucleic acid molecules which encode a polypeptide of the invention.
- nucleic acids include, for example, a DNA molecule having the nucleotide sequence listed in SEQ ID NO: 25 or some portion thereof or SEQ ID NO: 73 or some portion thereof, such as the portion which encodes mature TANGO 273 protein, immature TANGO 273 protein, or a domain of TANGO 273 protein. These nucleic acids are collectively referred to as nucleic acids of the invention.
- TANGO 273 proteins and nucleic acid molecules encoding them comprise a family of molecules having certain conserved structural and functional features. This family includes, by way of example, the human and murine TANGO 273 proteins.
- a common domain of TANGO 273 proteins is a signal sequence.
- a signal sequence includes a peptide of at least about 10 amino acid residues in length which occurs at the amino terminus of membrane-bound proteins and which contains at least about 45% hydrophobic amino acid residues such as alanine, leucine, isoleucine, phenylalanine, proline, tyrosine, tryptophan, or valine.
- a signal sequence contains at least about 10 to 35 amino acid residues, preferably about 10 to 20 amino acid residues, and has at least about 35-60%, more preferably 40-50%, and more preferably at least about 45% hydrophobic residues.
- a signal sequence serves to direct a protein containing such a sequence to a lipid bilayer.
- a TANGO 273 protein contains a signal sequence corresponding to amino acid residues 1 to 22 of SEQ ID NO: 27 (SEQ ID NO: 28) or to amino acid residues 1 to 22 of SEQ ID NO: 74.
- the signal sequence is cleaved during processing of the mature protein.
- TANGO 273 proteins can also include an extracellular domain.
- the human TANGO 273 protein extracellular domain is located from about amino acid residue 23 to about amino acid residue 60 of SEQ ID NO: 27, and the murine TANGO 273 protein extracellular domain is located from about amino acid residue 23 to about amino acid residue 60 of SEQ ID NO: 74.
- the present invention also includes TANGO 273 proteins having a transmembrane domain.
- a “transmembrane domain” refers to an amino acid sequence having at least about 15 to 30 amino acid residues in length and which contains at least about 65-70% hydrophobic amino acid residues such as alanine, leucine, phenylalanine, protein, tyrosine, tryptophan, or valine.
- a transmembrane domain contains at least about 15 to 20 amino acid residues, preferably about 20 to 25 amino acid residues, and has at least about 60-80%, more preferably 65-75%, and more preferably at least about 70% hydrophobic residues.
- a human TANGO 273 protein of the invention contains a transmembrane domain corresponding to about amino acid residues 61 to 81 of SEQ ID NO: 27 (SEQ ID NO: 31).
- a murine TANGO 273 protein of the invention contains a transmembrane domain corresponding to about amino acid residues 61 to 81 of SEQ ID NO: 74.
- TANGO 273 proteins include a cytoplasmic domain.
- the human TANGO 273 cytoplasmic domain is located from about amino acid residue 82 to amino acid residue 172 of SEQ ID NO: 27 (SEQ ID NO: 32), and the murine TANGO 273 cytoplasmic domain is located from about amino acid residue 82 to amino acid residue 172 of SEQ ID NO: 74.
- TANGO 273 proteins typically comprise a variety of potential post-translational modification sites (often within an extracellular domain), such as those described herein in Tables VII and VIII, as predicted by computerized sequence analysis of human and murine TANGO 273 proteins using amino acid sequence comparison software (comparing the amino acid sequence of TANGO 273 with the information in the PROSITE database ⁇ rel. 12.2; February, 1995 ⁇ and the Hidden Markov Models database ⁇ Rel. PFAM 3.3 ⁇ ).
- a protein of the invention has at least 1, 2, 3, 4, 5, or all 6 of the post-translational modification sites listed in Table VII.
- the protein of the invention has at least 1, 2, 3, 4, 5, 6, or all 7 of the post-translational modification sites listed in Table VIII.
- TABLE VII Amino Acid Type of Potential Modification Site or Residues of Amino Acid Domain SEQ ID NO: 27 Sequence N-glycosylation site 97 to 100 NVSY Casein kinase II phosphorylation site 41 to 44 SYED N-myristoylation site 31 to 36 GLYPTY 47 to 52 GSRCCV 70 to 75 GVLFCC 131 to 136 GNSMAM Src Homology 3 (SH3) domain binding 86 to 90 YPPPL site 103 to 107 QPPNP 113 to 117 QPGPP 121 to 125 DPGGP 140 to 145 VPPNSP 151 to 155 CPPPP 160 to 164 TPPPP
- the amino acid sequence of TANGO 273 protein includes about seven potential proline-rich Src homology 3 (SH3) domain binding sites nearer the cytoplasmic portion of the protein.
- SH3 domains mediate specific assembly of protein complexes, presumably by interacting with proline-rich protein domains (Morton and Campbell (1994) Curr. Biol. 4:615-617).
- SH3 domains also mediate interactions between proteins involved in transmembrane signal transduction. Coupling of proteins mediated by SH3 domains has been implicated in a variety of physiological systems, including those involving regulation of cell growth and proliferation, endocytosis, and activation of respiratory burst.
- SH3 domains have been described in the art (e.g., Mayer et al. (1988) Nature 332:272-275; Musacchio et al. (1992) FEBS Lett. 307:55-61; Pawson and Schlessinger (1993) Curr. Biol. 3:434-442; Mayer and Baltimore (1993) Trends Cell Biol. 3:8-13; Pawson (1993) Nature 373:573-580), and occur in a variety of cytoplasmic proteins, including several (e.g., protein tyrosine kinases) involved in transmembrane signal transduction.
- cytoplasmic proteins including several (e.g., protein tyrosine kinases) involved in transmembrane signal transduction.
- proteins in which one or more SH3 domains occur are protein tyrosine kinases such as those of the Src, Abl, Bkt, Csk and ZAP70 families, mammalian phosphatidylinositol-specific phospholipases C-gamma-1 and -2, mammalian phosphatidylinositol 3-kinase regulatory p85 subunit, mammalian Ras GTPase-activating protein (GAP), proteins which mediate binding of guanine nucleotide exchange factors and growth factor receptors (e.g., vertebrate GRB2 , Caenorhabditis elegans sem-5, and Drosophila DRK proteins), mammalian Vav oncoprotein, guanidine nucleotide releasing factors of the CDC 25 family (e.g., yeast CDC25, yeast SCD25, and fission yeast ste6 proteins), MAGUK proteins (e.g., mamm
- elegans protein lin-2 rat protein CASK, and mammalian synaptic proteins SAP90/PSD-95, CHAPSYN-110/PSD-93, SAP97/DLG1, and SAP102
- proteins which interact with vertebrate receptor protein tyrosine kinases e.g., mammalian cytoplasmic protein Nck and oncoprotein Crk
- human hemopoietic lineage cell specific protein Hs1 mammalian dihydrouridine-sensitive L-type calcium channel beta subunit
- MSYB mammalian neutrophil cytosolic activators of NADPH oxidase
- NADPH oxidase e.g., p47 ⁇ NCF-1 ⁇ , p67 ⁇ NCF-2 ⁇ , and C.
- myosin heavy chains from amoebae, from slime molds, and from yeast, vertebrate and Drosophila spectrin and fodrin alpha chain proteins, human amphiphysin, yeast actin-binding proteins ABP1 and SLA3, yeast protein BEM 1, fission yeast protein scd2 (ra13), yeast BEM1-binding proteins BOI2 (BEB1) and BOB1 (BOI1), yeast fusion protein FUS1, yeast protein RSV167, yeast protein SSU81, yeast hypothetical proteins YAR014c, YFR024c, YHL002w, YHR016c, YJL020C, and YHR114w, hypothetical fission yeast protein SpAC12C2.05c, and C.
- MYO3 myosin heavy chains
- multiple SH3 domains occur in vertebrate GRB2 protein, C. elegans sem-5 protein, Drosophila DRK protein, oncoprotein Crk, mammalian neutrophil cytosolic activators of NADPH oxidase p47 and p67, yeast protein BEM1, fission yeast protein scd2, yeast hypothetical protein YHR114w, mammalian cytoplasmic protein Nck, C. elegans neutrophil cytosolic activator of NADPH oxidase B0303.7, and yeast actin-binding protein SLA1.
- three or more SH3 domains occur in mammalian cytoplasmic protein Nck, C.
- TANGO 273 interacts with one or more of these and other SH3 domain-containing proteins and is thus involved in physiological processes in which one or more of these or other SH3 domain-containing proteins are involved.
- the signal peptide prediction program SIGNALP (Nielsen et al. (1997) Protein Engineering 10:1-6) predicted that human TANGO 273 protein includes a 22 amino acid signal peptide (amino acid residues 1 to 22 of SEQ ID NO: 27; SEQ ID NO: 28) preceding the mature TANGO 273 protein (amino acid residues 23 to 172 of SEQ ID NO: 27; SEQ ID NO: 29).
- Human TANGO 273 protein includes an extracellular domain (amino acid residues 23 to 60 of SEQ ID NO: 27; SEQ ID NO: 30); a transmembrane domain (amino acid residues 61 to 81 of SEQ ID NO: 27; SEQ ID NO: 31); and a cytoplasmic domain (amino acid residues 82 to 172 of SEQ ID NO: 27; SEQ ID NO: 32).
- FIG. 4I depicts a hydrophilicity plot of human TANGO 273 protein. Relatively hydrophobic regions are above the dashed horizontal line, and relatively hydrophilic regions are below the dashed horizontal line.
- the hydrophobic region which corresponds to amino acid residues 1 to 22 of SEQ ID NO: 27 is the signal sequence of human TANGO 273 (SEQ ID NO: 28).
- the hydrophobic region which corresponds to amino acid residues 61 to 81 of SEQ ID NO: 27 is the transmembrane domain of human TANGO 273 (SEQ ID NO: 31).
- relatively hydrophilic regions are generally located at or near the surface of a protein, and are more frequently effective immunogenic epitopes than are relatively hydrophobic regions.
- the region of human TANGO 273 protein from about amino acid residue 100 to about amino acid residue 120 appears to be located at or near the surface of the protein, while the region from about amino acid residue 130 to about amino acid residue 140 appears not to be located at or near the surface.
- Chromosomal mapping was performed by computerized comparison of TANGO 273 cDNA sequences against a chromosomal mapping database in order to identify the approximate location of the gene encoding human TANGO 273 protein. This analysis indicated that the gene was located on chromosome 7 between markers D7S2467 and D7S2552.
- the predicted molecular weight of human TANGO 273 protein without modification and prior to cleavage of the signal sequence is about 19.2 kilodaltons.
- the predicted molecular weight of the mature human TANGO 273 protein without modification and after cleavage of the signal sequence is about 16.8 kilodaltons.
- the full length of the cDNA encoding murine TANGO 273 protein (FIG. 4; SEQ ID NO: 72) is 2915 nucleotide residues.
- the signal peptide prediction program SIGNALP (Nielsen et al. (1997) Protein Engineering 10:1-6) predicted that murine TANGO 273 protein includes a 22 amino acid signal peptide (amino acid residues 1 to 22 of SEQ ID NO: 74) preceding the mature TANGO 273 protein (amino acid residues 23 to 172 of SEQ ID NO: 74; SEQ ID NO: 44).
- Murine TANGO 273 protein includes an extracellular domain (amino acid residues 23 to 60 of SEQ ID NO: 74); a transmembrane domain (amino acid residues 61 to 81 of SEQ ID NO: 74); and a cytoplasmic domain (amino acid residues 82 to 172 of SEQ ID NO: 74).
- FIG. 4J depicts a hydrophilicity plot of murine TANGO 273 protein. Relatively hydrophobic regions are above the dashed horizontal line, and relatively hydrophilic regions are below the dashed horizontal line.
- the hydrophobic region which corresponds to amino acid residues 1 to 22 of SEQ ID NO: 74 is the signal sequence of murine TANGO 273.
- relatively hydrophilic regions are generally located at or near the surface of a protein, and are more frequently effective immunogenic epitopes than are relatively hydrophobic regions.
- the region of murine TANGO 273 protein from about amino acid residue 100 to about amino acid residue 120 appears to be located at or near the surface of the protein, while the region from about amino acid residue 130 to about amino acid residue 140 appears not to be located at or near the surface.
- the predicted molecular weight of murine TANGO 273 protein without modification and prior to cleavage of the signal sequence is about 19.4 kilodaltons.
- the predicted molecular weight of the mature murine TANGO 273 protein without modification and after cleavage of the signal sequence is about 17.1 kilodaltons.
- TANGO 273 In situ analysis of murine TANGO 273 mRNA indicated that TANGO 273 is expressed with central nervous system (CNS) tissues during embryogenesis and into adulthood. Expression of TANGO 273 is widely observed in murine CNS tissues, including brain, spinal cord, eye, and olfactory epithelium at all embryonic ages examined (i.e., at embryonic days 13.5, 14.5, 15.5, 16.5, and 18.5 and at post-natal day 1.5).
- CNS central nervous system
- Human and murine TANGO 273 cDNA sequences exhibit significant nucleotide sequence identity with an expressed sequence tag (EST) isolated from a library of ESTs corresponding to proteins secreted from prostate tissue, as described in PCT publication number WO 99/06550, published Feb. 11, 1999.
- EST expressed sequence tag
- FIG. 4H depicts an alignment of human and murine TANGO 273 protein amino acid sequences (SEQ ID NOs: 27 and 74, respectively). In this alignment (pam120.mat scoring matrix, gap penalties ⁇ 12/ ⁇ 4), the proteins are 89.5% identical. Alignment of the ORF encoding human TANGO 273 protein and the ORF encoding murine TANGO 273 protein using the same software and parameters indicated that the nucleotide sequences are 84.1% identical.
- cDNAs encoding the human and murine TANGO 273 proteins were each isolated from LPS-stimulated osteoblast cDNA libraries. These proteins are involved in bone-related metabolism, homeostasis, and development disorders.
- proteins and nucleic acids of the invention which are identical to, similar to, or derived from human and murine TANGO 273 proteins and nucleic acids encoding them are useful for preventing, diagnosing, and treating, among others, bone-related disorders such as osteoporosis, cancer, skeletal development disorders, bone fragility, and the like.
- TANGO 273 expression of TANGO 273 in heart, brain, skeletal muscle, and pancreas, placenta, lung, liver, and kidney tissues is an indication that TANGO 273 proteins, nucleic acids encoding them, and agents that modulate activity or expression of either of these can be used to modulate growth, proliferation, survival, differentiation, adhesion, and activity of cells of these tissues, or to prognosticate, diagnose, and treat one or more disorders which affect these tissues.
- TANGO 273 proteins, nucleic acids, and modulators thereof can be used to modulate proliferation, differentiation, or function of neurological cells in these tissues (e.g., neuronal cells).
- TANGO 273 proteins, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, and treat one or more neurological disorders. Examples of such disorders include CNS disorders, CNS-related disorders, focal brain disorders, global-diffuse cerebral disorders, and other neurological and cerebrovascular disorders.
- CNS disorders include, but are not limited to cognitive and neurodegenerative disorders such as Alzheimer's disease, senile dementia, Huntington's disease, amyotrophic lateral sclerosis, and Parkinson's disease, as well as Gilles de la Tourette's syndrome, autonomic function disorders such as hypertension and sleep disorders (e.g., insomnia, hypersomnia, parasomnia, and sleep apnea); neuropsychiatric disorders (e.g., schizophrenia, schizoaffective disorder, attention deficit disorder, dysthymic disorder, major depressive disorder, mania, and obsessive-compulsive disorder); psychoactive substance use disorders; anxiety; panic disorder; and bipolar affective disorders (e.g., severe bipolar affective disorder and bipolar affective disorder with hypomania and major depression).
- cognitive and neurodegenerative disorders such as Alzheimer's disease, senile dementia, Huntington's disease, amyotrophic lateral sclerosis, and Parkinson's disease, as well as Gilles de la Tourette's
- CNS-related disorders include disorders associated with developmental, cognitive, and autonomic neural and neurological processes, such as pain, appetite, long term memory, and short term memory.
- Exemplary focal brain disorders include aphasia, apraxia, agnosia, and amnesias (e.g., posttraumatic amnesia, transient global amnesia, and psychogenic amnesia).
- Global-diffuse cerebral disorders with which TANGO 273 can be associated include coma, stupor, obtundation, and disorders of the reticular formation.
- TANGO 273 Other neurological disorders with which TANGO 273 can be associated include ischemic syndromes (e.g., stroke), hypertensive encephalopathy, hemorrhagic disorders, and disorders involving aberrant function of the blood-brain barrier (e.g., CNS infections such as meningitis and encephalitis, aseptic meningitis, metastasis of non-CNS tumor cells into the CNS, various pain disorders such as migraine, blindness and other vision problems, and CNS-related adverse drug reactions such as head pain, sleepiness, and confusion).
- CNS infections such as meningitis and encephalitis, aseptic meningitis, metastasis of non-CNS tumor cells into the CNS
- various pain disorders such as migraine, blindness and other vision problems
- CNS-related adverse drug reactions such as head pain, sleepiness, and confusion
- TANGO 273 proteins, nucleic acids encoding them, and agents that modulate activity or expression of either of these can be used to prognosticate, diagnose,
- TANGO 273 proteins, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, and treat one or more disorders which involve aberrant fetal neurological development.
- disorders include blindness, deafness, fetal death, mental retardation, dysraphia, anencephaly, malformation of cerebral hemispheres, encephalocele, porencephaly, hydranencephaly, hydrocephalus, and spina bifida.
- TANGO 273 is expressed in tissues which were exposed to LPS indicates that TANGO 273 mediates one or more physiological responses of cells to bacterial infection.
- TANGO 273 is involved in one or more of detection of bacteria in a tissue in which it is expressed, movement of cells with relation to sites of bacterial infection, production of biological molecules which inhibit bacterial infection, and production of biological molecules which alleviate cellular or other physiological damage wrought by bacterial infection.
- TANGO 273 protein mediates binding of proteins (i.e., binding of proteins to TANGO 273 and to one another to form protein complexes) in cells in which it is expressed.
- TANGO 273 is also involved in transduction of signals between the exterior environment of cells (i.e., including from other cells) and the interior of cells in which it is expressed.
- TANGO 273 mediates regulation of cell growth and proliferation, endocytosis, activation of respiratory burst, and other physiological processes triggered by transmission of a signal via a protein with which TANGO 273 interacts.
- TANGO 273 proteins, nucleic acids encoding them, and agents that modulate activity or expression of either of these can be used to treat prostate disorders.
- prostate disorders which can be treated in this manner include inflammatory prostatic diseases (e.g., acute and chronic prostatitis and granulomatous prostatitis), prostatic hyperplasia (e.g., benign prostatic hypertrophy or hyperplasia), and prostate tumors (e.g., carcinomas).
- TANGO 273 polypeptides, nucleic acids, or modulators thereof can be used to treat cardiovascular disorders, such as ischemic heart disease (e.g., angina pectoris, myocardial infarction, and chronic ischemic heart disease), hypertensive heart disease, pulmonary heart disease, valvular heart disease (e.g., rheumatic fever and rheumatic heart disease, endocarditis, mitral valve prolapse, and aortic valve stenosis), congenital heart disease (e.g., valvular and vascular obstructive lesions, atrial or ventricular septal defect, and patent ductus arteriosus), or myocardial disease (e.g., myocarditis, congestive cardiomyopathy, and hypertrophic cardiomyopathy).
- ischemic heart disease e.g., angina pectoris, myocardial infarction, and chronic ischemic heart disease
- hypertensive heart disease e.g., pulmonary heart
- TANGO 273 polypeptides, nucleic acids, or modulators thereof can be used to treat disorders of the brain, such as cerebral edema, hydrocephalus, brain herniations, iatrogenic disease (due to, e.g., infection, toxins, or drugs), inflammations (e.g., bacterial and viral meningitis, encephalitis, and cerebral toxoplasmosis), cerebrovascular diseases (e.g., hypoxia, ischemia, and infarction, intracranial hemorrhage and vascular malformations, and hypertensive encephalopathy), and tumors (e.g., neuroglial tumors, neuronal tumors, tumors of pineal cells, meningeal tumors, primary and secondary lymphomas, intracranial tumors, and medulloblastoma), and to treat injury or trauma to the brain.
- iatrogenic disease due to, e.g., infection, toxins, or drugs
- inflammations e.g.,
- TANGO 273 polypeptides, nucleic acids, or modulators thereof can be used to treat disorders of skeletal muscle, such as muscular dystrophy (e.g., Duchenne muscular dystrophy, Becker muscular dystrophy, Emery-Dreifuss muscular dystrophy, limb-girdle muscular dystrophy, facioscapulohumeral muscular dystrophy, myotonic dystrophy, oculopharyngeal muscular dystrophy, distal muscular dystrophy, and congenital muscular dystrophy), motor neuron diseases (e.g., amyotrophic lateral sclerosis, infantile progressive spinal muscular atrophy, intermediate spinal muscular atrophy, spinal bulbar muscular atrophy, and adult spinal muscular atrophy), myopathies (e.g., inflammatory myopathies such as dermatomyositis and polymyositis, myotonia congenita, paramyotonia congenita, central core disease, nemaline myopathy, myotub
- TANGO 273 polypeptides, nucleic acids, or modulators thereof can be used to treat pancreatic disorders, such as pancreatitis (e.g., acute hemorrhagic pancreatitis and chronic pancreatitis), pancreatic cysts (e.g., congenital cysts, pseudocysts, and benign or malignant neoplastic cysts), pancreatic tumors (e.g., pancreatic carcinoma and adenoma), diabetes mellitus (e.g., insulin- and non-insulin-dependent types, impaired glucose tolerance, and gestational diabetes), or islet cell tumors (e.g., insulinomas, adenomas, Zollinger-Ellison syndrome, glucagonomas, and somatostatinoma).
- pancreatitis e.g., acute hemorrhagic pancreatitis and chronic pancreatitis
- pancreatic cysts e.g., congenital cysts, pseudoc
- TANGO 273 polypeptides, nucleic acids, or modulators thereof can be used to treat placental disorders, such as toxemia of pregnancy (e.g., preeclampsia and eclampsia), placentitis, or spontaneous abortion.
- placental disorders such as toxemia of pregnancy (e.g., preeclampsia and eclampsia), placentitis, or spontaneous abortion.
- TANGO 273 polypeptides, nucleic acids, or modulators thereof can be used to treat pulmonary disorders, such as atelectasis, cystic fibrosis, rheumatoid lung disease, pulmonary congestion or edema, chronic obstructive airway disease (e.g., emphysema, chronic bronchitis, bronchial asthma, and bronchiectasis), diffuse interstitial diseases (e.g., sarcoidosis, pneumoconiosis, hypersensitivity pneumonitis, Goodpasture's syndrome, idiopathic pulmonary hemosiderosis, pulmonary alveolar proteinosis, desquamative interstitial pneumonitis, chronic interstitial pneumonia, fibrosing alveolitis, hamman-rich syndrome, pulmonary eosinophilia, diffuse interstitial fibrosis, Wegener's granulomatosis, lymphomatoid granul
- pulmonary disorders such as
- TANGO 273 polypeptides, nucleic acids, or modulators thereof can be used to treat hepatic (liver) disorders, such as jaundice, hepatic failure, hereditary hyperbilirubinemias (e.g., Gilbert's syndrome, Crigler-Naijar syndromes, and Dubin-Johnson and Rotor's syndromes), hepatic circulatory disorders (e.g., hepatic vein thrombosis and portal vein obstruction and thrombosis) hepatitis (e.g., chronic active hepatitis, acute viral hepatitis, and toxic and drug-induced hepatitis) cirrhosis (e.g., alcoholic cirrhosis, biliary cirrhosis, and hemochromatosis), or malignant tumors (e.g., primary carcinoma, hepatoblastoma, and angiosarcoma).
- hepatic circulatory disorders e.g., hepatic vein thrombo
- TANGO 273 polypeptides, nucleic acids, or modulators thereof can be used to treat renal (kidney) disorders, such as glomerular diseases (e.g., acute and chronic glomerulonephritis, rapidly progressive glomerulonephritis, nephrotic syndrome, focal proliferative glomerulonephritis, glomerular lesions associated with systemic disease such as systemic lupus erythematosus, Goodpasture's syndrome, multiple myeloma, diabetes, neoplasia, sickle cell disease, and chronic inflammatory diseases), tubular diseases (e.g., acute tubular necrosis and acute renal failure, polycystic renal disease, medullary sponge kidney, medullary cystic disease, nephrogenic diabetes, and renal tubular acidosis), tubulointerstitial diseases (e.g., pyelonephritis, drug and toxin induced tubulointerstitial
- a cDNA clone (designated jthkf042e03) encoding at least a portion of human TANGO 286 protein was isolated from a human keratinocyte cDNA library.
- the human TANGO 286 protein is predicted by structural analysis to be a secreted protein.
- the invention thus includes purified TANGO 286 protein, both in the form of the immature 455 amino acid residue protein (SEQ ID NO: 35) and in the form of the mature 432 amino acid residue protein (SEQ ID NO: 37).
- Mature TANGO 286 protein can be synthesized without the signal sequence polypeptide at the amino terminus thereof, or it can be synthesized by generating immature TANGO 286 protein and cleaving the signal sequence therefrom.
- the invention includes fragments, derivatives, and variants of these TANGO 286 proteins, as described herein. These proteins, fragments, derivatives, and variants are collectively referred to herein as polypeptides of the invention or proteins of the invention.
- the invention also includes nucleic acid molecules which encode a polypeptide of the invention.
- nucleic acids include, for example, a DNA molecule having the nucleotide sequence listed in SEQ ID NO: 33 or some portion thereof, such as the portion which encodes mature TANGO 286 protein, immature TANGO 286 protein, or a domain of TANGO 286 protein. These nucleic acids are collectively referred to as nucleic acids of the invention.
- TANGO 286 proteins and nucleic acid molecules encoding them comprise a family of molecules having certain conserved structural and functional features.
- a common domain of TANGO 286 proteins is a signal sequence.
- a signal sequence includes a peptide of at least about 10 amino acid residues in length which occurs at the amino terminus of membrane-bound proteins and which contains at least about 45% hydrophobic amino acid residues such as alanine, leucine, isoleucine, phenylalanine, proline, tyrosine, tryptophan, or valine.
- a signal sequence contains at least about 10 to 35 amino acid residues, preferably about 10 to 20 amino acid residues, and has at least about 35-60%, more preferably 40-50%, and more preferably at least about 45% hydrophobic residues.
- a signal sequence serves to direct a protein containing such a sequence to a lipid bilayer.
- a TANGO 286 protein contains a signal sequence corresponding to amino acid residues 1 to 23 of SEQ ID NO: 35 (SEQ ID NO: 36). The signal sequence is cleaved during processing of the mature protein.
- TANGO 286 is a secreted soluble protein (i.e., a secreted protein having a single extracellular domain), as indicated by computerized sequence analysis and comparison of the amino acid sequence of TANGO 286 with related proteins, such as the soluble proteins designated bactericidal permeability increasing (BPI) protein and recombinant endotoxin neutralizing polypeptide (RENP).
- BPI bactericidal permeability increasing
- RFP recombinant endotoxin neutralizing polypeptide
- TANGO 286 proteins typically comprise a variety of potential post-translational modification sites (often within an extracellular domain), such as those described herein in Table IX, as predicted by computerized sequence analysis of TANGO 286 proteins using amino acid sequence comparison software (comparing the amino acid sequence of TANGO 286 with the information in the PROSITE database ⁇ rel. 12.2; February, 1995 ⁇ and the Hidden Markov Models database ⁇ Rel. PFAM 3.3 ⁇ ).
- a protein of the invention has at least 1, 2, 4, 6, 10, 15, or 20 or more of the post-translational modification sites listed in Table IX.
- lipid-binding serum glycoproteins such as LPS-binding protein (LBP), bactericidal permeability-increasing protein (BPI), cholesteryl ester transfer protein (CETP), and phospholipid transfer protein (PLTP), share regions of sequence similarity which are herein designated a lipid-binding serum glycoprotein domain (Schumann et al., (1990) Science 249:1429-1431; Gray et al., (1989) J. Biol. Chem. 264:9505-9509; Day et al., (1994) J. Biol. Chem. 269:9388-9391).
- LBP LPS-binding protein
- BPI bactericidal permeability-increasing protein
- CETP cholesteryl ester transfer protein
- PLTP phospholipid transfer protein
- Proteins in which a lipid-binding serum glycoprotein domain occurs are often structurally related and exhibit related physiological activities.
- LBP binds to lipid A moieties of bacterial LPS and, once bound thereto, induces secretion of a-tumor necrosis factor, apparently by interacting with the CD14 receptor.
- BPI also binds LPS and exerts a cytotoxic effect on Gram-negative bacteria (Elsbach, (1998) J. Leukoc. Biol. 64:14-18).
- CETP is involved in transfer of insoluble cholesteryl esters during reverse cholesterol transport.
- PLTP appears to be involved in phospholipid transport and modulation of serum HDL particles.
- TANGO 286 protein includes a 23 amino acid signal peptide (amino acid residues 1 to 23 of SEQ ID NO: 35; SEQ ID NO: 36) preceding the mature TANGO 286 protein (amino acid residues 24 to 455 of SEQ ID NO: 35; SEQ ID NO: 37).
- Human TANGO 286 protein is a secreted soluble protein.
- FIG. 5E depicts a hydrophilicity plot of TANGO 286 protein. Relatively hydrophobic regions are above the dashed horizontal line, and relatively hydrophilic regions are below the dashed horizontal line. As described elsewhere herein, relatively hydrophilic regions are generally located at or near the surface of a protein, and are more frequently effective immunogenic epitopes than are relatively hydrophobic regions For example, the region of human TANGO 286 protein from about amino acid residue 420 to about amino acid residue 435 appears to be located at or near the surface of the protein, while the region from about amino acid residue 325 to about amino acid residue 345 appears not to be located at or near the surface.
- the predicted molecular weight of TANGO 286 protein without modification and prior to cleavage of the signal sequence is about 50.9 kilodaltons.
- the predicted molecular weight of the mature TANGO 286 protein without modification and after cleavage of the signal sequence is about 48.2 kilodaltons.
- the gene encoding human TANGO 286 protein was determined to be located on chromosome 22 by comparison of matching genomic clones such as the clones assigned GenBank Accession numbers W16806 and AL021937.
- a portion of TANGO 286 protein exhibits significant amino acid homology with a region of the human chromosome region 22q12-13 genomic nucleotide sequence having GenBank Accession number AL021937. Alignment of a 45 kilobase nucleotide sequence encoding TANGO 286 with AL021937, however, indicated the presence in TANGO 286 of exons which differ from those disclosed in L021937 (pam120.mat scoring matrix; gap penalties ⁇ 12/ ⁇ 4).
- This region of chromosome 22 comprises an immunoglobulin lambda chain C (IGLC) pseudogene, the Ret finger protein-like 3 (RFPL3) and Ret finger protein-like 3 antisense (RFPL3S) genes, a gene encoding a novel immunoglobulin lambda chain V family protein, a novel gene encoding a protein similar both to mouse RGDS protein (RALGDS, RALGEF, guanine nucleotide dissociation stimulator A) and to rabbit oncogene RSC, a novel gene encoding the human orthologue of worm F16A11.2 protein, a novel gene encoding a protein similar both to BPI and to rabbit liposaccharide-binding protein, and a 5′-portion of a novel gene.
- This region also comprises various ESTs, STSs, GSSs, genomic marker D22S1175, a ca repeat polymorphism and putative CpG islands.
- TANGO 286 protein thus shares one or more structural or functional
- TANGO 286 protein exhibits considerable sequence similarity with BPI protein, having 23.9% amino acid sequence identity therewith, as assessed using the ALIGN v. 2.0 computer software using a pam120.mat scoring matrix and gap penalties of ⁇ 12/ ⁇ 4.
- TANGO 286 protein also exhibits considerable sequence similarity with recombinant endotoxin neutralizing polypeptide (RENP), having 24.5% amino acid sequence identity therewith, as assessed using the ALIGN software.
- Physiological activities of BPI protein and RENP have been described (e.g., Gabay et al., (1989) Proc. Natl. Acad. Sci. USA 86:5610-5614; Elsbach, (1998) J. Leukoc. Biol.
- RENP for example, binds LPS and neutralizes bacterial endotoxins.
- BPI, RENP, and other proteins in which a lipid-binding serum glycoprotein domain occurs bind LPS and neutralize bacterial endotoxins, and are therefore useful for preventing, detecting, and treating LPS-related disorders such as shock, disseminated intravascular coagulation, anemia, thrombocytopenia, adult respiratory distress syndrome, renal failure, liver disease, and disorders associated with Gram negative bacterial infections.
- BPI protein is known to be involved in vasculitis and bronchiectasis, in that antibodies which bind specifically with BPI protein are present in at least some patients afflicted with these disorders (Mahadeva et al., supra).
- TANGO 286 in keratinocyte library indicates that this protein is involved in a disorders which involve keratinocytes.
- disorders include, for example, disorders involving extracellular matrix abnormalities, dermatological disorders, ocular disorders, inappropriate hair growth (e.g., baldness), infections of the nails of the fingers and toes, scalp disorders (e.g., dandruff), and the like.
- TANGO 286 protein contains a lipid-binding serum glycoprotein domain indicates that TANGO 286 is involved in one or more physiological processes in which these other lipid-binding serum glycoprotein domain-containing proteins are involved.
- TANGO 286 is involved in one or more of lipid transport, metabolism, serum lipid particle regulation, host anti-microbial defensive mechanisms, and the like.
- Human TANGO 286 shares physiological functionality with other proteins in which a lipid-binding serum glycoprotein domains occurs (e.g., LBP, BPI protein, CETP, and PLTP). Based on the amino acid sequence similarity of TANGO 286 with BPI protein and with RENP, TANGO 286 protein exhibits physiological activities exhibited by these proteins.
- TANGO 286 proteins are useful for preventing, diagnosing, and treating, among others, lipid transport disorders, lipid metabolism disorders, disorders of serum lipid particle regulation, obesity, disorders involving insufficient or inappropriate host anti-microbial defensive mechanisms, vasculitis, bronchiectasis, LPS-related disorders such as shock, disseminated intravascular coagulation, anemia, thrombocytopenia, adult respiratory distress syndrome, renal failure, liver disease, and disorders associated with Gram negative bacterial infections, such as bacteremia, endotoxemia, sepsis, and the like.
- a cDNA clone (designated jthrc145g07) encoding at least a portion of human TANGO 294 protein was isolated from a human pulmonary artery smooth muscle cell cDNA library.
- the human TANGO 294 protein is predicted by structural analysis to be a transmembrane membrane protein. Expression of DNA encoding TANGO 294 was observed, using a variety of methods, in pancreas, lung tumor, stomach, pulmonary artery smooth muscle cells, and colon tumor tissues and in activated peripheral blood mononuclear cells (PBMCs). More detailed expression data is described herein.
- the full length of the cDNA encoding TANGO 294 protein (FIG. 6; SEQ ID NO: 45) is 2044 nucleotide residues.
- the invention includes purified TANGO 294 protein, both in the form of the immature 423 amino acid residue protein (SEQ ID NO: 47) and in the form of the mature 390 amino acid residue protein (SEQ ID NO: 49).
- Mature TANGO 294 protein can be synthesized without the signal sequence polypeptide at the amino terminus thereof, or it can be synthesized by generating immature TANGO 294 protein and cleaving the signal sequence therefrom.
- the invention includes fragments, derivatives, and variants of TANGO 294 protein, as described herein. These proteins, fragments, derivatives, and variants are collectively referred to herein as polypeptides of the invention or proteins of the invention.
- the invention also includes nucleic acid molecules which encode a polypeptide of the invention.
- nucleic acids include, for example, a DNA molecule having the nucleotide sequence listed in SEQ ID NO: 45 or some portion thereof, such as the portion which encodes mature TANGO 294 protein, immature TANGO 294 protein, or a domain of TANGO 294 protein. These nucleic acids are collectively referred to as nucleic acids of the invention.
- TANGO 294 proteins and nucleic acid molecules encoding them comprise a family of molecules having certain conserved structural and functional features.
- TANGO 294 proteins having a signal sequence.
- a signal sequence includes a peptide of at least about 10 amino acid residues in length which occurs at the amino terminus of membrane-bound proteins and which contains at least about 45% hydrophobic amino acid residues such as alanine, leucine, isoleucine, phenylalanine, proline, tyrosine, tryptophan, or valine.
- a signal sequence contains at least about 10 to 35 amino acid residues, preferably about 10 to 20 amino acid residues, and has at least about 35-60%, more preferably 40-50%, and more preferably at least about 45% hydrophobic residues.
- a signal sequence serves to direct a protein containing such a sequence to a lipid bilayer.
- a TANGO 294 protein contains a signal sequence corresponding to amino acid residues 1 to 33 of SEQ ID NO: 47 (SEQ ID NO: 48). The signal sequence is cleaved during processing of the mature protein.
- TANGO 294 protein The naturally-occurring form of TANGO 294 protein is a secreted protein (i.e., not comprising the predicted signal sequence).
- TANGO 294 proteins can be transmembrane proteins which include an extracellular domain.
- the predicted TANGO 294 protein extracellular domain is located from about amino acid residue 34 to about amino acid residue 254 of SEQ ID NO: 47
- the predicted cytoplasmic domain is located from about amino acid residue 280 to amino acid residue 423 of SEQ ID NO: 47 (SEQ ID NO: 52)
- the predicted transmembrane domain is located from about amino acid residues 255 to 279 of SEQ ID NO: 47 (SEQ ID NO: 51).
- TANGO 294 proteins typically comprise a variety of potential post-translational modification sites (often within an extracellular domain), such as those described herein in Table X, as predicted by computerized sequence analysis of TANGO 294 proteins using amino acid sequence comparison software (comparing the amino acid sequence of TANGO 294 with the information in the PROSITE database ⁇ rel. 12.2; February, 1995 ⁇ and the Hidden Markov Models database ⁇ Rel. PFAM 3.3 ⁇ ).
- a protein of the invention has at least 1, 2, 4, 6, 10, 15, or 20 or more of the post-translational modification sites listed in Table X.
- Alpha/beta hydrolase fold domains occur in a wide variety of enzymes (Ollis et al., (1992) Protein Eng. 5:197-211).
- the alpha/beta fold domain is a conserved topological domain in which sequence homology is not necessarily conserved. Conservation of topology in the alpha/beta fold domain preserves arrangement of catalytic residues, even though those residues, and the reactions they catalyze, can vary. In many enzymes, particularly including alpha/beta hydrolases, this domain encompasses the active site of the enzyme.
- the protein of the invention has at least one domain that is at least 55%, preferably at least about 65%, more preferably at least about 75%, yet more preferably at least about 85%, and most preferably at least about 95% identical to the alpha/beta hydrolase fold domain described herein in Table X.
- the signal peptide prediction program SIGNALP (Nielsen et al. (1997) Protein Engineering 10:1-6) predicted that human TANGO 294 protein includes a 33 amino acid signal peptide (amino acid residues 1 to 33 of SEQ ID NO: 47; SEQ ID NO: 48) preceding the mature TANGO 294 protein (amino acid residues 34 to 423 of SEQ ID NO: 47; SEQ ID NO: 49).
- Human TANGO 294 protein is a soluble secreted protein.
- human TANGO 294 protein includes an extracellular domain (amino acid residues 34 to 254 of SEQ ID NO: 47; SEQ ID NO: 50); a transmembrane domain (amino acid residues 255 to 279 of SEQ ID NO: 47; SEQ ID NO: 51); and a cytoplasmic domain (amino acid residues 280 to 423 of SEQ ID NO: 47; SEQ ID NO: 52).
- FIG. 6F depicts a hydrophilicity plot of human TANGO 294 protein. Relatively hydrophobic regions are above the dashed horizontal line, and relatively hydrophilic regions are below the dashed horizontal line.
- the hydrophobic region which corresponds to amino acid residues 1 to 33 of SEQ ID NO: 47 is the signal sequence of human TANGO 294 (SEQ ID NO: 49).
- the hydrophobic region which corresponds to amino acid residues 255 to 279 of SEQ ID NO: 47 is the predicted transmembrane domain of human TANGO 294 (SEQ ID NO: 51).
- relatively hydrophilic regions are generally located at or near the surface of a protein, and are more frequently effective immunogenic epitopes than are relatively hydrophobic regions.
- the region of human TANGO 294 protein from about amino acid residue 130 to about amino acid residue 150 appears to be located at or near the surface of the protein, while the region from about amino acid residue 90 to about amino acid residue 100 appears not to be located at or near the surface.
- the predicted molecular weight of human TANGO 294 protein without modification and prior to cleavage of the signal sequence is about 48.2 kilodaltons.
- the predicted molecular weight of the mature human TANGO 294 protein without modification and after cleavage of the signal sequence is about 44.2 kilodaltons.
- amino acid residues 1 to 15 of SEQ ID NO: 47 do not occur in TANGO 294 protein. However, it is recognized that amino acid residues 16 to 33 of SEQ ID NO: 47 form a functional signal sequence even in the absence of residues 1 to 15. The amino acid sequence (and hence the properties) of mature TANGO 294 protein are unaffected by presence or absence of amino acid residues 1 to 15 of immature TANGO 294 protein.
- Human TANGO 294 protein exhibits considerable sequence similarity (i.e., about 75% amino acid sequence identity) to lingual and gastric lipase proteins of rat (Swissprot Accession no. P04634; Gasterty et al. (1985) Nucleic Acids Res. 13:1891-1903), dog (Swissprot Accession no. P80035; Carriere et al. (1991) Eur. J. Biochem. 202:75-83), and human (Swissprot Accession no. P07098; Bembaeck and Blaeckberg (1987) Biochim. Biophys. Acta 909:237-244), as assessed using the ALIGN v.
- FIGS. 6D and 6E depict an alignment of the amino acid sequences of human TANGO 294 protein (SEQ ID NO: 47) and the known human lipase protein (SEQ ID NO: 75), as assessed using the same software and parameters. In this alignment (pam120.mat scoring matrix, gap penalties ⁇ 12/ ⁇ 4), the amino acid sequences of the proteins are 49.8% identical.
- TANGO 294 also is distinct from the known human lysosomal acid lipase, as indicated in FIGS. 6G and 6H.
- 6G and 6H depicts an alignment of the amino acid sequences of human TANGO 294 protein (SEQ ID NO: 47) and the known human lysosomal acid lipase protein (SEQ ID NO: 41). In this alignment (pam120.mat scoring matrix, gap penalties ⁇ 12/ ⁇ 4), the amino acid sequences of the proteins are 56.9% identical.
- TANGO 294 is a human lipase distinct from the known human lipase and the known human lysosomal acid lipase. Furthermore, in view of the comparisons of the amino acid sequences of TANGO 294 and the two human lipases and the nature of transcriptional initiation sites, it is recognized that the transcriptional start site can correspond to either of the methionine residues located at residues 1 and 15 of SEQ ID NO: 47
- the present invention thus includes proteins in which the initially transcribed amino acid residue is the methionine residue at position 1 of SEQ ID NO: 47 and proteins in which the initially transcribed amino acid residue is the methionine residue at position 15 of SEQ ID NO: 47 (i.e., proteins in which the amino acid sequence of TANGO 294 does not include residues 1 to 14 of SEQ ID NO: 47). Furthermore, because amino acid residues 1 to 14 of SEQ ID NO: 47 are predicted to be part of a signal sequence, it is recognized that the protein not comprising this portion of the amino acid sequence
- Novel TANGO 294 expression was measured by TaqManTM quantitative PCR (Perkin Elmer Applied Biosystems) in cDNA prepared from the following human tissues:
- Tissue Panel One (Phase I, General Expression in normal and tumorigenic tissues): Artery normal, Aorta diseased, Vein normal, Coronary SMC, HUVEC, Hemangioma, Heart (normal), Congestive Heart Failure, Kidney, Skeletal Muscle, Adipose (normal), Pancreas, Primary Osteoblasts, Osteoclasts (differentiated), Skin (normal), Spinal Cord (normal), Brain Cortex (normal), Brain Hypothalamus (normal), Nerve, Dorsal Root Ganglia, Breast (normal), Breast Tumor, Ovary (normal), Ovary Tumor, Prostate (normal), Prostate Tumor, Salivary Glands, Colon (pools of 3 normal colon tissues), Colon Tumor (3 colon adenocarcinomas), Lung (normal), Lung Tumor, Lung (COPD), Colon (3 colon IBD samples), Liver (normal), Liver Fibrosis, Spleen (normal), Tonsil (normal), Lymph Node (normal),
- Tissue Panel Two (Phase II, General Expression Pattern in Solid Tumors): Breast (normal, 3 separate samples), Breast (tumor, 5 separate samples), Lymph node (metastasized from breast), Lung (metastasized from breast), Ovary (normal, 2 separate samples), Ovary (tumor, 5 separate samples), Lung (normal, 3 separate samples), Lung (tumor, 6 separate samples), Colon (normal, 3 separate samples), Colon (Adenocarcinoma, 4 separate samples), Liver (metastasized from colon, 3 separate samples), Liver (normal, female), Cervix Squamous Carcinoma (2 separate samples), Human Microvascular Endothelial Cells- Arr, Human Microvascular Endothelial Cells- Prol, Pooled Hemangiomas, HCT116N22 Normoxic, and HCT116H22 Hypoxic.
- Tissue Panel Three (Colon Cancer Expanded Panel: Specific expression pattern in various stages of colorectal cancer): Colon (normal, 6 separate samples), Colon (adenomas, 2 separate samples), Colon (stage B adenocarcinomas, 6 separate samples), Colon (stage C adenocarcinomas, 6 separate samples), Liver (normal, 6 separate samples), Liver (metastasized from colon, 6 separate samples), and 1 abdominal colon metastasis sample.
- Tissue Panel Four (Xenograft Panel): MCF-7 Breast T, ZR75 Breast T, T47D Breast T, MDA 231 Breast T, MDA 435 Breast T, SKBr3 Breast, DLD 1 ColonT (stage C), SW480 Colon T (stage B), SW620 ColonT (stage C), HCT116, HT29, Colon 205, NCIH125, NCIH67, NCIH322, NCIH460, A549, NHBE, SKOV-3 ovary, OVCAR-3 ovary, 293 Baby Kidney, and 293T Baby Kidney.
- Tissue Panel Five (Colon to Liver Metastases Panel: Specific expression patterns in late stage colon cancer (metastasis)): Colon (normal, 3 separate samples), Colonic ACA-C, Colonic ACA-C, Colonic ACA-B, Colon (adenocarcinoma), Liver (metastasized from colon, 17 separate samples), and Liver (normal, 3 separate samples).
- Probes were designed by PrimerExpress software (PE Biosystems) based on the sequence of each gene. Each gene probe was labeled using FAM (6-carboxyfluorescein), and the beta-2 microglobulin reference probe was labeled with a different fluorescent dye, VIC. The differential labeling of the target gene and internal reference gene thus enabled measurement in same well. Forward and reverse primers and the probes for both beta-2 microglobulin and target gene were added to the TaqManTM Universal PCR Master Mix (PE Applied Biosystems). Although the final concentration of primer and probe could vary, each was internally consistent within a given experiment.
- FAM 6-carboxyfluorescein
- VIC fluorescent dye
- a typical experiment contained 200 nanomolar of forward and reverse primers plus 100 nanomolar probe for beta-2 microglobulin and 600 nanomolar forward and reverse primers plus 200 nanomolar probe for the target gene.
- TaqMan matrix experiments were carried out on an ABI PRISM 7700 Sequence Detection System (PE Applied Biosystems). The thermal cycler conditions were as follows: hold for 2 minutes at 50° C. and 10 minutes at 95° C., followed by two-step PCR for 40 cycles of 95° C. for 15 seconds followed by 60° C. for 1 minute.
- the threshold cycle (Ct) value is defined as the cycle at which a statistically significant increase in fluorescence is detected. A lower Ct value is indicative of a higher mRNA concentration.
- ⁇ Ct ⁇ Ct- sample - ⁇ Ct- calibrator .
- Relative expression is then calculated using the arithmetic formula given by 2- ⁇ Ct . Expression of the target TANGO 294 gene in each of the tissues tested is discussed in more detail below.
- the TaqMan expression from Panel One shows restricted TANGO 294 expression in pancreas, colon tumors, and activated peripheral blood mononuclear cells, with highest expression in colon tumors.
- the TaqMan expression from Panel Two shows TANGO 294 expression restricted to colon tumors and lung tumors, with a 4-50 times increase in expression in colon tumor samples over normal colon samples.
- the colon tumor sample NDR 210 shows about 6 ⁇ expression over normal colon samples
- the colon tumor sample CHT 382 shows about 9 ⁇ expression over normal colon samples
- the colon tumor sample CHT 528 shows about 30 ⁇ expression over normal colon samples.
- the TaqMan expression from Panel Three shows TANGO 294 elevated expression in adenomas and stage A, B, and C, and metastatic tumors.
- the TaqMan expression from Panel Four shows TANGO 294 expression in breast, colon, and lung cell lines (NCIH322 and NHBE).
- the TaqMan expression from Panel Five shows upregulated TANGO 294 expression in 80% of colon to liver metastases. Both normal colon and normal liver show no expression.
- Transcriptional profiling data shows upregulation of TANGO 294 in early and late stage colon tumors, as compared to adenomas and normal colon tissue samples.
- In situ hybridization experiments confirmed expression of TANGO 294 in various tumor samples (restricted to a certain subset of tumors and metastatic lesions), as well as in pancreas and inflammatory cells (e.g., PBMCs). Expression of TANGO 294 in colon tumor samples was also confirmed by quantitative PCR amplification. Expression of TANGO 294 was detected in portions of hyperplastic colonic epithelium associated with colonic polyps.
- TANGO 294 The sequence similarity of TANGO 294 and mammalian lingual, gastric, and lysosomal acid lipase proteins indicates that TANGO 294 is involved in physiological processes identical or analogous to those involving these lipases.
- Lipases such as TANGO 294 catalyze formation and breakage of ester bonds between a fatty acid and a lipid moiety such as an acylglycerol, a sterol (e.g., cholesterol), and a lipoprotein.
- the lipases with which TANGO 294 exhibits the greatest similarity have acylglycerols and sterols among their substrates, indicating that TANGO 294 can exhibit preference for these substrates.
- TANGO 294 is involved in facilitating absorption and metabolism of fat.
- TANGO 294 can thus be used, for example, to prevent, detect, and treat disorders relating to fat absorption and metabolism, such as inadequate expression of gastric/pancreatic lipase, cystic fibrosis, exocrine pancreatic insufficiency, obesity, medical treatments which alter fat absorption, and the like.
- Lipases such as TANGO 294 are also involved in regulating transfer of fatty acid substrates such as linoleic acid and arachidonic acid among dietary lipids, intracellular lipid stores, and enzymes involved in biosynthesis of eicosanoids such as prostaglandins, thromboxanes, and leukotrienes.
- Eicosanoids are known to exert a variety of biological effects on cells, including modulating immune responses, growth of cells, and movement of cells.
- Prostaglandins produced by oxidation of arachidonic acid by cyclooxygenase-2 (Cox-2) enzymes have a role in formation, growth, and spread of colon tumors (Majerus, 1998, Curr. Biol.
- TANGO 294 is able to modulate the supply of eicosanoid precursor fatty acids such as linoleic acid, gamma-linoleic acid, gamma-dihomolinoleic acid, and arachidonic acid by modulating the amounts of these acids available for eicosanoid synthesis in colon tissue.
- eicosanoid precursor fatty acids such as linoleic acid, gamma-linoleic acid, gamma-dihomolinoleic acid, and arachidonic acid by modulating the amounts of these acids available for eicosanoid synthesis in colon tissue.
- eicosanoid precursor fatty acids such as linoleic acid, gamma-linoleic acid, gamma-dihomolinoleic acid, and arachidonic acid
- These acids can be obtained by action of TANGO 294 on dietary lipids (including lipids within the colon or serum
- TANGO 294 can catalyze formation of triacylglycerols containing one or more of these fatty acids, whereupon the triacylglycerol is stored in a cellular membrane or within a lysosome.
- eicosanoid synthesis can be modulated, and cellular processes (e.g., cellular growth or proliferation or movement of cells) that are affected by the presence or absence of eicosanoids can be modulated.
- restriction of the availability of eicosanoid fatty acid precursors can inhibit eicosanoid synthesis and exert a colon cancer-preventive effect analogous to that observed by administration of a Cox-2 inhibitor such as aspirin or sulindac.
- TANGO 294 protein is known to be expressed in human pulmonary artery smooth muscle tissue. This indicates that TANGO 294 protein is involved in transportation and metabolism of fats and lipids in the human vascular and cardiovascular systems. Thus, TANGO 294 proteins of the invention can be used to prevent, detect, and treat disorders involving these body systems.
- Various eicosanoids, including thromboxanes and prostaglandins, are known to modulate vascular smooth muscle contraction, affecting processes such as systemic blood pressure and local blood flow in tissues. The ability of TANGO 294 to modulate eicosanoid levels permits these processes to be affected.
- modulating expression or activity of TANGO 294 can be used to inhibit, prevent, or counteract hypo- or hypertension in a human or to modulate blood flow through a tissue in which the expression or activity is modulated.
- assessment of expression or activity of TANGO 294 in a patient, or in a tissue of a patient can predict or diagnose a blood flow or blood pressure disorder in a patient. Examples of such disorders include arterial hypertension, renovascular hypertension, syncope, orthostatic hypotension, and shock (including anaphylactic shock).
- TANGO 294 can modulate the ability of the cell to pass through an epithelial or endothelial membrane.
- a cell e.g., a tumor cell or a PBMC
- TANGO 294 can modulate the ability of the cell to pass through an epithelial or endothelial membrane.
- many PBMCs exhibit the ability to travel within the bloodstream to a certain body location, at which point the cells adhere to the vessel wall and pass through the endothelial membrane of the vessel in order to move to a tissue adjoining the vessel (i.e., the PBMCs exhibit the ability to extravasate).
- metastatic tumor cells often exhibit an enhanced ability to move through tissue membranes and colonize body sites at which they do not normally occur (e.g., colon tumor cells can metastasize to lung tissue and develop there into a tumor mass).
- the ability of TANGO 294 to modulate these processes indicates that TANGO 294 molecules can be used to prognosticate, diagnose, inhibit, prevent, or even reverse the ability of cells to exhibit these characteristics.
- TANGO 294 molecules are useful in prognosticating, diagnosing, inhibiting, preventing, or reversing conditions such as inappropriate inflammation, tumor growth, and tumor cell metastasis.
- TANGO 294 expression of TANGO 294 in tissues having an epithelial or endothelial component (e.g., colon and colon tumor, lung tumor, stomach, and pancreas tissues) indicates that TANGO 294 can influence the cohesiveness of an endothelial or epithelial membrane in one of these tissues or the ability of cells to pass through that membrane. These observations indicate that TANGO 294 can have a role in inflammatory disorders of these and other endothelium- or epithelium-containing tissues and that TANGO 294 can affect the likelihood that a tumor cell metastasis will enter into or take up residence within one of these tissues.
- epithelial or endothelial component e.g., colon and colon tumor, lung tumor, stomach, and pancreas tissues
- inflammatory disorders in which TANGO 294 can have a role include gastritis, ulcer, various types of colitis and other less definitively characterized lower gastrointestinal disorders (e.g., irritable and inflammatory bowel syndromes), and pancreatitis.
- TANGO 294 Expression of TANGO 294 was observed, at least at low levels, in a variety of tissues having an epithelial or endothelial portion, including colon, pancreas, small intestine, stomach, spleen, tonsil, and breast tissues. In many such tissues where corresponding tumor tissue samples were available (e.g., prostate, breast and lung tumor tissues), significantly greater expression of TANGO 294 was observed in the tumor tissue than in the non-tumor tissue. This observation indicates that TANGO 294 can have a role in a variety of tumors of epithelial and endothelial origin, including those in which TANGO 294 expression occurs. The TANGO 294 molecules described herein can therefore be used to modulate (e.g., inhibit, prevent, alleviate, reverse, or cure) tumorigenesis and growth, proliferation, invasion, and metastasis of these tumors.
- modulate e.g., inhibit, prevent, alleviate, reverse, or cure
- Expression of DNA encoding TANGO 294 is between 4 and 50 times greater in colon tumor tissue samples than in corresponding normal colon tissue samples. Expression of TANGO 294 is elevated, relative to normal colon tissue in colon adenomas and in colon tumors at stages A, B, and C. Elevated TANGO 294 expression is also observed in metastases of apparent colon origin, including those which are found in liver tissue. In situ hybridization experiments confirmed expression of TANGO 294 in various colon tumor samples, as well as in pancreas and inflammatory cells (e.g., PBMCs). Expression of TANGO 294 in colon tumor samples and colon metastases was also confirmed by quantitative PCR amplification. Expression of TANGO 294 was detected in portions of hyperplastic colonic epithelium associated with colonic polyps.
- TANGO 294 is useful as a marker for detecting occurrence of colon cancer in an individual.
- Expression of TANGO 294 in a sample e.g., a stool sample, a blood sample, or a polyp or other colon biopsy
- a sample obtained from a patient can indicate a predisposition for the patient to develop a colon cancer, that a growth observed in the patient's colon is a tumor, that a colon tumor in the patient is metastasizing or has significant metastatic potential, or that the patient has otherwise non-symptomatic colon cancer.
- TANGO 294 can have a role in (e.g., can be used to inhibit, prevent, alleviate, reverse, or cure) one or more of tumorigenesis, colon tumor growth, or colon tumor metastasis.
- Compounds which modulate the activity or expression of TANGO 294 e.g., antisense oligonucleotides, antibodies which specifically bind with TANGO 294, or relatively small molecules identified by screening
- TANGO 294 expression appears to be up-regulated in colon tumor cells, inhibiting activity, expression, or both, of TANGO 294 can inhibit or stop colon cell tumorigenesis, colon tumor growth, or colon tumor metastasis. Expression or activity of TANGO 294 can therefore be used in a screening assay to identify compounds which can have one of these effects in colon cancer.
- TANGO 294 is expressed in activated PBMCs. This expression is consistent with a role for TANGO 294 in eicosanoid (e.g., leukotriene) biosynthesis. Leukotrienes are known to strongly modulate inflammation and other immune processes mediated by PBMCs. Aberrant expression of TANGO 294 can induce PBMCs to proliferate or activate in an inappropriate manner, resulting in any of a variety of disorders. Inappropriate proliferation of PBMCs can lead to cancers such as leukemias, lymphomas, and plasma cell dyscrasias, and these cancers can be inhibited, prevented, alleviated, reversed, or cured using modulators of TANGO 294 expression or activity.
- eicosanoid e.g., leukotriene
- PBMCs can result in a variety of inflammatory and immune disorders.
- many autoimmune disorders involve activation of PBMCs in the absence of a pathogen, and others involve activation of PBMCs in the presence of a pathogen, but to an extent that immune-mediated cytotoxic activities seriously damage one or more tissues of the patient.
- Pancreatic cancer cell proliferation and survival requires a sufficient level of eicosanoid synthesis (see, e.g., Ding et al., 2000, Anticancer Res. 20(4):2625-2631). Involvement of TANGO 294 in eicosanoid synthesis and metabolism indicates that TANGO 294 can contribute to proliferation and survival of pancreatic cancer cells.
- TANGO 294 molecules described herein can be used to inhibit, prevent, alleviate, reverse, or cure one or more of tumorigenesis, tumor cell growth, tumor cell proliferation, tumor cell invasion, and metastasis in pancreatic tissue.
- TANGO 294 The ability of TANGO 294 to modulate synthesis and release of fatty acids in PBMCs which express it indicates that modulation of TANGO 294 expression, activity, or both, can predict, diagnose, inhibit, or prevent inappropriate immune and inflammatory responses in patients.
- modulation of TANGO 294 expression or activity can be used to treat patients afflicted with disorders such as arthritis (e.g., rheumatoid arthritis), psoriasis, myasthenia gravis, dermatitis (e.g., contact dermatitis), allergies, insulin resistance, systemic lupus erythematosus, scleroderma, and autoimmune diabetes mellitus.
- arthritis e.g., rheumatoid arthritis
- psoriasis myasthenia gravis
- dermatitis e.g., contact dermatitis
- allergies insulin resistance
- systemic lupus erythematosus sclero
- Involvement of TANGO 294 in activation of PBMCs indicates that inappropriately low activation of PBMCs can be predicted, diagnosed, inhibited, prevented, or reversed by increasing expression or activity of TANGO 294 in PBMCs.
- Certain infectious agents e.g., the human immunodeficiency virus
- Other infectious agents provoke an immune response, but the provoked response is not sufficient to remove the infectious agent from the patient's system.
- Enhancing expression, activation, or both of TANGO 294 in PBMCs in a patient can enhance the ability of the patient's immune system to react to the presence of an immunogen, thereby assisting the patient in clearing the pathogen from the patient or minimizing the pathogen's impact on the patient's health.
- Various eicosanoid compounds influence the ability of blood platelets to aggregate with one another or to adhere to cells of another type.
- the ability of TANGO 294 to modulate production of eicosanoids, including thromboxanes, indicates that modulation of TANGO 294 expression, activity, or both, can influence the course of thrombotic disorders and disorders involving inappropriate platelet adherence.
- some thrombotic disorders e.g., hemophilia
- Expression or activity of TANGO 294 can be modulated to enhance cellular production of thrombosis-enhancing eicosanoids, and assessing TANGO 294 expression or activity in a tissue can predict or diagnose whether the patient is afflicted with a disorder characterized by insufficient thrombosis.
- assessment of TANGO 294 expression or activity can be used to predict or diagnose if a patient is afflicted with (or predisposed to develop) a disorder characterized by inappropriate thrombus formation (e.g., stroke, myocardial infarction, or other abnormal blood coagulation) by inappropriate adherence of platelets to other tissues (e.g., coronary artery disease or atherosclerosis).
- Modulating TANGO 294 expression or activity can inhibit or prevent one of these disorders, or alleviate the disorder if it is already occurring in a patient.
- TANGO 294 or modulators thereof can be used to treat, for at least the above-mentioned reasons, include, but are not limited to, thrombocytopenia due to a reduced number of megakaryocytes in the bone marrow, for example, as a result of chemotherapy; invasive disorders, such as leukemia, idiopathic or drug- or toxin-induced aplasia of the marrow, or rare hereditary amegakaryocytic thrombocytopenias; ineffective thrombopoiesis, for example, as a result of megaloblastic anemia, alcohol toxicity, vitamin B12 or folate deficiency, myelodysplastic disorders, or rare hereditary disorders (e.g., Wiskott-Aldrich syndrome and May-hegglin anomaly); a reduction in platelet distribution, for example, as a result of cirrhosis, a splenic invasive disease (e.g.,
- thrombocytopenia secondary to intravascular clotting and thrombin induced damage to platelets as a result of, for example, obstetric complications, metastatic tumors, severe gram-negative bacteremia, thrombotic thrombocytopenic purpura, or severe illness. Also included is dilutional thrombocytopenia, for example, due to massive hemorrhage.
- Platelet associated disorders also include, but are not limited to, essential thrombocytosis and thrombocytosis associated with, for example, splenectomy, acute or chronic inflammatory diseases, hemolytic anemia, carcinoma, Hodgkin's disease, lymphoproliferative disorders, and malignant lymphomas.
- TANGO 294-related disorders The disorders mentioned in this section in connection with TANGO 294 are collectively referred to as “TANGO 294-related disorders.”
- a cDNA clone (designated jthEa030h09) encoding at least a portion of human INTERCEPT 296 protein was isolated from a human esophagus cDNA library.
- the human INTERCEPT 296 protein is predicted by structural analysis to be a transmembrane protein having three or more transmembrane domains. Expression of DNA encoding INTERCEPT 296 tissue has been detected by northern analysis of human lung tissue. In human lung tissue, two moieties corresponding to INTERCEPT 296 have been identified in Northern blots. It is recognized that these two moieties may represent alternatively polyadenylated INTERCEPT 296 mRNAs or alternatively spliced INTERCEPT 296 mRNAs. It has furthermore been observed that INTERCEPT 296 does not appear to be expressed in any of heart, brain, placenta, skeletal muscle, kidney, and pancreas tissues.
- the full length of the cDNA encoding INTERCEPT 296 protein (FIG. 7; SEQ ID NO: 53) is 2133 nucleotide residues.
- the invention includes purified INTERCEPT 296 protein, which has the amino acid sequence listed in SEQ ID NO: 55.
- the invention includes fragments, derivatives, and variants of these INTERCEPT 296 proteins, as described herein. These proteins, fragments, derivatives, and variants are collectively referred to herein as polypeptides of the invention or proteins of the invention.
- the invention also includes nucleic acid molecules which encode a polypeptide of the invention.
- nucleic acids include, for example, a DNA molecule having the nucleotide sequence SEQ ID NO: 53 or some portion thereof, such as the portion which encodes INTERCEPT 296 protein or a domain thereof. These nucleic acids are collectively referred to as nucleic acids of the invention.
- INTERCEPT 296 proteins and nucleic acid molecules encoding them comprise a family of molecules having certain conserved structural and functional features, such as the five transmembrane domains which occur in the protein.
- INTERCEPT 296 comprises at least five transmembrane domains, at least three cytoplasmic domains, and at least two extracellular domains. INTERCEPT 296 does not appear to comprise a cleavable signal sequence. Amino acid residues 1 to 70 of SEQ ID NO: 55 likely directs insertion of the protein into the cytoplasmic membrane. There are at least two mechanisms by which this can occur. Sequence analysis of residues 1 to 70 of SEQ ID NO: 55 indicates that this entire region may represent a signal sequence or that residues 1 to 47 represent a signal sequence, with residues 48-70 representing a transmembrane region.
- Human INTERCEPT 296 protein extracellular domains are located from about amino acid residue 70 to about amino acid residue 182 (SEQ ID NO: 57) and from about amino acid residue 228 to about amino acid residue 249 (SEQ ID NO: 58) of SEQ ID NO: 55.
- Human INTERCEPT 296 cytoplasmic domains are located from about amino acid residue 43 to amino acid residue 50 (SEQ ID NO: 64), from about amino acid residue 205 to amino acid residue 210 (SEQ ID NO: 65), and from amino acid residue 272 to amino acid residue 343 (SEQ ID NO: 66) of SEQ ID NO: 55.
- the five transmembrane domains of INTERCEPT 296 are located from about amino acid residues 24 to 42 (SEQ ID NO: 59), 51 to 70 (SEQ ID NO: 60), 183 to 204 (SEQ ID NO: 61),211 to 227 (SEQ ID NO: 62), and 250 to 271 (SEQ ID NO: 63) of SEQ ID NO: 55.
- INTERCEPT 296 proteins typically comprise a variety of potential post-translational modification sites (often within an extracellular domain), such as those described herein in Table XI, as predicted by computerized sequence analysis of INTERCEPT 296 proteins using amino acid sequence comparison software (comparing the amino acid sequence of INTERCEPT 296 with the information in the PROSITE database ⁇ rel. 12.2; February, 1995 ⁇ and the Hidden Markov Models database ⁇ Rel. PFAM 3.3 ⁇ ).
- a protein of the invention has at least 1, 2, 4, 6, 10, 15, or 20 or more of the post-translational modification sites listed in Table XI.
- FIG. 7D depicts a hydrophilicity plot of INTERCEPT 296 protein. Relatively hydrophobic regions are above the dashed horizontal line, and relatively hydrophilic regions are below the dashed horizontal line.
- the hydrophobic regions which corresponds to amino acid residues 24 to 42, 51 to 70, 183 to 204, 211 to 227, and 250 to 271 of SEQ ID NO: 55 are the transmembrane domains of human INTERCEPT 296 (SEQ ID NOs: 59 through 63, respectively).
- relatively hydrophilic regions are generally located at or near the surface of a protein, and are more frequently effective immunogenic epitopes than are relatively hydrophobic regions.
- the region of human INTERCEPT 296 protein from about amino acid residue 120 to about amino acid residue 140 appears to be located at or near the surface of the protein, while the region from about amino acid residue 95 to about amino acid residue 110 appears not to be located at or near the surface.
- the predicted molecular weight of INTERCEPT 296 protein without modification and prior to cleavage of the signal sequence is about 37.8 kilodaltons.
- the predicted molecular weight of the mature INTERCEPT 296 protein without modification and after cleavage of the signal sequence is about 30.2 kilodaltons.
- FIGS. 7E and 7F depicts an alignment of the amino acid sequences of human INTERCEPT 296 protein (SEQ ID NO: 55) and Caenorhabditis elegans C06E1.3 related protein (SEQ ID NO: 399). In this alignment (pam120.mat scoring matrix, gap penalties ⁇ 12/ ⁇ 4), the amino acid sequences of the proteins are 26.8% identical. The C. elegans protein has five predicted transmembrane domains.
- the cDNA encoding INTERCEPT 296 protein was obtained from a human esophagus cDNA library, and INTERCEPT 296 is expressed in lung tissue.
- the INTERCEPT 296-related proteins and nucleic acids of the invention are therefore useful for prevention, detection, and treatment of disorders of the human lung and esophagus.
- Such disorders include, for example, various cancers, bronchitis, cystic fibrosis, respiratory infections (e.g., influenza, bronchiolitis, pneumonia, and tuberculosis), asthma, emphysema, chronic bronchitis, bronchiectasis, pulmonary edema, pleural effusion, pulmonary embolus, adult and infant respiratory distress syndromes, heartburn, and gastric reflux esophageal disease.
- respiratory infections e.g., influenza, bronchiolitis, pneumonia, and tuberculosis
- Tables A and B summarize sequence data corresponding to the human proteins herein designated TANGO 202, TANGO 234, TANGO 265, TANGO 273, TANGO 286, TANGO 294, and INTERCEPT 296.
- nucleic acid molecules that encode a polypeptide of the invention or a biologically active portion thereof, as well as nucleic acid molecules sufficient for use as hybridization probes to identify nucleic acid molecules encoding a polypeptide of the invention and fragments of such nucleic acid molecules suitable for use as PCR primers for the amplification or mutation of nucleic acid molecules.
- nucleic acid molecule is intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs.
- the nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.
- an “isolated” nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid molecule.
- an “isolated” nucleic acid molecule is free of sequences (preferably protein-encoding sequences) which naturally flank the nucleic acid (i.e., sequences located at the 5′ and 3′ ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived.
- the isolated nucleic acid molecule can contain less than about 5 kB, 4 kB, 3 kB, 2 kB, 1 kB, 0.5 kB or 0.1 kB of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived.
- an “isolated” nucleic acid molecule such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.
- a nucleic acid molecule of the present invention e.g., a nucleic acid molecule having the nucleotide sequence of all or a portion of any of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73, or a complement thereof, or which has a nucleotide sequence comprising one of these sequences, can be isolated using standard molecular biology techniques and the sequence information provided herein.
- nucleic acid molecules of the invention can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook et al., eds., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989).
- a nucleic acid molecule of the invention can be amplified using cDNA, mRNA or genomic DNA as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques.
- the nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis.
- oligonucleotides corresponding to all or a portion of a nucleic acid molecule of the invention can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.
- an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is a complement of the nucleotide sequence of any of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73, or a portion thereof.
- a nucleic acid molecule which is complementary to a given nucleotide sequence is one which is sufficiently complementary to the given nucleotide sequence that it can hybridize to the given nucleotide sequence thereby forming a stable duplex.
- a nucleic acid molecule of the invention can comprise only a portion of a nucleic acid sequence encoding a full length polypeptide of the invention for example, a fragment which can be used as a probe or primer or a fragment encoding a biologically active portion of a polypeptide of the invention.
- the nucleotide sequence determined from the cloning one gene allows for the generation of probes and primers designed for use in identifying and/or cloning homologs in other cell types, e.g., from other tissues, as well as homologs from other mammals.
- the probe/primer typically comprises substantially purified oligonucleotide.
- the oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 15, preferably about 25, more preferably about 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, or 400 or more consecutive nucleotides of the sense or anti-sense sequence of any of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73, or of a naturally occurring mutant of any of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73.
- Probes based on the sequence of a nucleic acid molecule of the invention can be used to detect transcripts or genomic sequences encoding the same protein molecule encoded by a selected nucleic acid molecule.
- the probe comprises a label group attached thereto, e.g., a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor.
- Such probes can be used as part of a diagnostic test kit for identifying cells or tissues which mis-express the protein, such as by measuring levels of a nucleic acid molecule encoding the protein in a sample of cells from a subject, e.g., detecting mRNA levels or determining whether a gene encoding the protein has been mutated or deleted.
- a nucleic acid fragment encoding a biologically active portion of a polypeptide of the invention can be prepared by isolating a portion of any of SEQ ID NOs: 2, 10, 18, 26, 34, 46, 54, 68, and 73, expressing the encoded portion of the polypeptide protein (e.g., by recombinant expression in vitro), and assessing the activity of the encoded portion of the polypeptide.
- the invention further encompasses nucleic acid molecules that differ from the nucleotide sequence of any of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73 due to degeneracy of the genetic code and thus encode the same protein as that encoded by the nucleotide sequence of any of SEQ ID NOs: 2, 10, 18, 26, 34, 46, 54, 68,and 73.
- DNA sequence polymorphisms that lead to changes in the amino acid sequence can exist within a population (e.g., the human population). Such genetic polymorphisms can exist among individuals within a population due to natural allelic variation. An allele is one of a group of genes which occur alternatively at a given genetic locus.
- the phrase “allelic variant” refers to a nucleotide sequence which occurs at a given locus or to a polypeptide encoded by the nucleotide sequence.
- chromosomal mapping has been used to locate the gene encoding human TANGO 234 at chromosomal location h12p13 (with synteny to mo6), between chromosomal markers WI-6980 and GATA8A09.43.
- human TANGO 234 allelic variants can include TANGO 234 nucleotide sequence polymorphisms (e.g., nucleotide sequences that vary from SEQ ID NO: 9) that map to this chromosomal region.
- chromosomal mapping has been used to locate the gene encoding human TANGO 265 protein on chromosome 1, between markers D1S305 and D1S2635. Allelic variants of TANGO 265 occur at this chromosomal location. Further by way of example, the gene encoding human TANGO 273 protein has been located by chromosomal mapping on chromosome 7, between markers D7S2467 and D7S2552. Allelic variants of TANGO 273 occur at this chromosomal location.
- the terms “gene” and “recombinant gene” refer to nucleic acid molecules comprising an open reading frame encoding a polypeptide of the invention.
- Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of a given gene.
- Alternative alleles can be identified by sequencing the gene of interest in a number of different individuals. This can be readily carried out by using hybridization probes to identify the same genetic locus in a variety of individuals. Any and all such nucleotide variations and resulting amino acid polymorphisms or variations that are the result of natural allelic variation and that do not alter the functional activity are intended to be within the scope of the invention.
- nucleic acid molecules encoding proteins of the invention from other species which have a nucleotide sequence which differs from that of the specific proteins described herein are intended to be within the scope of the invention.
- Nucleic acid molecules corresponding to natural allelic variants and homologs of a cDNA of the invention can be isolated based on their homology with nucleic acid molecules described herein, using the specific cDNAs described herein, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions.
- a cDNA encoding a soluble form of a membrane-bound protein of the invention isolated based on its hybridization to a nucleic acid molecule encoding all or part of the membrane-bound form.
- a cDNA encoding a membrane-bound form can be isolated based on its hybridization to a nucleic acid molecule encoding all or part of the soluble form.
- an isolated nucleic acid molecule of the invention is at least 15 (25, 40, 60, 80, 100, 150, 200, 250, 300, 350, 400, 450, 550, 650, 700, 800, 900, 1000, 1200, 1400, 1600, 1800, 2000, 2200, 2400, 2600, 2800, 3000, 3500, 4000, 4500, or 4928) nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence, preferably the coding sequence, of any of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73, or a complement thereof.
- hybridizes under stringent conditions is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% (65%, 70%, preferably 75%) identical to each other typically remain hybridized to each other.
- stringent conditions are known to those skilled in the art and can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6.
- a preferred, non-limiting example of stringent hybridization conditions are hybridization in 6 ⁇ sodium chloride/sodium citrate (SSC) at about 45° C., followed by one or more washes in 0.2 ⁇ SSC, 0.1% SDS at 50-65° C.
- an isolated nucleic acid molecule of the invention that hybridizes under stringent conditions with the sequence of any of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73, or a complement thereof, corresponds to a naturally-occurring nucleic acid molecule.
- a “naturally-occurring” nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein).
- allelic variants of a nucleic acid molecule of the invention sequence that can exist in the population
- changes can be introduced by mutation thereby leading to changes in the amino acid sequence of the encoded protein, without altering the biological activity of the protein.
- a “non-essential” amino acid residue is a residue that can be altered from the wild-type sequence without altering the biological activity, whereas an “essential” amino acid residue is required for biological activity.
- amino acid residues that are not conserved or only semi-conserved among homologs of various species may be non-essential for activity and thus would be likely targets for alteration.
- amino acid residues that are conserved among the homologs of various species e.g., murine and human
- amino acid residues that are conserved among the homologs of various species may be essential for activity and thus would not be likely targets for alteration.
- nucleic acid molecules encoding a polypeptide of the invention that contain changes in amino acid residues that are not essential for activity.
- polypeptides differ in amino acid sequence from the sequence of any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74, yet retain biological activity.
- the isolated nucleic acid molecule includes a nucleotide sequence encoding a protein that includes an amino acid sequence that is at least about 40% identical, 50%, 60%, 70%, 80%, 90%, 95%, or 98% identical to the amino acid sequence of any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74.
- An isolated nucleic acid molecule encoding a variant protein can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of any of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73, such that one or more amino acid residue substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues.
- a “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain.
- Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).
- mutations can be introduced randomly along all or part of the coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for biological activity to identify mutants that retain activity.
- the encoded protein can be expressed recombinantly and the activity of the protein can be determined.
- a mutant polypeptide that is a variant of a polypeptide of the invention can be assayed for: (1) the ability to form protein:protein interactions with one or more polypeptides of the invention (e.g., in a signaling pathway); (2) the ability to bind a ligand of a polypeptide of the invention (e.g., another protein identified herein); (3) the ability to bind to an intracellular target protein of a polypeptide of the invention (e.g., a modulator or substrate of the polypeptide); or (4) the ability to modulate a physiological activity of the protein, such as one of those disclosed herein (e.g., ability to modulate cell proliferation, cell migration, chemotaxis, or cellular differentiation).
- a physiological activity of the protein such as one of those disclosed herein (e.g., ability to modulate cell proliferation, cell migration, chemotaxis, or cellular differentiation).
- the present invention encompasses antisense nucleic acid molecules, i.e., molecules which are complementary to a sense nucleic acid encoding a polypeptide of the invention, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid.
- the antisense nucleic acid can be complementary to an entire coding strand, or to only a portion thereof, e.g., all or part of the protein coding region (or open reading frame).
- An antisense nucleic acid molecule can be antisense to all or part of a non-coding region of the coding strand of a nucleotide sequence encoding a polypeptide of the invention.
- the non-coding regions (“5′ and 3′ untranslated regions”) are the 5′ and 3′ sequences which flank the coding region and are not translated into amino acids.
- An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 or more nucleotides in length.
- An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art.
- an antisense nucleic acid e.g., an antisense oligonucleotide
- an antisense nucleic acid can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used.
- modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N 6 -isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5′-methoxy
- the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been sub-cloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).
- the antisense nucleic acid molecules of the invention are typically administered to a subject or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a selected polypeptide of the invention to thereby inhibit expression, e.g., by inhibiting transcription and/or translation.
- the hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove of the double helix.
- An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site.
- antisense nucleic acid molecules can be modified to target selected cells and then administered systemically.
- antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, e.g., by linking the antisense nucleic acid molecules to peptides or antibodies which bind to cell surface receptors or antigens.
- the antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.
- An antisense nucleic acid molecule of the invention can be an alpha-anomeric nucleic acid molecule.
- An a-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual beta-units, the strands run parallel to each other (Gaultier et al. (1987) Nucleic Acids Res. 15:6625-6641).
- the antisense nucleic acid molecule can also comprise a 2′-o-methylribonucleotide (Inoue et al. (1987) Nucleic Acids Res. 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue et al. (1987) FEBS Lett. 215:327-330).
- Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region.
- ribozymes e.g., hammerhead ribozymes as described in Haselhoff and Gerlach (1988) Nature 334:585-591
- a ribozyme having specificity for a nucleic acid molecule encoding a polypeptide of the invention can be designed based upon the nucleotide sequence of a cDNA disclosed herein.
- a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a Cech et al. U.S. Pat. No. 4,987,071; and Cech et al. U.S. Pat. No. 5,116,742.
- an mRNA encoding a polypeptide of the invention can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel and Szostak (1993) Science 261:1411-1418.
- the invention also encompasses nucleic acid molecules which form triple helical structures.
- expression of a polypeptide of the invention can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the gene encoding the polypeptide (e.g., the promoter and/or enhancer) to form triple helical structures that prevent transcription of the gene in target cells.
- nucleotide sequences complementary to the regulatory region of the gene encoding the polypeptide e.g., the promoter and/or enhancer
- the nucleic acid molecules of the invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule.
- the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids (see Hyrup et al. (1996) Bioorganic & Medicinal Chemistry 4(1): 5-23).
- peptide nucleic acids refer to nucleic acid mimics, e.g., DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained.
- the neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength.
- the synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup et al. (1996), supra; Perry-O'Keefe et al. (1996) Proc. Natl. Acad. Sci. USA 93: 14670-675.
- PNAs can be used in therapeutic and diagnostic applications.
- PNAs can be used as antisense or anti-gene agents for sequence-specific modulation of gene expression by, e.g., inducing transcription or translation arrest or inhibiting replication.
- PNAs can also be used, e.g., in the analysis of single base pair mutations in a gene by, e.g., PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e.g., S1 nucleases (Hyrup (1996), supra; or as probes or primers for DNA sequence and hybridization (Hyrup (1996), supra; Perry-O'Keefe et al. (1996) Proc. Natl. Acad. Sci. USA 93: 14670-675).
- PNAs can be modified, e.g., to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art.
- PNA-DNA chimeras can be generated which can combine the advantageous properties of PNA and DNA.
- Such chimeras allow DNA recognition enzymes, e.g., RNase H and DNA polymerases, to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity.
- PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup (1996), supra).
- the synthesis of PNA-DNA chimeras can be performed as described in Hyrup (1996), supra, and Finn et al. (1996) Nucleic Acids Res. 24(17):3357-63.
- a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry and modified nucleoside analogs.
- the oligonucleotide can include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al. (1989) Proc. Natl. Acad. Sci. USA 86:6553-6556; Lemaitre et al. (1987) Proc. Natl. Acad. Sci. USA 84:648-652; PCT Publication No. WO 88/09810) or the blood-brain barrier (see, e.g., PCT Publication No. WO 89/10134).
- peptides e.g., for targeting host cell receptors in vivo
- agents facilitating transport across the cell membrane see, e.g., Letsinger et al. (1989) Proc. Natl. Acad. Sci. USA 86:6553-6556; Lemaitre et al. (1987) Proc. Natl.
- oligonucleotides can be modified with hybridization-triggered cleavage agents (see, e.g., Krol et al. (1988) Bio/Techniques 6:958-976) or intercalating agents (see, e.g., Zon (1988) Pharm. Res. 5:539-549).
- the oligonucleotide can be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.
- One aspect of the invention pertains to isolated proteins, and biologically active portions thereof, as well as polypeptide fragments suitable for use as immunogens to raise antibodies directed against a polypeptide of the invention.
- the native polypeptide can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques.
- polypeptides of the invention are produced by recombinant DNA techniques.
- a polypeptide of the invention can be synthesized chemically using standard peptide synthesis techniques.
- an “isolated” or “purified” protein or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the protein is derived, or substantially free of chemical precursors or other chemicals when chemically synthesized.
- the language “substantially free of cellular material” includes preparations of protein in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly produced.
- protein that is substantially free of cellular material includes preparations of protein having less than about 30%, 20%, 10%, or 5% (by dry weight) of heterologous protein (also referred to herein as a “contaminating protein”).
- the protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, 10%, or 5% of the volume of the protein preparation.
- culture medium represents less than about 20%, 10%, or 5% of the volume of the protein preparation.
- the protein is produced by chemical synthesis, it is preferably substantially free of chemical precursors or other chemicals, i.e., it is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. Accordingly such preparations of the protein have less than about 30%, 20%, 10%, 5% (by dry weight) of chemical precursors or compounds other than the polypeptide of interest.
- Biologically active portions of a polypeptide of the invention include polypeptides comprising amino acid sequences sufficiently identical to or derived from the amino acid sequence of the protein (e.g., the amino acid sequence shown in any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74), which include fewer amino acids than the full length protein, and exhibit at least one activity of the corresponding full-length protein.
- biologically active portions comprise a domain or motif with at least one activity of the corresponding protein.
- a biologically active portion of a protein of the invention can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acids in length.
- other biologically active portions, in which other regions of the protein are deleted can be prepared by recombinant techniques and evaluated for one or more of the functional activities of the native form of a polypeptide of the invention.
- Preferred polypeptides have the amino acid sequence of any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74.
- Other useful proteins are substantially identical (e.g., at least about 40%, preferably 50%, 60%, 70%, 80%, 90%, 95%, or 99%) to any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74 and retain the functional activity of the protein of the corresponding naturally-occurring protein yet differ in amino acid sequence due to natural allelic variation or mutagenesis.
- the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence).
- the amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position.
- the determination of percent identity between two sequences can be accomplished using a mathematical algorithm.
- a preferred, non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264-2268, modified as in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877.
- Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul, et al. (1990) J. Mol. Biol. 215:403-410.
- Gapped BLAST can be utilized as described in Altschul et al. (1997) Nucleic Acids Res. 25:3389-3402.
- PSI-Blast can be used to perform an iterated search which detects distant relationships between molecules. Id.
- the percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating percent identity, only exact matches are counted.
- the invention also provides chimeric or fusion proteins.
- a “chimeric protein” or “fusion protein” comprises all or part (preferably biologically active) of a polypeptide of the invention operably linked to a heterologous polypeptide (i.e., a polypeptide other than the same polypeptide of the invention).
- a heterologous polypeptide i.e., a polypeptide other than the same polypeptide of the invention.
- the term “operably linked” is intended to indicate that the polypeptide of the invention and the heterologous polypeptide are fused in-frame to each other.
- the heterologous polypeptide can be fused to the amino-terminus or the carboxyl-terminus of the polypeptide of the invention.
- One useful fusion protein is a GST fusion protein in which the polypeptide of the invention is fused to the carboxyl terminus of GST sequences. Such fusion proteins can facilitate the purification of a recombinant polypeptide of the invention.
- the fusion protein contains a heterologous signal sequence at its amino terminus.
- the native signal sequence of a polypeptide of the invention can be removed and replaced with a signal sequence from another protein.
- the gp67 secretory sequence of the baculovirus envelope protein can be used as a heterologous signal sequence (Current Protocols in Molecular Biology, Ausubel et al., eds., John Wiley & Sons, 1992).
- Other examples of eukaryotic heterologous signal sequences include the secretory sequences of melittin and human placental alkaline phosphatase (Stratagene; La Jolla, Calif.).
- useful prokaryotic heterologous signal sequences include the phoA secretory signal (Sambrook et al., supra) and the protein A secretory signal (Pharmacia Biotech; Piscataway, N.J.).
- the fusion protein is an immunoglobulin fusion protein in which all or part of a polypeptide of the invention is fused to sequences derived from a member of the immunoglobulin protein family.
- the immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a ligand (soluble or membrane-bound) and a protein on the surface of a cell (receptor), to thereby suppress signal transduction in vivo.
- the immunoglobulin fusion protein can be used to affect the bioavailability of a cognate ligand of a polypeptide of the invention.
- Inhibition of ligand/receptor interaction can be useful therapeutically, both for treating proliferative and differentiative disorders and for modulating (e.g., promoting or inhibiting) cell survival.
- the immunoglobulin fusion proteins of the invention can be used as immunogens to produce antibodies directed against a polypeptide of the invention in a subject, to purify ligands and in screening assays to identify molecules which inhibit the interaction of receptors with ligands.
- Chimeric and fusion proteins of the invention can be produced by standard recombinant DNA techniques.
- the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers.
- PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and re-amplified to generate a chimeric gene sequence (see, e.g., Ausubel et al., supra).
- many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide).
- a nucleic acid encoding a polypeptide of the invention can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the polypeptide of the invention.
- a signal sequence of a polypeptide of the invention can be used to facilitate secretion and isolation of the secreted protein or other proteins of interest.
- Signal sequences are typically characterized by a core of hydrophobic amino acids which are generally cleaved from the mature protein during secretion in one or more cleavage events.
- Such signal peptides contain processing sites that allow cleavage of the signal sequence from the mature proteins as they pass through the secretory pathway.
- a nucleic acid sequence encoding a signal sequence of the invention can be operably linked in an expression vector to a protein of interest, such as a protein which is ordinarily not secreted or is otherwise difficult to isolate.
- the signal sequence directs secretion of the protein, such as from a eukaryotic host into which the expression vector is transformed, and the signal sequence is subsequently or concurrently cleaved.
- the protein can then be readily purified from the extracellular medium by art recognized methods.
- the signal sequence can be linked to the protein of interest using a sequence which facilitates purification, such as with a GST domain.
- the signal sequences of the present invention can be used to identify regulatory sequences, e.g., promoters, enhancers, repressors. Since signal sequences are the most amino-terminal sequences of a peptide, it is expected that the nucleic acids which flank the signal sequence on its amino-terminal side will be regulatory sequences which affect transcription. Thus, a nucleotide sequence which encodes all or a portion of a signal sequence can be used as a probe to identify and isolate signal sequences and their flanking regions, and these flanking regions can be studied to identify regulatory elements therein.
- regulatory sequences e.g., promoters, enhancers, repressors.
- the present invention also pertains to variants of the polypeptides of the invention.
- variants have an altered amino acid sequence which can function as either agonists (mimetics) or as antagonists.
- Variants can be generated by mutagenesis, e.g., discrete point mutation or truncation.
- An agonist can retain substantially the same, or a subset, of the biological activities of the naturally occurring form of the protein.
- An antagonist of a protein can inhibit one or more of the activities of the naturally occurring form of the protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the protein of interest.
- specific biological effects can be elicited by treatment with a variant of limited function. Treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein can have fewer side effects in a subject relative to treatment with the naturally occurring form of the protein.
- Variants of a protein of the invention which function as either agonists (mimetics) or as antagonists can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of the protein of the invention for agonist or antagonist activity.
- a variegated library of variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library.
- a variegated library of variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential protein sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display).
- methods which can be used to produce libraries of potential variants of the polypeptides of the invention from a degenerate oligonucleotide sequence. Methods for synthesizing degenerate oligonucleotides are known in the art (see, e.g., Narang (1983) Tetrahedron 39:3; Itakura et al. (1984) Annu. Rev. Biochem. 53:323; Itakura et al. (1984) Science 198:1056; Ike et al. (1983) Nucleic Acid Res. 11:477).
- libraries of fragments of the coding sequence of a polypeptide of the invention can be used to generate a variegated population of polypeptides for screening and subsequent selection of variants.
- a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of the coding sequence of interest with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, re-naturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector.
- an expression library can be derived which encodes amino terminal and internal fragments of various sizes of the protein of interest.
- REM Recursive ensemble mutagenesis
- An isolated polypeptide of the invention, or a fragment thereof, can be used as an immunogen to generate antibodies using standard techniques for polyclonal and monoclonal antibody preparation.
- the full-length polypeptide or protein can be used or, alternatively, the invention provides antigenic peptide fragments for use as immunogens.
- the antigenic peptide of a protein of the invention comprises at least 8 (preferably 10, 15, 20, or 30 or more) amino acid residues of the amino acid sequence of any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74, and encompasses an epitope of the protein such that an antibody raised against the peptide forms a specific immune complex with the protein.
- Preferred epitopes encompassed by the antigenic peptide are regions that are located on the surface of the protein, e.g., hydrophilic regions.
- FIGS. 1L, 1M, 2 J, 3 U, 4 I, 4 J, 5 E, 6 F, and 7 D are hydrophobicity plots of the proteins of the invention. These plots or similar analyses can be used to identify hydrophilic regions.
- An immunogen typically is used to prepare antibodies by immunizing a suitable (i.e., immunocompetent) subject such as a rabbit, goat, mouse, or other mammal or vertebrate.
- a suitable (i.e., immunocompetent) subject such as a rabbit, goat, mouse, or other mammal or vertebrate.
- An appropriate immunogenic preparation can contain, for example, recombinantly-expressed or chemically-synthesized polypeptide.
- the preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or a similar immunostimulatory agent.
- antibody and “antibody substance” as used interchangeably herein refer to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site which specifically binds an antigen, such as a polypeptide of the invention (e.g., an epitope of a polypeptide of the invention).
- a molecule which specifically binds to a given polypeptide of the invention is a molecule which binds the polypeptide, but does not substantially bind other molecules in a sample, e.g., a biological sample, which naturally contains the polypeptide.
- immunologically active portions of immunoglobulin molecules include F(ab) and F(ab′) 2 fragments which can be generated by treating the antibody with an enzyme such as pepsin.
- the invention provides polyclonal and monoclonal antibodies.
- the term “monoclonal antibody” or “monoclonal antibody composition”, as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope.
- Polyclonal antibodies can be prepared as described above by immunizing a suitable subject with a polypeptide of the invention as an immunogen.
- Preferred polyclonal antibody compositions are ones that have been selected for antibodies directed against (i.e., which bind specifically with) one or more polypeptides of the invention.
- Particularly preferred polyclonal antibody preparations are ones that contain only antibodies directed against one or more polypeptides of the invention.
- Particularly preferred immunogen compositions are those that contain no other human proteins such as, for example, immunogen compositions made using a non-human host cell for recombinant expression of a polypeptide of the invention. In such a manner, the only human epitope or epitopes recognized by the resulting antibody compositions raised against this immunogen will be present as part of a polypeptide or polypeptides of the invention.
- the antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized polypeptide.
- ELISA enzyme linked immunosorbent assay
- the antibody molecules can be harvested or isolated from the subject (e.g., from the blood or serum of the subject) and further purified by well-known techniques, such as protein A chromatography to obtain the IgG fraction.
- antibodies which bind specifically with a protein or polypeptide of the invention can be selected or purified (e.g., partially purified) using chromatographic methods, such as affinity chromatography.
- a recombinantly expressed and purified (or partially purified) protein of the invention can be produced as described herein, and covalently or non-covalently coupled with a solid support such as, for example, a chromatography column.
- the column thus exhibits specific affinity for antibody substances which bind specifically with the protein of the invention, and these antibody substances can be purified from a sample containing antibody substances directed against a large number of different epitopes, thereby generating a substantially purified antibody substance composition, i.e., one that is substantially free of antibody substances which do not bind specifically with the protein.
- a substantially purified antibody composition in this context, means an antibody sample that contains at most only 30% (by dry weight) of contaminating antibodies directed against epitopes other than those on the desired protein or polypeptide of the invention, preferably at most 20%, more preferably at most 10%, most preferably at most 5% (by dry weight of the sample is contaminating antibodies).
- a purified antibody composition means that at least 99% of the antibodies in the composition are directed against the desired protein or polypeptide of the invention.
- antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein (1975) Nature 256:495-497, the human B cell hybridoma technique (Kozbor et al. (1983) Immunol. Today 4:72), the EBV-hybridoma technique (Cole et al. (1985), Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96) or trioma techniques.
- standard techniques such as the hybridoma technique originally described by Kohler and Milstein (1975) Nature 256:495-497, the human B cell hybridoma technique (Kozbor et al. (1983) Immunol. Today 4:72), the EBV-hybridoma technique (Cole et al. (1985), Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96) or trioma techniques.
- Hybridoma cells producing a monoclonal antibody of the invention are detected by screening the hybridoma culture supernatants for antibodies that bind the polypeptide of interest, e.g., using a standard ELISA assay.
- a monoclonal antibody directed against a polypeptide of the invention can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage display library) with the polypeptide of interest.
- Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia Recombinant Phage Antibody System, Catalog No. 27-9400-01; and the Stratagene SURFZAPTM Phage Display Kit, Catalog No. 240612).
- examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, U.S. Pat. No.
- recombinant antibodies such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention.
- a chimeric antibody is a molecule in which different portions of the antibody amino acid sequence are derived from different animal species, such as those having a variable region derived from a murine monoclonal antibody and a constant region derived from a human immunoglobulin. (See, e.g., Cabilly et al., U.S. Pat. No. 4,816,567; and Boss et al., U.S. Pat. No. 4,816,397).
- Humanized antibodies are antibody molecules which are obtained from non-human species, which have one or more complementarity-determining regions (CDRs) derived from the non-human species, and which have a framework region derived from a human immunoglobulin molecule. (See, e.g., Queen, U.S. Pat. No. 5,585,089).
- CDRs complementarity-determining regions
- Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in PCT Publication No. WO 87/02671; European Patent Application 184,187; European Patent Application 171,496; European Patent Application 173,494; PCT Publication No. WO 86/01533; U.S. Pat. No.
- Completely human antibodies are particularly desirable for therapeutic treatment of human patients.
- Such antibodies can be produced, for example, using transgenic mice which are incapable of expressing endogenous immunoglobulin heavy and light chains genes, but which can express human heavy and light chain genes
- the transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide of the invention.
- Monoclonal antibodies directed against the antigen can be obtained using conventional hybridoma technology.
- the human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA and IgE antibodies.
- Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as “guided selection.”
- a selected non-human monoclonal antibody e.g., a murine antibody
- a completely human antibody recognizing the same epitope Jespers et al. (1994) Bio/technology 12:899-903.
- An antibody directed against a polypeptide of the invention can be used to isolate the polypeptide by standard techniques, such as affinity chromatography or immunoprecipitation. Moreover, such an antibody can be used to detect the protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the polypeptide.
- the antibodies can also be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance.
- detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials.
- suitable enzymes include horseradish peroxidase, alkaline phosphatase, ⁇ -galactosidase, or acetylcholinesterase;
- suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin;
- suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin;
- an example of a luminescent material includes luminol;
- bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include 125 I, 131 I, 35 S or 3 H.
- an antibody substance can be conjugated with a therapeutic moiety such as a cytotoxin, a therapeutic agent, or a radioactive metal ion.
- Cytotoxins and cytotoxic agents include any agent that is detrimental to cells. Examples include taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, and analogs or homologs of these compounds.
- Therapeutic agents include, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil, and decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine ⁇ BSNU ⁇ , lomustine ⁇ CCNU ⁇ , cyclothosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin ⁇ formerly daunomycin ⁇ and doxorubicin), antibiotics (e.g., dactinomycin ⁇ formerly actinomycin ⁇ , bleomycin, mithramycin, and anthramycin ⁇ AMC ⁇ ), and anti-mitotic agents (e
- the conjugates of the invention can be used to modify a biological response; the drug moiety is not to be construed as limited to classical chemical therapeutic agents.
- the drug moiety can be a protein or polypeptide which exhibits a desired biological activity.
- Such proteins include, for example, toxins such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; proteins such as tumor necrosis factor, alpha-interferon, beta-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator; and biological response modifiers such as lymphokines, interleukin-1 (IL-1), interleukin-2 (IL-2), interleukin-6 (IL-6), granulocyte macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), and other growth factors.
- toxins such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin
- proteins such as tumor necrosis factor, alpha-interferon, beta-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator
- biological response modifiers such as lymphokines, interleukin-1 (IL-1), interleukin
- an antibody can be conjugated with a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Pat. No. 4,676,980.
- the invention provides substantially purified antibodies or fragment thereof, and non-human antibodies or fragments thereof, which antibodies or fragments specifically bind with a polypeptide having an amino acid sequence which comprises a sequence selected from the group consisting of:
- nucleic acid molecule which hybridizes with a nucleic acid having a sequence selected from the group consisting of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73 under conditions of hybridization of 6 ⁇ SSC (standard saline citrate) at 45° C. and washing in 0.2 ⁇ SSC, 0.1% SDS at 65° C.
- 6 ⁇ SSC standard saline citrate
- the invention provides non-human antibodies or fragments thereof, which antibodies or fragments specifically bind with a polypeptide having an amino acid sequence which comprises a sequence selected from the group consisting of:
- SSC standard saline citrate
- Such non-human antibodies can be goat, mouse, sheep, horse, chicken, rabbit, or rat antibodies.
- the non-human antibodies of the invention can be chimeric and/or humanized antibodies.
- the non-human antibodies of the invention can be polyclonal antibodies or monoclonal antibodies.
- the invention provides monoclonal antibodies or fragments thereof, which antibodies or fragments specifically bind with a polypeptide having an amino acid sequence which comprises a sequence selected from the group consisting of:
- the monoclonal antibodies can be human, humanized, chimeric and/or non-human antibodies.
- the substantially purified antibodies or fragments thereof can specifically bind with a signal peptide, a secreted sequence, an extracellular domain, a transmembrane or a cytoplasmic domain cytoplasmic membrane of a polypeptide of the invention.
- the substantially purified antibodies or fragments thereof, the non-human antibodies or fragments thereof and/or the monoclonal antibodies or fragments thereof, of the invention specifically bind with a secreted sequence or with an extracellular domain of one of TANGO 202, TANGO 234, TANGO 265, TANGO 273, TANGO 286, TANGO 294, and INTERCEPT 296.
- the extracellular domain with which the antibody substance binds has an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 6, 14, 22, 30, 37, 49, 50, and 56-58.
- any of the antibody substances of the invention can be conjugated with a therapeutic moiety or to a detectable substance.
- detectable substances include an enzyme, a prosthetic group, a fluorescent material (i.e., a fluorophore), a luminescent material, a bioluminescent material, and a radioactive material (e.g., a radionuclide or a substituent comprising a radionuclide).
- the invention also provides a kit containing an antibody substance of the invention conjugated with a detectable substance, and instructions for use.
- Still another aspect of the invention is a pharmaceutical composition comprising an antibody substance of the invention and a pharmaceutically acceptable carrier.
- the pharmaceutical composition contains an antibody substance of the invention, a therapeutic moiety (preferably conjugated with the antibody substance), and a pharmaceutically acceptable carrier.
- Still another aspect of the invention is a method of making an antibody that specifically recognizes one of TANGO 202, TANGO 234, TANGO 265, TANGO 273, TANGO 286, TANGO 294, and INTERCEPT 296.
- This method comprises immunizing a vertebrate (e.g., a mammal such as a rabbit, goat, or pig) with a polypeptide.
- the polypeptide used as an immunogen has an amino acid sequence that comprises a sequence selected from the group consisting of:
- nucleic acid molecule which hybridizes with a nucleic acid having a sequence selected from the group consisting of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73 under conditions of hybridization of 6 ⁇ SSC (standard saline citrate) at 45° C. and washing in 0.2 ⁇ SSC, 0.1% SDS at 65° C.
- 6 ⁇ SSC standard saline citrate
- a sample is collected from the vertebrate that contains an antibody that specifically recognizes the polypeptide with which the vertebrate was immunized.
- the polypeptide is recombinantly produced using a non-human host cell.
- an antibody substance can be further purified from the sample using techniques well known to those of skill in the art.
- the method can further comprise making a monoclonal antibody-producing cell from a cell of the vertebrate.
- antibodies can be collected from the antibody-producing cell.
- vectors preferably expression vectors, containing a nucleic acid encoding a polypeptide of the invention (or a portion thereof).
- vector refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
- plasmid refers to a circular double stranded DNA loop into which additional DNA segments can be ligated.
- viral vector Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome.
- vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors, expression vectors, are capable of directing the expression of genes to which they are operably linked. In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids (vectors). However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.
- viral vectors e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses
- the recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell.
- the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operably linked to the nucleic acid sequence to be expressed.
- operably linked is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).
- regulatory sequence is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, and the like.
- the expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein.
- the recombinant expression vectors of the invention can be designed for expression of a polypeptide of the invention in prokaryotic (e.g., E. coli ) or eukaryotic cells (e.g., insect cells (using baculovirus expression vectors), yeast cells or mammalian cells). Suitable host cells are discussed further in Goeddel, supra.
- the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.
- Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein.
- Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification.
- a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein.
- enzymes, and their cognate recognition sequences include Factor Xa, thrombin and enterokinase.
- Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson (1988) Gene 67:31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Phannacia, Piscataway, N.J.) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.
- GST glutathione S-transferase
- maltose E binding protein or protein A, respectively
- Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amann et al., (1988) Gene 69:301-315) and pET 1 Id (Studier et al., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990) 60-89).
- Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter.
- Target gene expression from the pET 11d vector relies on transcription from a T7 gn10-lac fusion promoter mediated by a co-expressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident lambda prophage harboring a T7 gn1 gene under the transcriptional control of the lacUV 5 promoter.
- One strategy to maximize recombinant protein expression in E. coli is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990) 119-128).
- Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in E. coli (Wada et al. (1992) Nucleic Acids Res. 20:2111-2118).
- Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.
- the expression vector is a yeast expression vector.
- yeast expression vectors for expression in yeast S. cerevisiae include pYepSec1 (Baldari et al. (1987) EMBO J. 6:229-234), pMFa (Kurjan and Herskowitz, (1982) Cell 30:933-943), pJRY88 (Schultz et al. (1987) Gene 54:113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and pPicZ (Invitrogen Corp, San Diego, Calif.).
- the expression vector is a baculovirus expression vector.
- Baculovirus vectors available for expression of proteins in cultured insect cells include the pAc series (Smith et al. (1983) Mol. Cell Biol. 3:2156-2165) and the pVL series (Lucklow and Summers (1989) Virology 170:31-39).
- a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector.
- mammalian expression vectors include pCDM8 (Seed (1987) Nature 329:840) and pMT2PC (Kaufman et al. (1987) EMBO J. 6:187-195).
- the expression vector's control functions are often provided by viral regulatory elements.
- commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40.
- suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook et al., supra.
- the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid).
- tissue-specific regulatory elements are known in the art.
- suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert et al. (1987) Genes Dev. 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) Adv. Immunol. 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) EMBO J.
- promoters are also encompassed, for example the murine hox promoters (Kessel and Gruss (1990) Science 249:374-379) and the ⁇ -fetoprotein promoter (Campes and Tilghman (1989) Genes Dev. 3:537-546).
- the invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operably linked to a regulatory sequence in a manner which allows for expression (by transcription of the DNA molecule) of an RNA molecule which is antisense to the mRNA encoding a polypeptide of the invention.
- Regulatory sequences operably linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA.
- the antisense expression vector can be in the form of a recombinant plasmid, phagemid, or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced.
- Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced.
- host cell and “recombinant host cell” are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.
- a host cell can be any prokaryotic (e.g., E. coli ) or eukaryotic cell (e.g., insect cells, yeast or mammalian cells).
- prokaryotic e.g., E. coli
- eukaryotic cell e.g., insect cells, yeast or mammalian cells.
- Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques.
- transformation and “transfection” are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (supra), and other laboratory manuals.
- a gene that encodes a selectable marker (e.g., for resistance to antibiotics) is generally introduced into the host cells along with the gene of interest.
- selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate.
- Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).
- an endogenous nucleic acid within a cell, cell line, or microorganism e.g., a TANGO 202, TANGO 234, TANGO 265, TANGO 273, TANGO 286, TANGO 294, or INTERCEPT 296 nucleic acid, as described herein
- a heterologous DNA regulatory element i.e., one that is heterologous with respect to the endogenous gene
- the inserted regulatory element can be operatively linked with the endogenous gene (e.g., TANGO 202, TANGO 234, TANGO 265, TANGO 273, TANGO 286, TANGO 294, or INTERCEPT 296) and thereby control, modulate, or activate the endogenous gene.
- the endogenous gene e.g., TANGO 202, TANGO 234, TANGO 265, TANGO 273, TANGO 286, TANGO 294, or INTERCEPT 296
- an endogenous TANGO 202, TANGO 234, TANGO 265, TANGO 273, TANGO 286, TANGO 294, or INTERCEPT 296 gene which is normally “transcriptionally silent” i.e., a TANGO 202, TANGO 234, TANGO 265, TANGO 273, TANGO 286, TANGO 294, or INTERCEPT 296 gene which is normally not expressed, or is normally expressed only at only a very low level
- a regulatory element which is capable of promoting expression of the gene in the cell, cell line, or microorganism.
- a transcriptionally silent, endogenous TANGO 202, TANGO 234, TANGO 265, TANGO 273, TANGO 286, TANGO 294, or INTERCEPT 296 gene can be activated by inserting a promiscuous regulatory element that works across cell types.
- a heterologous regulatory element can be inserted into a stable cell line or cloned microorganism such that it is operatively linked with and activates expression of an endogenous TANGO 202, TANGO 234, TANGO 265, TANGO 273, TANGO 286, TANGO 294, or INTERCEPT 296 gene, using techniques, such as targeted homologous recombination, which are well known to those of skill in the art (described e.g., in Chappel, U.S. Pat. No. 5,272,071; PCT publication No. WO 91/06667, published May 16, 1991).
- a host cell of the invention such as a prokaryotic or eukaryotic host cell in culture, can be used to produce a polypeptide of the invention. Accordingly, the invention further provides methods for producing a polypeptide of the invention using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding a polypeptide of the invention has been introduced) in a suitable medium such that the polypeptide is produced. In another embodiment, the method further comprises isolating the polypeptide from the medium or the host cell.
- the host cells of the invention can also be used to produce non-human transgenic animals.
- a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which a sequences encoding a polypeptide of the invention have been introduced.
- Such host cells can then be used to create non-human transgenic animals in which exogenous sequences encoding a polypeptide of the invention have been introduced into their genome or homologous recombinant animals in which endogenous encoding a polypeptide of the invention sequences have been altered.
- Such animals are useful for studying the function and/or activity of the polypeptide and for identifying and/or evaluating modulators of polypeptide activity.
- a “transgenic animal” is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene.
- Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc.
- a transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal.
- an “homologous recombinant animal” is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.
- a transgenic animal of the invention can be created by introducing nucleic acid encoding a polypeptide of the invention (or a homologue thereof) into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal.
- Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene.
- a tissue-specific regulatory sequence(s) can be operably linked to the transgene to direct expression of the polypeptide of the invention to particular cells.
- transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Pat. Nos. 4,736,866 and 4,870,009, U.S. Pat. No. 4,873,191, in Hogan, Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986, and in Wakayama et al., 1999, Proc. Natl. Acad. Sci. USA 96:14984-14989. Similar methods can be used to produce other transgenic animals.
- a transgenic founder animal can be identified based upon the presence of the transgene in its genome and/or expression of mRNA encoding the transgene in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying the transgene can further be bred to other transgenic animals carrying other transgenes.
- a vector which contains at least a portion of a gene encoding a polypeptide of the invention into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the gene.
- the vector is designed such that, upon homologous recombination, the endogenous gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a “knock out” vector).
- the vector can be designed such that, upon homologous recombination, the endogenous gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous protein).
- the altered portion of the gene is flanked at its 5′ and 3′ ends by additional nucleic acid of the gene to allow for homologous recombination to occur between the exogenous gene carried by the vector and an endogenous gene in an embryonic stem cell.
- the additional flanking nucleic acid sequences are of sufficient length for successful homologous recombination with the endogenous gene.
- flanking DNA both at the 5′ and 3′ ends
- flanking DNA both at the 5′ and 3′ ends
- the vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced gene has homologously recombined with the endogenous gene are selected (see, e.g., Li et al. (1992) Cell 69:915).
- the selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras (see, e.g., Bradley in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, Robertson, ed. (IRL, Oxford, 1987) pp. 113-152).
- a chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term.
- Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene.
- transgenic non-human animals can be produced which contain selected systems which allow for regulated expression of the transgene.
- a system is the cre/loxP recombinase system of bacteriophage P1.
- Cre/loxP recombinase system of bacteriophage P1.
- a recombinase system is the FLP recombinase system of Saccharomyces cerevisiae (O'Gorman et al. (1991) Science 251:1351-1355.
- mice containing transgenes encoding both the Cre recombinase and a selected protein are required.
- Such animals can be provided through the construction of “double” transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.
- Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut et al. (1997) Nature 385:810-813 and PCT Publication Nos. WO 97/07668 and WO 97/07669.
- compositions suitable for administration typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier.
- pharmaceutically acceptable carrier is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
- the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
- the invention includes methods for preparing pharmaceutical compositions for modulating the expression or activity of a polypeptide or nucleic acid of the invention. Such methods comprise formulating a pharmaceutically acceptable carrier with an agent which modulates expression or activity of a polypeptide or nucleic acid of the invention. Such compositions can further include additional active agents. Thus, the invention further includes methods for preparing a pharmaceutical composition by formulating a pharmaceutically acceptable carrier with an agent which modulates expression or activity of a polypeptide or nucleic acid of the invention and one or more additional active compounds.
- the agent which modulates expression or activity can, for example, be a small molecule other than a nucleic acid, polypeptide, or antibody of the invention.
- small molecules include peptides, peptidomimetics, amino acids, amino acid analogs, polynucleotides, polynucleotide analogs, nucleotides, nucleotide analogs, organic or inorganic compounds (i.e., including heteroorganic and organometallic compounds) having a molecular weight less than about 10,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 5,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 1,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 500 grams per mole, and salts, esters, and other pharmaceutically acceptable forms of such compounds.
- Exemplary doses of a small molecule include milligram or microgram amounts per kilogram of subject or sample weight (e.g., about 1 microgram per kilogram to about 500 milligrams per kilogram, about 100 micrograms per kilogram to about 5 milligrams per kilogram, or about 1 microgram per kilogram to about 50 micrograms per kilogram).
- Exemplary doses of a protein or polypeptide include gram, milligram or microgram amounts per kilogram of subject or sample weight (e.g., about 1 microgram per kilogram to about 5 grams per kilogram, about 100 micrograms per kilogram to about 500 milligrams per kilogram, or about 1 milligram per kilogram to about 50 milligrams per kilogram).
- appropriate doses of one of these agents depend upon the potency of the agent with respect to the expression or activity to be modulated. Such appropriate doses can be determined using the assays described herein.
- an animal e.g., a human
- a physician, veterinarian, or researcher can, for example, prescribe a relatively low dose at first, subsequently increasing the dose until an appropriate response is obtained.
- the specific dose level for any particular animal subject will depend upon a variety of factors including the activity of the specific agent employed, the age, body weight, general health, gender, and diet of the subject, the time of administration, the route of administration, the rate of excretion, any drug combination, and the degree of expression or activity to be modulated.
- a pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration.
- routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), (topical), transmucosal, and rectal administration.
- Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediamine-tetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
- the parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose vials made of glass or plastic.
- compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
- suitable carriers include physiological saline, bacteriostatic water, Cremophor EL (BASF; Parsippany, N.J.) or phosphate buffered saline (PBS).
- the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof.
- the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
- isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition.
- Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a polypeptide or antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
- the active compound e.g., a polypeptide or antibody
- dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium, and then incorporating the required other ingredients from those enumerated above.
- the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed.
- compositions can be included as part of the composition.
- the tablets, pills, capsules, troches, and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
- a binder such as microcrystalline cellulose, gum tragacanth or gelatin
- an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch
- a lubricant such as magnesium stearate or Sterotes
- the compounds are delivered in the form of an aerosol spray from a pressurized container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
- a suitable propellant e.g., a gas such as carbon dioxide, or a nebulizer.
- Systemic administration can also be by transmucosal or transdermal means.
- penetrants appropriate to the barrier to be permeated are used in the formulation.
- penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives.
- Transmucosal administration can be accomplished through the use of nasal sprays or suppositories.
- the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
- the compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
- suppositories e.g., with conventional suppository bases such as cocoa butter and other glycerides
- retention enemas for rectal delivery.
- the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
- a controlled release formulation including implants and microencapsulated delivery systems.
- Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
- the materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc.
- Liposomal suspensions (including liposomes which can be targeted to bind with virus-infected cells using a monoclonal antibody which binds specifically with a viral antigen) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.
- Dosage unit form refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
- the specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.
- the preferred dosage is 0.1 mg/kg to 100 mg/kg of body weight (generally 10 mg/kg to 20 mg/kg). If the antibody is to act in the brain, a dosage of 50 mg/kg to 100 mg/kg is usually appropriate. Generally, partially human antibodies and fully human antibodies have a longer half-life within the human body than other antibodies. Accordingly, lower dosages and less frequent administration is often possible. Modifications such as lipidation can be used to stabilize antibodies and to enhance uptake and tissue penetration (e.g., into the brain). A method for lipidation of antibodies is described by Cruikshank et al. ((1997) J. Acquired Immune Deficiency Syndromes and Human Retrovirology 14:193).
- the nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors.
- Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (U.S. Pat. No. 5,328,470), or by stereotactic injection (see, e.g., Chen et al. (1994) Proc. Natl. Acad. Sci. USA 91:3054-3057).
- the pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded.
- the pharmaceutical preparation can include one or more cells which produce the gene delivery system.
- compositions can be included in a container, pack, or dispenser together with instructions for administration.
- nucleic acid molecules, proteins, protein homologs, and antibodies described herein can be used in one or more of the following methods: a) screening assays; b) detection assays (e.g., chromosomal mapping, tissue typing, forensic biology); c) predictive medicine (e.g., diagnostic assays, prognostic assays, monitoring clinical trials, and pharmacogenomics); and d) methods of treatment (e.g., therapeutic and prophylactic).
- detection assays e.g., chromosomal mapping, tissue typing, forensic biology
- predictive medicine e.g., diagnostic assays, prognostic assays, monitoring clinical trials, and pharmacogenomics
- methods of treatment e.g., therapeutic and prophylactic.
- polypeptides of the invention can to used for all of the purposes identified herein in portions of the disclosure relating to individual types of protein of the invention (e.g., TANGO 202 proteins, TANGO 234 proteins, TANGO 265 proteins, TANGO 273 proteins, TANGO 286 proteins, TANGO 294 proteins, and INTERCEPT 296 proteins).
- Polypeptides of the invention can also be used to modulate cellular proliferation, cellular differentiation, cellular adhesion, or some combination of these.
- the isolated nucleic acid molecules of the invention can be used to express proteins (e.g., via a recombinant expression vector in a host cell in gene therapy applications), to detect mRNA (e.g., in a biological sample) or a genetic lesion, and to modulate activity of a polypeptide of the invention.
- the polypeptides of the invention can be used to screen drugs or compounds which modulate activity or expression of a polypeptide of the invention as well as to treat disorders characterized by insufficient or excessive production of a protein of the invention or production of a form of a protein of the invention which has decreased or aberrant activity compared to the wild type protein.
- the antibodies of the invention can be used to detect and isolate a protein of the and modulate activity of a protein of the invention.
- This invention further pertains to novel agents identified by the above-described screening assays and uses thereof for treatments as described herein.
- the invention provides a method (also referred to herein as a “screening assay”) for identifying modulators, i.e., candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules or other drugs) which bind to polypeptide of the invention or have a stimulatory or inhibitory effect on, for example, expression or activity of a polypeptide of the invention.
- modulators i.e., candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules or other drugs) which bind to polypeptide of the invention or have a stimulatory or inhibitory effect on, for example, expression or activity of a polypeptide of the invention.
- the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of the membrane-bound form of a polypeptide of the invention or biologically active portion thereof.
- the test compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the “one-bead one-compound” library method; and synthetic library methods using affinity chromatography selection.
- the biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam (1997) Anticancer Drug Des. 12:145).
- an assay is a cell-based assay in which a cell which expresses a membrane-bound form of a polypeptide of the invention, or a biologically active portion thereof, on the cell surface is contacted with a test compound and the ability of the test compound to bind to the polypeptide determined.
- the cell for example, can be a yeast cell or a cell of mammalian origin. Determining the ability of the test compound to bind to the polypeptide can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that binding of the test compound to the polypeptide or biologically active portion thereof can be determined by detecting the labeled compound in a complex.
- test compounds can be labeled with 125 I, 35 S, 14 C, or 3 H, either directly or indirectly, and the radioisotope detected by direct counting of radio-emission or by scintillation counting.
- test compounds can be enzymatically labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product.
- the assay comprises contacting a cell which expresses a membrane-bound form of a polypeptide of the invention, or a biologically active portion thereof, on the cell surface with a known compound which binds the polypeptide to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with the polypeptide, wherein determining the ability of the test compound to interact with the polypeptide comprises determining the ability of the test compound to preferentially bind to the polypeptide or a biologically active portion thereof as compared to the known compound.
- the assay involves assessment of an activity characteristic of the polypeptide, wherein binding of the test compound with the polypeptide or a biologically active portion thereof alters (i.e., increases or decreases) the activity of the polypeptide.
- an assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of a polypeptide of the invention, or a biologically active portion thereof, on the cell surface with a test compound and determining the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the polypeptide or biologically active portion thereof. Determining the ability of the test compound to modulate the activity of the polypeptide or a biologically active portion thereof can be accomplished, for example, by determining the ability of the polypeptide to bind to or interact with a target molecule or to transport molecules across the cytoplasmic membrane.
- a “target molecule” is a molecule with which a selected polypeptide (e.g., a polypeptide of the invention binds or interacts with in nature, for example, a molecule on the surface of a cell which expresses the selected protein, a molecule on the surface of a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule.
- a target molecule can be a polypeptide of the invention or some other polypeptide or protein.
- a target molecule can be a component of a signal transduction pathway which facilitates transduction of an extracellular signal (e.g., a signal generated by binding of a compound to a polypeptide of the invention) through the cell membrane and into the cell or a second intercellular protein which has catalytic activity or a protein which facilitates the association of downstream signaling molecules with a polypeptide of the invention. Determining the ability of a polypeptide of the invention to bind to or interact with a target molecule can be accomplished by determining the activity of the target molecule.
- an extracellular signal e.g., a signal generated by binding of a compound to a polypeptide of the invention
- the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (e.g., an mRNA, intracellular Ca 2+ , diacylglycerol, IP3, and the like), detecting catalytic/enzymatic activity of the target on an appropriate substrate, detecting the induction of a reporter gene (e.g., a regulatory element that is responsive to a polypeptide of the invention operably linked to a nucleic acid encoding a detectable marker, e.g. luciferase), or detecting a cellular response, for example, cellular differentiation, or cell proliferation.
- a reporter gene e.g., a regulatory element that is responsive to a polypeptide of the invention operably linked to a nucleic acid encoding a detectable marker, e.g. luciferase
- detecting a cellular response for example, cellular differentiation, or cell proliferation.
- an assay of the present invention is a cell-free assay comprising contacting a polypeptide of the invention or biologically active portion thereof with a test compound and determining the ability of the test compound to bind to the polypeptide or biologically active portion thereof. Binding of the test compound to the polypeptide can be determined either directly or indirectly as described above.
- the assay includes contacting the polypeptide of the invention or biologically active portion thereof with a known compound which binds the polypeptide to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with the polypeptide, wherein determining the ability of the test compound to interact with the polypeptide comprises determining the ability of the test compound to preferentially bind to the polypeptide or biologically active portion thereof as compared to the known compound.
- an assay is a cell-free assay comprising contacting a polypeptide of the invention or biologically active portion thereof with a test compound and determining the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the polypeptide or biologically active portion thereof. Determining the ability of the test compound to modulate the activity of the polypeptide can be accomplished, for example, by determining the ability of the polypeptide to bind to a target molecule by one of the methods described above for determining direct binding.
- determining the ability of the test compound to modulate the activity of the polypeptide can be accomplished by determining the ability of the polypeptide of the invention to further modulate the target molecule For example, the catalytic activity, the enzymatic activity, or both, of the target molecule on an appropriate substrate can be determined as previously described.
- the cell-free assay comprises contacting a polypeptide of the invention or biologically active portion thereof with a known compound which binds the polypeptide to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with the polypeptide, wherein determining the ability of the test compound to interact with the polypeptide comprises determining the ability of the polypeptide to preferentially bind to or modulate the activity of a target molecule.
- the cell-free assays of the present invention are amenable to use of both a soluble form or the membrane-bound form of a polypeptide of the invention.
- solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-octylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton X-100, Triton X-114, Thesit, Isotridecypoly(ethylene glycol ether)n, 3-[(3-cholamidopropyl)dimethylamminio]-1-propane sulfonate (CHAPS), 3-[(3-cholamidopropyl)dimethylamminio]-2-hydroxy-1-propane sulfonate (CHAP S O), or N-dodecyl-N,N-dimethyl-3-ammonio-1-propane sulfonate.
- non-ionic detergents such as n-octylglucoside, n-do
- binding of a test compound to the polypeptide, or interaction of the polypeptide with a target molecule in the presence and absence of a candidate compound can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes.
- a fusion protein can be provided which adds a domain that allows one or both of the proteins to be bound to a matrix.
- glutathione-S-transferase fusion proteins or glutathione-S-transferase fusion proteins can be adsorbed onto glutathione SEPHAROSETM beads (Sigma Chemical; St. Louis, Mo.) or glutathione derivatized microtiter plates, which are then combined with the test compound or the test compound and either the non-adsorbed target protein or A polypeptide of the invention, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components and complex formation is measured either directly or indirectly, for example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of binding or activity of the polypeptide of the invention can be determined using standard techniques.
- polypeptide of the invention or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin.
- Biotinylated polypeptide of the invention or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well known in the art (e.g., biotinylation kit, Pierce Chemicals; Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical).
- antibodies reactive with the polypeptide of the invention or target molecules but which do not interfere with binding of the polypeptide of the invention to its target molecule can be derivatized to the wells of the plate, and unbound target or polypeptide of the invention trapped in the wells by antibody conjugation.
- Methods for detecting such complexes include immunodetection of complexes using antibodies reactive with the polypeptide of the invention or target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the polypeptide of the invention or target molecule.
- modulators of expression of a polypeptide of the invention are identified in a method in which a cell is contacted with a candidate compound and the expression of the selected mRNA or protein (i.e., the mRNA or protein corresponding to a polypeptide or nucleic acid of the invention) in the cell is determined.
- the level of expression of the selected mRNA or protein in the presence of the candidate compound is compared to the level of expression of the selected mRNA or protein in the absence of the candidate compound.
- the candidate compound can then be identified as a modulator of expression of the polypeptide of the invention based on this comparison.
- the candidate compound when expression of the selected mRNA or protein is greater (i.e., statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of the selected mRNA or protein expression.
- the candidate compound when expression of the selected mRNA or protein is less (i.e., statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of the selected mRNA or protein expression.
- the level of the selected mRNA or protein expression in the cells can be determined by methods described herein.
- a polypeptide of the inventions can be used as “bait proteins” in a two-hybrid assay or three hybrid assay (see, e.g., U.S. Pat. No. 5,283,317; Zervos et al. (1993) Cell 72:223-232; Madura et al. (1993) J. Biol. Chem. 268:12046-12054; Bartel et al. (1993) Bio/Techniques 14:920-924; Iwabuchi et al. (1993) Oncogene 8:1693-1696; and PCT Publication No.
- binding proteins are also likely to be involved in the propagation of signals by the polypeptide of the inventions as, for example, upstream or downstream elements of a signaling pathway involving the polypeptide of the invention.
- This invention further pertains to novel agents identified by the above-described screening assays and uses thereof for treatments as described herein.
- portions or fragments of the cDNA sequences identified herein can be used in numerous ways as polynucleotide reagents. For example, these sequences can be used to: (i) map their respective genes on a chromosome and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. These applications are described in the subsections below.
- sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. Accordingly, nucleic acid molecules described herein or fragments thereof, can be used to map the location of the corresponding genes on a chromosome. The mapping of the sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.
- genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 base pairs in length) from the sequence of a gene of the invention.
- Computer analysis of the sequence of a gene of the invention can be used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process.
- These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the gene sequences will yield an amplified fragment.
- D'Eustachio et al. see D'Eustachio et al. ((1983) Science 220:919-924).
- PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the nucleic acid sequences of the invention to design oligonucleotide primers, sub-localization can be achieved with panels of fragments from specific chromosomes. Other mapping strategies which can similarly be used to map a gene to its chromosome include in situ hybridization (described in Fan et al. (1990) Proc. Natl. Acad. Sci. USA 87:6223-27), pre-screening with labeled flow-sorted chromosomes, and pre-selection by hybridization to chromosome specific cDNA libraries.
- Fluorescence in situ hybridization of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one step.
- FISH Fluorescence in situ hybridization
- Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to non-coding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.
- differences in the DNA sequences between individuals affected and unaffected with a disease associated with a gene of the invention can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.
- nucleic acid sequences disclosed herein can be used to perform searches against “mapping databases”, e.g., BLAST-type search, such that the chromosome position of the gene is identified by sequence homology or identity with known sequence fragments which have been mapped to chromosomes.
- “mapping databases” e.g., BLAST-type search
- the human gene for TANGO 265 is located on chromosome 1 between markers D1 S305 and D1S2635, and the human gene for TANGO 273 is located on chromosome 7 between markers D7S2467 and D7S2552.
- the human gene for TANGO 286 exhibits significant amino acid homology with a region of the human chromosome region 22q12-13 genomic nucleotide sequence having GenBank Accession number AL021937. Alignment of a 45 kilobase nucleotide sequence encoding TANGO 286 with AL021937, however, indicated the presence in TANGO 286 of exons which differ from those disclosed in L021937 (pam120.mat scoring matrix; gap penalties ⁇ 12/ ⁇ 4).
- This region of chromosome 22 comprises an immunoglobulin lambda chain C (IGLC) pseudogene, the Ret finger protein-like 3 (RFPL3) and Ret finger protein-like 3 antisense (RFPL3S) genes, a gene encoding a novel immunoglobulin lambda chain V family protein, a novel gene encoding a protein similar both to mouse RGDS protein (RALGDS, RALGEF, guanine nucleotide dissociation stimulator A) and to rabbit oncogene RSC, a novel gene encoding the human orthologue of worm F16A11.2 protein, a novel gene encoding a protein similar both to BPI and to rabbit liposaccharide-binding protein, and a 5′-portion of a novel gene.
- This region also comprises various ESTs, STSs, GSSs, genomic marker D22S1175, a ca repeat polymorphism and putative CpG islands.
- a polypeptide and fragments and sequences thereof and antibodies which bind specifically with such polypeptides/fragments can be used to map the location of the gene encoding the polypeptide on a chromosome. This mapping can be performed by specifically detecting the presence of the polypeptide/fragments in members of a panel of somatic cell hybrids between cells obtained from a first species of animal from which the protein originates and cells obtained from a second species of animal, determining which somatic cell hybrid(s) expresses the polypeptide, and noting the chromosome(s) of the first species of animal that it contains. For examples of this technique (see Pajunen et al., 1988, Cytogenet. Cell Genet.
- the presence of the polypeptide in the somatic cell hybrids can be determined by assaying an activity or property of the polypeptide (e.g., enzymatic activity, as described in Bordelon-Riser et al., 1979, Som. Cell Genet. 5:597-613 and Owerbach et al., 1978, Proc. Natl. Acad. Sci. USA 75:5640-5644).
- an activity or property of the polypeptide e.g., enzymatic activity, as described in Bordelon-Riser et al., 1979, Som. Cell Genet. 5:597-613 and Owerbach et al., 1978, Proc. Natl. Acad. Sci. USA 75:5640-5644.
- the human gene for TANGO 234 protein indicated that the gene is located at chromosomal location h12p13. Flanking chromosomal markers include WI-6980 and GATA8A09.43. Nearby human loci include IBD2 (inflammatory bowel disease 2), FPF (familial periodic fever), and HPDR2 (hypophosphatemia vitamin D resistant rickets 2). Nearby genes are KLRC (killer cell receptor cluster), DRPLA (dentatorubro-pallidoluysian atrophy), GAPD (glyceraldehyde-3-phosphate) dehydrogenase, and PXR1 peroxisome receptor 1). This region is syntenic to mouse chromosome mo6.
- Murine chromosomal mapping indicated that the murine orthologue is located near the scr (scruffy) locus.
- Nearby mouse genes include drpla (dentatorubral phillidoluysian atrophy), prp (proline rich protein), and kap (kidney androgen regulated protein).
- the nucleic acid sequences of the present invention can also be used to identify individuals from minute biological samples.
- the United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel.
- RFLP restriction fragment length polymorphism
- an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification.
- This method does not suffer from the current limitations of “Dog Tags” which can be lost, switched, or stolen, making positive identification difficult.
- the sequences of the present invention are useful as additional DNA markers for RFLP (described in U.S. Pat. No. 5,272,057).
- sequences of the present invention can be used to provide an alternative technique which determines the actual base-by-base DNA sequence of selected portions of an individual's genome.
- the nucleic acid sequences described herein can be used to prepare two PCR primers from the 5′ and 3′ ends of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.
- Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences.
- the sequences of the present invention can be used to obtain such identification sequences from individuals and from tissue.
- the nucleic acid sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the non-coding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases.
- Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes.
- non-coding sequences of any of SEQ ID NOs: 1, 9, 17, 25, 33, 45, and 53 can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers which each yield a non-coding amplified sequence of 100 bases. If predicted coding sequences, such as those in any of SEQ ID NOs: 2, 10, 18, 26, 34, 46, and 54 are used, a more appropriate number of primers for positive individual identification would be 500-2,000.
- a panel of reagents from the nucleic acid sequences described herein is used to generate a unique identification database for an individual, those same reagents can later be used to identify tissue from that individual.
- positive identification of the individual, living or dead can be made from extremely small tissue samples.
- DNA-based identification techniques can also be used in forensic biology. Forensic biology is a scientific field employing genetic typing of biological evidence found at a crime scene as a means for positively identifying, for example, a perpetrator of a crime.
- PCR technology can be used to amplify DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, or semen found at a crime scene. The amplified sequence can then be compared to a standard, thereby allowing identification of the origin of the biological sample.
- sequences of the present invention can be used to provide polynucleotide reagents, e.g., PCR primers, targeted to specific loci in the human genome, which can enhance the reliability of DNA-based forensic identifications by, for example, providing another “identification marker” (i.e., another DNA sequence that is unique to a particular individual).
- another “identification marker” i.e., another DNA sequence that is unique to a particular individual.
- actual base sequence information can be used for identification as an accurate alternative to patterns formed by restriction enzyme generated fragments.
- Sequences targeted to non-coding regions are particularly appropriate for this use as greater numbers of polymorphisms occur in the non-coding regions, making it easier to differentiate individuals using this technique.
- polynucleotide reagents include the nucleic acid sequences of the invention or portions thereof, e.g., fragments derived from non-coding regions having a length of at least 20 or 30 bases.
- nucleic acid sequences described herein can further be used to provide polynucleotide reagents, e.g., labeled or labelable probes which can be used in, for example, an in situ hybridization technique, to identify a specific tissue, e.g., brain tissue. This can be very useful in cases where a forensic pathologist is presented with a tissue of unknown origin. Panels of such probes can be used to identify tissue by species and/or by organ type.
- polynucleotide reagents e.g., labeled or labelable probes which can be used in, for example, an in situ hybridization technique, to identify a specific tissue, e.g., brain tissue. This can be very useful in cases where a forensic pathologist is presented with a tissue of unknown origin. Panels of such probes can be used to identify tissue by species and/or by organ type.
- the present invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically.
- one aspect of the present invention relates to diagnostic assays for determining expression of a polypeptide or nucleic acid of the invention and/or activity of a polypeptide of the invention (e.g., expression or activity of one of TANGO 202, TANGO 234, TANGO 265, TANGO 273, TANGO 286, TANGO 294, or INTERCEPT 296 genes or proteins), in the context of a biological sample (e.g., blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant expression or activity of a polypeptide of the invention.
- a biological sample e.g., blood, serum, cells, tissue
- the invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with aberrant expression or activity of a polypeptide of the invention. For example, mutations in a gene of the invention can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with aberrant expression or activity of a polypeptide of the invention.
- determinations can be based on normalized expression levels of the gene.
- a gene expression level is normalized by correcting the absolute expression level of the gene (e.g., a TANGO 202, TANGO 234, TANGO 265, TANGO 273, TANGO 286, TANGO 294, or INTERCEPT 296 gene as described herein) by comparing its expression to expression of a gene for which expression is not believed to be co-regulated with the gene of interest, e.g., a housekeeping gene that is constitutively expressed.
- Suitable genes for normalization include housekeeping genes such as the actin gene.
- Such normalization allows comparison of the expression level in one sample, e.g., a patient sample, with the expression level in another sample, e.g., a sample obtained from a patient known not to be afflicted with a disease or condition, or between samples obtained from different sources.
- the expression level can be assessed as a relative expression level.
- a gene e.g., a TANGO 202, TANGO 234, TANGO 265, TANGO 273, TANGO 286, TANGO 294, or INTERCEPT 296 gene, as described herein
- the level of expression of the gene is determined for 10 or more samples (preferably 50 or more samples) of different isolates of cells in which the gene is believed to be expressed, prior to assessing the level of expression of the gene in the sample of interest.
- the mean expression level of the gene detected in the large number of samples is determined, and this value is used as a baseline expression level for the gene.
- the expression level of the gene assessed in the test sample (i.e., its absolute level of expression) is divided by the mean expression value to yield a relative expression level.
- Such a method can identify tissues or individuals which are afflicted with a disorder associated with aberrant expression of a gene of the invention.
- the samples used in the baseline determination are generated either using cells obtained from a tissue or individual known to be afflicted with a disorder (e.g., a disorder associated with aberrant expression of one of the TANGO 202, TANGO 234, TANGO 265, TANGO 273, TANGO 286, TANGO 294, or INTERCEPT 296 genes) or using cells obtained from a tissue or individual known not to be afflicted with the disorder.
- a disorder e.g., a disorder associated with aberrant expression of one of the TANGO 202, TANGO 234, TANGO 265, TANGO 273, TANGO 286, TANGO 294, or INTERCEPT 296 genes
- levels of expression of these genes in tissues or individuals known to be or not to be afflicted with the disorder can be used to assess whether the aberrant expression of the gene is associated with the disorder (e.g., with onset of the disorder, or as a symptom of the disorder over time).
- Another aspect of the invention pertains to monitoring the influence of agents (e.g., drugs or other compounds) on the expression or activity of one or more of TANGO 202, TANGO 234, TANGO 265, TANGO 273, TANGO 286, TANGO 294, and INTERCEPT 296 in clinical trials.
- agents e.g., drugs or other compounds
- TANGO 202 TANGO 234, TANGO 265, TANGO 273, TANGO 286, TANGO 294, and INTERCEPT 296 in clinical trials.
- An exemplary method for detecting the presence or absence of a polypeptide or nucleic acid of the invention in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting a polypeptide or nucleic acid (e.g., mRNA, genomic DNA) of the invention such that the presence of a polypeptide or nucleic acid of the invention is detected in the biological sample.
- a preferred agent for detecting mRNA or genomic DNA encoding a polypeptide of the invention is a labeled nucleic acid probe capable of hybridizing to mRNA or genomic DNA encoding a polypeptide of the invention.
- the nucleic acid probe can be, for example, a full-length cDNA, such as the nucleic acid of any of SEQ ID NOs: 1, 9, 17, 25, 33, 45, 53, 67, and 72, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to a mRNA or genomic DNA encoding a polypeptide of the invention.
- a full-length cDNA such as the nucleic acid of any of SEQ ID NOs: 1, 9, 17, 25, 33, 45, 53, 67, and 72, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to a mRNA or genomic DNA encoding a polypeptide of the invention.
- Other suitable probes for use in the diagnostic assays of the invention are described herein.
- a preferred agent for detecting a polypeptide of the invention is an antibody capable of binding to a polypeptide of the invention, preferably an antibody with a detectable label
- Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab′) 2 ) can be used.
- the term “labeled”, with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled.
- Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin.
- biological sample is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo.
- in vitro techniques for detection of mRNA include Northern hybridizations and in situ hybridizations.
- In vitro techniques for detection of a polypeptide of the invention include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence.
- In vitro techniques for detection of genomic DNA include Southern hybridizations.
- in vivo techniques for detection of a polypeptide of the invention include introducing into a subject a labeled antibody directed against the polypeptide.
- the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.
- the biological sample contains protein molecules from the test subject.
- the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject.
- a preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.
- the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting a polypeptide of the invention or mRNA or genomic DNA encoding a polypeptide of the invention, such that the presence of the polypeptide or mRNA or genomic DNA encoding the polypeptide is detected in the biological sample, and comparing the presence of the polypeptide or mRNA or genomic DNA encoding the polypeptide in the control sample with the presence of the polypeptide or mRNA or genomic DNA encoding the polypeptide in the test sample.
- kits for detecting the presence of a polypeptide or nucleic acid of the invention in a biological sample can be used to determine if a subject is suffering from or is at increased risk of developing a disorder associated with aberrant expression of a polypeptide of the invention (e.g., one of the disorders described in the section of this disclosure wherein the individual polypeptide of the invention is discussed).
- the kit can comprise a labeled compound or agent capable of detecting the polypeptide or mRNA encoding the polypeptide in a biological sample and means for determining the amount of the polypeptide or mRNA in the sample (e.g., an antibody which binds the polypeptide or an oligonucleotide probe which binds to DNA or mRNA encoding the polypeptide).
- Kits can also include instructions for observing that the tested subject is suffering from or is at risk of developing a disorder associated with aberrant expression of the polypeptide if the amount of the polypeptide or mRNA encoding the polypeptide is above or below a normal level.
- the kit can comprise, for example: (1) a first antibody (e.g., attached to a solid support) which binds to a polypeptide of the invention; and, optionally, (2) a second, different antibody which binds to either the polypeptide or the first antibody and is conjugated to a detectable agent.
- a first antibody e.g., attached to a solid support
- a second, different antibody which binds to either the polypeptide or the first antibody and is conjugated to a detectable agent.
- the kit can comprise, for example: (1) an oligonucleotide, e.g., a detectably labeled oligonucleotide, which hybridizes to a nucleic acid sequence encoding a polypeptide of the invention or (2) a pair of primers useful for amplifying a nucleic acid molecule encoding a polypeptide of the invention.
- the kit can also comprise, e.g., a buffering agent, a preservative, or a protein stabilizing agent.
- the kit can also comprise components necessary for detecting the detectable agent (e.g., an enzyme or a substrate).
- the kit can also contain a control sample or a series of control samples which can be assayed and compared to the test sample contained.
- Each component of the kit is usually enclosed within an individual container and all of the various containers are within a single package along with instructions for observing whether the tested subject is suffering from or is at risk of developing a disorder associated with aberrant expression of the polypeptide.
- the methods described herein can furthermore be utilized as diagnostic or prognostic assays to identify subjects having or at risk of developing a disease or disorder associated with aberrant expression or activity of a polypeptide of the invention.
- the assays described herein such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with aberrant expression or activity of a polypeptide of the invention (e.g., one of the disorders described in the section of this disclosure wherein the individual polypeptide of the invention is discussed).
- the prognostic assays can be utilized to identify a subject having or at risk for developing such a disease or disorder.
- test sample refers to a biological sample obtained from a subject of interest.
- a test sample can be a biological fluid (e.g., serum), cell sample, or tissue.
- the prognostic assays described herein can be used to determine whether a subject can be administered an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant expression or activity of a polypeptide of the invention.
- an agent e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate
- agents e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate
- agents e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate
- such methods can be used to determine whether a subject can be effectively treated with a specific agent or class of agents (e.g., agents of a type which decrease activity of the
- the present invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant expression or activity of a polypeptide of the invention in which a test sample is obtained and the polypeptide or nucleic acid encoding the polypeptide is detected (e.g., wherein the presence of the polypeptide or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant expression or activity of the polypeptide).
- the methods of the invention can also be used to detect genetic lesions or mutations in a gene of the invention, thereby determining if a subject with the lesioned gene is at risk for a disorder characterized aberrant expression or activity of a polypeptide of the invention.
- the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion or mutation characterized by at least one of an alteration affecting the integrity of a gene encoding the polypeptide of the invention, or the mis-expression of the gene encoding the polypeptide of the invention.
- such genetic lesions or mutations can be detected by ascertaining the existence of at least one of: 1) a deletion of one or more nucleotides from the gene; 2) an addition of one or more nucleotides to the gene; 3) a substitution of one or more nucleotides of the gene; 4) a chromosomal rearrangement of the gene; 5) an alteration in the level of a messenger RNA transcript of the gene; 6) an aberrant modification of the gene, such as of the methylation pattern of the genomic DNA; 7) the presence of a non-wild type splicing pattern of a messenger RNA transcript of the gene; 8) a non-wild type level of the protein encoded by the gene; 9) an allelic loss of the gene; and 10) an inappropriate post-translational modification of the protein encoded by the gene.
- assay techniques known in the art which can be used for detecting lesions in a gene.
- detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g., U.S. Pat. Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran et al. (1988) Science 241:1077-1080; and Nakazawa et al. (1994) Proc. Natl. Acad. Sci. USA 91:360-364), the latter of which can be particularly useful for detecting point mutations in a gene (see, e.g., Abravaya et al.
- PCR polymerase chain reaction
- LCR ligation chain reaction
- This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to the selected gene under conditions such that hybridization and amplification of the gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample.
- PCR and/or LCR can be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.
- Alternative amplification methods include: self-sustained sequence replication (Guatelli et al. (1990) Proc. Natl. Acad. Sci. USA 87:1874-1878), transcriptional amplification system (Kwoh, et al. (1989) Proc. Natl. Acad. Sci. USA 86:1173-1177), Q-Beta Replicase (Lizardi et al. (1988) Bio/Technology 6:1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.
- mutations in a selected gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns.
- sample and control DNA is isolated, (optionally) amplified, digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA.
- sequence specific ribozymes see, e.g., U.S. Pat. No. 5,498,531
- sequence specific ribozymes can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.
- genetic mutations can be identified by hybridizing a sample and control nucleic acids, e.g., DNA or RNA, to high density arrays containing hundreds or thousands of oligonucleotides probes (Cronin et al. (1996) Human Mutation 7:244-255; Kozal et al. (1996) Nature Medicine 2:753-759).
- genetic mutations can be identified in two-dimensional arrays containing light-generated DNA probes as described in Cronin et al., supra. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes.
- This step allows the identification of point mutations.
- This step is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected.
- Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.
- any of a variety of sequencing reactions known in the art can be used to directly sequence the selected gene and detect mutations by comparing the sequence of the sample nucleic acids with the corresponding wild-type (control) sequence.
- Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert ((1977) Proc. Natl. Acad. Sci. USA 74:560) or Sanger ((1977) Proc. Natl. Acad. Sci. USA 74:5463). It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays ((1995) Bio/Techniques 19:448), including sequencing by mass spectrometry (see, e.g., PCT Publication No. WO 94/16101; Cohen et al. (1996) Adv. Chromatogr. 36:127-162; and Griffin et al. (1993) Appl. Biochem. Biotechnol. 38:147-159).
- RNA/RNA or RNA/DNA heteroduplexes Other methods for detecting mutations in a selected gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes (Myers et al. (1985) Science 230:1242).
- the technique of mismatch cleavage entails providing heteroduplexes formed by hybridizing (labeled) RNA or DNA containing the wild-type sequence with potentially mutant RNA or DNA obtained from a tissue sample.
- the double-stranded duplexes are treated with an agent which cleaves single-stranded regions of the duplex such as which will exist due to base pair mismatches between the control and sample strands.
- RNA/DNA duplexes can be treated with RNase to digest mismatched regions, and DNA/DNA hybrids can be treated with S1 nuclease to digest mismatched regions.
- either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. See, e.g., Cotton et al. (1988) Proc. Natl. Acad. Sci. USA 85:4397; Saleeba et al. (1992) Methods Enzymol. 217:286-295.
- the control DNA or RNA can be labeled for detection.
- the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called DNA mismatch repair enzymes) in defined systems for detecting and mapping point mutations in cDNAs obtained from samples of cells.
- DNA mismatch repair enzymes proteins that recognize mismatched base pairs in double-stranded DNA
- the mutY enzyme of E. coli cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches (Hsu et al. (1994) Carcinogenesis 15:1657-1662).
- a probe based on a selected sequence is hybridized to a cDNA or other DNA product from a test cell(s).
- the duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, e.g., U.S. Pat. No. 5,459,039.
- alterations in electrophoretic mobility will be used to identify mutations in genes.
- SSCP single strand conformation polymorphism
- Single-stranded DNA fragments of sample and control nucleic acids will be denatured and allowed to re-nature.
- the secondary structure of single-stranded nucleic acids varies according to sequence, and the resulting alteration in electrophoretic mobility enables the detection of even a single base change.
- the DNA fragments can be labeled or detected with labeled probes.
- the sensitivity of the assay can be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence.
- the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility (Keen et al. (1991) Trends Genet. 7:5).
- the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE) (Myers et al. (1985) Nature 313:495).
- DGGE denaturing gradient gel electrophoresis
- DNA will be modified to insure that it does not completely denature, for example by adding a ‘GC clamp’ of approximately 40 base pairs of high-melting GC-rich DNA by PCR.
- a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA (Rosenbaum and Reissner (1987) Biophys. Chem. 265:12753).
- oligonucleotide primers can be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions which permit hybridization only if a perfect match is found (Saiki et al. (1986) Nature 324:163); Saiki et al. (1989) Proc. Natl. Acad. Sci. USA 86:6230).
- Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.
- allele specific amplification technology which depends on selective PCR amplification can be used in conjunction with the instant invention.
- Oligonucleotides used as primers for specific amplification can carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization; Gibbs et al. (1989) Nucleic Acids Res. 17:2437-2448) or at the extreme 3′ end of one primer where, under appropriate conditions, mismatching can prevent or reduce polymerase extension (Prossner (1993) Tibtech 11:238).
- it can be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection (Gasparini et al. (1992) Mol.
- Amplification can also be performed using Taq ligase for amplification (Barany (1991) Proc. Natl. Acad. Sci. USA 88:189). In such cases, ligation will occur only if there is a perfect match at the 3′ end of the 5′ sequence making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.
- the methods described herein can be performed, for example, using pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which can be conveniently used, e.g., in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving a gene encoding a polypeptide of the invention.
- any cell type or tissue, preferably peripheral blood leukocytes, in which the polypeptide of the invention is expressed can be utilized in the prognostic assays described herein.
- Agents, or modulators which have a stimulatory or inhibitory effect on activity or expression of a polypeptide of the invention as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) disorders associated with aberrant activity of the polypeptide.
- the pharmacogenomics i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug
- Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug.
- the pharmacogenomics of the individual permits the selection of effective agents (e.g., drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of a polypeptide of the invention, expression of a nucleic acid of the invention, or mutation content of a gene of the invention in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.
- Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, e.g., Linder (1997) Clin. Chem. 43(2):254-266.
- two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body are referred to as “altered drug action.” Genetic conditions transmitted as single factors altering the way the body acts on drugs are referred to as “altered drug metabolism”. These pharmacogenetic conditions can occur either as rare defects or as polymorphisms.
- G6PD glucose-6-phosphate dehydrogenase
- the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action.
- drug metabolizing enzymes e.g., N-acetyltransferase 2 (NAT 2) and cytochrome P450 enzymes CYP2D6 and CYP2C19
- NAT 2 N-acetyltransferase 2
- CYP2D6 and CYP2C19 cytochrome P450 enzymes
- the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, a PM will show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. The other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.
- the activity of a polypeptide of the invention, expression of a nucleic acid encoding the polypeptide, or mutation content of a gene encoding the polypeptide in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.
- pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding drug-metabolizing enzymes to the identification of an individual's drug responsiveness phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with a modulator of activity or expression of the polypeptide, such as a modulator identified by one of the exemplary screening assays described herein.
- Monitoring the influence of agents (e.g., drug compounds) on the expression or activity of a polypeptide of the invention can be applied not only in basic drug screening, but also in clinical trials.
- agents e.g., drug compounds
- the effectiveness of an agent, as determined by a screening assay as described herein, to increase gene expression, protein levels, or protein activity can be monitored in clinical trials of subjects exhibiting decreased gene expression, protein levels, or protein activity.
- the effectiveness of an agent, as determined by a screening assay, to decrease gene expression, protein levels or protein activity can be monitored in clinical trials of subjects exhibiting increased gene expression, protein levels, or protein activity.
- expression or activity of a polypeptide of the invention and preferably, that of other polypeptide that have been implicated in for example, a cellular proliferation disorder can be used as a marker of the immune responsiveness of a particular cell.
- genes including those of the invention, that are modulated in cells by treatment with an agent (e.g., compound, drug or small molecule) which modulates activity or expression of a polypeptide of the invention (e.g., as identified in a screening assay described herein) can be identified.
- an agent e.g., compound, drug or small molecule
- a polypeptide of the invention e.g., as identified in a screening assay described herein
- cells can be isolated and RNA prepared and analyzed for the levels of expression of a gene of the invention and other genes implicated in the disorder.
- the levels of gene expression can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of a gene of the invention or other genes.
- the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state can be determined before, and at various points during, treatment of the individual with the agent.
- the present invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of the polypeptide or nucleic acid of the invention in the pre-administration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level the of the polypeptide or nucleic acid of the invention in the post-administration samples; (v) comparing the level of the polypeptide or nucleic acid of the invention in the pre-administration sample with the level of the polypeptide or nucleic acid of the invention in the post-administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly.
- an agent e.g., an agonist, antagonist,
- increased administration of the agent can be desirable to increase the expression or activity of the polypeptide to higher levels than detected, i.e., to increase the effectiveness of the agent.
- decreased administration of the agent can be desirable to decrease expression or activity of the polypeptide to lower levels than detected, i.e., to decrease the effectiveness of the agent.
- the present invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant expression or activity of a polypeptide of the invention and/or in which the polypeptide of the invention is involved. Disorders characterized by aberrant expression or activity of the polypeptides of the invention are described elsewhere in this disclosure.
- the invention provides a method for preventing in a subject, a disease or condition associated with an aberrant expression or activity of a polypeptide of the invention, by administering to the subject an agent which modulates expression or at least one activity of the polypeptide.
- Subjects at risk for a disease which is caused or contributed to by aberrant expression or activity of a polypeptide of the invention can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein.
- Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the aberrance, such that a disease or disorder is prevented or, alternatively, delayed in its progression.
- an agonist or antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein.
- Another aspect of the invention pertains to methods of modulating expression or activity of a polypeptide of the invention for therapeutic purposes.
- the modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of the polypeptide.
- An agent that modulates activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of the polypeptide, a peptide, a peptidomimetic, or other small molecule.
- the agent stimulates one or more of the biological activities of the polypeptide.
- stimulatory agents include the active polypeptide of the invention and a nucleic acid molecule encoding the polypeptide of the invention that has been introduced into the cell.
- the agent inhibits one or more of the biological activities of the polypeptide of the invention.
- inhibitory agents include antisense nucleic acid molecules and antibodies.
- the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., up-regulates or down-regulates) expression or activity.
- an agent e.g., an agent identified by a screening assay described herein
- the method involves administering a polypeptide of the invention or a nucleic acid molecule of the invention as therapy to compensate for reduced or aberrant expression or activity of the polypeptide.
- Stimulation of activity is desirable in situations in which activity or expression is abnormally low or down-regulated and/or in which increased activity is likely to have a beneficial effect. Conversely, inhibition of activity is desirable in situations in which activity or expression is abnormally high or up-regulated and/or in which decreased activity is likely to have a beneficial effect.
- Clone EpT202 encoding human TANGO 202 was deposited with the American Type Culture Collection (ATCC®, 10801 University Boulevard, Manassas, V. 20110-2209) on Apr. 21, 1999 and was assigned Accession Number 207219. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure.
- Clone EpTm202, encoding murine TANGO 202 was deposited with ATCC® on Apr. 21, 1999 and was assigned (composite) Accession Number 207221. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure.
- Clone EpT234, encoding human TANGO 234 was deposited with ATCC® on Apr. 2, 1999 and was assigned Accession Number 207184. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure.
- Clone EpT265 encoding human TANGO 265 was deposited with ATCC® on Apr. 28, 1999 and was assigned Accession Number 207228. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure.
- Clone EpT286, encoding human TANGO 286 was deposited with ATCC® on Apr. 20, 1999 and was assigned (composite) Accession Number 207220. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure.
- Clone EpT294, encoding human TANGO 294 was deposited with ATCC® on Apr. 20, 1999 and was assigned (composite) Accession Number 207220. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure.
- Clones containing cDNA molecules encoding human TANGO 286, human TANGO 294, and INTERCEPT 296 were deposited with ATCC® on Apr. 21, 1999 as Accession Number 207220, as part of a composite deposit representing a mixture of five strains, each carrying one recombinant plasmid harboring a particular cDNA clone.
- human TANGO 286 (clone EpT286): 1.85 kB and 0.1 kB (human TANGO 286 has a DraII cut site at about base pair 1856).
- human TANGO 294 (clone EpT294): 1.4 kB and 0.6 kB (human TANGO 294 has a DraII cut site at about base pair 1447).
- human INTERCEPT 296 (clone EpT296): 0.4 kB, 1.6 kB, and 0.1 kB (human INTERCEPT 296 has DraII cut sites at about base pair 410 and at about base pair 1933). The identity of the strains can be inferred from the fragments liberated.
- Clones containing cDNA molecules encoding mouse TANGO 202 and mouse TANGO 273 were deposited with ATCC® on Apr. 21, 1999 and were assigned Accession Number 207221, as part of a composite deposit representing a mixture of five strains, each carrying one recombinant plasmid harboring a particular cDNA clone.
- an aliquot of the mixture is streaked out to single colonies on nutrient medium (e.g., LB plates) supplemented with 100 mg/ml ampicillin, single colonies are grown, and then plasmid DNA is extracted using a standard mini-preparation procedure.
- mouse TANGO 202 (clone EpTm202): 3.5 kB and 1.4 kB (mouse TANGO 202 has a Apa I cut site at about base pair 3519).
- mouse TANGO 273 (clone EpTm273): 0.3 kB and 2.6 kB (mouse TANGO 273 has a Apa I cut site at about base pair 298).
- the identity of the strains can be inferred from the fragments liberated.
- Human TANGO 202, human TANGO 234, human TANGO 265, and human TANGO 273 were each deposited as single deposits. Their clone names, deposit dates, and accession numbers are as follows:
- human TANGO 202 clone EpT202 was deposited with ATCC® on Apr. 21, 1999, and was assigned Accession Number 207219.
- human TANGO 234 clone EpT234 was deposited with ATCC® on Apr. 2, 1999, and was assigned Accession Number 207184.
- human TANGO 265 clone EpT265 was deposited with ATCC® on Apr. 28, 1999, and was assigned Accession Number 207228.
- human TANGO 273 clone EpT273 was deposited with ATCC® on Apr. 2, 1999, and was assigned Accession Number 207185.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.
Description
- This application is a continuation-in-part of co-pending U.S. patent application Ser. No 09/578,063, filed May 24, 2000, which is a continuation-in-part of co-pending U.S. patent application Ser. No. 09/333,159, filed Jun. 14, 1999.
- Not applicable.
- Not applicable.
- The molecular bases underlying many human and animal physiological states (e.g., diseased and homeostatic states of various tissues) remain unknown. Nonetheless, it is well understood that these states result from interactions among the proteins and nucleic acids present in the cells of the relevant tissues. In the past, the complexity of biological systems overwhelmed the ability of practitioners to understand the molecular interactions giving rise to normal and abnormal physiological states. More recently, though, the techniques of molecular biology, transgenic and null mutant animal production, computational biology, pharmacogenomics, and the like have enabled practitioners to discern the role and importance of individual genes and proteins in particular physiological states.
- Knowledge of the sequences and other properties of genes (particularly including the portions of genes encoding proteins) and the proteins encoded thereby enables the practitioner to design and screen agents which will affect, prospectively or retrospectively, the physiological state of an animal tissue in a favorable way. Such knowledge also enables the practitioner, by detecting the levels of gene expression and protein production, to diagnose the current physiological state of a tissue or animal and to predict such physiological states in the future. This knowledge furthermore enables the practitioner to identify and design molecules which bind with the polynucleotides and proteins, in vitro, in vivo, or both.
- The present invention provides sequence information for polynucleotides derived from human and murine genes and for proteins encoded thereby, and thus enables the practitioner to assess, predict, and affect the physiological state of various human and murine tissues.
- The present invention is based, at least in part, on the discovery of a variety of human and murine cDNA molecules which encode proteins which are herein designated TANGO 202, TANGO 234, TANGO 265, TANGO 273, TANGO 286, TANGO 294, and INTERCEPT 296. These seven proteins, fragments thereof, derivatives thereof, and variants thereof are collectively referred to herein as the polypeptides of the invention or the proteins of the invention. Nucleic acid molecules encoding polypeptides of the invention are collectively referred to as nucleic acids of the invention.
- The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes. Accordingly, in one aspect, the present invention provides isolated nucleic acid molecules encoding a polypeptide of the invention or a biologically active portion thereof. The present invention also provides nucleic acid molecules which are suitable as primers or hybridization probes for the detection of nucleic acids encoding a polypeptide of the invention.
- The invention also features nucleic acid molecules which are at least 40% (or 50%, 60%, 70%, 80%, 90%, 95%, or 98%) identical to the nucleotide sequence of any of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73, the nucleotide sequence of a cDNA clone deposited with ATCC® as one of Accession numbers 207219, 207184, 207228, 207185, 207220, and 207221 (“a cDNA of a clone deposited as one of ATCC® 207219, 207184, 207228, 207185, 207220, and 207221”), or a complement thereof.
- The invention features nucleic acid molecules which include a fragment of at least 15 (25, 40, 60, 80, 100, 150, 200, 250, 300, 350, 400, 450, 550, 650, 700, 800, 900, 1000, 1200, 1400, 1600, 1800, 2000, 2200, 2400, 2600, 2800, 3000, 3500, 4000, 4500, or 4928) consecutive nucleotide residues of any of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73, the nucleotide sequence of a cDNA of a clone deposited as one of ATCC® 207219, 207184, 207228, 207185, 207220, and 207221, or a complement thereof.
- The invention also features nucleic acid molecules which include a nucleotide sequence encoding a protein having an amino acid sequence that is at least 50% (or 60%, 70%, 80%, 90%, 95%, or 98%) identical to the amino acid sequence of any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74, or the amino acid sequence encoded by a cDNA of a clone deposited as one of ATCC® 207219, 207184, 207228, 207185, 207220, and 207221, or a complement thereof.
- In preferred embodiments, the nucleic acid molecules have the nucleotide sequence of any of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73, or the nucleotide sequence of a cDNA of a clone deposited as one of ATCC® 207219, 207184, 207228, 207185, 207220, and 207221.
- Also within the invention are nucleic acid molecules which encode a fragment of a polypeptide having the amino acid sequence of any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74, or the amino acid sequence encoded by a cDNA of a clone deposited as one of ATCC® 207219, 207184, 207228, 207185, 207220, and 207221, the fragment including at least 8 (10, 15, 20, 25, 30, 40, 50, 75, 100, 125, 150, or 200) consecutive amino acids of any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74, or the amino acid sequence encoded by a cDNA of a clone deposited as one of ATCC® 207219, 207184, 207228, 207185, 207220, and 207221.
- The invention includes nucleic acid molecules which encode a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74, or the amino acid sequence encoded by a cDNA of a clone deposited as one of ATCC® 207219, 207184, 207228, 207185, 207220, and 207221, wherein the nucleic acid molecule hybridizes under stringent conditions to a nucleic acid molecule having a nucleic acid sequence encoding any of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73, the nucleotide sequence of a cDNA of a clone deposited as one of ATCC® 207219, 207184, 207228, 207185, 207220, and 207221, or a complement thereof.
- Also within the invention are isolated polypeptides or proteins having an amino acid sequence that is at least about 50%, preferably 60%, 75%, 90%, 95%, or 98% identical to the amino acid sequence of any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74.
- Also within the invention are isolated polypeptides or proteins which are encoded by a nucleic acid molecule having a nucleotide sequence that is at least about 40%, preferably 50%, 75%, 85%, or 95% identical the nucleic acid sequence encoding any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74, and isolated polypeptides or proteins which are encoded by a nucleic acid molecule consisting of the nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule having the nucleotide sequence of any of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73.
- Also within the invention are polypeptides which are naturally occurring allelic variants of a polypeptide that includes the amino acid sequence of any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74, or the amino acid sequence encoded by a cDNA of a clone deposited as one of ATCC® 207219, 207184, 207228, 207185, 207220, and 207221, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes under stringent conditions to a nucleic acid molecule having the nucleotide sequence of any of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73, or a complement thereof.
- The invention also features nucleic acid molecules that hybridize under stringent conditions to a nucleic acid molecule having the nucleotide sequence of any of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73, the nucleotide sequence of a cDNA of a clone deposited as one of ATCC® 207219, 207184, 207228, 207185, 207220, and 207221, or a complement thereof. In other embodiments, the nucleic acid molecules are at least 15 (25, 40, 60, 80, 100, 150, 200, 250, 300, 350, 400, 450, 550, 650, 700, 800, 900, 1000, 1200, 1400, 1600, 1800, 2000, 2200, 2400, 2600, 2800, 3000, 3500, 4000, 4500, or 4928) nucleotides in length and hybridize under stringent conditions to a nucleic acid molecule having the nucleotide sequence of any of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73, the nucleotide sequence of a cDNA of a clone deposited as one of ATCC® 207219, 207184, 207228, 207185, 207220, and 207221, or a complement thereof. In some embodiments, the isolated nucleic acid molecules encode a cytoplasmic, transmembrane, extracellular, or other domain of a polypeptide of the invention. In other embodiments, the invention provides an isolated nucleic acid molecule which is antisense to the coding strand of a nucleic acid of the invention.
- Another aspect of the invention provides vectors, e.g., recombinant expression vectors, comprising a nucleic acid molecule of the invention. In another embodiment, the invention provides isolated host cells, e.g., mammalian and non-mammalian cells, containing such a vector or a nucleic acid of the invention. The invention also provides methods for producing a polypeptide of the invention by culturing, in a suitable medium, a host cell of the invention containing a recombinant expression vector encoding a polypeptide of the invention such that the polypeptide of the invention is produced.
- Another aspect of this invention features isolated or recombinant proteins and polypeptides of the invention. Preferred proteins and polypeptides possess at least one biological activity possessed by the corresponding naturally-occurring human polypeptide. An activity, a biological activity, and a functional activity of a polypeptide of the invention refers to an activity exerted by a protein or polypeptide of the invention on a responsive cell as determined in vivo, or in vitro, according to standard techniques.
- Such activities can be a direct activity, such as an association with or an enzymatic activity on a second protein, or an indirect activity, such as a cellular process (e.g., signaling activity) mediated by interaction of the protein with a second protein. Such activities include, by way of example, formation of protein-protein interactions with proteins of one or more signaling pathways (e.g., with a protein with which the naturally-occurring polypeptide interacts); binding with a ligand of the naturally-occurring protein; and binding with an intracellular target of the naturally-occurring protein. Other activities include modulation of one or more of cellular proliferation, of cellular differentiation, of chemotaxis, of cellular migration, and of cell death (e.g., apoptosis).
- By way of example, TANGO 202 exhibits the ability to affect growth, proliferation, survival, differentiation, and activity of human hematopoietic cells (e.g., bone marrow stromal cells) and fetal cells. TANGO 202 modulates cellular binding to one or more mediators, modulates proteolytic activity in vivo, modulates developmental processes, and modulates cell growth, proliferation, survival, differentiation, and activity. Thus, TANGO 202 can be used to prevent, diagnose, or treat disorders relating to aberrant cellular protease activity, inappropriate interaction (or non-interaction) of cells with mediators, inappropriate development, and blood and hematopoietic cell-related disorders. Exemplary disorders for which TANGO 202 is useful include immune disorders, infectious diseases, auto-immune disorders, vascular and cardiovascular disorders, disorders related to mal-expression of growth factors, cancers, hematological disorders, various cancers, birth defects, developmental defects, and the like.
- Further by way of example, TANGO 234 exhibits the ability to affect growth, proliferation, survival, differentiation, and activity of human lung, hematopoietic, and fetal cells and of (e.g., bacterial or fungal) cells and viruses which infect humans. TANGO 234 modulates growth, proliferation, survival, differentiation, and activity of gamma delta T cells, for example. Furthermore, TANGO 234 modulates cholesterol deposition on human arterial walls, and is involved in uptake and metabolism of low density lipoprotein and regulation of serum cholesterol levels.
- Thus, TANGO 234 can be used to affect development and persistence of atherogenesis and arteriosclerosis, as well as other vascular and cardiovascular disorders. Other exemplary disorders for which TANGO 234 is useful include immune development disorders and disorders involving generation and persistence of an immune response to bacterial, fungal, and viral infections.
- Still further by way of example, TANGO 265 modulates growth and regeneration of neuronal and epithelial tissues, and guides neuronal axon development. TANGO 265 is a transmembrane protein which mediates cellular interaction with cells, molecules and structures (e.g., extracellular matrix) in the extracellular environment. TANGO 265 is therefore involved in growth, organization, and adhesion of tissues and the cells which constitute those tissues. Furthermore, TANGO 265 modulates growth, proliferation, survival, differentiation, and activity of neuronal cells and immune system cells. Thus, TANGO 265 can be used, for example, to prevent, diagnose, or treat disorders characterized by aberrant organization or development of a tissue or organ, for guiding neural axon development, for modulating differentiation of cells of the immune system, for modulating cytokine production by cells of the immune system, for modulating reactivity of cells of the immune system toward cytokines, for modulating initiation and persistence of an inflammatory response, and for modulating proliferation of epithelial cells.
- Yet further by way of example, TANGO 273 protein mediates one or more physiological responses of cells to bacterial infection, e.g., by mediating one or more of detection of bacteria in a tissue in which it is expressed, movement of cells with relation to sites of bacterial infection, production of biological molecules which inhibit bacterial infection, and production of biological molecules which alleviate cellular or other physiological damage wrought by bacterial infection. TANGO 273, a transmembrane protein, is also involved in transmembrane signal transduction, and therefore mediates transmission of signals between the extracellular and intracellular environments of cells. TANGO 273 mediates regulation of cell growth and proliferation, endocytosis, activation of respiratory burst, and other physiological processes triggered by transmission of a signal via a protein with which TANGO 273 interacts. The compositions and methods of the invention can therefore be used to prevent, diagnose, and treat disorders involving one or more physiological activities mediated by TANGO 273 protein. Such disorders include, for example, various bone-related disorders such as metabolic, homeostatic, and developmental bone disorders (e.g., osteoporosis, various cancers, skeletal development disorders, bone fragility and the like), disorders caused by or related to bacterial infection, and disorders characterized by aberrant transmembrane signal transduction by TANGO 273.
- As an additional example,
TANGO 286 protein is involved in lipid-binding physiological processes such as lipid transport, metabolism, serum lipid particle regulation, host anti-microbial defensive mechanisms, and the like. Thus, the compositions and methods of the invention can therefore be used to prevent, diagnose, and treat disorders involving one or more physiological activities mediated byTANGO 286 protein. Such disorders include, for example, lipid transport disorders, lipid metabolism disorders, obesity, disorders of serum lipid particle regulation, disorders involving insufficient or inappropriate host anti-microbial defensive mechanisms, vasculitis, bronchiectasis, LPS-related disorders such as shock, disseminated intravascular coagulation, anemia, thrombocytopenia, adult respiratory distress syndrome, renal failure, liver disease, and disorders associated with Gram negative bacterial infections, such as bacteremia, endotoxemia, sepsis, and the like. - Further by way of example,
TANGO 294 protein is involved in facilitating absorption and metabolism of fat. Thus, the compositions and methods of the invention can therefore be used to prevent, diagnose, and treat disorders involving one or more physiological activities mediated byTANGO 294 protein. Such disorders include, for example, inadequate expression of gastric/pancreatic lipase, cystic fibrosis, exocrine pancreatic insufficiency, medical treatments which alter fat absorption, obesity, and the like. - As another example,
INTERCEPT 296 protein is involved in physiological processes related to disorders of the human lung and esophagus. Thus, the compositions and methods of the invention can be used to prevent, diagnose, and treat these disorders. Such disorders include, for example, various cancers, bronchitis, cystic fibrosis, respiratory infections (e.g., influenza, bronchiolitis, pneumonia, and tuberculosis), asthma, emphysema, chronic bronchitis, bronchiectasis, pulmonary edema, pleural effusion, pulmonary embolus, adult and infant respiratory distress syndromes, heartburn, and gastric reflux esophageal disease. - In one embodiment, a polypeptide of the invention has an amino acid sequence sufficiently identical to an identified domain of a polypeptide of the invention. As used herein, the term “sufficiently identical” refers to a first amino acid or nucleotide sequence which contains a sufficient or minimum number of identical or equivalent (e.g., with a similar side chain) amino acid residues or nucleotides to a second amino acid or nucleotide sequence such that the first and second amino acid or nucleotide sequences have a common structural domain and/or common functional activity. For example, amino acid or nucleotide sequences which contain a common structural domain having about 65% identity, preferably 75% identity, more preferably 85%, 95%, or 98% identity are defined herein as sufficiently identical.
- In one embodiment, the isolated polypeptide of the invention lacks both a transmembrane and a cytoplasmic domain. In another embodiment, the polypeptide lacks both a transmembrane domain and a cytoplasmic domain and is soluble under physiological conditions.
- The polypeptides of the present invention, or biologically active portions thereof, can be operably linked to a heterologous amino acid sequence to form fusion proteins. The invention further features antibody substances that specifically bind a polypeptide of the invention such as monoclonal or polyclonal antibodies, antibody fragments, single-chain antibodies, and the like. In addition, the polypeptides of the invention or biologically active portions thereof can be incorporated into pharmaceutical compositions, which optionally include pharmaceutically acceptable carriers. These antibody substances can be made, for example, by providing the polypeptide of the invention to an immunocompetent vertebrate and thereafter harvesting blood or serum from the vertebrate.
- In another aspect, the present invention provides methods for detecting the presence of the activity or expression of a polypeptide of the invention in a biological sample by contacting the biological sample with an agent capable of detecting an indicator of activity such that the presence of activity is detected in the biological sample.
- In another aspect, the invention provides methods for modulating activity of a polypeptide of the invention comprising contacting a cell with an agent that modulates (inhibits or enhances) the activity or expression of a polypeptide of the invention such that activity or expression in the cell is modulated. In one embodiment, the agent is an antibody that specifically binds to a polypeptide of the invention.
- In another embodiment, the agent modulates expression of a polypeptide of the invention by modulating transcription, splicing, or translation of an mRNA encoding a polypeptide of the invention. In yet another embodiment, the agent is a nucleic acid molecule having a nucleotide sequence that is antisense with respect to the coding strand of an mRNA encoding a polypeptide of the invention.
- The present invention also provides methods to treat a subject having a disorder characterized by aberrant activity of a polypeptide of the invention or aberrant expression of a nucleic acid of the invention by administering an agent which is a modulator of the activity of a polypeptide of the invention or a modulator of the expression of a nucleic acid of the invention to the subject. In one embodiment, the modulator is a protein of the invention. In another embodiment, the modulator is a nucleic acid of the invention. In other embodiments, the modulator is a peptide, peptidominetic, or other small molecule (e.g., a small organic molecule).
- The present invention also provides diagnostic assays for identifying the presence or absence of a genetic lesion or mutation characterized by at least one of: (i) aberrant modification or mutation of a gene encoding a polypeptide of the invention, (ii) mis-regulation of a gene encoding a polypeptide of the invention, and (iii) aberrant post-translational modification of a polypeptide of the invention wherein a wild-type form of the gene encodes a polypeptide having the activity of the polypeptide of the invention.
- In another aspect, the invention provides a method for identifying a compound that binds to or modulates the activity of a polypeptide of the invention. In general, such methods entail measuring a biological activity of the polypeptide in the presence and absence of a test compound and identifying those compounds which alter the activity of the polypeptide.
- The invention also features methods for identifying a compound which modulates the expression of a polypeptide or nucleic acid of the invention by measuring the expression of the polypeptide or nucleic acid in the presence and absence of the compound.
- In yet a further aspect, the invention provides substantially purified antibodies or fragments thereof (i.e., antibody substances), including non-human antibodies or fragments thereof, which specifically bind with a polypeptide of the invention or with a portion thereof. In various embodiments, these substantially purified antibodies/fragments can be human, non-human, chimeric, and/or humanized antibodies. Non-human antibodies included in the invention include, by way of example, goat, mouse, sheep, horse, chicken, rabbit, and rat antibodies. In addition, the antibodies of the invention can be polyclonal antibodies or monoclonal antibodies.
- In a particularly preferred embodiment, the antibody substance of the invention specifically binds with an extracellular domain of one of
TANGO 202, TANGO 234, TANGO 265,TANGO 273,TANGO 286,TANGO 294, andINTERCEPT 296. Preferably, the extracellular domain with which the antibody substance binds has an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 6, 14, 22, 30, 37, 49, 50, and 56-58. - Any of the antibody substances of the invention can be conjugated with a therapeutic moiety or with a detectable substance. Non-limiting examples of detectable substances that can be conjugated with the antibody substances of the invention include an enzyme, a prosthetic group, a fluorescent material (i.e., a fluorophore), a luminescent material, a bioluminescent material, and a radioactive material (e.g., a radionuclide or a substituent comprising a radionuclide).
- The invention also provides a kit containing an antibody substance of the invention conjugated with a detectable substance, and instructions for use. Still another aspect of the invention is a pharmaceutical composition comprising an antibody substance of the invention and a pharmaceutically acceptable carrier. In preferred embodiments, the pharmaceutical composition contains an antibody substance of the invention, a therapeutic moiety (preferably conjugated with the antibody substance), and a pharmaceutically acceptable carrier.
- The invention includes a method of assessing whether a first human patient is afflicted with an epithelial or endothelial tumor (e.g., a colon, prostate, pancreatic, lung, or breast tumor). The method comprises comparing:
- a) occurrence of a nucleic acid molecule of
claim 1 in a sample obtained from the first patient and - b) occurrence of the nucleic acid molecule in a control sample selected from the group consisting of
- i) a control sample obtained from a tissue that is obtained from the first patient and that is known not to comprise the tumor; and
- ii) a control sample obtained from a second patient who is known not to be afflicted with the tumor.
- A difference between the first sample and the control sample is an indication that the patient is afflicted with the tumor.
- The invention also includes a method of assessing whether a first human patient is afflicted with an epithelial or endothelial tumor. This method comprises comparing
- a) occurrence of a nucleic acid molecule of
claim 1 in a sample obtained from the first patient and - b) occurrence of the nucleic acid molecule in a control sample selected from the group consisting of
- i) a control sample obtained from a tissue that is obtained from the first patient and that is known to comprise the tumor; and
- ii) a control sample obtained from a second patient who is known to be afflicted with the tumor.
- A difference between the first sample and the control sample is an indication that the patient is not afflicted with the tumor.
- In another embodiment, the invention includes a method of screening for agents which decrease the activity of a TANGO-294-like lipase protein. The method comprises:
- contacting a test compound with a TANGO 294-like lipase polypeptide encoded by an isolated nucleic acid molecule of
claim 1 and - detecting binding between the test compound and the TANGO 294-like lipase polypeptide,
- Binding between the test compound and the TANGO 294-like lipase polypeptide is an indication that the test compound is an agent which decreases the activity of the TANGO 294-like lipase protein.
- A pharmaceutical composition can be made by identifying an agent according to this method and combining the agent and a pharmaceutically acceptable carrier to form the pharmaceutical composition. This pharmaceutical composition can be administered to a human afflicted with a disorder in order to modulate the activity of a TANGO 294-like lipase protein in the disorder. The disorder can, for example be a tumor, a disorder of fat absorption, a disorder of fat metabolism, a blood flow disorder, a blood pressure disorder, an inflammatory disorder, an immune disorder, a thrombotic disorder, or a disorder involving inappropriate platelet adherence. Specific examples of these disorders include tumors of endothelial or epithelial origin, colon tumors, pancreatic tumors, inadequate expression of gastric lipase, inadequate expression of pancreatic lipase, cystic fibrosis, exocrine pancreatic insufficiency, obesity, arterial hypertension, renovascular hypertension, syncope, orthostatic hypotension, shock, gastritis, gastric ulcer, colitis, irritable bowel syndrome, inflammatory bowel syndrome, dermatitis, pancreatitis, rheumatoid arthritis, psoriasis, myasthenia gravis, an allergy, insulin resistance, systemic lupus erythematosus, scleroderma, and autoimmune diabetes mellitus, an infection of a human by an infectious agent (e.g., human immunodeficiency virus), hemophilia, stroke, myocardial infarction, coronary artery disease, and atherosclerosis.
- In still another embodiment, the invention includes a method of screening for agents which modulate the activity of a TANGO 294-like lipase protein. This method comprises:
- contacting a test compound with a TANGO 294-like lipase polypeptide encoded by an isolated nucleic acid molecule of
claim 1 and - detecting a TANGO 294-like lipase activity of the polypeptide,
- Increased TANGO 294-like lipase activity in the presence of the test compound is an indication that the test compound is an agent useful for increasing the activity of the TANGO 294-like lipase protein. Decreased TANGO 294-like lipase activity in the presence of the test compound is an indication that the test compound is an agent useful for decreasing the activity of the TANGO 294-like lipase protein.
- A pharmaceutical composition can be made by identifying an agent according to this method and combining the agent and a pharmaceutically acceptable carrier to form the pharmaceutical composition. This pharmaceutical composition can be administered to a human afflicted with a disorder in order to modulate the activity of a TANGO 294-like lipase protein in the disorder. The disorder can, for example be a tumor, a disorder of fat absorption, a disorder of fat metabolism, a blood flow disorder, a blood pressure disorder, an inflammatory disorder, an immune disorder, a thrombotic disorder, or a disorder involving inappropriate platelet adherence. Specific examples of these disorders include tumors of endothelial or epithelial origin, colon tumors, pancreatic tumors, inadequate expression of gastric lipase, inadequate expression of pancreatic lipase, cystic fibrosis, exocrine pancreatic insufficiency, obesity, arterial hypertension, renovascular hypertension, syncope, orthostatic hypotension, shock, gastritis, gastric ulcer, colitis, irritable bowel syndrome, inflammatory bowel syndrome, dermatitis, pancreatitis, rheumatoid arthritis, psoriasis, myasthenia gravis, an allergy, insulin resistance, systemic lupus erythematosus, scleroderna, and autoimmune diabetes mellitus, an infection of a human by an infectious agent (e.g., human immunodeficiency virus), hemophilia, stroke, myocardial infarction, coronary artery disease, and atherosclerosis.
- In yet another embodiment, the invention includes a method of screening for agents which decrease the activity of a TANGO 294-like lipase protein. This method comprises:
- contacting a test compound with an isolated nucleic acid molecule of
claim 1 and - detecting binding of the test compound with the isolated nucleic acid molecule,
- Binding between the test compound and the isolated nucleic acid molecule is an indication that the test compound is a agent useful for decreasing the activity of the TANGO 294-like lipase protein.
- A pharmaceutical composition can be made by identifying an agent according to this method and combining the agent and a pharmaceutically acceptable carrier to form the pharmaceutical composition. This pharmaceutical composition can be administered to a human afflicted with a disorder in order to modulate the activity of a TANGO 294-like lipase protein in the disorder. The disorder can, for example be a tumor, a disorder of fat absorption, a disorder of fat metabolism, a blood flow disorder, a blood pressure disorder, an inflammatory disorder, an immune disorder, a thrombotic disorder, or a disorder involving inappropriate platelet adherence. Specific examples of these disorders include tumors of endothelial or epithelial origin, colon tumors, pancreatic tumors, inadequate expression of gastric lipase, inadequate expression of pancreatic lipase, cystic fibrosis, exocrine pancreatic insufficiency, obesity, arterial hypertension, renovascular hypertension, syncope, orthostatic hypotension, shock, gastritis, gastric ulcer, colitis, irritable bowel syndrome, inflammatory bowel syndrome, dermatitis, pancreatitis, rheumatoid arthritis, psoriasis, myasthenia gravis, an allergy, insulin resistance, systemic lupus erythematosus, scleroderma, and autoimmune diabetes mellitus, an infection of a human by an infectious agent (e.g., human immunodeficiency virus), hemophilia, stroke, myocardial infarction, coronary artery disease, and atherosclerosis.
- The invention also includes a method of reducing the activity of a TANGO 294-like lipase protein (i.e.,
TANGO 294, or a variant or alternative form thereof as disclosed herein) of a cell. The method comprises contacting the cell with a reagent which specifically binds with anisolated TANGO 294 nucleic acid molecule or with anisolated TANGO 294 polypeptide. - Other features and advantages of the invention will be apparent from the following detailed description and claims.
- FIG. 1 comprises FIGS.1A-1M. The nucleotide sequence (SEQ ID NO: 1) of a cDNA encoding the
human TANGO 202 protein described herein is listed in FIGS 1A-1D. The open reading frame (ORF; residues 34 to 1458; SEQ ID NO: 2) of the cDNA is indicated by nucleotide triplets, above which the amino acid sequence (SEQ ID NO: 3) ofhuman TANGO 202 is listed. The nucleotide sequence (SEQ ID NO: 67) of a cDNA encoding themurine TANGO 202 protein described herein is listed in FIGS. 1E-1I. The ORF (residues 81 to 1490; SEQ ID NO: 68) of the cDNA is indicated by nucleotide triplets, above which the amino acid sequence (SEQ ID NO: 69) ofmurine TANGO 202 is listed. An alignment of the amino acid sequences of human (“Hum.”; SEQ ID NO: 3) and murine (“Mur.”; SEQ ID NO: 69)TANGO 202 protein is shown in FIGS. 1J and 1K, wherein identical amino acid residues are indicated by “:” and similar amino acid residues are indicated by “.”. - FIG. 1L is a hydrophilicity plot of
human TANGO 202 protein, in which the locations of cysteine residues (“Cys”) and potential N-glycosylation sites (“Ngly”) are indicated by vertical bars and the predicted extracellular (“out”), intracellular (“ins”), or transmembrane (“TM”) locations of the protein backbone is indicated by a horizontal bar. - FIG. 1M is a hydrophilicity plot of
murine TANGO 202 protein. - FIG. 2 comprises FIGS. 2A to2Q-17. The nucleotide sequence (SEQ ID NO: 9) of a cDNA encoding the human TANGO 234 protein described herein is listed in FIGS. 2A-2I. The ORF (
residues 28 to 4386; SEQ ID NO: 10) of the cDNA is indicated by nucleotide triplets, above which the amino acid sequence (SEQ ID NO: 11) of human TANGO 234 is listed. - FIG. 2J is a hydrophilicity plot of human TANGO 234 protein. An alignment of the amino acid sequences of human TANGO 234 (“Hum”; SEQ ID NO: 11) and bovine WC1 (“WC1”; SEQ ID NO: 78) proteins is shown in FIGS.2K-2P, wherein identical amino acid residues are indicated by “:” and similar amino acid residues are indicated by “.”. An alignment of the nucleotide sequences of an ORF encoding human TANGO 234 (“Hum”; SEQ ID NO: 10) and an ORF encoding bovine WC1 (“WC1”; SEQ ID NO: 79) proteins is shown in FIGS. 2Q-1 to 2Q-17, wherein identical nucleotide residues are indicated by “:”.
- FIG. 3 comprises FIGS.3A-3U. The nucleotide sequence (SEQ ID NO: 17) of a cDNA encoding the human TANGO 265 protein described herein is listed in FIGS. 3A-3E. The ORF (
residues 32 to 2314; SEQ ID NO: 18) of the cDNA is indicated by nucleotide triplets, above which the amino acid sequence (SEQ ID NO: 19) of human TANGO 265 is listed. An alignment of the amino acid sequences of human TANGO 265 protein (“Hum.”; SEQ ID NO: 19) and murine semaphorin B protein (“Mur.”; SEQ ID NO: 70; GenBank Accession No. X85991) is shown in FIGS. 3F-3H, wherein identical amino acid residues are indicated by “:” and similar amino acid residues are indicated by “.”. - In FIGS.31-3T, an alignment of the nucleotide sequences of the cDNA encoding human TANGO 265 protein (“Hum.”; SEQ ID NO: 17) and the nucleotide sequences of the cDNA encoding murine semaphorin B protein (“Mur.”; SEQ ID NO: 71; GenBank Accession No. X85991) is shown.
- FIG. 3U is a hydrophilicity plot of TANGO 265 protein.
- FIG. 4 comprises FIGS.4A-4J. The nucleotide sequence (SEQ ID NO: 25) of a cDNA encoding the
human TANGO 273 protein described herein is listed in FIGS. 4A-4C. The ORF (residues 135 to 650; SEQ ID NO: 26) of the cDNA is indicated by nucleotide triplets, above which the amino acid sequence (SEQ ID NO: 27) ofhuman TANGO 273 is listed. The nucleotide sequence (SEQ ID NO: 72) of a cDNA encoding themurine TANGO 273 protein described herein is listed in FIGS. 4D-4G. The ORF (residues 137 to 652; SEQ ID NO: 73) of the cDNA is indicated by nucleotide triplets, above which the amino acid sequence (SEQ ID NO: 74) ofmurine TANGO 273 is listed. An alignment of the amino acid sequences of human (“Hum.”; SEQ ID NO: 27) and murine (“Mur.”; SEQ ID NO: 74)TANGO 273 protein is shown in FIG. 4H, wherein identical amino acid residues are indicated by “:” and similar amino acid residues are indicated by “.”. - FIG. 4J is a hydrophilicity plot of
human TANGO 273 protein, and - FIG. 4J is a hydrophilicity plot of
murine TANGO 273 protein. - FIG. 5 comprises FIGS.5A-5I. The nucleotide sequence (SEQ ID NO: 33) of a cDNA encoding the
human TANGO 286 protein described herein is listed in FIGS. 5A-5D. The ORF (residues 133 to 1497; SEQ ID NO: 34) of the cDNA is indicated by nucleotide triplets, above which the amino acid sequence (SEQ ID NO: 35) ofhuman TANGO 286 is listed. - FIG. 5E is a hydrophilicity plot of
TANGO 286 protein. An alignment of the amino acid sequences of human TANGO 286 (“286”; SEQ ID NO: 35) and BPI protein (“BPI”; SEQ ID NO: 38) protein is shown in FIGS. 5F and 5G, wherein identical amino acid residues are indicated by “:” and similar amino acid residues are indicated by “.”. An alignment of the amino acid sequences of human TANGO 286 (“286”; SEQ ID NO: 35) and RENP protein (“RENP”; SEQ ID NO: 39) is shown in FIGS. 5H and 5I, wherein identical amino acid residues are indicated by “:” and similar amino acid residues are indicated by “.”. - FIG. 6 comprises FIGS.6A-6H. The nucleotide sequence (SEQ ID NO: 45) of a cDNA encoding the
human TANGO 294 protein described herein is listed in FIGS. 6A-6C. The ORF (residues 126 to 1394; SEQ ID NO: 46) of the cDNA is indicated by nucleotide triplets, above which the amino acid sequence (SEQ ID NO: 47) ofhuman TANGO 294 is listed. An alignment of the amino acid sequences ofhuman TANGO 294 protein (“294”; SEQ ID NO: 47) and a known human lipase protein (“HLP”; SEQ ID NO: 75; GenBank Accession No. NP—004181) is shown in FIGS. 6D and 6E, wherein identical amino acid residues are indicated by “:” and similar amino acid residues are indicated by “.”. - FIG. 6F is a hydrophilicity plot of
TANGO 294 protein. An alignment of the amino acid sequences ofhuman TANGO 294 protein (“294”; SEQ ID NO: 47) and a known human lysosomal acid lipase protein (“LAL”; SEQ ID NO: 41) is shown in FIGS. 6G and 6H, wherein identical amino acid residues are indicated by and similar amino acid residues are indicated by “.” - FIG. 7 comprises FIGS.7A-7F. The nucleotide sequence (SEQ ID NO: 53) of a cDNA encoding the
human INTERCEPT 296 protein described herein is listed in FIGS. 7A-7C. The ORF (residues 70 to 1098; SEQ ID NO: 54) of the cDNA is indicated by nucleotide triplets, above which the amino acid sequence (SEQ ID NO: 55) ofhuman INTERCEPT 296 protein is listed. - FIG. 7D is a hydrophilicity plot of
INTERCEPT 296 protein. An alignment of the amino acid sequences ofhuman INTERCEPT 296 protein (“296”; SEQ ID NO: 55) and C. elegans C06E1.3 related protein (“CRP”; SEQ ID NO: 40) is shown in FIGS. 7E and 7F, wherein identical amino acid residues are indicated by “:” and similar amino acid residues are indicated by “.”. - The present invention is based, at least in part, on the discovery of a variety of human and murine cDNA molecules which encode proteins which are herein designated
TANGO 202, TANGO 234, TANGO 265,TANGO 273,TANGO 286,TANGO 294, andINTERCEPT 296. These proteins exhibit a variety of physiological activities, and are included in a single application for the sake of convenience. It is understood that the allowability or non-allowability of claims directed to one of these proteins has no bearing on the allowability of claims directed to the others. The characteristics of each of these proteins and the cDNAs encoding them are now described separately. -
TANGO 202 - A cDNA clone (designated jthke096b05) encoding at least a portion of
human TANGO 202 protein was isolated from a human fetal skin cDNA library. The corresponding murine cDNA was isolated as a clone (designated jtmMa044f07) from a bone marrow stromal cell cDNA library. Thehuman TANGO 202 protein is predicted by structural analysis to be a type I membrane protein, although it can exist in a secreted form as well. Themurine TANGO 202 protein is predicted by structural analysis to be a secreted protein. - The full length of the cDNA encoding
human TANGO 202 protein (FIG. 1; SEQ ID NO: 1) is 1656 nucleotide residues. The open reading frame (ORF) of this cDNA, nucleotide residues 34 to 1458 of SEQ ID NO: 1 (i.e., SEQ ID NO: 2), encodes a 475-amino acid transmembrane protein (FIG. 1; SEQ ID NO: 3). - The invention thus includes purified
human TANGO 202 protein, both in the form of the immature 475 amino acid residue protein (SEQ ID NO: 3) and in the form of the mature 456 amino acid residue protein (SEQ ID NO: 5). The invention also includes purifiedmurine TANGO 202 protein, both in the form of the immature 470 amino acid residue protein (SEQ ID NO: 67) and in the form of the mature 451 amino acid residue protein (SEQ ID NO: 43). Mature human ormurine TANGO 202 proteins can be synthesized without the signal sequence polypeptide at the amino terminus thereof, or they can be synthesized by generatingimmature TANGO 202 protein and cleaving the signal sequence therefrom. - In addition to full length mature and immature human and
murine TANGO 202 proteins, the invention includes fragments, derivatives, and variants of theseTANGO 202 proteins, as described herein. These proteins, fragments, derivatives, and variants are collectively referred to herein as polypeptides of the invention or proteins of the invention. - The invention also includes nucleic acid molecules which encode a polypeptide of the invention. Such nucleic acids include, for example, a DNA molecule having the nucleotide sequence listed in SEQ ID NO: 1 or some portion thereof or SEQ ID NO: 67 or some portion thereof, such as the portion which encodes mature human or
murine TANGO 202 protein, immature human ormurine TANGO 202 protein, or a domain of human ormurine TANGO 202 protein. These nucleic acids are collectively referred to as nucleic acids of the invention. -
TANGO 202 proteins and nucleic acid molecules encoding them comprise a family of molecules having certain conserved structural and functional features. As used herein, the term “family” is intended to mean two or more proteins or nucleic acid molecules having a common or similar domain structure and having sufficient amino acid or nucleotide sequence identity as defined herein. Family members can be from either the same or different species (e.g., human and mouse, as described herein). For example, a family can comprise two or more proteins of human origin, or can comprise one or more proteins of human origin and one or more of non-human origin. - A common domain present in
TANGO 202 proteins is a signal sequence. As used herein, a signal sequence includes a peptide of at least about 10 amino acid residues in length which occurs at the amino terminus of membrane-bound and secreted proteins and which contains at least about 45% hydrophobic amino acid residues such as alanine, leucine, isoleucine, phenylalanine, proline, tyrosine, tryptophan, or valine. In a preferred embodiment, a signal sequence contains at least about 10 to 35 amino acid residues, preferably about 10 to 20 amino acid residues, and has at least about 35-60%, more preferably 40-50%, and more preferably at least about 45% hydrophobic residues. A signal sequence serves to direct a protein containing such a sequence to a lipid bilayer. Thus, in one embodiment, aTANGO 202 protein contains a signal sequence corresponding toamino acid residues 1 to 19 of SEQ ID NO: 3 (SEQ ID NO: 4) or toamino acid residues 1 to 19 of SEQ ID NO: 69 (SEQ ID NO: 42). The signal sequence is cleaved during processing of the mature protein. -
TANGO 202 proteins can also include an extracellular domain. As used herein, an “extracellular domain” refers to a portion of a protein which is localized to the non-cytoplasmic side of a lipid bilayer of a cell when a nucleic acid encoding the protein is expressed in the cell. Thehuman TANGO 202 protein extracellular domain is located from aboutamino acid residue 20 to aboutamino acid residue 392 of SEQ ID NO: 3 in the non-secreted form, and from aboutamino acid residue 20 to amino acid residue 475 of SEQ ID NO: 3 (i.e., the entire mature human protein). Themurine TANGO 202 protein extracellular domain is located from aboutamino acid residue 20 toamino acid residue 470 of SEQ ID NO: 69 (i.e., the entire mature murine protein). -
TANGO 202 proteins of the invention can also include a transmembrane domain. As used herein, a “transmembrane domain” refers to an amino acid sequence having at least about 20 to 25 amino acid residues in length and which contains at least about 65-70% hydrophobic amino acid residues such as alanine, leucine, phenylalanine, protein, tyrosine, tryptophan, or valine. In a preferred embodiment, a transmembrane domain contains at least about 15 to 30 amino acid residues, preferably about 20-25 amino acid residues, and has at least about 60-80%, more preferably 65-75%, and more preferably at least about 70% hydrophobic residues. Thus, in one embodiment, aTANGO 202 protein of the invention contains a transmembrane domain corresponding to aboutamino acid residues 393 to 415 of SEQ ID NO: 3 (SEQ ID NO: 7). - In addition,
TANGO 202 proteins of the invention can include a cytoplasmic domain, particularly including a carboxyl-terminal cytoplasmic domain. As used herein, a “cytoplasmic domain” refers to a portion of a protein which is localized to the cytoplasmic side of a lipid bilayer of a cell when a nucleic acid encoding the protein is expressed in the cell. The cytoplasmic domain is located from about amino acid residue 416 to amino acid residue 475 of SEQ ID NO: 3 (SEQ ID NO: 8) in the non-secreted form ofhuman TANGO 202 protein. -
TANGO 202 proteins typically comprise a variety of potential post-translational modification sites (often within an extracellular domain), such as those described herein in Tables I (for human TANGO 202) and II (for murine TANGO 202), as predicted by computerized sequence analysis ofTANGO 202 proteins using amino acid sequence comparison software (comparing the amino acid sequence ofTANGO 202 with the information in the PROSITE database {rel. 12.2; February, 1995} and the Hidden Markov Models database {Rel. PFAM 3.3}).TABLE I Amino Acid Type of Potential Modification Site or Residues of Amino Acid Domain SEQ ID NO: 3 Sequence N-glycosylation site 47 to 50 NWTA 61 to 64 NETF 219 to 222 NYSA 295 to 298 NVSL 335 to 338 NQTV 347 to 350 NLSV Protein kinase C phosphorylation site 70 to 72 TLK 137 to 139 TSK 141 to 143 SNK 155 to 157 SQR 238 to 240 TGR 245 to 247 TIR 277 to 279 THR 307 to 309 SDR 355 to 357 SSK 387 to 389 SHR 418 to 420 TFK 421 to 423 SHR Casein kinase II phosphorylation site 337 to 340 TVAE 438 to 441 TSGE 464 to 467 SQQD N- myristoylation site 53 to 58 GGKPCL 120 to 125 GNLGCY 136 to 141 GTSKTS 162 to 167 GMESGY 214 to 219 GACGGN Kringle domain signature 85 to 90 YCRNPD Kringle Domain 34 to 116 See FIG. 1 CUB domain 216 to 320 See FIG. 1 -
TABLE II Amino Acid Type of Potential Modification Residues of Amino Acid Site or Domain SEQ ID NO: 69 Sequence N- glycosylation site 59 to 62 NETF 217 to 220 NYSA 255 to 258 NFTL 293 to 296 NVSL 333 to 336 NQTL 345 to 348 NLSV cAMP- or cGMP-dependent protein 455 to 458 RRSS kinase phosphorylation site Protein kinase C phosphorylation site 68 to 70 TLK 135 to 137 TSK 139 to 141 SNK 153 to 155 SQR 236 to 238 TGR 243 to 245 TIR 275 to 277 THR 283 to 285 SGR 305 to 307 SDR 353 to 355 SSK 408 to 410 SQR 453 to 455 SLR 457 to 459 SSR Casein kinase II phosphorylation site 28 to 31 SGPE 257 to 260 TLFD 321 to 324 TKEE 335 to 338 TLAE 384 to 387 TATE N- myristoylation site 51 TO 56 GGKPCL 118 TO 123 GNLGCY 134 TO 139 GTSKTS 160 TO 165 GMESGY 212 TO 217 GACGGN 391 TO 396 GLCTAW 429 TO 434 GTVVSL Kringle domain signature 83 to 88 YCRNPD Kringle Domain 32 to 114 See FIG. 1 CUB domain 214 to 318 See FIG. 1 - As used herein, the term “post-translational modification site” refers to a protein domain that includes about 3 to 10 amino acid residues, more preferably about 3 to 6 amino acid residues wherein the domain has an amino acid sequence which comprises a consensus sequence which is recognized and modified by a protein-modifying enzyme. Exemplary protein-modifying enzymes include amino acid glycosylases, cAMP- and cGMP-dependent protein kinases, protein kinase C, casein kinase II, myristoylases, and prenyl transferases. In various embodiments, the protein of the invention has at least 1, 2, 4, 6, 10, 15, or 20 or more of the post-translational modification sites described herein in Tables I and II.
- Exemplary additional domains present in human and
murine TANGO 202 protein include Kringle domains and CUB domains. In one embodiment, the protein of the invention has at least one domain that is at least 55%, preferably at least about 65%, more preferably at least about 75%, yet more preferably at least about 85%, and most preferably at least about 95% identical to one of the domains described herein in Tables I and II. Preferably, the protein of the invention has at least one Kringle domain and one CUB domain. - A Kringle domain has a characteristic profile that has been described in the art (Castellino and Beals (1987) J. Mol. Evol. 26:358-369; Patthy (1985) Cell 41:657-663; Ikeo et al. (1991) FEBS Lett. 287:146-148). Many, but not all, Kringle domains comprise a conserved hexapeptide signature sequence, namely
- (F or Y)-C-R-N-P-(D or N or R).
- The cysteine residue is involved in a disulfide bond.
- Kringle domains are triple-looped, disulfide cross-linked domains found in a varying number of copies in, for example, some serine proteases and plasma proteins. Kringle domains have a role in binding mediators (e.g., membranes, other proteins, or phospholipids) and in regulation of proteolytic activity. Kringle domains have been identified in the following proteins, for example: apolipoprotein A, blood coagulation factor XII (Hageman factor), hepatocyte growth factor (HGF), HGF-like protein (Friezner Degen et al., (1991) Biochemistry 30:9781-9791), HGF activator (Miyazawa et al., (1993) J. Biol. Chem. 268:10024-10028), plasminogen, thrombin, tissue plasminogen activator, urokinase-type plasminogen activator, and four influenza neuraminidases. The presence of a Kringle domain in each of human and
murine TANGO 202 protein indicates thatTANGO 202 is involved in one or more physiological processes in which these other Kringle domain-containing proteins are involved, has biological activity in common with one or more of these other Kringle domain-containing proteins, or both. - CUB domains are extracellular domains of about 110 amino acid residues which occur in functionally diverse, mostly developmentally regulated proteins (Bork and Beckmann (1993) J. Mol. Biol. 231:539-545; Bork (1991) FEBS Lett. 282:9-12). Many CUB domains contain four conserved cysteine residues, although some, like that of
TANGO 202, contain only two of the conserved cysteine residues. The structure of the CUB domain has been predicted to assume a beta-barrel configuration, similar to that of immunoglobulins. Other proteins which have been found to comprise one or more CUB domains include, for example, mammalian complement sub-components Cls and Clr, hamster serine protease Casp, mammalian complement activating component of Ra-reactive factor, vertebrate enteropeptidase, vertebrate bonemorphogenic protein 1, sea urchin blastula proteins BP10 and SpAN, Caenorhabditis elegans hypothetical proteins F42A10.8 and R151.5, neuropilin (A5 antigen), sea urchin fibropellins I and III, mammalian hyaluronate-binding protein TSG-6 (PS4), mammalian spermadhesins, and Xenopus embryonic protein UVS.2. The presence of a CUB domain in each of human andmurine TANGO 202 protein indicates thatTANGO 202 is involved in one or more physiological processes in which these other CUB domain-containing proteins are involved, has biological activity in common with one or more of these other CUB domain-containing proteins, or both. - The signal peptide prediction program SIGNALP (Nielsen et al. (1997) Protein Engineering 10:1-6) predicted that
human TANGO 202 protein includes a 19 amino acid signal peptide (amino acid residues 1 to 19 of SEQ ID NO: 3; SEQ ID NO: 4) preceding themature TANGO 202 protein (amino acid residues 20 to 475 of SEQ ID NO: 3; SEQ ID NO: 5).Human TANGO 202 protein includes an extracellular domain (amino acid residues 20 to 392 of SEQ ID NO: 3; SEQ ID NO: 6); a transmembrane domain (amino acid residues 393 to 415 of SEQ ID NO: 3; SEQ ID NO: 7); and a cytoplasmic domain (amino acid residues 416 to 475 of SEQ ID NO: 3; SEQ ID NO: 8). The murine homolog ofTANGO 202 protein is predicted to be a secreted protein. Thus, it is recognized thathuman TANGO 202 can also exist in the form of a secreted protein, likely being translated from an alternatively splicedTANGO 202 mRNA. In a variant form of the protein, an extracellular portion ofTANGO 202 protein (e.g.,amino acid residues 20 to 392 of SEQ ID NO: 3) can be cleaved from the mature protein to generate a soluble fragment ofTANGO 202. - FIG. 1L depicts a hydrophilicity plot of
human TANGO 202 protein. Relatively hydrophobic regions are above the dashed horizontal line, and relatively hydrophilic regions are below the dashed horizontal line. The hydrophobic region which corresponds toamino acid residues 1 to 19 of SEQ ID NO: 3 is the signal sequence of human TANGO 202 (SEQ ID NO: 4). The hydrophobic region which corresponds toamino acid residues 393 to 415 of SEQ ID NO: 3 is the transmembrane domain of human TANGO 202 (SEQ ID NO: 7). As described elsewhere herein, relatively hydrophilic regions are generally located at or near the surface of a protein, and are more frequently effective immunogenic epitopes than are relatively hydrophobic regions. For example, the region ofhuman TANGO 202 protein from about amino acid residue 61 to about amino acid residue 95 appears to be located at or near the surface of the protein, while the region from about amino acid residue 395 to aboutamino acid residue 420 appears not to be located at or near the surface. - The predicted molecular weight of
human TANGO 202 protein without modification and prior to cleavage of the signal sequence is about 51.9 kilodaltons. The predicted molecular weight of the maturehuman TANGO 202 protein without modification and after cleavage of the signal sequence is about 50.1 kilodaltons. - The full length of the cDNA encoding
murine TANGO 202 protein (FIG. 1; SEQ ID NO: 67) is 4928 nucleotide residues. The ORF of this cDNA,nucleotide residues 81 to 1490 of SEQ ID NO: 67 (i.e., SEQ ID NO: 68), encodes a 470-amino acid secreted protein (FIG. 1; SEQ ID NO: 69). - The signal peptide prediction program SIGNALP (Nielsen et al. (1997) Protein Engineering 10:1-6) predicted that
murine TANGO 202 protein includes a 19 amino acid signal peptide (amino acid residues 1 to 19 of SEQ ID NO: 69; SEQ ID NO: 42) preceding themature TANGO 202 protein (amino acid residues 20 to 470 of SEQ ID NO: 69; SEQ ID NO: 43).Murine TANGO 202 protein is a secreted protein. - FIG. 1M depicts a hydrophilicity plot of
murine TANGO 202 protein. Relatively hydrophobic regions are above the dashed horizontal line, and relatively hydrophilic regions are below the dashed horizontal line. The hydrophobic region which corresponds toamino acid residues 1 to 19 of SEQ ID NO: 69 is the signal sequence of murine TANGO 202 (SEQ ID NO: 42). As described elsewhere herein, relatively hydrophilic regions are generally located at or near the surface of a protein, and are more frequently effective immunogenic epitopes than are relatively hydrophobic regions. For example, the region ofmurine TANGO 202 protein from about amino acid residue 61 to about amino acid residue 95 appears to be located at or near the surface of the protein, while the region from about amino acid residue 295 to about amino acid residue 305 appears not to be located at or near the surface - The predicted molecular weight of
murine TANGO 202 protein without modification and prior to cleavage of the signal sequence is about 51.5 kilodaltons. The predicted molecular weight of the maturemurine TANGO 202 protein without modification and after cleavage of the signal sequence is about 49.7 kilodaltons. - Human and
murine TANGO 202 proteins exhibit considerable sequence similarity, as indicated herein in FIGS. 1J and 1K. FIGS. 1J and 1K depict an aligmnent of human andmurine TANGO 202 amino acid sequences (SEQ ID NOs: 3 and 69, respectively). In this alignment (made using the ALIGN software {Myers and Miller (1989) CABIOS, ver. 2.0}; pam120.mat scoring matrix; gap penalties −12/−4), the proteins are 76.5% identical. The human and murineORFs encoding TANGO 202 are 87.4% identical, as assessed using the same software and parameters. - In situ hybridization experiments in mouse tissues indicated that mRNA corresponding to the
cDNA encoding TANGO 202 is expressed in the tissues listed in Table III, wherein “+” indicates detectable expression and “++” indicates a greater level of expression than “+”.TABLE III Relative Level of Animal Tissue Expression Mouse bladder, especially in ++ (Adult) transitional epithelium renal glomeruli + brain + heart + liver + spleen + placenta + Mouse ubiquitous + (Embryo) - Biological Function of
TANGO 202 Proteins, Nucleic Acids, and Modulators Thereof -
TANGO 202 proteins are involved in disorders which affect both tissues in which they are normally expressed and tissues in which they are normally not expressed. Based on the observation thatTANGO 202 is expressed in human fetal skin, ubiquitously in fetal mouse tissues, in adult murine bone marrow stromal cells, and in cells of adult murine bladder, renal glomeruli, brain, heart, liver, spleen and placenta,TANGO 202 protein is involved in one or more biological processes which occur in these tissues. In particular,TANGO 202 is involved in modulating growth, proliferation, survival, differentiation, and activity of cells of these tissues including, but not limited to, hematopoietic and fetal cells. Thus,TANGO 202 has a role in disorders which affect these cells and their growth, proliferation, survival, differentiation, and activity. Ubiquitous expression ofTANGO 202 in fetal murine tissues, contrasted with limited expression in adult murine tissues further indicates thatTANGO 202 is involved in disorders in which it is inappropriately expressed (e.g., disorders in whichTANGO 202 is expressed in adult murine tissues other than bone marrow stromal cells and disorders in whichTANGO 202 is not expressed in one or more developing fetal tissues). - The presence of a Kringle domain in both the murine and
human TANGO 202 proteins indicates that this protein is involved in modulating cellular binding to one or more mediators (e.g., proteins, phospholipids, intracellular organelles, or other cells), in modulating proteolytic activity, or both. The presence of a Kringle domain in other proteins (e.g., growth factors) indicates activities that these proteins share withTANGO 202 protein (e.g., modulating cell dissociation and migration into and through extracellular matrices). The presence of Kringle domains in numerous plasma proteins, particularly coupled with the observation thatTANGO 202 is expressed in adult murine bone marrow stromal cells, indicates a role forTANGO 202 protein in modulating binding of blood or hematopoietic cells (or both) to one or more mediators. Thus,TANGO 202 is involved in disorders relating to aberrant cellular protease activity, inappropriate interaction or non-interaction of cells with mediators, and in blood and hematopoietic cell-related disorders. Such disorders include, by way of example and not limitation, immune disorders, infectious diseases, auto-immune disorders, vascular and cardiovascular disorders, disorders related to mal-expression of growth factors, cancers, hematological disorders, and the like. - The
cDNA encoding TANGO 202 exhibits significant nucleotide sequence similarity with a polynucleotide encoding a kringle-domain-containing protein (designated HTHBZ47) described in the European Patent Application No. EP 0 911 399 A2 (published Apr. 28, 1999). Thus, theTANGO 202 protein can exhibit one or more of the activities exhibited by HTHBZ47, and can be used to prevent, inhibit, diagnose, and treat one or more disorders for which HTHBZ47 is useful. These disorders include cancer, inflammation, autoimmune disorders, allergic disorders, asthma, rheumatoid arthritis, inflammation of central nervous system tissues, cerebellar degeneration, Alzheimer's disease, Parkinson's disease, multiple sclerosis, amylotrophic lateral sclerosis, head injury damage and other neurological abnormalities, septic shock, sepsis, stroke, osteoporosis, osteoarthritis, ischemic reperfusion injury, cardiovascular disease, kidney disease, liver disease, ischemic injury, myocardial infarction, hypotension, hypertension, AIDS, myelodysplastic syndromes and other hematologic abnormalities, aplastic anemia, male pattern baldness, and bacterial, fungal, protozoan, and viral infections. - The presence of a CUB domain in both the murine and
human TANGO 202 proteins indicates that this protein is involved in biological processes common to other CUB domain-containing proteins, such as developmental processes and binding to mediators. Therefore,TANGO 202 protein has a role in disorders which involve inappropriate developmental processes (e.g., abnormally high proliferation or un-differentiation of a differentiated tissue or abnormally low differentiation or proliferation of a non-developed or non-differentiated tissue) and modulation of cell growth, proliferation, survival, differentiation, and activity. Such disorders include, by way of example and not limitation, various cancers and birth and developmental defects. - Thus, proteins and nucleic acids of the invention which are identical to, similar to, or derived from human and
murine TANGO 202 proteins and nucleic acids encoding them are useful for preventing, diagnosing, and treating, among others, vascular and cardiovascular disorders, hematological disorders, disorders related to mal-expression of growth factors, and cancer. Other uses for these proteins and nucleic acids of the invention relate to modulating cell growth (e.g., angiogenesis), proliferation (e.g., cancers), survival (e.g., apoptosis), differentiation (e.g., hematopoiesis), and activity (e.g., ligand-binding capacity).TANGO 202 proteins and nucleic acids encoding them are also useful for modulating cell dissociation and modulating migration of cells in extracellular matrices. - TANGO 234
- A cDNA clone (designated jthsa104d11) encoding at least a portion of human TANGO 234 protein was isolated from a human fetal spleen cDNA library. The human TANGO 234 protein is predicted by structural analysis to be a transmembrane protein, although it can exist in a secreted form as well.
- The full length of the cDNA encoding human TANGO 234 protein (FIG. 2; SEQ ID NO: 9) is 4628 nucleotide residues. The ORF of this cDNA,
nucleotide residues 28 to 4386 of SEQ ID NO: 9 (i.e., SEQ ID NO: 10), encodes a 1453-amino acid transmembrane protein (FIG. 2; SEQ ID NO: 11). - The invention thus includes purified human TANGO 234 protein, both in the form of the immature 1453 amino acid residue protein (SEQ ID NO: 11) and in the form of the mature 1413 amino acid residue protein (SEQ ID NO: 13). Mature human TANGO 234 protein can be synthesized without the signal sequence polypeptide at the amino terminus thereof, or it can be synthesized by generating immature TANGO 234 protein and cleaving the signal sequence therefrom.
- In addition to full length mature and immature human TANGO 234 proteins, the invention includes fragments, derivatives, and variants of these TANGO 234 proteins, as described herein. These proteins, fragments, derivatives, and variants are collectively referred to herein as polypeptides of the invention or proteins of the invention.
- The invention also includes nucleic acid molecules which encode a polypeptide of the invention. Such nucleic acids include, for example, a DNA molecule having the nucleotide sequence listed in SEQ ID NO: 9 or some portion thereof, such as the portion which encodes mature TANGO 234 protein, immature TANGO 234 protein, or a domain of TANGO 234 protein. These nucleic acids are collectively referred to as nucleic acids of the invention.
- TANGO 234 proteins and nucleic acid molecules encoding them comprise a family of molecules having certain conserved structural and functional features, as indicated by the conservation of amino acid sequence between human TANGO 234 protein and bovine WC1 protein, as shown in FIGS. 2K through 2P, and the conservation of nucleotide sequence between the ORFs encoding human TANGO 234 protein and bovine WC1 protein, as shown in FIGS.2Q-1 through 2Q-17.
- A common domain present in TANGO 234 proteins is a signal sequence. As used herein, a signal sequence includes a peptide of at least about 10 amino acid residues in length which occurs at the amino terminus of membrane-bound proteins and which contains at least about 45% hydrophobic amino acid residues such as alanine, leucine, isoleucine, phenylalanine, proline, tyrosine, tryptophan, or valine. In a preferred embodiment, a signal sequence contains at least about 10 to 35 amino acid residues, preferably about 10 to 20 amino acid residues, and has at least about 35-60%, more preferably 40-50%, and more preferably at least about 45% hydrophobic residues. A signal sequence serves to direct a protein containing such a sequence to a lipid bilayer. Thus, in one embodiment, a TANGO 234 protein contains a signal sequence corresponding to
amino acid residues 1 to 40 of SEQ ID NO: 11 (SEQ ID NO: 12). The signal sequence is cleaved during processing of the mature protein. - TANGO 234 proteins can include an extracellular domain. The human TANGO 234 protein extracellular domain is located from about
amino acid residue 41 to about amino acid residue 1359 of SEQ ID NO: 3. TANGO 234 can alternately exist in a secreted form, such as a mature protein having the amino acid sequence ofamino acid residues 41 to 1453 orresidues 41 to about 1359 of SEQ ID NO: 11. - In addition, TANGO 234 include a transmembrane domain. In one embodiment, a TANGO 234 protein of the invention contains a transmembrane domain corresponding to about
amino acid residues 1360 to 1383 of SEQ ID NO: 11 (SEQ ID NO: 15). - The present invention includes TANGO 234 proteins having a cytoplasmic domain, particularly including proteins having a carboxyl-terminal cytoplasmic domain. The human TANGO 234 cytoplasmic domain is located from about amino acid residue 1384 to amino acid residue 1453 of SEQ ID NO: 11 (SEQ ID NO: 16).
- TANGO 234 proteins typically comprise a variety of potential post-translational modification sites (often within an extracellular domain), such as those described herein in Table IV, as predicted by computerized sequence analysis of TANGO 234 proteins using amino acid sequence comparison software (comparing the amino acid sequence of TANGO 234 with the information in the PROSITE database {rel. 12.2; February, 1995} and the Hidden Markov Models database {Rel. PFAM 3.3 }). In certain embodiments, a protein of the invention has at least 1, 2, 4, 6, 10, 15, or 20 or more of the post-translational modification sites listed in Table IV.
TABLE IV Amino Acid Type of Potential Modification Site or Residues of Amino Acid Domain SEQ ID NO: 11 Sequence N-glycosylation site 42 to 45 NGTD 78 to 81 NTTA 120 to 123 NESA 161 to 164 NNSC 334 to 337 NESF 377 to 380 NCSG 441 to 444 NESA 548 to 551 NESN 637 to 640 NAST 972 to 975 NESL 1013 to 1016 NVSD 1084 to 1087 NATV 11O4 to 1107 NCTG 1161 to 1164 NGTW 1171 to 1174 NITT 1318 to 1321 NESF 1354 to 1357 NASS Glycosaminoglycan attachment site 558 to 561 SGWG 665 to 668 SGWG cAMP- or cGMP-dependent protein 1229 to 1232 RRIS kinase phosphorylation site 1399 to 1402 RRGS Protein kinase C phosphorylation site 165 to 167 SGR 268 to 270 TNR 379 to 381 SGR 419 to 421 SRR 469 to 471 SDK 506 to 508 STR 589 to 591 SNR 593 to 595 SGR 661 to 663 SCR 696 to 698 SSR 746 to 748 TER 805 to 807 SGR 815 to 817 TWR 959 to 961 SVR 1256 to 1258 SGR 1349 to 1351 SLK 1396 to 1398 STR Casein kinase II phosphorylation site 44 to 47 TDLE 71 to 74 TVCD 178 to 181 TICD 245 to 248 SHNE 253 to 256 TCYD 258 to 261 SDLE 319 to 322 SGSD 332 to 335 SGNE 392 to 395 TICD 439 to 442 TGNE 606 to 609 TVCD 622 to 625 SQLD 673 to 676 SHSE 686 to 689 SDME 760 to 763 TGGE 765 to 768 SLWD 818 to 821 SVCD 845 to 848 SVGD 857 to 860 TWAE 907 to 910 SQCD 923 to 926 SLCD 927 to 930 THWD 974 to 977 SLLD 1059 to 1062 TICD 1106 to 1109 TGTE 1145 to 1148 SETE 1233 to 1236 SPAE 1241 to 1244 TCED 1269 to 1272 TVCD 1402 to 1405 SLEE 1425 to 1428 TSDD N-myristoylation site 67 to 72 GQWGTV 90 to 95 GCPFSF 101 to 106 GQAVTR 119 to 124 GNESAL 133 to 138 GSHNCY 160 to 165 GNNSCS 197 to 202 GCPSSF 226 to 231 GNELAL 240 to 245 GNHDCS 267 to 272 GTNRCM 304 to 309 GCGTAL 328 to 333 GVSCSG 374 to 379 GSNNCS 411 to 416 GCPFSV 418 to 423 GSRRAK 440 to 445 GNESAL 465 to 470 GVICSD 547 to 552 GNESNI 588 to 593 GSNRCS 632 to 637 GMGLGN 668 to 673 GNNDCS 679 to 684 GVICSD 695 to 700 GSSRCA 712 to 717 GILCAN 720 to 725 GMNIAE 758 to 763 GCTGGE 853 to 858 GNGLTW 891 to 896 GVVCSR 944 to 949 GTALST 985 to 990 GAPPCI 992 to 997 GNTVSV 1078 to 1083 GCGVAF 1121 to 1126 GQHDCR 1132 to 1137 GVICSE 1162 to 1167 GTWGSV 1185 to 1190 GCGENG 1265 to 1270 GSWGTV 1288 to 1293 GCGSAL 1302 to 1307 GQGTGT 1331 to 1336 GQSDCG 1342 to 1347 GVRCSG 1422 to 1427 GTRTSD 1443 to 1438 GCEDAS 1444 to 1449 GVLPAS Amidation site 1167 to 1170 VGRR Speract receptor repeated (SRR) 53 to 90 See FIG. 2 domain signature 160 to 197 See FIG. 2 267 to 304 See FIG. 2 1041 to 1078 See FIG. 2 1251 to 1288 See FIG. 2 Scavenger receptor cysteine-rich 51 to 148 See FIG. 2 (SRCR) domain 158 to 255 See FIG. 2 265 to 362 See FIG. 2 372 to 469 See FIG. 2 479 to 576 See FIG. 2 586 to 683 See FIG. 2 693 to 790 See FIG. 2 798 to 895 See FIG. 2 903 to 1000 See FIG. 2 1039 to 1136 See FIG. 2 1146 to 1243 See FIG. 2 1249 to 1346 See FIG. 2 - Among the domains that occur in TANGO 234 protein are SRR domains and SRCR domains. In one embodiment, the protein of the invention has at least one domain that is at least 55%, preferably at least about 65%, more preferably at least about 75%, yet more preferably at least about 85%, and most preferably at least about 95% identical to one of these domains. In other embodiments, the protein has at least two of the SRR and SRCR domains described herein in Table IV. In other embodiments, the protein has at least one SRR domain and at least one SRCR domain.
- The SRR domain is named after a receptor domain identified in a sea urchin egg protein designated speract. The consensus sequence of this domain (using standard one-letter amino acid codes, wherein X is any amino acid residue) is as follows.
- -G-X5-G-X2-E-X6-W-G-X2-C-X3-(F or Y or W)-X8-C-X3-G-.
- Speract is a transmembrane glycoprotein of 500 amino acid residues (Dangott et al. (1989) Proc. Natl. Acad. Sci. USA 86:2128-2132). Structurally, this receptor consists of a large extracellular domain of 450 residues, followed by a transmembrane region and a small cytoplasmic domain of 12 amino acid residues. The extracellular domain contains four repeats of an approximately 115 amino acid domain. There are 17 amino acid residues that are perfectly conserved in the four repeats in speract, including six cysteine residues, six glycine residues, and two glutamate residues. TANGO 234 has five SRR domains, in which 16 of the 17 conserved speract residues are present of four of the SRR domains and 15 are present in the remaining SRR domain. This domain is designated the speract receptor repeated domain. The amino acid sequence of mammalian macrophage scavenger receptor type I (MSRI) exhibits such a domain (Freeman et al. (1990) Proc. Natl. Acad. Sci. USA 87:8810-8814). MSRI proteins are membrane glycoproteins implicated in the pathologic deposition of cholesterol in arterial walls during atherogenesis. TANGO 234 is involved in one or more physiological processes related to cholesterol deposition and atherogenesis, as well as other vascular and cardiovascular disorders.
- Scavenger receptor cysteine-rich (SRCR) domains are disulfide rich extracellular domains which are present in certain cell surface and secreted proteins. Proteins having SRCR domains exhibit diverse ligand binding specificity. For example, in addition to modified lipoproteins, some of these proteins bind a variety of surface components of pathogenic microorganisms, and some of the proteins bind apoptotic cells. SRCR domains are also involved in mediating immune development and response. Other SRCR-containing proteins are involved in binding of modified lipoproteins (e.g., oxidized low density lipoprotein {LDL}) by specialized macrophages, leading to the formation of macrophages filled with cholesteryl ester droplets (i.e., foam cells). TANGO 234 is involved in one or more physiological processes in which these other SRCR domain-containing proteins are involved, such as LDL uptake and metabolism, regulation of serum cholesterol level, atherogenesis, atherosclerosis, bacterial or viral infections, immune development, and generation and perseverance of immune responses.
- WC1 is a ruminant protein having an SRCR domain. WC1 and gamma delta T-cell receptor are the only known gamma delta T-cell specific antigens. Antibodies which bind specifically with WC1 induce growth arrest in IL-2-dependent gamma delta T-cell and augment proliferation of gamma delta T-cells in an autologous mixed lymphocyte reaction or in the presence of anti-CD2 or anti-CD5 antibodies. Injection of antibodies which bind specifically with WC1 into calves results in long-lasting depletion of gamma delta T-cells. Furthermore, antibodies which bind specifically with WC1 can be used to purify gamma delta T-cells.
- Gamma delta T-cells are involved in a variety of physiological processes. For example, these cells are potential mediators of allergic airway inflammation and lyme disease. Furthermore, these cells are involved in natural resistance to viral infections and can mediate autoimmune diseases. Elimination of gamma delta T-cells by injection of antibodies which bind specifically therewith can affect the outcomes of these disorders.
- TANGO 234 is likely the human orthologue of ruminant protein WC1, and thus is involved with the physiological processes described above in humans. An alignment of the amino acid sequences of (human) TANGO 234 and bovine WC1 protein is shown in FIGS.2K-2P. In this alignment (made using the ALIGN software {Myers and Miller (1989) CABIOS, ver. 2.0}; pam120.mat scoring matrix; gap penalties −12/−4), the proteins are 40.4% identical. An alignment of the nucleotide sequences of the ORFs encoding (human) TANGO 234 and bovine WC1 protein is shown in FIGS. 2Q-1 to 2Q-17. The two ORFs are 54.3% identical, as assessed using the same software and parameters.
- The signal peptide prediction program SIGNALP (Nielsen et al. (1997) Protein Engineering 10:1-6) predicted that human TANGO 234 protein includes a 40 amino acid signal peptide (
amino acid residues 1 to 40 of SEQ ID NO: 11; SEQ ID NO: 12) preceding the mature TANGO 234 protein (amino acid residues 41 to 4386 of SEQ ID NO: 11; SEQ ID NO: 13). Human TANGO 234 protein includes an extracellular domain (amino acid residues 41 to 1359 of SEQ ID NO: 11; SEQ ID NO: 14); a transmembrane domain (amino acid residues 1360 to 1383 of SEQ ID NO: 11; SEQ ID NO: 15); and a cytoplasmic domain (amino acid residues 1384 to 1453 of SEQ ID NO: 11; SEQ ID NO: 16). - FIG. 2J depicts a hydrophilicity plot of human TANGO 234 protein. Relatively hydrophobic regions are above the dashed horizontal line, and relatively hydrophilic regions are below the dashed horizontal line. The hydrophobic region which corresponds to
amino acid residues 1 to 40 of SEQ ID NO: 11 is the signal sequence of human TANGO 234 (SEQ ID NO: 12). The hydrophobic region which corresponds toamino acid residues 1360 to 1383 of SEQ ID NO: 11 is the transmembrane domain of human TANGO 234 (SEQ ID NO: 15). As described elsewhere herein, relatively hydrophilic regions are generally located at or near the surface of a protein, and are more frequently effective immunogenic epitopes than are relatively hydrophobic regions. For example, the region of human TANGO 234 protein from about amino acid residue 225 to aboutamino acid residue 250 appears to be located at or near the surface of the protein, while the region from aboutamino acid residue 990 to aboutamino acid residue 1000 appears not to be located at or near the surface. - The predicted molecular weight of human TANGO 234 protein without modification and prior to cleavage of the signal sequence is about 159.3 kilodaltons. The predicted molecular weight of the mature human TANGO 234 protein without modification and after cleavage of the signal sequence is about 154.7 kilodaltons.
- Chromosomal mapping to identify the location of the gene encoding human TANGO 234 protein indicated that the gene was located at chromosomal location h12p13 (with synteny to mo6). Flanking chromosomal markers include WI-6980 and GATA8A09.43. Nearby human loci include IBD2 (inflammatory bowel disease 2), FPF (familial periodic fever), and HPDR2 (hypophosphatemia vitamin D resistant rickets 2). Nearby genes are KLRC (killer cell receptor cluster), DRPLA (dentatorubro-pallidoluysian atrophy), GAPD (glyceraldehyde-3-phosphate) dehydrogenase, and PXR1 (peroxisome receptor 1). Murine chromosomal mapping indicated that the murine orthologue is located near the scr (scruffy) locus. Nearby mouse genes include drpla (dentatorubral phillidoluysian atrophy), prp (proline rich protein), and kap (kidney androgen regulated protein).
- Northern analysis experiments indicated that mRNA corresponding to the cDNA encoding TANGO 234 is expressed in the tissues listed in Table V, wherein “++” indicates moderate expression, “+” indicates lower expression, and “−” indicates no detectable expression.
TABLE V Animal Tissue Relative Level of Expression Human spleen ++ fetal lung ++ lung + thymus + bone marrow − peripheral blood leukocytes − - Biological Function of TANGO 234 Proteins, Nucleic Acids, and Modulators Thereof
- TANGO 234 proteins are involved in disorders which affect both tissues in which they are normally expressed and tissues in which they are normally not expressed. Based on the observation that TANGO 234 is expressed in human fetal lung, spleen, and, to a lesser extent in adult lung and thymus tissue, TANGO 234 protein is involved in one or more biological processes which occur in these tissues. In particular, TANGO 234 is involved in modulating growth, proliferation, survival, differentiation, and activity of cells including, but not limited to, lung, spleen, thymus bone marrow, hematopoietic, peripheral blood leukocytes, and fetal cells of the animal in which it is normally expressed. Thus, TANGO 234 has a role in disorders which affect these cells and their growth, proliferation, survival, differentiation, and activity. Expression of TANGO 234 in an animal is also involved in modulating growth, proliferation, survival, differentiation, and activity of cells and viruses which are foreign to the host (i.e., bacterial, fungal, and viral infections).
- Homology of human TANGO 234 with bovine WC1 protein indicates that TANGO 234 has physiological functions in humans analogous to the functions of WC1 in ruminants. Thus, TANGO 234 is involved in modulating growth, proliferation, survival, differentiation, and activity of gamma delta T cells. For example, TANGO 234 affects the ability of gamma delta T cells to interact with chemokines such as interleukin-2. TANGO 234 therefore is involved in the physiological processes associated with allergic airway inflammation, lyme arthritis, resistance to viral infection, auto-immune diseases, and the like.
- In addition, presence in TANGO 234 of SRR and SRCR domains indicates that TANGO 234 is involved in physiological functions identical or analogous to the functions performed by other proteins having such domains. For example, like other SRR domain-containing proteins, TANGO 234 modulates cholesterol deposition in arterial walls, and is thus involved in development and persistence of atherogenesis and arteriosclerosis, as well as other vascular and cardiovascular disorders. Like other SRCR domain-containing proteins, TANGO 234 is involved in uptake and metabolism of LDL, regulation of serum cholesterol level, and can modulate these processes as well as the processes of atherogenesis, arteriosclerosis, immune development, and generation and perseverance of immune responses to bacterial, fungal, and viral infections.
- TANGO 265
- A cDNA clone (designated jthsa079g01) encoding at least a portion of human TANGO 265 protein was isolated from a human fetal spleen cDNA library. The human TANGO 265 protein is predicted by structural analysis to be a transmembrane membrane protein, although it can exist in a secreted form as well.
- The full length of the cDNA encoding human TANGO 265 protein (FIG. 3; SEQ ID NO: 17) is 3104 nucleotide residues. The ORF of this cDNA,
nucleotide residues 32 to 2314 of SEQ ID NO: 17 (i.e., SEQ ID NO: 18), encodes a 761-amino acid transmembrane protein (FIG. 3; SEQ ID NO: 19). - The invention thus includes purified TANGO 265 protein, both in the form of the immature 761 amino acid residue protein (SEQ ID NO: 19) and in the form of the mature 730 amino acid residue protein (SEQ ID NO: 21). Mature TANGO 265 protein can be synthesized without the signal sequence polypeptide at the amino terminus thereof, or it can be synthesized by generating immature TANGO 265 protein and cleaving the signal sequence therefrom.
- In addition to full length mature and immature TANGO 265 proteins, the invention includes fragments, derivatives, and variants of TANGO 265 protein, as described herein. These proteins, fragments, derivatives, and variants are collectively referred to herein as polypeptides of the invention or proteins of the invention.
- The invention also includes nucleic acid molecules which encode a polypeptide of the invention. Such nucleic acids include, for example, a DNA molecule having the nucleotide sequence listed in SEQ ID NO: 17 or some portion thereof, such as the portion which encodes mature TANGO 265 protein, immature TANGO 265 protein, or a domain of TANGO 265 protein. These nucleic acids are collectively referred to as nucleic acids of the invention.
- TANGO 265 proteins and nucleic acid molecules encoding them comprise a family of molecules having certain conserved structural and functional features.
- A common domain present in TANGO 265 proteins is a signal sequence. As used herein, a signal sequence includes a peptide of at least about 10 amino acid residues in length which occurs at the amino terminus of membrane-bound proteins and which contains at least about 45% hydrophobic amino acid residues such as alanine, leucine, isoleucine, phenylalanine, proline, tyrosine, tryptophan, or valine. In a preferred embodiment, a signal sequence contains at least about 10 to 35 amino acid residues, preferably about 10 to 20 amino acid residues, and has at least about 35-60%, more preferably 40-50%, and more preferably at least about 45% hydrophobic residues. A signal sequence serves to direct a protein containing such a sequence to a lipid bilayer. Thus, in one embodiment, a TANGO 265 protein contains a signal sequence corresponding to
amino acid residues 1 to 31 of SEQ ID NO: 19 (SEQ ID NO: 20). The signal sequence is cleaved during processing of the mature protein - TANGO 265 proteins can also include an extracellular domain. The human TANGO 265 protein extracellular domain is located from about
amino acid residue 32 to about amino acid residue 683 of SEQ ID NO: 17. TANGO 265 can alternately exist in a secreted form, such as a mature protein having the amino acid sequence ofamino acid residues 32 to 761 orresidues 32 to about 683 of SEQ ID NO: 19. - TANGO 265 proteins can also include a transmembrane domain. In one embodiment, a TANGO 265 protein of the invention contains a transmembrane domain corresponding to about amino acid residues 684 to 704 of SEQ ID NO: 19 (SEQ ID NO: 23).
- In addition, TANGO 265 proteins include a cytoplasmic domain, particularly including proteins having a carboxyl-terminal cytoplasmic domain. The human TANGO 265 cytoplasmic domain is located from about amino acid residue 705 to
amino acid residue 761 of SEQ ID NO: 19 (SEQ ID NO: 24). - TANGO 265 proteins typically comprise a variety of potential post-translational modification sites (often within an extracellular domain), such as those described herein in Table VI, as predicted by computerized sequence analysis of TANGO 265 proteins using amino acid sequence comparison software (comparing the amino acid sequence of TANGO 265 with the information in the PROSITE database {rel. 12.2; February, 1995} and the Hidden Markov Models database {Rel. PFAM 3.3 }). In certain embodiments, a protein of the invention has at least 1, 2, 4, 6, 10, 15, or 20 or more of the post-translational modification sites listed in Table VI.
TABLE VI Amino Acid Type of Potential Modification Site or Residues of Amino Acid Domain SEQ ID NO: 19 Sequence N- glycosylation site 120 to 123 NETQ 135 to 138 NVTH 496 to 499 NCSV 607 to 610 NGLS Glycosaminoglycan attachment site 70 to 73 SGDG cAMP- or cGMP- dependent protein 108 to 111 RKKS kinase phosphorylation site 116 to 119 KKKS 281 to 284 KKWT Protein kinase C phosphorylation site 106 to 108 SDR 262 to 264 TSR 361 to 363 TSR 366 to 368 TYR 385 to 387 SDK 533 to 535 SWK 555 to 557 SLR 721 to 723 TLR 738 to 740 SPK Casein kinase II phosphorylation site 152 to 155 TFIE 176 to 179 SPFD 250 to 253 TASE 342 to 345 SLLD 411 to 414 SGVE 498 to 501 SVYE 502 to 505 SCVD 574 to 577 SILE 738 to 741 SPKE 745 to 748 SASD N- myristoylation site 79 to 84 GAREAI 191 to 196 GMLYSG 331 to 336 GGTRSS 412 to 417 GVEYTR 437 to 442 GTTTGS 620 to 625 GLYQCW 671 to 676 GAALAA Sema domain 64 to 478 See FIG. 3 - An exemplary domains which occurs in TANGO 265 proteins is a sema domain. In one embodiment, the protein of the invention has at least one domain that is at least 55%, preferably at least about 65%, more preferably at least about 75%, yet more preferably at least about 85%, and most preferably at least about 95% identical to one of the sema domains described herein in Table VI.
- Sema domains occur in semaphorin proteins. Semaphorins are a large family of secreted and transmembrane proteins, some of which function as repellent signals during neural axon guidance. The sema domain and a variety of semaphorin proteins in which it occurs are described, for example, in Winberg et al. (1998 Cell 95:903-916). Sema domains also occur in human hepatocyte growth factor receptor (Swissprot Accession no. P08581) and the similar neuronal and epithelial transmembrane receptor protein (Swissprot Accession no. P51805). The presence of an sema domain in human TANGO 265 protein indicates that TANGO 265 is involved in one or more physiological processes in which the semaphorins are involved, has biological activity in common with one or more of the semaphorins, or both.
- Human TANGO 265 protein exhibits considerable sequence similarity to murine semaphorin B protein (GenBank Accession no. X85991), as indicated herein in FIGS.3F-3H. FIGS. 3F-3H depict an alignment of the amino acid sequences of human TANGO 265 protein (SEQ ID NO: 19) and murine semaphorin B protein (SEQ ID NO: 76). In this alignment (pam120.mat scoring matrix, gap penalties −12/−4), the amino acid sequences of the proteins are 82.3% identical. FIGS. 31 through 3T depict an alignment of the nucleotide sequences of cDNA encoding human TANGO 265 protein (SEQ ID NO: 17) and murine cDNA encoding semaphorin B protein (SEQ ID NO: 77). In this alignment (Pam120.mat scoring matrix, gap penalties −12/−4), the nucleic acid sequences of the cDNAs are 76.2% identical. Thus, TANGO 265 is the human orthologue of murine semaphorin B and shares functional similarities to that protein.
- It is known that semaphorins are bi-functional, capable of functioning either as attractive axonal guidance proteins or as repellent axonal guidance proteins (Wong et al. (1997) Development 124:3597-3607). Furthermore, semaphorins bind with neuronal cell surface proteins designated plexins, which are expressed on both neuronal cells and cells of the immune system (Comeau et al. (1998) Immunity 8:473-482; Jin and Strittmatter (1997) J. Neurosci. 17:6256-6263).
- The signal peptide prediction program SIGNALP (Nielsen et al. (1997) Protein Engineering 10:1-6) predicted that human TANGO 265 protein includes a 31 amino acid signal peptide (
amino acid residues 1 to 31 of SEQ ID NO: 19; SEQ ID NO: 20) preceding the mature TANGO 265 protein (amino acid residues 32 to 761 of SEQ ID NO: 19; SEQ ID NO: 21). Human TANGO 265 protein includes an extracellular domain (amino acid residues 32 to 683 of SEQ ID NO: 19; SEQ ID NO: 22); a transmembrane domain (amino acid residues 684 to 704 of SEQ ID NO: 19; SEQ ID NO: 23); and a cytoplasmic domain (amino acid residues 705 to 761 of SEQ ID NO: 19; SEQ ID NO: 24). - FIG. 3U depicts a hydrophilicity plot of human TANGO 265 protein. Relatively hydrophobic regions are above the dashed horizontal line, and relatively hydrophilic regions are below the dashed horizontal line. The hydrophobic region which corresponds to
amino acid residues 1 to 31 of SEQ ID NO: 19 is the signal sequence of human TANGO 265 (SEQ ID NO: 20). The hydrophobic region which corresponds to amino acid residues 684 to 704 of SEQ ID NO: 19 is the transmembrane domain of human TANGO 265 (SEQ ID NO: 23). As described elsewhere herein, relatively hydrophilic regions are generally located at or near the surface of a protein, and are more frequently effective immunogenic epitopes than are relatively hydrophobic regions. For example, the region of human TANGO 265 protein from aboutamino acid residue 350 to aboutamino acid residue 375 appears to be located at or near the surface of the protein, while the region from aboutamino acid residue 230 to aboutamino acid residue 250 appears not to be located at or near the surface. - The predicted molecular weight of human TANGO 265 protein without modification and prior to cleavage of the signal sequence is about 83.6 kilodaltons. The predicted molecular weight of the mature human TANGO 265 protein without modification and after cleavage of the signal sequence is about 80.2 kilodaltons.
- Chromosomal mapping was performed by computerized comparison of TANGO 265 cDNA sequences against a chromosomal mapping database in order to identify the approximate location of the gene encoding human TANGO 265 protein. This analysis indicated that the gene was located on
chromosome 1 between markers D1S305 and D1S2635. - Biological Function of TANGO 265 Proteins, Nucleic Acids, and Modulators Thereof
- TANGO 265 proteins are involved in disorders which affect both tissues in which they are normally expressed and tissues in which they are normally not expressed. Based on the observation that TANGO 265 is expressed in human fetal spleen, involvement of
TANGO 202 protein in immune system development and modulation is indicated. - The presence of the sema domain in TANGO 265 indicates that this protein is involved in development of neuronal and epithelial tissues and also functions as a repellant protein which guides axonal development. TANGO 265 modulates nerve growth and regeneration and also modulates growth and regeneration of other epithelial tissues.
- The observation that TANGO 265 shares significant identity with murine semaphorin B suggests that it has activity identical or analogous to the activity of this protein. These observations indicate that TANGO 265 modulates growth, proliferation, survival, differentiation, and activity of neuronal cells and immune system cells. Thus, TANGO 265 protein is useful, for example, for guiding neural axon development, for modulating differentiation of cells of the immune system, for modulating cytokine production by cells of the immune system, for modulating reactivity of cells of the immune system toward cytokines, for modulating initiation and persistence of an inflammatory response, and for modulating proliferation of epithelial cells.
-
TANGO 273 - A cDNA clone (designated jthoc028g06) encoding at least a portion of
human TANGO 273 protein was isolated from a lipopolysaccharide-(LPS-)stimulated human osteoblast cDNA library. The corresponding murine cDNA clone (designated jtmoa001c04) was isolated from an LPS-stimulated murine osteoblast cDNA library. The human andmurine TANGO 273 proteins are predicted by structural analysis to be transmembrane proteins. - The full length of the cDNA encoding
human TANGO 273 protein (FIG. 4; SEQ ID NO: 25) is 2964 nucleotide residues. The ORF of this cDNA,nucleotide residues 135 to 650 of SEQ ID NO: 25 (i.e., SEQ ID NO: 26), encodes a 172-amino acid transmembrane protein (FIG. 4; SEQ ID NO: 27). - The invention thus includes purified
human TANGO 273 protein, both in the form of the immature 172 amino acid residue protein (SEQ ID NO: 27) and in the form of the mature 150 amino acid residue protein (SEQ ID NO: 29). The invention also includes purifiedmurine TANGO 273 protein, both in the form of the immature 172 amino acid residue protein (SEQ ID NO: 74) and in the form of the mature 150 amino acid residue protein (SEQ ID NO: 44). Mature human ormurine TANGO 273 proteins can be synthesized without the signal sequence polypeptide at the amino terminus thereof, or they can be synthesized by generatingimmature TANGO 273 protein and cleaving the signal sequence therefrom. - In addition to full length mature and immature human and
murine TANGO 273 proteins, the invention includes fragments, derivatives, and variants of theseTANGO 273 proteins, as described herein. These proteins, fragments, derivatives, and variants are collectively referred to herein as polypeptides of the invention or proteins of the invention. - The invention also includes nucleic acid molecules which encode a polypeptide of the invention. Such nucleic acids include, for example, a DNA molecule having the nucleotide sequence listed in SEQ ID NO: 25 or some portion thereof or SEQ ID NO: 73 or some portion thereof, such as the portion which encodes
mature TANGO 273 protein,immature TANGO 273 protein, or a domain ofTANGO 273 protein. These nucleic acids are collectively referred to as nucleic acids of the invention. -
TANGO 273 proteins and nucleic acid molecules encoding them comprise a family of molecules having certain conserved structural and functional features. This family includes, by way of example, the human andmurine TANGO 273 proteins. - A common domain of
TANGO 273 proteins is a signal sequence. As used herein, a signal sequence includes a peptide of at least about 10 amino acid residues in length which occurs at the amino terminus of membrane-bound proteins and which contains at least about 45% hydrophobic amino acid residues such as alanine, leucine, isoleucine, phenylalanine, proline, tyrosine, tryptophan, or valine. In a preferred embodiment, a signal sequence contains at least about 10 to 35 amino acid residues, preferably about 10 to 20 amino acid residues, and has at least about 35-60%, more preferably 40-50%, and more preferably at least about 45% hydrophobic residues. A signal sequence serves to direct a protein containing such a sequence to a lipid bilayer. Thus, in one embodiment, aTANGO 273 protein contains a signal sequence corresponding toamino acid residues 1 to 22 of SEQ ID NO: 27 (SEQ ID NO: 28) or toamino acid residues 1 to 22 of SEQ ID NO: 74. The signal sequence is cleaved during processing of the mature protein. -
TANGO 273 proteins can also include an extracellular domain. Thehuman TANGO 273 protein extracellular domain is located from about amino acid residue 23 to aboutamino acid residue 60 of SEQ ID NO: 27, and themurine TANGO 273 protein extracellular domain is located from about amino acid residue 23 to aboutamino acid residue 60 of SEQ ID NO: 74. - The present invention also includes
TANGO 273 proteins having a transmembrane domain. As used herein, a “transmembrane domain” refers to an amino acid sequence having at least about 15 to 30 amino acid residues in length and which contains at least about 65-70% hydrophobic amino acid residues such as alanine, leucine, phenylalanine, protein, tyrosine, tryptophan, or valine. In a preferred embodiment, a transmembrane domain contains at least about 15 to 20 amino acid residues, preferably about 20 to 25 amino acid residues, and has at least about 60-80%, more preferably 65-75%, and more preferably at least about 70% hydrophobic residues. Thus, in one embodiment, ahuman TANGO 273 protein of the invention contains a transmembrane domain corresponding to about amino acid residues 61 to 81 of SEQ ID NO: 27 (SEQ ID NO: 31). In another embodiment, amurine TANGO 273 protein of the invention contains a transmembrane domain corresponding to about amino acid residues 61 to 81 of SEQ ID NO: 74. - In addition,
TANGO 273 proteins include a cytoplasmic domain. Thehuman TANGO 273 cytoplasmic domain is located from aboutamino acid residue 82 toamino acid residue 172 of SEQ ID NO: 27 (SEQ ID NO: 32), and themurine TANGO 273 cytoplasmic domain is located from aboutamino acid residue 82 toamino acid residue 172 of SEQ ID NO: 74. -
TANGO 273 proteins typically comprise a variety of potential post-translational modification sites (often within an extracellular domain), such as those described herein in Tables VII and VIII, as predicted by computerized sequence analysis of human andmurine TANGO 273 proteins using amino acid sequence comparison software (comparing the amino acid sequence ofTANGO 273 with the information in the PROSITE database {rel. 12.2; February, 1995} and the Hidden Markov Models database {Rel. PFAM 3.3}). In certain embodiments, a protein of the invention has at least 1, 2, 3, 4, 5, or all 6 of the post-translational modification sites listed in Table VII. In other embodiments, the protein of the invention has at least 1, 2, 3, 4, 5, 6, or all 7 of the post-translational modification sites listed in Table VIII.TABLE VII Amino Acid Type of Potential Modification Site or Residues of Amino Acid Domain SEQ ID NO: 27 Sequence N-glycosylation site 97 to 100 NVSY Casein kinase II phosphorylation site 41 to 44 SYED N- myristoylation site 31 to 36 GLYPTY 47 to 52 GSRCCV 70 to 75 GVLFCC 131 to 136 GNSMAM Src Homology 3 (SH3) domain binding 86 to 90 YPPPL site 103 to 107 QPPNP 113 to 117 QPGPP 121 to 125 DPGGP 140 to 145 VPPNSP 151 to 155 CPPPP 160 to 164 TPPPP -
TABLE VIII Amino Acid Type of Potential Modification Site or Residues of Amino Acid Domain SEQ ID NO: 74 Sequence N-glycosylation site 97 to 100 NVSY Casein kinase II phosphorylation site 41 to 44 SYED N- myristoylation site 31 to 36 GLYPTY 47 to 52 GSRCCV 70 to 75 GVLFCC 131 to 136 GNTMAM Src Homology 3 (SH3) domain binding 86 to 90 YPPPL site 103 to 107 QPPNP 115 to 119 GPPYY 121 to 125 DPGGP 141 to 145 QPNSP 151 to 155 YPPPP 160 to 164 TPPPP Amidation site 1 to 4 MGRR - The amino acid sequence of
TANGO 273 protein includes about seven potential proline-rich Src homology 3 (SH3) domain binding sites nearer the cytoplasmic portion of the protein. SH3 domains mediate specific assembly of protein complexes, presumably by interacting with proline-rich protein domains (Morton and Campbell (1994) Curr. Biol. 4:615-617). SH3 domains also mediate interactions between proteins involved in transmembrane signal transduction. Coupling of proteins mediated by SH3 domains has been implicated in a variety of physiological systems, including those involving regulation of cell growth and proliferation, endocytosis, and activation of respiratory burst. - SH3 domains have been described in the art (e.g., Mayer et al. (1988) Nature 332:272-275; Musacchio et al. (1992) FEBS Lett. 307:55-61; Pawson and Schlessinger (1993) Curr. Biol. 3:434-442; Mayer and Baltimore (1993) Trends Cell Biol. 3:8-13; Pawson (1993) Nature 373:573-580), and occur in a variety of cytoplasmic proteins, including several (e.g., protein tyrosine kinases) involved in transmembrane signal transduction. Among the proteins in which one or more SH3 domains occur are protein tyrosine kinases such as those of the Src, Abl, Bkt, Csk and ZAP70 families, mammalian phosphatidylinositol-specific phospholipases C-gamma-1 and -2, mammalian phosphatidylinositol 3-kinase regulatory p85 subunit, mammalian Ras GTPase-activating protein (GAP), proteins which mediate binding of guanine nucleotide exchange factors and growth factor receptors (e.g., vertebrate GRB2, Caenorhabditis elegans sem-5, and Drosophila DRK proteins), mammalian Vav oncoprotein, guanidine nucleotide releasing factors of the CDC 25 family (e.g., yeast CDC25, yeast SCD25, and fission yeast ste6 proteins), MAGUK proteins (e.g., mammalian tight junction protein ZO-1, vertebrate erythrocyte membrane protein p55, C. elegans protein lin-2, rat protein CASK, and mammalian synaptic proteins SAP90/PSD-95, CHAPSYN-110/PSD-93, SAP97/DLG1, and SAP102), proteins which interact with vertebrate receptor protein tyrosine kinases (e.g., mammalian cytoplasmic protein Nck and oncoprotein Crk), chicken Src substrate p80/85 protein (cortactin), human hemopoietic lineage cell specific protein Hs1, mammalian dihydrouridine-sensitive L-type calcium channel beta subunit, human myasthenic syndrome antigen B (MSYB), mammalian neutrophil cytosolic activators of NADPH oxidase (e.g., p47 {NCF-1}, p67 {NCF-2}, and C. elegans protein B0303.7) myosin heavy chains (MYO3) from amoebae, from slime molds, and from yeast, vertebrate and Drosophila spectrin and fodrin alpha chain proteins, human amphiphysin, yeast actin-binding proteins ABP1 and SLA3, yeast protein BEM 1, fission yeast protein scd2 (ra13), yeast BEM1-binding proteins BOI2 (BEB1) and BOB1 (BOI1), yeast fusion protein FUS1, yeast protein RSV167, yeast protein SSU81, yeast hypothetical proteins YAR014c, YFR024c, YHL002w, YHR016c, YJL020C, and YHR114w, hypothetical fission yeast protein SpAC12C2.05c, and C. elegans hypothetical protein F42H10.3. Of these proteins, multiple SH3 domains occur in vertebrate GRB2 protein, C. elegans sem-5 protein, Drosophila DRK protein, oncoprotein Crk, mammalian neutrophil cytosolic activators of NADPH oxidase p47 and p67, yeast protein BEM1, fission yeast protein scd2, yeast hypothetical protein YHR114w, mammalian cytoplasmic protein Nck, C. elegans neutrophil cytosolic activator of NADPH oxidase B0303.7, and yeast actin-binding protein SLA1. Of these proteins, three or more SH3 domains occur in mammalian cytoplasmic protein Nck, C. elegans neutrophil cytosolic activator of NADPH oxidase B0303.7, and yeast actin-binding protein SLA1. The presence of SH3 domain binding sites in
TANGO 273 indicates thatTANGO 273 interacts with one or more of these and other SH3 domain-containing proteins and is thus involved in physiological processes in which one or more of these or other SH3 domain-containing proteins are involved. - The signal peptide prediction program SIGNALP (Nielsen et al. (1997) Protein Engineering 10:1-6) predicted that
human TANGO 273 protein includes a 22 amino acid signal peptide (amino acid residues 1 to 22 of SEQ ID NO: 27; SEQ ID NO: 28) preceding themature TANGO 273 protein (amino acid residues 23 to 172 of SEQ ID NO: 27; SEQ ID NO: 29).Human TANGO 273 protein includes an extracellular domain (amino acid residues 23 to 60 of SEQ ID NO: 27; SEQ ID NO: 30); a transmembrane domain (amino acid residues 61 to 81 of SEQ ID NO: 27; SEQ ID NO: 31); and a cytoplasmic domain (amino acid residues 82 to 172 of SEQ ID NO: 27; SEQ ID NO: 32). - FIG. 4I depicts a hydrophilicity plot of
human TANGO 273 protein. Relatively hydrophobic regions are above the dashed horizontal line, and relatively hydrophilic regions are below the dashed horizontal line. The hydrophobic region which corresponds toamino acid residues 1 to 22 of SEQ ID NO: 27 is the signal sequence of human TANGO 273 (SEQ ID NO: 28). The hydrophobic region which corresponds to amino acid residues 61 to 81 of SEQ ID NO: 27 is the transmembrane domain of human TANGO 273 (SEQ ID NO: 31). As described elsewhere herein, relatively hydrophilic regions are generally located at or near the surface of a protein, and are more frequently effective immunogenic epitopes than are relatively hydrophobic regions. For example, the region ofhuman TANGO 273 protein from aboutamino acid residue 100 to aboutamino acid residue 120 appears to be located at or near the surface of the protein, while the region from aboutamino acid residue 130 to aboutamino acid residue 140 appears not to be located at or near the surface. - Chromosomal mapping was performed by computerized comparison of
TANGO 273 cDNA sequences against a chromosomal mapping database in order to identify the approximate location of the gene encodinghuman TANGO 273 protein. This analysis indicated that the gene was located on chromosome 7 between markers D7S2467 and D7S2552. - The predicted molecular weight of
human TANGO 273 protein without modification and prior to cleavage of the signal sequence is about 19.2 kilodaltons. The predicted molecular weight of the maturehuman TANGO 273 protein without modification and after cleavage of the signal sequence is about 16.8 kilodaltons. - Northern analysis experiments indicated that mRNA corresponding to the
cDNA encoding TANGO 273 is expressed in the tissues listed in Table VIIa, wherein “++” indicates moderate expression and “+” indicates lower expression.TABLE VIIa Animal Tissue Relative Level of Expression Human heart ++ brain ++ skeletal muscle ++ pancreas ++ placenta + lung + liver + kidney + - The full length of the cDNA encoding
murine TANGO 273 protein (FIG. 4; SEQ ID NO: 72) is 2915 nucleotide residues. The ORF of this cDNA,nucleotide residues 137 to 650 of SEQ ID NO: 72 (i.e., SEQ ID NO: 73), encodes a 172-amino acid transmembrane protein (FIG. 4; SEQ ID NO: 74). - The signal peptide prediction program SIGNALP (Nielsen et al. (1997) Protein Engineering 10:1-6) predicted that
murine TANGO 273 protein includes a 22 amino acid signal peptide (amino acid residues 1 to 22 of SEQ ID NO: 74) preceding themature TANGO 273 protein (amino acid residues 23 to 172 of SEQ ID NO: 74; SEQ ID NO: 44).Murine TANGO 273 protein includes an extracellular domain (amino acid residues 23 to 60 of SEQ ID NO: 74); a transmembrane domain (amino acid residues 61 to 81 of SEQ ID NO: 74); and a cytoplasmic domain (amino acid residues 82 to 172 of SEQ ID NO: 74). - FIG. 4J depicts a hydrophilicity plot of
murine TANGO 273 protein. Relatively hydrophobic regions are above the dashed horizontal line, and relatively hydrophilic regions are below the dashed horizontal line. The hydrophobic region which corresponds toamino acid residues 1 to 22 of SEQ ID NO: 74 is the signal sequence ofmurine TANGO 273. As described elsewhere herein, relatively hydrophilic regions are generally located at or near the surface of a protein, and are more frequently effective immunogenic epitopes than are relatively hydrophobic regions. For example, the region ofmurine TANGO 273 protein from aboutamino acid residue 100 to aboutamino acid residue 120 appears to be located at or near the surface of the protein, while the region from aboutamino acid residue 130 to aboutamino acid residue 140 appears not to be located at or near the surface. - The predicted molecular weight of
murine TANGO 273 protein without modification and prior to cleavage of the signal sequence is about 19.4 kilodaltons. The predicted molecular weight of the maturemurine TANGO 273 protein without modification and after cleavage of the signal sequence is about 17.1 kilodaltons. - In situ analysis of
murine TANGO 273 mRNA indicated thatTANGO 273 is expressed with central nervous system (CNS) tissues during embryogenesis and into adulthood. Expression ofTANGO 273 is widely observed in murine CNS tissues, including brain, spinal cord, eye, and olfactory epithelium at all embryonic ages examined (i.e., at embryonic days 13.5, 14.5, 15.5, 16.5, and 18.5 and at post-natal day 1.5). - Human and
murine TANGO 273 cDNA sequences exhibit significant nucleotide sequence identity with an expressed sequence tag (EST) isolated from a library of ESTs corresponding to proteins secreted from prostate tissue, as described in PCT publication number WO 99/06550, published Feb. 11, 1999. - Human and
murine TANGO 273 proteins exhibit considerable sequence similarity, as indicated herein in FIG. 4H. FIG. 4H depicts an alignment of human andmurine TANGO 273 protein amino acid sequences (SEQ ID NOs: 27 and 74, respectively). In this alignment (pam120.mat scoring matrix, gap penalties −12/−4), the proteins are 89.5% identical. Alignment of the ORF encodinghuman TANGO 273 protein and the ORF encodingmurine TANGO 273 protein using the same software and parameters indicated that the nucleotide sequences are 84.1% identical. - Biological Function of
TANGO 273 Proteins, Nucleic Acids, and Modulators Thereof - cDNAs encoding the human and
murine TANGO 273 proteins were each isolated from LPS-stimulated osteoblast cDNA libraries. These proteins are involved in bone-related metabolism, homeostasis, and development disorders. Thus, proteins and nucleic acids of the invention which are identical to, similar to, or derived from human andmurine TANGO 273 proteins and nucleic acids encoding them are useful for preventing, diagnosing, and treating, among others, bone-related disorders such as osteoporosis, cancer, skeletal development disorders, bone fragility, and the like. - Expression of
TANGO 273 in heart, brain, skeletal muscle, and pancreas, placenta, lung, liver, and kidney tissues is an indication thatTANGO 273 proteins, nucleic acids encoding them, and agents that modulate activity or expression of either of these can be used to modulate growth, proliferation, survival, differentiation, adhesion, and activity of cells of these tissues, or to prognosticate, diagnose, and treat one or more disorders which affect these tissues. - The fact that
TANGO 273 is expressed at high levels in neurological tissues is an indication thatTANGO 273 proteins, nucleic acids, and modulators thereof can be used to modulate proliferation, differentiation, or function of neurological cells in these tissues (e.g., neuronal cells). Thus,TANGO 273 proteins, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, and treat one or more neurological disorders. Examples of such disorders include CNS disorders, CNS-related disorders, focal brain disorders, global-diffuse cerebral disorders, and other neurological and cerebrovascular disorders. - CNS disorders include, but are not limited to cognitive and neurodegenerative disorders such as Alzheimer's disease, senile dementia, Huntington's disease, amyotrophic lateral sclerosis, and Parkinson's disease, as well as Gilles de la Tourette's syndrome, autonomic function disorders such as hypertension and sleep disorders (e.g., insomnia, hypersomnia, parasomnia, and sleep apnea); neuropsychiatric disorders (e.g., schizophrenia, schizoaffective disorder, attention deficit disorder, dysthymic disorder, major depressive disorder, mania, and obsessive-compulsive disorder); psychoactive substance use disorders; anxiety; panic disorder; and bipolar affective disorders (e.g., severe bipolar affective disorder and bipolar affective disorder with hypomania and major depression).
- CNS-related disorders include disorders associated with developmental, cognitive, and autonomic neural and neurological processes, such as pain, appetite, long term memory, and short term memory.
- Exemplary focal brain disorders include aphasia, apraxia, agnosia, and amnesias (e.g., posttraumatic amnesia, transient global amnesia, and psychogenic amnesia). Global-diffuse cerebral disorders with which
TANGO 273 can be associated include coma, stupor, obtundation, and disorders of the reticular formation. - Other neurological disorders with which
TANGO 273 can be associated include ischemic syndromes (e.g., stroke), hypertensive encephalopathy, hemorrhagic disorders, and disorders involving aberrant function of the blood-brain barrier (e.g., CNS infections such as meningitis and encephalitis, aseptic meningitis, metastasis of non-CNS tumor cells into the CNS, various pain disorders such as migraine, blindness and other vision problems, and CNS-related adverse drug reactions such as head pain, sleepiness, and confusion).TANGO 273 proteins, nucleic acids encoding them, and agents that modulate activity or expression of either of these can be used to prognosticate, diagnose, and treat one or more of these disorders. - Developmental regulation of
TANGO 273 expression in fetal neurological tissues, as described herein, is an indication thatTANGO 273 proteins, nucleic acids, and modulators thereof can be used to prognosticate, diagnose, and treat one or more disorders which involve aberrant fetal neurological development. Examples of such disorders include blindness, deafness, fetal death, mental retardation, dysraphia, anencephaly, malformation of cerebral hemispheres, encephalocele, porencephaly, hydranencephaly, hydrocephalus, and spina bifida. - The fact that
TANGO 273 is expressed in tissues which were exposed to LPS indicates thatTANGO 273 mediates one or more physiological responses of cells to bacterial infection. Thus,TANGO 273 is involved in one or more of detection of bacteria in a tissue in which it is expressed, movement of cells with relation to sites of bacterial infection, production of biological molecules which inhibit bacterial infection, and production of biological molecules which alleviate cellular or other physiological damage wrought by bacterial infection. - Presence in
TANGO 273 protein of multiple SH3 domain binding sites indicates thatTANGO 273 protein interacts with one or more SH3 domain- containing proteins. Thus,TANGO 273 protein mediates binding of proteins (i.e., binding of proteins to TANGO 273 and to one another to form protein complexes) in cells in which it is expressed.TANGO 273 is also involved in transduction of signals between the exterior environment of cells (i.e., including from other cells) and the interior of cells in which it is expressed.TANGO 273 mediates regulation of cell growth and proliferation, endocytosis, activation of respiratory burst, and other physiological processes triggered by transmission of a signal via a protein with whichTANGO 273 interacts. - Sequence similarity of
TANGO 273 cDNA with an EST expressed in prostate tissue indicates thatTANGO 273 can be expressed in prostate tissue, and can thus be involved in disorders of the prostate. Thus,TANGO 273 proteins, nucleic acids encoding them, and agents that modulate activity or expression of either of these can be used to treat prostate disorders. Examples of prostate disorders which can be treated in this manner include inflammatory prostatic diseases (e.g., acute and chronic prostatitis and granulomatous prostatitis), prostatic hyperplasia (e.g., benign prostatic hypertrophy or hyperplasia), and prostate tumors (e.g., carcinomas). - In another example,
TANGO 273 polypeptides, nucleic acids, or modulators thereof, can be used to treat cardiovascular disorders, such as ischemic heart disease (e.g., angina pectoris, myocardial infarction, and chronic ischemic heart disease), hypertensive heart disease, pulmonary heart disease, valvular heart disease (e.g., rheumatic fever and rheumatic heart disease, endocarditis, mitral valve prolapse, and aortic valve stenosis), congenital heart disease (e.g., valvular and vascular obstructive lesions, atrial or ventricular septal defect, and patent ductus arteriosus), or myocardial disease (e.g., myocarditis, congestive cardiomyopathy, and hypertrophic cardiomyopathy). - In another example,
TANGO 273 polypeptides, nucleic acids, or modulators thereof, can be used to treat disorders of the brain, such as cerebral edema, hydrocephalus, brain herniations, iatrogenic disease (due to, e.g., infection, toxins, or drugs), inflammations (e.g., bacterial and viral meningitis, encephalitis, and cerebral toxoplasmosis), cerebrovascular diseases (e.g., hypoxia, ischemia, and infarction, intracranial hemorrhage and vascular malformations, and hypertensive encephalopathy), and tumors (e.g., neuroglial tumors, neuronal tumors, tumors of pineal cells, meningeal tumors, primary and secondary lymphomas, intracranial tumors, and medulloblastoma), and to treat injury or trauma to the brain. - In another example,
TANGO 273 polypeptides, nucleic acids, or modulators thereof, can be used to treat disorders of skeletal muscle, such as muscular dystrophy (e.g., Duchenne muscular dystrophy, Becker muscular dystrophy, Emery-Dreifuss muscular dystrophy, limb-girdle muscular dystrophy, facioscapulohumeral muscular dystrophy, myotonic dystrophy, oculopharyngeal muscular dystrophy, distal muscular dystrophy, and congenital muscular dystrophy), motor neuron diseases (e.g., amyotrophic lateral sclerosis, infantile progressive spinal muscular atrophy, intermediate spinal muscular atrophy, spinal bulbar muscular atrophy, and adult spinal muscular atrophy), myopathies (e.g., inflammatory myopathies such as dermatomyositis and polymyositis, myotonia congenita, paramyotonia congenita, central core disease, nemaline myopathy, myotubular myopathy, and periodic paralysis), and metabolic diseases of muscle (e.g., phosphorylase deficiency, acid maltase deficiency, phosphofructokinase deficiency, debrancher enzyme deficiency, mitochondrial myopathy, camitine deficiency, camitine palmityl transferase deficiency, phosphoglycerate kinase deficiency, phosphoglycerate mutase deficiency, lactate dehydrogenase deficiency, and myoadenylate deaminase deficiency). - In another example,
TANGO 273 polypeptides, nucleic acids, or modulators thereof, can be used to treat pancreatic disorders, such as pancreatitis (e.g., acute hemorrhagic pancreatitis and chronic pancreatitis), pancreatic cysts (e.g., congenital cysts, pseudocysts, and benign or malignant neoplastic cysts), pancreatic tumors (e.g., pancreatic carcinoma and adenoma), diabetes mellitus (e.g., insulin- and non-insulin-dependent types, impaired glucose tolerance, and gestational diabetes), or islet cell tumors (e.g., insulinomas, adenomas, Zollinger-Ellison syndrome, glucagonomas, and somatostatinoma). - In another example,
TANGO 273 polypeptides, nucleic acids, or modulators thereof, can be used to treat placental disorders, such as toxemia of pregnancy (e.g., preeclampsia and eclampsia), placentitis, or spontaneous abortion. - In another example,
TANGO 273 polypeptides, nucleic acids, or modulators thereof, can be used to treat pulmonary disorders, such as atelectasis, cystic fibrosis, rheumatoid lung disease, pulmonary congestion or edema, chronic obstructive airway disease (e.g., emphysema, chronic bronchitis, bronchial asthma, and bronchiectasis), diffuse interstitial diseases (e.g., sarcoidosis, pneumoconiosis, hypersensitivity pneumonitis, Goodpasture's syndrome, idiopathic pulmonary hemosiderosis, pulmonary alveolar proteinosis, desquamative interstitial pneumonitis, chronic interstitial pneumonia, fibrosing alveolitis, hamman-rich syndrome, pulmonary eosinophilia, diffuse interstitial fibrosis, Wegener's granulomatosis, lymphomatoid granulomatosis, and lipid pneumonia), or tumors (e.g., bronchogenic carcinoma, bronchioalveolar carcinoma, bronchial carcinoid, hamartoma, and mesenchymal tumors). - In another example,
TANGO 273 polypeptides, nucleic acids, or modulators thereof, can be used to treat hepatic (liver) disorders, such as jaundice, hepatic failure, hereditary hyperbilirubinemias (e.g., Gilbert's syndrome, Crigler-Naijar syndromes, and Dubin-Johnson and Rotor's syndromes), hepatic circulatory disorders (e.g., hepatic vein thrombosis and portal vein obstruction and thrombosis) hepatitis (e.g., chronic active hepatitis, acute viral hepatitis, and toxic and drug-induced hepatitis) cirrhosis (e.g., alcoholic cirrhosis, biliary cirrhosis, and hemochromatosis), or malignant tumors (e.g., primary carcinoma, hepatoblastoma, and angiosarcoma). - In another example,
TANGO 273 polypeptides, nucleic acids, or modulators thereof, can be used to treat renal (kidney) disorders, such as glomerular diseases (e.g., acute and chronic glomerulonephritis, rapidly progressive glomerulonephritis, nephrotic syndrome, focal proliferative glomerulonephritis, glomerular lesions associated with systemic disease such as systemic lupus erythematosus, Goodpasture's syndrome, multiple myeloma, diabetes, neoplasia, sickle cell disease, and chronic inflammatory diseases), tubular diseases (e.g., acute tubular necrosis and acute renal failure, polycystic renal disease, medullary sponge kidney, medullary cystic disease, nephrogenic diabetes, and renal tubular acidosis), tubulointerstitial diseases (e.g., pyelonephritis, drug and toxin induced tubulointerstitial nephritis, hypercalcemic nephropathy, and hypokalemic nephropathy) acute and rapidly progressive renal failure, chronic renal failure, nephrolithiasis, vascular diseases (e.g., hypertension and nephrosclerosis, microangiopathic hemolytic anemia, atheroembolic renal disease, diffuse cortical necrosis, and renal infarcts), or tumors (e.g., renal cell carcinoma and nephroblastoma). -
TANGO 286 - A cDNA clone (designated jthkf042e03) encoding at least a portion of
human TANGO 286 protein was isolated from a human keratinocyte cDNA library. Thehuman TANGO 286 protein is predicted by structural analysis to be a secreted protein. - The full length of the
cDNA encoding TANGO 286 protein (FIG. 5; SEQ ID NO: 33) is 1980 nucleotide residues. The ORF of this cDNA,nucleotide residues 133 to 1497 of SEQ ID NO: 33 (i.e., SEQ ID NO: 34), encodes a 455-amino acid secreted protein (FIG. 5; SEQ ID NO: 35). - The invention thus includes purified
TANGO 286 protein, both in the form of the immature 455 amino acid residue protein (SEQ ID NO: 35) and in the form of the mature 432 amino acid residue protein (SEQ ID NO: 37).Mature TANGO 286 protein can be synthesized without the signal sequence polypeptide at the amino terminus thereof, or it can be synthesized by generatingimmature TANGO 286 protein and cleaving the signal sequence therefrom. - In addition to full length mature and
immature TANGO 286 proteins, the invention includes fragments, derivatives, and variants of theseTANGO 286 proteins, as described herein. These proteins, fragments, derivatives, and variants are collectively referred to herein as polypeptides of the invention or proteins of the invention. - The invention also includes nucleic acid molecules which encode a polypeptide of the invention. Such nucleic acids include, for example, a DNA molecule having the nucleotide sequence listed in SEQ ID NO: 33 or some portion thereof, such as the portion which encodes
mature TANGO 286 protein,immature TANGO 286 protein, or a domain ofTANGO 286 protein. These nucleic acids are collectively referred to as nucleic acids of the invention. -
TANGO 286 proteins and nucleic acid molecules encoding them comprise a family of molecules having certain conserved structural and functional features. - A common domain of
TANGO 286 proteins is a signal sequence. As used herein, a signal sequence includes a peptide of at least about 10 amino acid residues in length which occurs at the amino terminus of membrane-bound proteins and which contains at least about 45% hydrophobic amino acid residues such as alanine, leucine, isoleucine, phenylalanine, proline, tyrosine, tryptophan, or valine. In a preferred embodiment, a signal sequence contains at least about 10 to 35 amino acid residues, preferably about 10 to 20 amino acid residues, and has at least about 35-60%, more preferably 40-50%, and more preferably at least about 45% hydrophobic residues. A signal sequence serves to direct a protein containing such a sequence to a lipid bilayer. Thus, in one embodiment, aTANGO 286 protein contains a signal sequence corresponding toamino acid residues 1 to 23 of SEQ ID NO: 35 (SEQ ID NO: 36). The signal sequence is cleaved during processing of the mature protein. -
TANGO 286 is a secreted soluble protein (i.e., a secreted protein having a single extracellular domain), as indicated by computerized sequence analysis and comparison of the amino acid sequence ofTANGO 286 with related proteins, such as the soluble proteins designated bactericidal permeability increasing (BPI) protein and recombinant endotoxin neutralizing polypeptide (RENP). -
TANGO 286 proteins typically comprise a variety of potential post-translational modification sites (often within an extracellular domain), such as those described herein in Table IX, as predicted by computerized sequence analysis ofTANGO 286 proteins using amino acid sequence comparison software (comparing the amino acid sequence ofTANGO 286 with the information in the PROSITE database {rel. 12.2; February, 1995} and the Hidden Markov Models database {Rel. PFAM 3.3 }). In certain embodiments, a protein of the invention has at least 1, 2, 4, 6, 10, 15, or 20 or more of the post-translational modification sites listed in Table IX.TABLE IX Amino Acid Type of Potential Modification Site or Residues of Amino Acid Domain SEQ ID NO: 35 Sequence N- glycosylation site 79 to 82 NFSN 92 to 95 NTSL 113 to 116 NIST 161 to 164 NLST 173 to 176 NYTL 205 to 208 NLTD 249 to 252 NLTL 303 to 306 NFTL 320 to 323 NSTV 363 to 366 NRSN Protein kinase C phosphorylation site 35 to 37 TQR 362 to 364 SNR 429 to 431 SSK Casein kinase II phosphorylation site 63 to 66 SGSE 130 to 133 SFAE 163 to 166 STLE 169 to 172 TKID 175 to 178 TLLD 183 to 186 SSPE 253 to 256 STEE 321 to 324 STVE 365 to 368 SNIE 409 to 412 SDIE N- myristoylation site 42 to 47 GVQAGM 269 to 274 GNVLSR Lipid-binding serum glycoprotein 12 to 427 see FIG. 5 domain - Certain lipid-binding serum glycoproteins, such as LPS-binding protein (LBP), bactericidal permeability-increasing protein (BPI), cholesteryl ester transfer protein (CETP), and phospholipid transfer protein (PLTP), share regions of sequence similarity which are herein designated a lipid-binding serum glycoprotein domain (Schumann et al., (1990) Science 249:1429-1431; Gray et al., (1989) J. Biol. Chem. 264:9505-9509; Day et al., (1994) J. Biol. Chem. 269:9388-9391). The consensus pattern of lipid-binding serum glycoprotein domains is as follows (using standard single letter amino acid abbreviations wherein X is any amino acid residue).
- -(P or A)-(G or A)-(L or I or V or M or C)-X2-R-(I or V)-(S or T)-X3-L-X(4 or 5)-(E or Q)-X4-(L or I or V or M)-X(0 or 1)-(E or Q or K)-X8-P-(e.g., amino acid residues 28-60 of SEQ ID NO: 35).
- Proteins in which a lipid-binding serum glycoprotein domain occurs are often structurally related and exhibit related physiological activities. LBP binds to lipid A moieties of bacterial LPS and, once bound thereto, induces secretion of a-tumor necrosis factor, apparently by interacting with the CD14 receptor. BPI also binds LPS and exerts a cytotoxic effect on Gram-negative bacteria (Elsbach, (1998) J. Leukoc. Biol. 64:14-18). CETP is involved in transfer of insoluble cholesteryl esters during reverse cholesterol transport. PLTP appears to be involved in phospholipid transport and modulation of serum HDL particles.
- The signal peptide prediction program SIGNALP (Nielsen et al. (1997) Protein Engineering 10:1-6) predicted that
TANGO 286 protein includes a 23 amino acid signal peptide (amino acid residues 1 to 23 of SEQ ID NO: 35; SEQ ID NO: 36) preceding themature TANGO 286 protein (amino acid residues 24 to 455 of SEQ ID NO: 35; SEQ ID NO: 37).Human TANGO 286 protein is a secreted soluble protein. - FIG. 5E depicts a hydrophilicity plot of
TANGO 286 protein. Relatively hydrophobic regions are above the dashed horizontal line, and relatively hydrophilic regions are below the dashed horizontal line. As described elsewhere herein, relatively hydrophilic regions are generally located at or near the surface of a protein, and are more frequently effective immunogenic epitopes than are relatively hydrophobic regions For example, the region ofhuman TANGO 286 protein from aboutamino acid residue 420 to aboutamino acid residue 435 appears to be located at or near the surface of the protein, while the region from about amino acid residue 325 to about amino acid residue 345 appears not to be located at or near the surface. - The predicted molecular weight of
TANGO 286 protein without modification and prior to cleavage of the signal sequence is about 50.9 kilodaltons. The predicted molecular weight of themature TANGO 286 protein without modification and after cleavage of the signal sequence is about 48.2 kilodaltons. - The gene encoding
human TANGO 286 protein was determined to be located onchromosome 22 by comparison of matching genomic clones such as the clones assigned GenBank Accession numbers W16806 and AL021937. - A portion of
TANGO 286 protein exhibits significant amino acid homology with a region of the human chromosome region 22q12-13 genomic nucleotide sequence having GenBank Accession number AL021937. Alignment of a 45 kilobase nucleotidesequence encoding TANGO 286 with AL021937, however, indicated the presence inTANGO 286 of exons which differ from those disclosed in L021937 (pam120.mat scoring matrix; gap penalties −12/−4). This region ofchromosome 22 comprises an immunoglobulin lambda chain C (IGLC) pseudogene, the Ret finger protein-like 3 (RFPL3) and Ret finger protein-like 3 antisense (RFPL3S) genes, a gene encoding a novel immunoglobulin lambda chain V family protein, a novel gene encoding a protein similar both to mouse RGDS protein (RALGDS, RALGEF, guanine nucleotide dissociation stimulator A) and to rabbit oncogene RSC, a novel gene encoding the human orthologue of worm F16A11.2 protein, a novel gene encoding a protein similar both to BPI and to rabbit liposaccharide-binding protein, and a 5′-portion of a novel gene. This region also comprises various ESTs, STSs, GSSs, genomic marker D22S1175, a ca repeat polymorphism and putative CpG islands.TANGO 286 protein thus shares one or more structural or functional features of these molecules. -
TANGO 286 protein exhibits considerable sequence similarity with BPI protein, having 23.9% amino acid sequence identity therewith, as assessed using the ALIGN v. 2.0 computer software using a pam120.mat scoring matrix and gap penalties of −12/−4.TANGO 286 protein also exhibits considerable sequence similarity with recombinant endotoxin neutralizing polypeptide (RENP), having 24.5% amino acid sequence identity therewith, as assessed using the ALIGN software. Physiological activities of BPI protein and RENP have been described (e.g., Gabay et al., (1989) Proc. Natl. Acad. Sci. USA 86:5610-5614; Elsbach, (1998) J. Leukoc. Biol. 64:14-18; Mahadeva et al., (1997) Chest 112:1699-1701; International patent application WO96/34873). RENP, for example, binds LPS and neutralizes bacterial endotoxins. BPI, RENP, and other proteins in which a lipid-binding serum glycoprotein domain occurs bind LPS and neutralize bacterial endotoxins, and are therefore useful for preventing, detecting, and treating LPS-related disorders such as shock, disseminated intravascular coagulation, anemia, thrombocytopenia, adult respiratory distress syndrome, renal failure, liver disease, and disorders associated with Gram negative bacterial infections. In addition to the physiological conditions described above, BPI protein is known to be involved in vasculitis and bronchiectasis, in that antibodies which bind specifically with BPI protein are present in at least some patients afflicted with these disorders (Mahadeva et al., supra). - Biological Function of
TANGO 286 Proteins, Nucleic Acids, and Modulators Thereof - Expression of
TANGO 286 in keratinocyte library indicates that this protein is involved in a disorders which involve keratinocytes. Such disorders include, for example, disorders involving extracellular matrix abnormalities, dermatological disorders, ocular disorders, inappropriate hair growth (e.g., baldness), infections of the nails of the fingers and toes, scalp disorders (e.g., dandruff), and the like. - The fact that
TANGO 286 protein contains a lipid-binding serum glycoprotein domain indicates thatTANGO 286 is involved in one or more physiological processes in which these other lipid-binding serum glycoprotein domain-containing proteins are involved. Thus,TANGO 286 is involved in one or more of lipid transport, metabolism, serum lipid particle regulation, host anti-microbial defensive mechanisms, and the like. -
Human TANGO 286 shares physiological functionality with other proteins in which a lipid-binding serum glycoprotein domains occurs (e.g., LBP, BPI protein, CETP, and PLTP). Based on the amino acid sequence similarity ofTANGO 286 with BPI protein and with RENP,TANGO 286 protein exhibits physiological activities exhibited by these proteins. Thus,TANGO 286 proteins are useful for preventing, diagnosing, and treating, among others, lipid transport disorders, lipid metabolism disorders, disorders of serum lipid particle regulation, obesity, disorders involving insufficient or inappropriate host anti-microbial defensive mechanisms, vasculitis, bronchiectasis, LPS-related disorders such as shock, disseminated intravascular coagulation, anemia, thrombocytopenia, adult respiratory distress syndrome, renal failure, liver disease, and disorders associated with Gram negative bacterial infections, such as bacteremia, endotoxemia, sepsis, and the like. -
TANGO 294 - A cDNA clone (designated jthrc145g07) encoding at least a portion of
human TANGO 294 protein was isolated from a human pulmonary artery smooth muscle cell cDNA library. Thehuman TANGO 294 protein is predicted by structural analysis to be a transmembrane membrane protein. Expression ofDNA encoding TANGO 294 was observed, using a variety of methods, in pancreas, lung tumor, stomach, pulmonary artery smooth muscle cells, and colon tumor tissues and in activated peripheral blood mononuclear cells (PBMCs). More detailed expression data is described herein. - The full length of the
cDNA encoding TANGO 294 protein (FIG. 6; SEQ ID NO: 45) is 2044 nucleotide residues. The ORF of this cDNA,nucleotide residues 126 to 1394 of SEQ ID NO: 45 (i.e., SEQ ID NO: 46), encodes a 423-amino acid transmembrane protein (FIG. 6; SEQ ID NO: 47). - The invention includes purified
TANGO 294 protein, both in the form of the immature 423 amino acid residue protein (SEQ ID NO: 47) and in the form of the mature 390 amino acid residue protein (SEQ ID NO: 49).Mature TANGO 294 protein can be synthesized without the signal sequence polypeptide at the amino terminus thereof, or it can be synthesized by generatingimmature TANGO 294 protein and cleaving the signal sequence therefrom. - In addition to full length mature and
immature TANGO 294 proteins, the invention includes fragments, derivatives, and variants ofTANGO 294 protein, as described herein. These proteins, fragments, derivatives, and variants are collectively referred to herein as polypeptides of the invention or proteins of the invention. - The invention also includes nucleic acid molecules which encode a polypeptide of the invention. Such nucleic acids include, for example, a DNA molecule having the nucleotide sequence listed in SEQ ID NO: 45 or some portion thereof, such as the portion which encodes
mature TANGO 294 protein,immature TANGO 294 protein, or a domain ofTANGO 294 protein. These nucleic acids are collectively referred to as nucleic acids of the invention. -
TANGO 294 proteins and nucleic acid molecules encoding them comprise a family of molecules having certain conserved structural and functional features. - Also included within the scope of the invention are
TANGO 294 proteins having a signal sequence. As used herein, a signal sequence includes a peptide of at least about 10 amino acid residues in length which occurs at the amino terminus of membrane-bound proteins and which contains at least about 45% hydrophobic amino acid residues such as alanine, leucine, isoleucine, phenylalanine, proline, tyrosine, tryptophan, or valine. In a preferred embodiment, a signal sequence contains at least about 10 to 35 amino acid residues, preferably about 10 to 20 amino acid residues, and has at least about 35-60%, more preferably 40-50%, and more preferably at least about 45% hydrophobic residues. A signal sequence serves to direct a protein containing such a sequence to a lipid bilayer. Thus, in one embodiment, aTANGO 294 protein contains a signal sequence corresponding toamino acid residues 1 to 33 of SEQ ID NO: 47 (SEQ ID NO: 48). The signal sequence is cleaved during processing of the mature protein. - The naturally-occurring form of
TANGO 294 protein is a secreted protein (i.e., not comprising the predicted signal sequence). However, in variant forms,TANGO 294 proteins can be transmembrane proteins which include an extracellular domain. In this transmembrane variant form, the predictedTANGO 294 protein extracellular domain is located from about amino acid residue 34 to about amino acid residue 254 of SEQ ID NO: 47, the predicted cytoplasmic domain is located from aboutamino acid residue 280 to amino acid residue 423 of SEQ ID NO: 47 (SEQ ID NO: 52), and the predicted transmembrane domain is located from aboutamino acid residues 255 to 279 of SEQ ID NO: 47 (SEQ ID NO: 51). -
TANGO 294 proteins typically comprise a variety of potential post-translational modification sites (often within an extracellular domain), such as those described herein in Table X, as predicted by computerized sequence analysis ofTANGO 294 proteins using amino acid sequence comparison software (comparing the amino acid sequence ofTANGO 294 with the information in the PROSITE database {rel. 12.2; February, 1995} and the Hidden Markov Models database {Rel. PFAM 3.3}). In certain embodiments, a protein of the invention has at least 1, 2, 4, 6, 10, 15, or 20 or more of the post-translational modification sites listed in Table X.TABLE X Amino Acid Type of Potential Modification Site Residues of Amino Acid or Domain SEQ ID NO: 47 Sequence N- glycosylation site 48 to 51 NISE 113 to 116 NNSL 285 to 288 NMSR 413 to 416 NLSQ Protein kinase C phosphorylation 12 to 14 SHR site 138 to 140 SRK 217 to 219 TVK Casein kinase II phosphorylation 155 to 158 SYDE site 175 to 178 TGQE 198 to 201 TMPE 360 to 363 SNPE Tyrosine kinase phosphorylation 174 to 182 KTGQEKIYY site N- myristoylation site 99 to 104 GLVGGA 130 to 135 GNSRGN 188 to 193 GTTMGF 277 to 282 GGFNTN Amidation site 240 to 243 FGKK Lipase serine active site 180 to 189 IYYVGYSQGT Lipase Conserved Active Site 186 5 Residues 357 D 386 H Lipase Conserved Cysteine 260 C Residues 269 C Lipase Conserved Oxyanion Hole 100 L Residues 187 Q Alpha/beta hydrolase fold domain 125 to 404 See FIG. 6 - Alpha/beta hydrolase fold domains occur in a wide variety of enzymes (Ollis et al., (1992) Protein Eng. 5:197-211). The alpha/beta fold domain is a conserved topological domain in which sequence homology is not necessarily conserved. Conservation of topology in the alpha/beta fold domain preserves arrangement of catalytic residues, even though those residues, and the reactions they catalyze, can vary. In many enzymes, particularly including alpha/beta hydrolases, this domain encompasses the active site of the enzyme. In one embodiment, the protein of the invention has at least one domain that is at least 55%, preferably at least about 65%, more preferably at least about 75%, yet more preferably at least about 85%, and most preferably at least about 95% identical to the alpha/beta hydrolase fold domain described herein in Table X.
- The signal peptide prediction program SIGNALP (Nielsen et al. (1997) Protein Engineering 10:1-6) predicted that
human TANGO 294 protein includes a 33 amino acid signal peptide (amino acid residues 1 to 33 of SEQ ID NO: 47; SEQ ID NO: 48) preceding themature TANGO 294 protein (amino acid residues 34 to 423 of SEQ ID NO: 47; SEQ ID NO: 49).Human TANGO 294 protein is a soluble secreted protein. However, in the transmembrane variant form,human TANGO 294 protein includes an extracellular domain (amino acid residues 34 to 254 of SEQ ID NO: 47; SEQ ID NO: 50); a transmembrane domain (amino acid residues 255 to 279 of SEQ ID NO: 47; SEQ ID NO: 51); and a cytoplasmic domain (amino acid residues 280 to 423 of SEQ ID NO: 47; SEQ ID NO: 52). - FIG. 6F depicts a hydrophilicity plot of
human TANGO 294 protein. Relatively hydrophobic regions are above the dashed horizontal line, and relatively hydrophilic regions are below the dashed horizontal line. The hydrophobic region which corresponds toamino acid residues 1 to 33 of SEQ ID NO: 47 is the signal sequence of human TANGO 294 (SEQ ID NO: 49). The hydrophobic region which corresponds toamino acid residues 255 to 279 of SEQ ID NO: 47 is the predicted transmembrane domain of human TANGO 294 (SEQ ID NO: 51). As described elsewhere herein, relatively hydrophilic regions are generally located at or near the surface of a protein, and are more frequently effective immunogenic epitopes than are relatively hydrophobic regions. For example, the region ofhuman TANGO 294 protein from aboutamino acid residue 130 to aboutamino acid residue 150 appears to be located at or near the surface of the protein, while the region from aboutamino acid residue 90 to aboutamino acid residue 100 appears not to be located at or near the surface. - The predicted molecular weight of
human TANGO 294 protein without modification and prior to cleavage of the signal sequence is about 48.2 kilodaltons. The predicted molecular weight of the maturehuman TANGO 294 protein without modification and after cleavage of the signal sequence is about 44.2 kilodaltons. - It may be that
amino acid residues 1 to 15 of SEQ ID NO: 47 do not occur inTANGO 294 protein. However, it is recognized that amino acid residues 16 to 33 of SEQ ID NO: 47 form a functional signal sequence even in the absence ofresidues 1 to 15. The amino acid sequence (and hence the properties) ofmature TANGO 294 protein are unaffected by presence or absence ofamino acid residues 1 to 15 ofimmature TANGO 294 protein. -
Human TANGO 294 protein exhibits considerable sequence similarity (i.e., about 75% amino acid sequence identity) to lingual and gastric lipase proteins of rat (Swissprot Accession no. P04634; Docherty et al. (1985) Nucleic Acids Res. 13:1891-1903), dog (Swissprot Accession no. P80035; Carriere et al. (1991) Eur. J. Biochem. 202:75-83), and human (Swissprot Accession no. P07098; Bembaeck and Blaeckberg (1987) Biochim. Biophys. Acta 909:237-244), as assessed using the ALIGN v. 2.0 computer software using a pam12.mat scoring matrix and gap penalties of −12/−4.TANGO 294 is distinct from the known human lipase, as indicated in FIGS. 6D and 6E. FIGS. 6D and 6E depict an alignment of the amino acid sequences ofhuman TANGO 294 protein (SEQ ID NO: 47) and the known human lipase protein (SEQ ID NO: 75), as assessed using the same software and parameters. In this alignment (pam120.mat scoring matrix, gap penalties −12/−4), the amino acid sequences of the proteins are 49.8% identical.TANGO 294 also is distinct from the known human lysosomal acid lipase, as indicated in FIGS. 6G and 6H. FIGS. 6G and 6H depicts an alignment of the amino acid sequences ofhuman TANGO 294 protein (SEQ ID NO: 47) and the known human lysosomal acid lipase protein (SEQ ID NO: 41). In this alignment (pam120.mat scoring matrix, gap penalties −12/−4), the amino acid sequences of the proteins are 56.9% identical. -
TANGO 294 is a human lipase distinct from the known human lipase and the known human lysosomal acid lipase. Furthermore, in view of the comparisons of the amino acid sequences ofTANGO 294 and the two human lipases and the nature of transcriptional initiation sites, it is recognized that the transcriptional start site can correspond to either of the methionine residues located atresidues 1 and 15 of SEQ ID NO: 47 The present invention thus includes proteins in which the initially transcribed amino acid residue is the methionine residue atposition 1 of SEQ ID NO: 47 and proteins in which the initially transcribed amino acid residue is the methionine residue at position 15 of SEQ ID NO: 47 (i.e., proteins in which the amino acid sequence ofTANGO 294 does not includeresidues 1 to 14 of SEQ ID NO: 47). Furthermore, becauseamino acid residues 1 to 14 of SEQ ID NO: 47 are predicted to be part of a signal sequence, it is recognized that the protein not comprising this portion of the amino acid sequence will nonetheless exhibit a functional signal sequence at its amino terminus. -
TANGO 294 Expression Analysis - TaqMan™ Experiments
- Total RNA was prepared from various human tissues by a single step extraction method using RNA STAT-60 according to the manufacturer's instructions (TelTest, Inc). Each RNA preparation was treated with DNase I (Ambion) at 37° C. for 1 hour. DNAse I treatment was determined to be complete if the sample required at least 38 PCR amplification cycles to reach a threshold level of fluorescence using beta-2 microglobulin as an internal amplicon reference. The integrity of the RNA samples following DNase I treatment was confirmed by agarose gel electrophoresis and ethidium bromide staining. After phenol extraction cDNA was prepared from the sample using the SUPERSCRIPT™ Choice System following the manufacturer's instructions (Gibco BRL). A negative control of RNA without reverse transcriptase was mock reverse transcribed for each RNA sample.
-
Novel TANGO 294 expression was measured by TaqMan™ quantitative PCR (Perkin Elmer Applied Biosystems) in cDNA prepared from the following human tissues: - Tissue Panel One (Phase I, General Expression in normal and tumorigenic tissues): Artery normal, Aorta diseased, Vein normal, Coronary SMC, HUVEC, Hemangioma, Heart (normal), Congestive Heart Failure, Kidney, Skeletal Muscle, Adipose (normal), Pancreas, Primary Osteoblasts, Osteoclasts (differentiated), Skin (normal), Spinal Cord (normal), Brain Cortex (normal), Brain Hypothalamus (normal), Nerve, Dorsal Root Ganglia, Breast (normal), Breast Tumor, Ovary (normal), Ovary Tumor, Prostate (normal), Prostate Tumor, Salivary Glands, Colon (pools of 3 normal colon tissues), Colon Tumor (3 colon adenocarcinomas), Lung (normal), Lung Tumor, Lung (COPD), Colon (3 colon IBD samples), Liver (normal), Liver Fibrosis, Spleen (normal), Tonsil (normal), Lymph Node (normal), Small Intestine (normal), Macrophages, Synovium, Bone Marrow-MNC, Activated Peripheral Blood Mononuclear Cells (PBMC), Neutrophils, Megakaryocytes, and Erthyroid.
- Tissue Panel Two (Phase II, General Expression Pattern in Solid Tumors): Breast (normal, 3 separate samples), Breast (tumor, 5 separate samples), Lymph node (metastasized from breast), Lung (metastasized from breast), Ovary (normal, 2 separate samples), Ovary (tumor, 5 separate samples), Lung (normal, 3 separate samples), Lung (tumor, 6 separate samples), Colon (normal, 3 separate samples), Colon (Adenocarcinoma, 4 separate samples), Liver (metastasized from colon, 3 separate samples), Liver (normal, female), Cervix Squamous Carcinoma (2 separate samples), Human Microvascular Endothelial Cells- Arr, Human Microvascular Endothelial Cells- Prol, Pooled Hemangiomas, HCT116N22 Normoxic, and HCT116H22 Hypoxic.
- Tissue Panel Three (Colon Cancer Expanded Panel: Specific expression pattern in various stages of colorectal cancer): Colon (normal, 6 separate samples), Colon (adenomas, 2 separate samples), Colon (stage B adenocarcinomas, 6 separate samples), Colon (stage C adenocarcinomas, 6 separate samples), Liver (normal, 6 separate samples), Liver (metastasized from colon, 6 separate samples), and 1 abdominal colon metastasis sample.
- Tissue Panel Four (Xenograft Panel): MCF-7 Breast T, ZR75 Breast T, T47D Breast T,
MDA 231 Breast T,MDA 435 Breast T, SKBr3 Breast,DLD 1 ColonT (stage C), SW480 Colon T (stage B), SW620 ColonT (stage C), HCT116, HT29, Colon 205, NCIH125, NCIH67, NCIH322, NCIH460, A549, NHBE, SKOV-3 ovary, OVCAR-3 ovary, 293 Baby Kidney, and 293T Baby Kidney. - Tissue Panel Five (Colon to Liver Metastases Panel: Specific expression patterns in late stage colon cancer (metastasis)): Colon (normal, 3 separate samples), Colonic ACA-C, Colonic ACA-C, Colonic ACA-B, Colon (adenocarcinoma), Liver (metastasized from colon, 17 separate samples), and Liver (normal, 3 separate samples).
- Probes were designed by PrimerExpress software (PE Biosystems) based on the sequence of each gene. Each gene probe was labeled using FAM (6-carboxyfluorescein), and the beta-2 microglobulin reference probe was labeled with a different fluorescent dye, VIC. The differential labeling of the target gene and internal reference gene thus enabled measurement in same well. Forward and reverse primers and the probes for both beta-2 microglobulin and target gene were added to the TaqMan™ Universal PCR Master Mix (PE Applied Biosystems). Although the final concentration of primer and probe could vary, each was internally consistent within a given experiment. A typical experiment contained 200 nanomolar of forward and reverse primers plus 100 nanomolar probe for beta-2 microglobulin and 600 nanomolar forward and reverse primers plus 200 nanomolar probe for the target gene. TaqMan matrix experiments were carried out on an ABI PRISM 7700 Sequence Detection System (PE Applied Biosystems). The thermal cycler conditions were as follows: hold for 2 minutes at 50° C. and 10 minutes at 95° C., followed by two-step PCR for 40 cycles of 95° C. for 15 seconds followed by 60° C. for 1 minute.
- The following method was used to quantitatively calculate
TANGO 294 gene expression in the various tissues relative to beta-2 microglobulin expression in the same tissue. The threshold cycle (Ct) value is defined as the cycle at which a statistically significant increase in fluorescence is detected. A lower Ct value is indicative of a higher mRNA concentration. The Ct value of theTANGO 294 gene is normalized by subtracting the Ct value of the beta-2 microglobulin gene to obtain a ΔCt value using the following formula: ΔCt=CtTANGO 294-Ctbeta-2 microglobulin. Expression is then calibrated against a cDNA sample showing a comparatively low level of expression of theTANGO 294 gene. The ΔCt value for the calibrator sample is then subtracted from ΔCt for each tissue sample according to the following formula: ΔΔCt=ΔCt-sample-ΔCt-calibrator. Relative expression is then calculated using the arithmetic formula given by 2-ΔΔCt. Expression of thetarget TANGO 294 gene in each of the tissues tested is discussed in more detail below. - The TaqMan expression from Panel One shows
restricted TANGO 294 expression in pancreas, colon tumors, and activated peripheral blood mononuclear cells, with highest expression in colon tumors. - The TaqMan expression from Panel Two shows
TANGO 294 expression restricted to colon tumors and lung tumors, with a 4-50 times increase in expression in colon tumor samples over normal colon samples. For example, the colontumor sample NDR 210 shows about 6× expression over normal colon samples, the colon tumor sample CHT 382 shows about 9× expression over normal colon samples, and the colon tumor sample CHT 528 shows about 30× expression over normal colon samples. - The TaqMan expression from Panel Three shows
TANGO 294 elevated expression in adenomas and stage A, B, and C, and metastatic tumors. - The TaqMan expression from Panel Four shows
TANGO 294 expression in breast, colon, and lung cell lines (NCIH322 and NHBE). - The TaqMan expression from Panel Five shows
upregulated TANGO 294 expression in 80% of colon to liver metastases. Both normal colon and normal liver show no expression. -
Other TANGO 294 Expression - Transcriptional profiling data shows upregulation of
TANGO 294 in early and late stage colon tumors, as compared to adenomas and normal colon tissue samples. - In situ hybridization experiments confirmed expression of
TANGO 294 in various tumor samples (restricted to a certain subset of tumors and metastatic lesions), as well as in pancreas and inflammatory cells (e.g., PBMCs). Expression ofTANGO 294 in colon tumor samples was also confirmed by quantitative PCR amplification. Expression ofTANGO 294 was detected in portions of hyperplastic colonic epithelium associated with colonic polyps. - Biological Function of
TANGO 294 proteins, nucleic acids, and modulators thereof - The sequence similarity of
TANGO 294 and mammalian lingual, gastric, and lysosomal acid lipase proteins indicates thatTANGO 294 is involved in physiological processes identical or analogous to those involving these lipases. Lipases such asTANGO 294 catalyze formation and breakage of ester bonds between a fatty acid and a lipid moiety such as an acylglycerol, a sterol (e.g., cholesterol), and a lipoprotein. The lipases with whichTANGO 294 exhibits the greatest similarity have acylglycerols and sterols among their substrates, indicating thatTANGO 294 can exhibit preference for these substrates. Thus,TANGO 294 is involved in facilitating absorption and metabolism of fat.TANGO 294 can thus be used, for example, to prevent, detect, and treat disorders relating to fat absorption and metabolism, such as inadequate expression of gastric/pancreatic lipase, cystic fibrosis, exocrine pancreatic insufficiency, obesity, medical treatments which alter fat absorption, and the like. - Lipases such as
TANGO 294 are also involved in regulating transfer of fatty acid substrates such as linoleic acid and arachidonic acid among dietary lipids, intracellular lipid stores, and enzymes involved in biosynthesis of eicosanoids such as prostaglandins, thromboxanes, and leukotrienes. Eicosanoids are known to exert a variety of biological effects on cells, including modulating immune responses, growth of cells, and movement of cells. Prostaglandins produced by oxidation of arachidonic acid by cyclooxygenase-2 (Cox-2) enzymes have a role in formation, growth, and spread of colon tumors (Majerus, 1998, Curr. Biol. 8(3):R87-R89). It has been hypothesized that at least part of the preventive effect of aspirin and other non-steroidal anti-inflammatory drugs on colon tumor formation is attributable to the inhibitory action of these agents on Cox-2 enzymes (Gustafson-Svard, 1997, Ann. Med. 29(3):247-252). Furthermore, abnormal expression of hormone-sensitive lipases has been observed in certain colon cancer cell lines (Remaury et al., 1995, Biochem. Biophys. Res. Commun. 208(1):456), suggesting that these enzymes can have a role in colon cancer development. Taken together, these observations and the data disclosed herein indicate thatTANGO 294 can modulate formation, growth, and metastasis of colon tumors. - While not being bound by any particular theory of operation, it is believed that
TANGO 294 is able to modulate the supply of eicosanoid precursor fatty acids such as linoleic acid, gamma-linoleic acid, gamma-dihomolinoleic acid, and arachidonic acid by modulating the amounts of these acids available for eicosanoid synthesis in colon tissue. These acids can be obtained by action ofTANGO 294 on dietary lipids (including lipids within the colon or serum) or by esterification or de-esterification of fatty acids and lipid stores within cells. By way of example,TANGO 294 can catalyze formation of triacylglycerols containing one or more of these fatty acids, whereupon the triacylglycerol is stored in a cellular membrane or within a lysosome. By modulating the cellular supply of these fatty acids, eicosanoid synthesis can be modulated, and cellular processes (e.g., cellular growth or proliferation or movement of cells) that are affected by the presence or absence of eicosanoids can be modulated. Thus, restriction of the availability of eicosanoid fatty acid precursors can inhibit eicosanoid synthesis and exert a colon cancer-preventive effect analogous to that observed by administration of a Cox-2 inhibitor such as aspirin or sulindac. -
TANGO 294 protein is known to be expressed in human pulmonary artery smooth muscle tissue. This indicates thatTANGO 294 protein is involved in transportation and metabolism of fats and lipids in the human vascular and cardiovascular systems. Thus,TANGO 294 proteins of the invention can be used to prevent, detect, and treat disorders involving these body systems. Various eicosanoids, including thromboxanes and prostaglandins, are known to modulate vascular smooth muscle contraction, affecting processes such as systemic blood pressure and local blood flow in tissues. The ability ofTANGO 294 to modulate eicosanoid levels permits these processes to be affected. Thus, modulating expression or activity ofTANGO 294 can be used to inhibit, prevent, or counteract hypo- or hypertension in a human or to modulate blood flow through a tissue in which the expression or activity is modulated. Similarly, assessment of expression or activity ofTANGO 294 in a patient, or in a tissue of a patient, can predict or diagnose a blood flow or blood pressure disorder in a patient. Examples of such disorders include arterial hypertension, renovascular hypertension, syncope, orthostatic hypotension, and shock (including anaphylactic shock). - Certain eicosanoids are known to strongly influence epithelial and endothelial cell proliferation and the tightness of adhesion between epithelial or endothelial cells. By modulating eicosanoid production in a cell (e.g., a tumor cell or a PBMC),
TANGO 294 can modulate the ability of the cell to pass through an epithelial or endothelial membrane. For example, many PBMCs exhibit the ability to travel within the bloodstream to a certain body location, at which point the cells adhere to the vessel wall and pass through the endothelial membrane of the vessel in order to move to a tissue adjoining the vessel (i.e., the PBMCs exhibit the ability to extravasate). Similarly, metastatic tumor cells often exhibit an enhanced ability to move through tissue membranes and colonize body sites at which they do not normally occur (e.g., colon tumor cells can metastasize to lung tissue and develop there into a tumor mass). The ability ofTANGO 294 to modulate these processes indicates thatTANGO 294 molecules can be used to prognosticate, diagnose, inhibit, prevent, or even reverse the ability of cells to exhibit these characteristics. Thus,TANGO 294 molecules are useful in prognosticating, diagnosing, inhibiting, preventing, or reversing conditions such as inappropriate inflammation, tumor growth, and tumor cell metastasis. - Expression of
TANGO 294 in tissues having an epithelial or endothelial component (e.g., colon and colon tumor, lung tumor, stomach, and pancreas tissues) indicates thatTANGO 294 can influence the cohesiveness of an endothelial or epithelial membrane in one of these tissues or the ability of cells to pass through that membrane. These observations indicate thatTANGO 294 can have a role in inflammatory disorders of these and other endothelium- or epithelium-containing tissues and thatTANGO 294 can affect the likelihood that a tumor cell metastasis will enter into or take up residence within one of these tissues. Examples of inflammatory disorders in whichTANGO 294 can have a role include gastritis, ulcer, various types of colitis and other less definitively characterized lower gastrointestinal disorders (e.g., irritable and inflammatory bowel syndromes), and pancreatitis. - Expression of
TANGO 294 was observed, at least at low levels, in a variety of tissues having an epithelial or endothelial portion, including colon, pancreas, small intestine, stomach, spleen, tonsil, and breast tissues. In many such tissues where corresponding tumor tissue samples were available (e.g., prostate, breast and lung tumor tissues), significantly greater expression ofTANGO 294 was observed in the tumor tissue than in the non-tumor tissue. This observation indicates thatTANGO 294 can have a role in a variety of tumors of epithelial and endothelial origin, including those in whichTANGO 294 expression occurs. TheTANGO 294 molecules described herein can therefore be used to modulate (e.g., inhibit, prevent, alleviate, reverse, or cure) tumorigenesis and growth, proliferation, invasion, and metastasis of these tumors. - Expression of
DNA encoding TANGO 294 is between 4 and 50 times greater in colon tumor tissue samples than in corresponding normal colon tissue samples. Expression ofTANGO 294 is elevated, relative to normal colon tissue in colon adenomas and in colon tumors at stages A, B, and C.Elevated TANGO 294 expression is also observed in metastases of apparent colon origin, including those which are found in liver tissue. In situ hybridization experiments confirmed expression ofTANGO 294 in various colon tumor samples, as well as in pancreas and inflammatory cells (e.g., PBMCs). Expression ofTANGO 294 in colon tumor samples and colon metastases was also confirmed by quantitative PCR amplification. Expression ofTANGO 294 was detected in portions of hyperplastic colonic epithelium associated with colonic polyps. - The strong correlation described herein between expression of
TANGO 294 and occurrence of colon tumor cells in a sample indicates thatTANGO 294 is useful as a marker for detecting occurrence of colon cancer in an individual. Expression ofTANGO 294 in a sample (e.g., a stool sample, a blood sample, or a polyp or other colon biopsy) obtained from a patient can indicate a predisposition for the patient to develop a colon cancer, that a growth observed in the patient's colon is a tumor, that a colon tumor in the patient is metastasizing or has significant metastatic potential, or that the patient has otherwise non-symptomatic colon cancer. - The strong correlation between
TANGO 294 expression and colon tumor occurrence also indicates that expression ofTANGO 294 can have a role in (e.g., can be used to inhibit, prevent, alleviate, reverse, or cure) one or more of tumorigenesis, colon tumor growth, or colon tumor metastasis. Compounds which modulate the activity or expression of TANGO 294 (e.g., antisense oligonucleotides, antibodies which specifically bind withTANGO 294, or relatively small molecules identified by screening) can affect the rate at which or the degree to which these processes occur. BecauseTANGO 294 expression appears to be up-regulated in colon tumor cells, inhibiting activity, expression, or both, ofTANGO 294 can inhibit or stop colon cell tumorigenesis, colon tumor growth, or colon tumor metastasis. Expression or activity ofTANGO 294 can therefore be used in a screening assay to identify compounds which can have one of these effects in colon cancer. -
TANGO 294 is expressed in activated PBMCs. This expression is consistent with a role forTANGO 294 in eicosanoid (e.g., leukotriene) biosynthesis. Leukotrienes are known to strongly modulate inflammation and other immune processes mediated by PBMCs. Aberrant expression ofTANGO 294 can induce PBMCs to proliferate or activate in an inappropriate manner, resulting in any of a variety of disorders. Inappropriate proliferation of PBMCs can lead to cancers such as leukemias, lymphomas, and plasma cell dyscrasias, and these cancers can be inhibited, prevented, alleviated, reversed, or cured using modulators ofTANGO 294 expression or activity. Inappropriate activation of PBMCs can result in a variety of inflammatory and immune disorders. By way of example, many autoimmune disorders involve activation of PBMCs in the absence of a pathogen, and others involve activation of PBMCs in the presence of a pathogen, but to an extent that immune-mediated cytotoxic activities seriously damage one or more tissues of the patient. - Pancreatic cancer cell proliferation and survival requires a sufficient level of eicosanoid synthesis (see, e.g., Ding et al., 2000, Anticancer Res. 20(4):2625-2631). Involvement of
TANGO 294 in eicosanoid synthesis and metabolism indicates thatTANGO 294 can contribute to proliferation and survival of pancreatic cancer cells.TANGO 294 molecules described herein can be used to inhibit, prevent, alleviate, reverse, or cure one or more of tumorigenesis, tumor cell growth, tumor cell proliferation, tumor cell invasion, and metastasis in pancreatic tissue. - It has been observed that circulating fatty acids can affect the inflammatory activity of leukocytes and ameliorate inflammatory disorders such as rheumatoid arthritis (Crocker et al., 2001, Q.J.M. 94(9):475-484). Synthesis and release of eicosanoids by leukocytes can affect the reactivity of those leukocytes and can also affect the properties of other leukocytes and eicosanoid-sensitive tissues in the physiological neighborhood of those leukocytes. The ability of
TANGO 294 to modulate synthesis and release of fatty acids in PBMCs which express it indicates that modulation ofTANGO 294 expression, activity, or both, can predict, diagnose, inhibit, or prevent inappropriate immune and inflammatory responses in patients. Thus, modulation ofTANGO 294 expression or activity can be used to treat patients afflicted with disorders such as arthritis (e.g., rheumatoid arthritis), psoriasis, myasthenia gravis, dermatitis (e.g., contact dermatitis), allergies, insulin resistance, systemic lupus erythematosus, scleroderma, and autoimmune diabetes mellitus. - Involvement of
TANGO 294 in activation of PBMCs indicates that inappropriately low activation of PBMCs can be predicted, diagnosed, inhibited, prevented, or reversed by increasing expression or activity ofTANGO 294 in PBMCs. Certain infectious agents (e.g., the human immunodeficiency virus) can deplete certain types of cells within the immune system. Other infectious agents provoke an immune response, but the provoked response is not sufficient to remove the infectious agent from the patient's system. Enhancing expression, activation, or both ofTANGO 294 in PBMCs in a patient can enhance the ability of the patient's immune system to react to the presence of an immunogen, thereby assisting the patient in clearing the pathogen from the patient or minimizing the pathogen's impact on the patient's health. - Various eicosanoid compounds, including several thromboxanes, influence the ability of blood platelets to aggregate with one another or to adhere to cells of another type. The ability of
TANGO 294 to modulate production of eicosanoids, including thromboxanes, indicates that modulation ofTANGO 294 expression, activity, or both, can influence the course of thrombotic disorders and disorders involving inappropriate platelet adherence. By way of example, some thrombotic disorders (e.g., hemophilia) are characterized by insufficient thrombosis. Expression or activity ofTANGO 294 can be modulated to enhance cellular production of thrombosis-enhancing eicosanoids, and assessingTANGO 294 expression or activity in a tissue can predict or diagnose whether the patient is afflicted with a disorder characterized by insufficient thrombosis. Conversely, assessment ofTANGO 294 expression or activity can be used to predict or diagnose if a patient is afflicted with (or predisposed to develop) a disorder characterized by inappropriate thrombus formation (e.g., stroke, myocardial infarction, or other abnormal blood coagulation) by inappropriate adherence of platelets to other tissues (e.g., coronary artery disease or atherosclerosis). ModulatingTANGO 294 expression or activity can inhibit or prevent one of these disorders, or alleviate the disorder if it is already occurring in a patient. - Other platelet associated disorders that TANGO 294 (or modulators thereof) can be used to treat, for at least the above-mentioned reasons, include, but are not limited to, thrombocytopenia due to a reduced number of megakaryocytes in the bone marrow, for example, as a result of chemotherapy; invasive disorders, such as leukemia, idiopathic or drug- or toxin-induced aplasia of the marrow, or rare hereditary amegakaryocytic thrombocytopenias; ineffective thrombopoiesis, for example, as a result of megaloblastic anemia, alcohol toxicity, vitamin B12 or folate deficiency, myelodysplastic disorders, or rare hereditary disorders (e.g., Wiskott-Aldrich syndrome and May-hegglin anomaly); a reduction in platelet distribution, for example, as a result of cirrhosis, a splenic invasive disease (e.g., Gaucher's disease), or myelofibrosis with extramedullary myeloid metaplasia; increased platelet destruction, for example, as a result of removal of IgG-coated platelets by the mononuclear phagocytic system (e.g., idiopathic thrombocytopenic purpura (ITP), secondary immune thrombocytopenia (e.g., systemic lupus erythematosus, lymphoma, or chronic lymphocytic leukemia), drug-related immune thrombocytopenias (e.g., as with quinidine, aspirin, and heparin), post-transfusion purpura, and neonatal thrombocytopenia as a result of maternal platelet autoantibodies or maternal platelet alloantibodies). Also included are thrombocytopenia secondary to intravascular clotting and thrombin induced damage to platelets as a result of, for example, obstetric complications, metastatic tumors, severe gram-negative bacteremia, thrombotic thrombocytopenic purpura, or severe illness. Also included is dilutional thrombocytopenia, for example, due to massive hemorrhage.
- Platelet associated disorders also include, but are not limited to, essential thrombocytosis and thrombocytosis associated with, for example, splenectomy, acute or chronic inflammatory diseases, hemolytic anemia, carcinoma, Hodgkin's disease, lymphoproliferative disorders, and malignant lymphomas.
- The disorders mentioned in this section in connection with
TANGO 294 are collectively referred to as “TANGO 294-related disorders.” -
INTERCEPT 296 - A cDNA clone (designated jthEa030h09) encoding at least a portion of
human INTERCEPT 296 protein was isolated from a human esophagus cDNA library. Thehuman INTERCEPT 296 protein is predicted by structural analysis to be a transmembrane protein having three or more transmembrane domains. Expression ofDNA encoding INTERCEPT 296 tissue has been detected by northern analysis of human lung tissue. In human lung tissue, two moieties corresponding to INTERCEPT 296 have been identified in Northern blots. It is recognized that these two moieties may represent alternativelypolyadenylated INTERCEPT 296 mRNAs or alternatively splicedINTERCEPT 296 mRNAs. It has furthermore been observed thatINTERCEPT 296 does not appear to be expressed in any of heart, brain, placenta, skeletal muscle, kidney, and pancreas tissues. - The full length of the
cDNA encoding INTERCEPT 296 protein (FIG. 7; SEQ ID NO: 53) is 2133 nucleotide residues. The ORF of this cDNA,nucleotide residues 70 to 1098 of SEQ ID NO: 53 (i.e., SEQ ID NO: 54), encodes a 343-amino acid transmembrane protein (FIG. 7; SEQ ID NO: 55). - The invention includes purified
INTERCEPT 296 protein, which has the amino acid sequence listed in SEQ ID NO: 55. In addition tofull length INTERCEPT 296 proteins, the invention includes fragments, derivatives, and variants of theseINTERCEPT 296 proteins, as described herein. These proteins, fragments, derivatives, and variants are collectively referred to herein as polypeptides of the invention or proteins of the invention. - The invention also includes nucleic acid molecules which encode a polypeptide of the invention. Such nucleic acids include, for example, a DNA molecule having the nucleotide sequence SEQ ID NO: 53 or some portion thereof, such as the portion which encodes
INTERCEPT 296 protein or a domain thereof. These nucleic acids are collectively referred to as nucleic acids of the invention. -
INTERCEPT 296 proteins and nucleic acid molecules encoding them comprise a family of molecules having certain conserved structural and functional features, such as the five transmembrane domains which occur in the protein. -
INTERCEPT 296 comprises at least five transmembrane domains, at least three cytoplasmic domains, and at least two extracellular domains.INTERCEPT 296 does not appear to comprise a cleavable signal sequence.Amino acid residues 1 to 70 of SEQ ID NO: 55 likely directs insertion of the protein into the cytoplasmic membrane. There are at least two mechanisms by which this can occur. Sequence analysis ofresidues 1 to 70 of SEQ ID NO: 55 indicates that this entire region may represent a signal sequence or thatresidues 1 to 47 represent a signal sequence, with residues 48-70 representing a transmembrane region.Human INTERCEPT 296 protein extracellular domains are located from aboutamino acid residue 70 to about amino acid residue 182 (SEQ ID NO: 57) and from aboutamino acid residue 228 to about amino acid residue 249 (SEQ ID NO: 58) of SEQ ID NO: 55.Human INTERCEPT 296 cytoplasmic domains are located from about amino acid residue 43 to amino acid residue 50 (SEQ ID NO: 64), from about amino acid residue 205 to amino acid residue 210 (SEQ ID NO: 65), and fromamino acid residue 272 to amino acid residue 343 (SEQ ID NO: 66) of SEQ ID NO: 55. The five transmembrane domains ofINTERCEPT 296 are located from about amino acid residues 24 to 42 (SEQ ID NO: 59), 51 to 70 (SEQ ID NO: 60), 183 to 204 (SEQ ID NO: 61),211 to 227 (SEQ ID NO: 62), and 250 to 271 (SEQ ID NO: 63) of SEQ ID NO: 55. -
INTERCEPT 296 proteins typically comprise a variety of potential post-translational modification sites (often within an extracellular domain), such as those described herein in Table XI, as predicted by computerized sequence analysis ofINTERCEPT 296 proteins using amino acid sequence comparison software (comparing the amino acid sequence ofINTERCEPT 296 with the information in the PROSITE database {rel. 12.2; February, 1995} and the Hidden Markov Models database {Rel. PFAM 3.3}). In certain embodiments, a protein of the invention has at least 1, 2, 4, 6, 10, 15, or 20 or more of the post-translational modification sites listed in Table XI.TABLE XI Amino Acid Type of Potential Modification Site Residues of Amino Acid or Domain SEQ ID NO: 55 Sequence N- glycosylation site 71 to 74 NFSS 84 to 87 NTSY 109 to 112 NITL 121 to 124 NETI 284 to 287 NQSV Protein kinase C phosphorylation 86 to 88 SYK site 131 to 133 TWR 162 to 164 TPR 304 to 306 SPR 313 to 315 SPK 326 to 328 STK Casein kinase II phosphorylation 286 to 289 SVDE site 296 to 299 SPEE 309 to 312 SMAD Tyrosine kinase phosphorylation 148 to 156 KGLPDPVLY site N- myristoylation site 79 to 84 GQVSTN 100 to 105 GLQVGL 107 to 112 GVNITL 265 to 270 GLAMAV - FIG. 7D depicts a hydrophilicity plot of
INTERCEPT 296 protein. Relatively hydrophobic regions are above the dashed horizontal line, and relatively hydrophilic regions are below the dashed horizontal line. The hydrophobic regions which corresponds to amino acid residues 24 to 42, 51 to 70, 183 to 204, 211 to 227, and 250 to 271 of SEQ ID NO: 55 are the transmembrane domains of human INTERCEPT 296 (SEQ ID NOs: 59 through 63, respectively). As described elsewhere herein, relatively hydrophilic regions are generally located at or near the surface of a protein, and are more frequently effective immunogenic epitopes than are relatively hydrophobic regions. For example, the region ofhuman INTERCEPT 296 protein from aboutamino acid residue 120 to aboutamino acid residue 140 appears to be located at or near the surface of the protein, while the region from about amino acid residue 95 to aboutamino acid residue 110 appears not to be located at or near the surface. - The predicted molecular weight of
INTERCEPT 296 protein without modification and prior to cleavage of the signal sequence is about 37.8 kilodaltons. The predicted molecular weight of themature INTERCEPT 296 protein without modification and after cleavage of the signal sequence is about 30.2 kilodaltons. - FIGS. 7E and 7F depicts an alignment of the amino acid sequences of
human INTERCEPT 296 protein (SEQ ID NO: 55) and Caenorhabditis elegans C06E1.3 related protein (SEQ ID NO: 399). In this alignment (pam120.mat scoring matrix, gap penalties −12/−4), the amino acid sequences of the proteins are 26.8% identical. The C. elegans protein has five predicted transmembrane domains. - Biological Function of
INTERCEPT 296 Proteins, Nucleic Acids, and Modulators Thereof - The
cDNA encoding INTERCEPT 296 protein was obtained from a human esophagus cDNA library, andINTERCEPT 296 is expressed in lung tissue. The INTERCEPT 296-related proteins and nucleic acids of the invention are therefore useful for prevention, detection, and treatment of disorders of the human lung and esophagus. Such disorders include, for example, various cancers, bronchitis, cystic fibrosis, respiratory infections (e.g., influenza, bronchiolitis, pneumonia, and tuberculosis), asthma, emphysema, chronic bronchitis, bronchiectasis, pulmonary edema, pleural effusion, pulmonary embolus, adult and infant respiratory distress syndromes, heartburn, and gastric reflux esophageal disease. - Tables A and B summarize sequence data corresponding to the human proteins herein designated
TANGO 202, TANGO 234, TANGO 265,TANGO 273,TANGO 286,TANGO 294, andINTERCEPT 296.TABLE A Protein SEQ ID NOs Depicted in ATCC ® Designation cDNA ORF Protein Figure # Accession # TANGO 202 1 2 3 1 207219 TANGO 234 9 10 11 2 207184 TANGO 265 17 18 19 3 207228 TANGO 27325 26 27 4 207185 TANGO 28633 34 35 5 207220 TANGO 29445 46 47 6 207220 INTERCEPT 53 54 55 7 207220 296 -
TABLE B Amino Acid Residues SEQ ID NOs Extracellular Transmembrane Cytoplasmic Protein Desig. Signal Sequence Mature Protein Domain(s) Domain(s) Domain(s) TANGO 202 1 to 19 4 20 to 475 5 20 to 392 6 393 to 415 7 416 to 475 8 (variant) (1 to 19) (4) (20 to 475) (5) (20 to 475) (5) (N/A) (N/A) TANGO 234 1 to 40 12 41 to 1453 13 41 to 1359 14 1360 to 1383 15 1384 to 1453 16 TANGO 265 1 to 31 20 32 to 761 21 32 to 683 22 684 to 704 23 705 to 761 24 TANGO 273 1 to 22 28 23 to 172 29 23 to 60 30 61 to 81 31 82 to 172 32 TANGO 286 1 to 23 36 24 to 455 37 24 to 455 37 N/A N/A TANGO 294 1 to 33 48 34 to 423 49 34 to 254 50 255 to 279 51 280 to 423 52 (variant 1) (15 to 33) (40) (34 to 423) (49) (34 to 254) (50) (255 to 279) (51) (280 to 423) (52) <variant 2> <1 to 33> <48> <34 to 423> <49> <34 to 423> <49> <N/A> <N/A> {variant 3} {15 to 33} {40} {34 to 423} {49} {34 to 423} {49} { N/A } { N/A } INTERCEPT N/A 1 to 343 55 1 to 23 56 24 to 42 59 43 to 50 64 296 71 to 182 57 51 to 70 60 205 to 210 65 228 to 249 58 183 to 204 61 272 to 343 66 211 to 227 62 250 to 271 63 - Various aspects of the invention are described in further detail in the following subsections.
- Isolated Nucleic Acid Molecules
- One aspect of the invention pertains to isolated nucleic acid molecules that encode a polypeptide of the invention or a biologically active portion thereof, as well as nucleic acid molecules sufficient for use as hybridization probes to identify nucleic acid molecules encoding a polypeptide of the invention and fragments of such nucleic acid molecules suitable for use as PCR primers for the amplification or mutation of nucleic acid molecules. As used herein, the term “nucleic acid molecule” is intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.
- An “isolated” nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid molecule. Preferably, an “isolated” nucleic acid molecule is free of sequences (preferably protein-encoding sequences) which naturally flank the nucleic acid (i.e., sequences located at the 5′ and 3′ ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated nucleic acid molecule can contain less than about 5 kB, 4 kB, 3 kB, 2 kB, 1 kB, 0.5 kB or 0.1 kB of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. Moreover, an “isolated” nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.
- A nucleic acid molecule of the present invention, e.g., a nucleic acid molecule having the nucleotide sequence of all or a portion of any of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73, or a complement thereof, or which has a nucleotide sequence comprising one of these sequences, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using a nucleic acid comprising at least one of the sequences of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73 as a hybridization probe, nucleic acid molecules of the invention can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook et al., eds., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989).
- A nucleic acid molecule of the invention can be amplified using cDNA, mRNA or genomic DNA as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to all or a portion of a nucleic acid molecule of the invention can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.
- In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is a complement of the nucleotide sequence of any of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73, or a portion thereof. A nucleic acid molecule which is complementary to a given nucleotide sequence is one which is sufficiently complementary to the given nucleotide sequence that it can hybridize to the given nucleotide sequence thereby forming a stable duplex.
- Moreover, a nucleic acid molecule of the invention can comprise only a portion of a nucleic acid sequence encoding a full length polypeptide of the invention for example, a fragment which can be used as a probe or primer or a fragment encoding a biologically active portion of a polypeptide of the invention. The nucleotide sequence determined from the cloning one gene allows for the generation of probes and primers designed for use in identifying and/or cloning homologs in other cell types, e.g., from other tissues, as well as homologs from other mammals. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 15, preferably about 25, more preferably about 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, or 400 or more consecutive nucleotides of the sense or anti-sense sequence of any of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73, or of a naturally occurring mutant of any of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73.
- Probes based on the sequence of a nucleic acid molecule of the invention can be used to detect transcripts or genomic sequences encoding the same protein molecule encoded by a selected nucleic acid molecule. The probe comprises a label group attached thereto, e.g., a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as part of a diagnostic test kit for identifying cells or tissues which mis-express the protein, such as by measuring levels of a nucleic acid molecule encoding the protein in a sample of cells from a subject, e.g., detecting mRNA levels or determining whether a gene encoding the protein has been mutated or deleted.
- A nucleic acid fragment encoding a biologically active portion of a polypeptide of the invention can be prepared by isolating a portion of any of SEQ ID NOs: 2, 10, 18, 26, 34, 46, 54, 68, and 73, expressing the encoded portion of the polypeptide protein (e.g., by recombinant expression in vitro), and assessing the activity of the encoded portion of the polypeptide.
- The invention further encompasses nucleic acid molecules that differ from the nucleotide sequence of any of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73 due to degeneracy of the genetic code and thus encode the same protein as that encoded by the nucleotide sequence of any of SEQ ID NOs: 2, 10, 18, 26, 34, 46, 54, 68,and 73.
- In addition to the nucleotide sequences of SEQ ID NOs: 2, 10, 18, 26, 34, 46, 54, 68, and 73, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequence can exist within a population (e.g., the human population). Such genetic polymorphisms can exist among individuals within a population due to natural allelic variation. An allele is one of a group of genes which occur alternatively at a given genetic locus.
- As used herein, the phrase “allelic variant” refers to a nucleotide sequence which occurs at a given locus or to a polypeptide encoded by the nucleotide sequence. For example, chromosomal mapping has been used to locate the gene encoding human TANGO 234 at chromosomal location h12p13 (with synteny to mo6), between chromosomal markers WI-6980 and GATA8A09.43. Thus, human TANGO 234 allelic variants can include TANGO 234 nucleotide sequence polymorphisms (e.g., nucleotide sequences that vary from SEQ ID NO: 9) that map to this chromosomal region. Similarly, chromosomal mapping has been used to locate the gene encoding human TANGO 265 protein on
chromosome 1, between markers D1S305 and D1S2635. Allelic variants of TANGO 265 occur at this chromosomal location. Further by way of example, the gene encodinghuman TANGO 273 protein has been located by chromosomal mapping on chromosome 7, between markers D7S2467 and D7S2552. Allelic variants ofTANGO 273 occur at this chromosomal location. - As used herein, the terms “gene” and “recombinant gene” refer to nucleic acid molecules comprising an open reading frame encoding a polypeptide of the invention. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of a given gene. Alternative alleles can be identified by sequencing the gene of interest in a number of different individuals. This can be readily carried out by using hybridization probes to identify the same genetic locus in a variety of individuals. Any and all such nucleotide variations and resulting amino acid polymorphisms or variations that are the result of natural allelic variation and that do not alter the functional activity are intended to be within the scope of the invention.
- Moreover, nucleic acid molecules encoding proteins of the invention from other species (homologs), which have a nucleotide sequence which differs from that of the specific proteins described herein are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and homologs of a cDNA of the invention can be isolated based on their homology with nucleic acid molecules described herein, using the specific cDNAs described herein, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions. For example, a cDNA encoding a soluble form of a membrane-bound protein of the invention isolated based on its hybridization to a nucleic acid molecule encoding all or part of the membrane-bound form. Likewise, a cDNA encoding a membrane-bound form can be isolated based on its hybridization to a nucleic acid molecule encoding all or part of the soluble form.
- Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 15 (25, 40, 60, 80, 100, 150, 200, 250, 300, 350, 400, 450, 550, 650, 700, 800, 900, 1000, 1200, 1400, 1600, 1800, 2000, 2200, 2400, 2600, 2800, 3000, 3500, 4000, 4500, or 4928) nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence, preferably the coding sequence, of any of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73, or a complement thereof. As used herein, the term “hybridizes under stringent conditions” is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% (65%, 70%, preferably 75%) identical to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. A preferred, non-limiting example of stringent hybridization conditions are hybridization in 6× sodium chloride/sodium citrate (SSC) at about 45° C., followed by one or more washes in 0.2× SSC, 0.1% SDS at 50-65° C. Preferably, an isolated nucleic acid molecule of the invention that hybridizes under stringent conditions with the sequence of any of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73, or a complement thereof, corresponds to a naturally-occurring nucleic acid molecule. As used herein, a “naturally-occurring” nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein).
- In addition to naturally-occurring allelic variants of a nucleic acid molecule of the invention sequence that can exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation thereby leading to changes in the amino acid sequence of the encoded protein, without altering the biological activity of the protein. For example, one can make nucleotide substitutions leading to amino acid substitutions at “non-essential” amino acid residues. A “non-essential” amino acid residue is a residue that can be altered from the wild-type sequence without altering the biological activity, whereas an “essential” amino acid residue is required for biological activity. For example, amino acid residues that are not conserved or only semi-conserved among homologs of various species may be non-essential for activity and thus would be likely targets for alteration. Alternatively, amino acid residues that are conserved among the homologs of various species (e.g., murine and human) may be essential for activity and thus would not be likely targets for alteration.
- Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding a polypeptide of the invention that contain changes in amino acid residues that are not essential for activity. Such polypeptides differ in amino acid sequence from the sequence of any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74, yet retain biological activity. In one embodiment, the isolated nucleic acid molecule includes a nucleotide sequence encoding a protein that includes an amino acid sequence that is at least about 40% identical, 50%, 60%, 70%, 80%, 90%, 95%, or 98% identical to the amino acid sequence of any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74.
- An isolated nucleic acid molecule encoding a variant protein can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of any of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73, such that one or more amino acid residue substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Alternatively, mutations can be introduced randomly along all or part of the coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for biological activity to identify mutants that retain activity. Following mutagenesis, the encoded protein can be expressed recombinantly and the activity of the protein can be determined.
- In a preferred embodiment, a mutant polypeptide that is a variant of a polypeptide of the invention can be assayed for: (1) the ability to form protein:protein interactions with one or more polypeptides of the invention (e.g., in a signaling pathway); (2) the ability to bind a ligand of a polypeptide of the invention (e.g., another protein identified herein); (3) the ability to bind to an intracellular target protein of a polypeptide of the invention (e.g., a modulator or substrate of the polypeptide); or (4) the ability to modulate a physiological activity of the protein, such as one of those disclosed herein (e.g., ability to modulate cell proliferation, cell migration, chemotaxis, or cellular differentiation).
- The present invention encompasses antisense nucleic acid molecules, i.e., molecules which are complementary to a sense nucleic acid encoding a polypeptide of the invention, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid. The antisense nucleic acid can be complementary to an entire coding strand, or to only a portion thereof, e.g., all or part of the protein coding region (or open reading frame). An antisense nucleic acid molecule can be antisense to all or part of a non-coding region of the coding strand of a nucleotide sequence encoding a polypeptide of the invention. The non-coding regions (“5′ and 3′ untranslated regions”) are the 5′ and 3′ sequences which flank the coding region and are not translated into amino acids.
- An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 or more nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5′-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been sub-cloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).
- The antisense nucleic acid molecules of the invention are typically administered to a subject or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a selected polypeptide of the invention to thereby inhibit expression, e.g., by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, e.g., by linking the antisense nucleic acid molecules to peptides or antibodies which bind to cell surface receptors or antigens. The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.
- An antisense nucleic acid molecule of the invention can be an alpha-anomeric nucleic acid molecule. An a-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual beta-units, the strands run parallel to each other (Gaultier et al. (1987) Nucleic Acids Res. 15:6625-6641). The antisense nucleic acid molecule can also comprise a 2′-o-methylribonucleotide (Inoue et al. (1987) Nucleic Acids Res. 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue et al. (1987) FEBS Lett. 215:327-330).
- The invention also encompasses ribozymes. Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes as described in Haselhoff and Gerlach (1988) Nature 334:585-591) can be used to catalytically cleave mRNA transcripts to thereby inhibit translation of the protein encoded by the mRNA. A ribozyme having specificity for a nucleic acid molecule encoding a polypeptide of the invention can be designed based upon the nucleotide sequence of a cDNA disclosed herein. For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a Cech et al. U.S. Pat. No. 4,987,071; and Cech et al. U.S. Pat. No. 5,116,742. Alternatively, an mRNA encoding a polypeptide of the invention can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel and Szostak (1993) Science 261:1411-1418.
- The invention also encompasses nucleic acid molecules which form triple helical structures. For example, expression of a polypeptide of the invention can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the gene encoding the polypeptide (e.g., the promoter and/or enhancer) to form triple helical structures that prevent transcription of the gene in target cells. See generally Helene (1991) Anticancer Drug Des. 6(6):569-84; Helene (1992) Ann. N.Y. Acad. Sci. 660:27-36; and Maher (1992) Bioassays 14(12):807-15.
- In various embodiments, the nucleic acid molecules of the invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids (see Hyrup et al. (1996) Bioorganic & Medicinal Chemistry 4(1): 5-23). As used herein, the terms “peptide nucleic acids” or “PNAs” refer to nucleic acid mimics, e.g., DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup et al. (1996), supra; Perry-O'Keefe et al. (1996) Proc. Natl. Acad. Sci. USA 93: 14670-675.
- PNAs can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or anti-gene agents for sequence-specific modulation of gene expression by, e.g., inducing transcription or translation arrest or inhibiting replication. PNAs can also be used, e.g., in the analysis of single base pair mutations in a gene by, e.g., PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e.g., S1 nucleases (Hyrup (1996), supra; or as probes or primers for DNA sequence and hybridization (Hyrup (1996), supra; Perry-O'Keefe et al. (1996) Proc. Natl. Acad. Sci. USA 93: 14670-675).
- In another embodiment, PNAs can be modified, e.g., to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras can be generated which can combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes, e.g., RNase H and DNA polymerases, to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup (1996), supra). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup (1996), supra, and Finn et al. (1996) Nucleic Acids Res. 24(17):3357-63. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry and modified nucleoside analogs. Compounds such as 5′-(4-methoxytrityl)amino-5′-deoxy-thymidine phosphoramidite can be used as a link between the PNA and the 5′ end of DNA (Mag et al. (1989) Nucleic Acids Res. 17:5973-88). PNA monomers are then coupled in a step-wise manner to produce a chimeric molecule with a 5′ PNA segment and a 3′ DNA segment (Finn et al. (1996) Nucleic Acids Res. 24(17):3357-63). Alternatively, chimeric molecules can be synthesized with a 5′ DNA segment and a 3′ PNA segment (Peterser et al. (1975) Bioorganic Med. Chem. Lett. 5:1119-11124).
- In other embodiments, the oligonucleotide can include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al. (1989) Proc. Natl. Acad. Sci. USA 86:6553-6556; Lemaitre et al. (1987) Proc. Natl. Acad. Sci. USA 84:648-652; PCT Publication No. WO 88/09810) or the blood-brain barrier (see, e.g., PCT Publication No. WO 89/10134). In addition, oligonucleotides can be modified with hybridization-triggered cleavage agents (see, e.g., Krol et al. (1988) Bio/Techniques 6:958-976) or intercalating agents (see, e.g., Zon (1988) Pharm. Res. 5:539-549). To this end, the oligonucleotide can be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.
- Isolated Proteins and Antibodies
- One aspect of the invention pertains to isolated proteins, and biologically active portions thereof, as well as polypeptide fragments suitable for use as immunogens to raise antibodies directed against a polypeptide of the invention. In one embodiment, the native polypeptide can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, polypeptides of the invention are produced by recombinant DNA techniques. Alternative to recombinant expression, a polypeptide of the invention can be synthesized chemically using standard peptide synthesis techniques.
- An “isolated” or “purified” protein or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the protein is derived, or substantially free of chemical precursors or other chemicals when chemically synthesized. The language “substantially free of cellular material” includes preparations of protein in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly produced. Thus, protein that is substantially free of cellular material includes preparations of protein having less than about 30%, 20%, 10%, or 5% (by dry weight) of heterologous protein (also referred to herein as a “contaminating protein”). When the protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, 10%, or 5% of the volume of the protein preparation. When the protein is produced by chemical synthesis, it is preferably substantially free of chemical precursors or other chemicals, i.e., it is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. Accordingly such preparations of the protein have less than about 30%, 20%, 10%, 5% (by dry weight) of chemical precursors or compounds other than the polypeptide of interest.
- Biologically active portions of a polypeptide of the invention include polypeptides comprising amino acid sequences sufficiently identical to or derived from the amino acid sequence of the protein (e.g., the amino acid sequence shown in any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74), which include fewer amino acids than the full length protein, and exhibit at least one activity of the corresponding full-length protein. Typically, biologically active portions comprise a domain or motif with at least one activity of the corresponding protein. A biologically active portion of a protein of the invention can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acids in length. Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of the native form of a polypeptide of the invention.
- Preferred polypeptides have the amino acid sequence of any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74. Other useful proteins are substantially identical (e.g., at least about 40%, preferably 50%, 60%, 70%, 80%, 90%, 95%, or 99%) to any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74 and retain the functional activity of the protein of the corresponding naturally-occurring protein yet differ in amino acid sequence due to natural allelic variation or mutagenesis.
- To determine the percent identity of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity=# of identical positions/total # of positions (e.g., overlapping positions)×100). In one embodiment the two sequences are the same length.
- The determination of percent identity between two sequences can be accomplished using a mathematical algorithm. A preferred, non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264-2268, modified as in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul, et al. (1990) J. Mol. Biol. 215:403-410. BLAST nucleotide searches can be performed with the NBLAST program, score=100, wordlength=12 to obtain nucleotide sequences homologous to a nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3 to obtain amino acid sequences homologous to a protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (1997) Nucleic Acids Res. 25:3389-3402. Alternatively, PSI-Blast can be used to perform an iterated search which detects distant relationships between molecules. Id. When utilizing BLAST, Gapped BLAST, and PSI-Blast programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See http://www.ncbi.nlm.nih.gov. Another preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, (1988) CABIOS 4:11-17. Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used.
- The percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating percent identity, only exact matches are counted.
- The invention also provides chimeric or fusion proteins. As used herein, a “chimeric protein” or “fusion protein” comprises all or part (preferably biologically active) of a polypeptide of the invention operably linked to a heterologous polypeptide (i.e., a polypeptide other than the same polypeptide of the invention). Within the fusion protein, the term “operably linked” is intended to indicate that the polypeptide of the invention and the heterologous polypeptide are fused in-frame to each other. The heterologous polypeptide can be fused to the amino-terminus or the carboxyl-terminus of the polypeptide of the invention.
- One useful fusion protein is a GST fusion protein in which the polypeptide of the invention is fused to the carboxyl terminus of GST sequences. Such fusion proteins can facilitate the purification of a recombinant polypeptide of the invention.
- In another embodiment, the fusion protein contains a heterologous signal sequence at its amino terminus. For example, the native signal sequence of a polypeptide of the invention can be removed and replaced with a signal sequence from another protein. For example, the gp67 secretory sequence of the baculovirus envelope protein can be used as a heterologous signal sequence (Current Protocols in Molecular Biology, Ausubel et al., eds., John Wiley & Sons, 1992). Other examples of eukaryotic heterologous signal sequences include the secretory sequences of melittin and human placental alkaline phosphatase (Stratagene; La Jolla, Calif.). In yet another example, useful prokaryotic heterologous signal sequences include the phoA secretory signal (Sambrook et al., supra) and the protein A secretory signal (Pharmacia Biotech; Piscataway, N.J.).
- In yet another embodiment, the fusion protein is an immunoglobulin fusion protein in which all or part of a polypeptide of the invention is fused to sequences derived from a member of the immunoglobulin protein family. The immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a ligand (soluble or membrane-bound) and a protein on the surface of a cell (receptor), to thereby suppress signal transduction in vivo. The immunoglobulin fusion protein can be used to affect the bioavailability of a cognate ligand of a polypeptide of the invention. Inhibition of ligand/receptor interaction can be useful therapeutically, both for treating proliferative and differentiative disorders and for modulating (e.g., promoting or inhibiting) cell survival. Moreover, the immunoglobulin fusion proteins of the invention can be used as immunogens to produce antibodies directed against a polypeptide of the invention in a subject, to purify ligands and in screening assays to identify molecules which inhibit the interaction of receptors with ligands.
- Chimeric and fusion proteins of the invention can be produced by standard recombinant DNA techniques. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and re-amplified to generate a chimeric gene sequence (see, e.g., Ausubel et al., supra). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). A nucleic acid encoding a polypeptide of the invention can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the polypeptide of the invention.
- A signal sequence of a polypeptide of the invention (e.g., the signal sequence in one of SEQ ID NOs: 3, 4, 11, 12, 19, 20, 27, 28, 35, 36, 47, 48, 69, and 74) can be used to facilitate secretion and isolation of the secreted protein or other proteins of interest. Signal sequences are typically characterized by a core of hydrophobic amino acids which are generally cleaved from the mature protein during secretion in one or more cleavage events. Such signal peptides contain processing sites that allow cleavage of the signal sequence from the mature proteins as they pass through the secretory pathway. Thus, the invention pertains to the described polypeptides having a signal sequence, as well as to the signal sequence itself and to the polypeptide in the absence of the signal sequence (i.e., the cleavage products). In one embodiment, a nucleic acid sequence encoding a signal sequence of the invention can be operably linked in an expression vector to a protein of interest, such as a protein which is ordinarily not secreted or is otherwise difficult to isolate. The signal sequence directs secretion of the protein, such as from a eukaryotic host into which the expression vector is transformed, and the signal sequence is subsequently or concurrently cleaved. The protein can then be readily purified from the extracellular medium by art recognized methods. Alternatively, the signal sequence can be linked to the protein of interest using a sequence which facilitates purification, such as with a GST domain.
- In another embodiment, the signal sequences of the present invention can be used to identify regulatory sequences, e.g., promoters, enhancers, repressors. Since signal sequences are the most amino-terminal sequences of a peptide, it is expected that the nucleic acids which flank the signal sequence on its amino-terminal side will be regulatory sequences which affect transcription. Thus, a nucleotide sequence which encodes all or a portion of a signal sequence can be used as a probe to identify and isolate signal sequences and their flanking regions, and these flanking regions can be studied to identify regulatory elements therein.
- The present invention also pertains to variants of the polypeptides of the invention. Such variants have an altered amino acid sequence which can function as either agonists (mimetics) or as antagonists. Variants can be generated by mutagenesis, e.g., discrete point mutation or truncation. An agonist can retain substantially the same, or a subset, of the biological activities of the naturally occurring form of the protein. An antagonist of a protein can inhibit one or more of the activities of the naturally occurring form of the protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the protein of interest. Thus, specific biological effects can be elicited by treatment with a variant of limited function. Treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein can have fewer side effects in a subject relative to treatment with the naturally occurring form of the protein.
- Variants of a protein of the invention which function as either agonists (mimetics) or as antagonists can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of the protein of the invention for agonist or antagonist activity. In one embodiment, a variegated library of variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential protein sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display). There are a variety of methods which can be used to produce libraries of potential variants of the polypeptides of the invention from a degenerate oligonucleotide sequence. Methods for synthesizing degenerate oligonucleotides are known in the art (see, e.g., Narang (1983) Tetrahedron 39:3; Itakura et al. (1984) Annu. Rev. Biochem. 53:323; Itakura et al. (1984) Science 198:1056; Ike et al. (1983) Nucleic Acid Res. 11:477).
- In addition, libraries of fragments of the coding sequence of a polypeptide of the invention can be used to generate a variegated population of polypeptides for screening and subsequent selection of variants. For example, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of the coding sequence of interest with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, re-naturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes amino terminal and internal fragments of various sizes of the protein of interest.
- Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. The most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify variants of a protein of the invention (Arkin and Yourvan (1992) Proc. Natl. Acad. Sci. USA 89:7811-7815; Delgrave et al. (1993) Protein Engineering 6(3):327-331).
- An isolated polypeptide of the invention, or a fragment thereof, can be used as an immunogen to generate antibodies using standard techniques for polyclonal and monoclonal antibody preparation. The full-length polypeptide or protein can be used or, alternatively, the invention provides antigenic peptide fragments for use as immunogens. The antigenic peptide of a protein of the invention comprises at least 8 (preferably 10, 15, 20, or 30 or more) amino acid residues of the amino acid sequence of any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74, and encompasses an epitope of the protein such that an antibody raised against the peptide forms a specific immune complex with the protein.
- Preferred epitopes encompassed by the antigenic peptide are regions that are located on the surface of the protein, e.g., hydrophilic regions. FIGS. 1L, 1M,2J, 3U, 4I, 4J, 5E, 6F, and 7D are hydrophobicity plots of the proteins of the invention. These plots or similar analyses can be used to identify hydrophilic regions.
- An immunogen typically is used to prepare antibodies by immunizing a suitable (i.e., immunocompetent) subject such as a rabbit, goat, mouse, or other mammal or vertebrate. An appropriate immunogenic preparation can contain, for example, recombinantly-expressed or chemically-synthesized polypeptide. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or a similar immunostimulatory agent.
- Accordingly, another aspect of the invention pertains to antibodies directed against a polypeptide of the invention. The terms “antibody” and “antibody substance” as used interchangeably herein refer to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site which specifically binds an antigen, such as a polypeptide of the invention (e.g., an epitope of a polypeptide of the invention). A molecule which specifically binds to a given polypeptide of the invention is a molecule which binds the polypeptide, but does not substantially bind other molecules in a sample, e.g., a biological sample, which naturally contains the polypeptide. Examples of immunologically active portions of immunoglobulin molecules include F(ab) and F(ab′)2 fragments which can be generated by treating the antibody with an enzyme such as pepsin. The invention provides polyclonal and monoclonal antibodies. The term “monoclonal antibody” or “monoclonal antibody composition”, as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope.
- Polyclonal antibodies can be prepared as described above by immunizing a suitable subject with a polypeptide of the invention as an immunogen. Preferred polyclonal antibody compositions are ones that have been selected for antibodies directed against (i.e., which bind specifically with) one or more polypeptides of the invention. Particularly preferred polyclonal antibody preparations are ones that contain only antibodies directed against one or more polypeptides of the invention. Particularly preferred immunogen compositions are those that contain no other human proteins such as, for example, immunogen compositions made using a non-human host cell for recombinant expression of a polypeptide of the invention. In such a manner, the only human epitope or epitopes recognized by the resulting antibody compositions raised against this immunogen will be present as part of a polypeptide or polypeptides of the invention.
- The antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized polypeptide. If desired, the antibody molecules can be harvested or isolated from the subject (e.g., from the blood or serum of the subject) and further purified by well-known techniques, such as protein A chromatography to obtain the IgG fraction. Alternatively, antibodies which bind specifically with a protein or polypeptide of the invention can be selected or purified (e.g., partially purified) using chromatographic methods, such as affinity chromatography. For example, a recombinantly expressed and purified (or partially purified) protein of the invention can be produced as described herein, and covalently or non-covalently coupled with a solid support such as, for example, a chromatography column. The column thus exhibits specific affinity for antibody substances which bind specifically with the protein of the invention, and these antibody substances can be purified from a sample containing antibody substances directed against a large number of different epitopes, thereby generating a substantially purified antibody substance composition, i.e., one that is substantially free of antibody substances which do not bind specifically with the protein. A substantially purified antibody composition, in this context, means an antibody sample that contains at most only 30% (by dry weight) of contaminating antibodies directed against epitopes other than those on the desired protein or polypeptide of the invention, preferably at most 20%, more preferably at most 10%, most preferably at most 5% (by dry weight of the sample is contaminating antibodies). A purified antibody composition means that at least 99% of the antibodies in the composition are directed against the desired protein or polypeptide of the invention.
- At an appropriate time after immunization, e.g., when the specific antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein (1975) Nature 256:495-497, the human B cell hybridoma technique (Kozbor et al. (1983) Immunol. Today 4:72), the EBV-hybridoma technique (Cole et al. (1985), Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96) or trioma techniques. The technology for producing hybridomas is well known (see generally Current Protocols in Immunology (1994) Coligan et al. (eds.) John Wiley & Sons, Inc., New York, N.Y.). Hybridoma cells producing a monoclonal antibody of the invention are detected by screening the hybridoma culture supernatants for antibodies that bind the polypeptide of interest, e.g., using a standard ELISA assay.
- Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal antibody directed against a polypeptide of the invention can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage display library) with the polypeptide of interest. Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia Recombinant Phage Antibody System, Catalog No. 27-9400-01; and the Stratagene SURFZAP™ Phage Display Kit, Catalog No. 240612). Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, U.S. Pat. No. 5,223,409; PCT Publication No. WO 92/18619; PCT Publication No. WO 91/17271; PCT Publication No. WO 92/20791; PCT Publication No. WO 92/15679; PCT Publication No. WO 93/01288; PCT Publication No. WO 92/01047; PCT Publication No. WO 92/09690; PCT Publication No. WO 90/02809; Fuchs et al. (1991) Bio/Technology 9:1370-1372; Hay et al. (1992) Hum. Antibod. Hybridomas 3:81-85; Huse et al. (1989) Science 246:1275-1281; Griffiths et al. (1993) EMBO J. 12:725-734.
- Additionally, recombinant antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. A chimeric antibody is a molecule in which different portions of the antibody amino acid sequence are derived from different animal species, such as those having a variable region derived from a murine monoclonal antibody and a constant region derived from a human immunoglobulin. (See, e.g., Cabilly et al., U.S. Pat. No. 4,816,567; and Boss et al., U.S. Pat. No. 4,816,397). Humanized antibodies are antibody molecules which are obtained from non-human species, which have one or more complementarity-determining regions (CDRs) derived from the non-human species, and which have a framework region derived from a human immunoglobulin molecule. (See, e.g., Queen, U.S. Pat. No. 5,585,089). Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in PCT Publication No. WO 87/02671; European Patent Application 184,187; European Patent Application 171,496; European Patent Application 173,494; PCT Publication No. WO 86/01533; U.S. Pat. No. 4,816,567; European Patent Application 125,023; Better et al. (1988) Science 240:1041-1043; Liu et al. (1987) Proc. Natl. Acad. Sci. USA 84:3439-3443; Liu et al. (1987) J. Immunol. 139:3521-3526; Sun et al. (1987) Proc. Natl. Acad. Sci. USA 84:214-218; Nishimura et al. (1987) Canc. Res. 47:999-1005; Wood et al. (1985) Nature 314:446-449; and Shaw et al. (1988) J. Natl. Cancer Inst. 80:1553-1559); Morrison (1985) Science 229:1202-1207; Oi et al. (1986) Bio/Techniques 4:214; U.S. Pat. No. 5,225,539; Jones et al. (1986) Nature 321:552-525; Verhoeyan et al. (1988) Science 239:1534; and Beidler et al. (1988) J. Immunol. 141:4053-4060.
- Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Such antibodies can be produced, for example, using transgenic mice which are incapable of expressing endogenous immunoglobulin heavy and light chains genes, but which can express human heavy and light chain genes The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide of the invention. Monoclonal antibodies directed against the antigen can be obtained using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA and IgE antibodies. For an overview of this technology for producing human antibodies, see Lonberg and Huszar (1995, Int. Rev. Immunol. 13:65-93). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., U.S. Pat. Nos. 5,625,126; 5,633,425; 5,569,825; 5,661,016; and 5,545,806. In addition, companies such as Abgenix, Inc. (Freemont, Calif.), can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.
- Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as “guided selection.” In this approach a selected non-human monoclonal antibody, e.g., a murine antibody, is used to guide the selection of a completely human antibody recognizing the same epitope (Jespers et al. (1994) Bio/technology 12:899-903).
- An antibody directed against a polypeptide of the invention (e.g., monoclonal antibody) can be used to isolate the polypeptide by standard techniques, such as affinity chromatography or immunoprecipitation. Moreover, such an antibody can be used to detect the protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the polypeptide. The antibodies can also be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include125I, 131I, 35S or 3H.
- Further, an antibody substance can be conjugated with a therapeutic moiety such as a cytotoxin, a therapeutic agent, or a radioactive metal ion. Cytotoxins and cytotoxic agents include any agent that is detrimental to cells. Examples include taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, and analogs or homologs of these compounds. Therapeutic agents include, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil, and decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine {BSNU}, lomustine {CCNU}, cyclothosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin {formerly daunomycin} and doxorubicin), antibiotics (e.g., dactinomycin {formerly actinomycin}, bleomycin, mithramycin, and anthramycin {AMC}), and anti-mitotic agents (e.g., vincristine and vinblastine).
- The conjugates of the invention can be used to modify a biological response; the drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety can be a protein or polypeptide which exhibits a desired biological activity. Such proteins include, for example, toxins such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; proteins such as tumor necrosis factor, alpha-interferon, beta-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator; and biological response modifiers such as lymphokines, interleukin-1 (IL-1), interleukin-2 (IL-2), interleukin-6 (IL-6), granulocyte macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), and other growth factors.
- Techniques for conjugating a therapeutic moiety with an antibody substance are well known (see, e.g., Arnon et al., “Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy”, in Monoclonal Antibodies and Cancer Therapy, Reisfeld et al., eds., pp. 243-256, Alan R. Liss, Inc., 1985; Hellstrom et al., “Antibodies For Drug Delivery”, in Controlled Drug Delivery, 2nd Ed., Robinson et al., eds., pp. 623-653, Marcel Dekker, Inc., 1987; Thorpe, “Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review”, in Monoclonal Antibodies '84: Biological and Clinical Applications, Pinchera et al., eds., pp. 475-506, 1985; “Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy”, in Monoclonal Antibodies for Cancer Detection and Therapy, Baldwin et al., eds., pp. 303-316, Academic Press, 1985; and Thorpe et al., “The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates”, Immunol. Rev. 62:119-58, 1982). Alternatively, an antibody can be conjugated with a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Pat. No. 4,676,980.
- Accordingly, in one aspect, the invention provides substantially purified antibodies or fragment thereof, and non-human antibodies or fragments thereof, which antibodies or fragments specifically bind with a polypeptide having an amino acid sequence which comprises a sequence selected from the group consisting of:
- (i) SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74;
- (ii) the amino acid sequence encoded by a cDNA of a clone deposited as one of ATCC® 207219, 207184, 207228, 207185, 207220, and 207221;
- (iii) at least 15 amino acid residues of the amino acid sequence of any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74;
- (iv) an amino acid sequence which is at least 95% identical to the amino acid sequence of any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74, wherein the percent identity is determined using the ALIGN program of the GCG software package with a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4; and
- (v) an amino acid sequence which is encoded by a nucleic acid molecule which hybridizes with a nucleic acid having a sequence selected from the group consisting of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73 under conditions of hybridization of 6× SSC (standard saline citrate) at 45° C. and washing in 0.2× SSC, 0.1% SDS at 65° C.
- In another aspect, the invention provides non-human antibodies or fragments thereof, which antibodies or fragments specifically bind with a polypeptide having an amino acid sequence which comprises a sequence selected from the group consisting of:
- (i) SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74;
- (ii) the amino acid sequence encoded by a cDNA of a clone deposited as one of ATCC® 207219, 207184, 207228, 207185, 207220, and 207221;
- (iii) at least 15 amino acid residues of the amino acid sequence of any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74;
- (iv) an amino acid sequence which is at least 95% identical to the amino acid sequence of any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74, wherein the percent identity is determined using the ALIGN program of the GCG software package with a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4; and
- (v) an amino acid sequence which is encoded by a nucleic acid molecule which hybridizes with a nucleic acid having a sequence selected from the group consisting of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73 under conditions of hybridization of 6× SSC (standard saline citrate) at 45° C. and washing in 0.2× SSC, 0.1% SDS at 65° C. Such non-human antibodies can be goat, mouse, sheep, horse, chicken, rabbit, or rat antibodies. Alternatively, the non-human antibodies of the invention can be chimeric and/or humanized antibodies. In addition, the non-human antibodies of the invention can be polyclonal antibodies or monoclonal antibodies.
- In still a further aspect, the invention provides monoclonal antibodies or fragments thereof, which antibodies or fragments specifically bind with a polypeptide having an amino acid sequence which comprises a sequence selected from the group consisting of:
- (i) SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74;
- (ii) the amino acid sequence encoded by a cDNA of a clone deposited as one of ATCC® 207219, 207184, 207228, 207185, 207220, and 207221;
- (iii) at least 15 amino acid residues of the amino acid sequence of any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74;
- (iv) an amino acid sequence which is at least 95% identical to the amino acid sequence of any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74, wherein the percent identity is determined using the ALIGN program of the GCG software package with a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4; and
- (v) an amino acid sequence which is encoded by a nucleic acid molecule which hybridizes with a nucleic acid having a sequence selected from the group consisting of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73 under conditions of hybridization of 6× SSC (standard saline citrate) at 45° C. and washing in 0.2× SSC, 0.1% SDS at 65° C. The monoclonal antibodies can be human, humanized, chimeric and/or non-human antibodies.
- The substantially purified antibodies or fragments thereof can specifically bind with a signal peptide, a secreted sequence, an extracellular domain, a transmembrane or a cytoplasmic domain cytoplasmic membrane of a polypeptide of the invention. In a particularly preferred embodiment, the substantially purified antibodies or fragments thereof, the non-human antibodies or fragments thereof and/or the monoclonal antibodies or fragments thereof, of the invention specifically bind with a secreted sequence or with an extracellular domain of one of
TANGO 202, TANGO 234, TANGO 265,TANGO 273,TANGO 286,TANGO 294, andINTERCEPT 296. Preferably, the extracellular domain with which the antibody substance binds has an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 6, 14, 22, 30, 37, 49, 50, and 56-58. - Any of the antibody substances of the invention can be conjugated with a therapeutic moiety or to a detectable substance. Non-limiting examples of detectable substances that can be conjugated with the antibody substances of the invention include an enzyme, a prosthetic group, a fluorescent material (i.e., a fluorophore), a luminescent material, a bioluminescent material, and a radioactive material (e.g., a radionuclide or a substituent comprising a radionuclide).
- The invention also provides a kit containing an antibody substance of the invention conjugated with a detectable substance, and instructions for use. Still another aspect of the invention is a pharmaceutical composition comprising an antibody substance of the invention and a pharmaceutically acceptable carrier. In preferred embodiments, the pharmaceutical composition contains an antibody substance of the invention, a therapeutic moiety (preferably conjugated with the antibody substance), and a pharmaceutically acceptable carrier.
- Still another aspect of the invention is a method of making an antibody that specifically recognizes one of
TANGO 202, TANGO 234, TANGO 265,TANGO 273,TANGO 286,TANGO 294, andINTERCEPT 296. This method comprises immunizing a vertebrate (e.g., a mammal such as a rabbit, goat, or pig) with a polypeptide. The polypeptide used as an immunogen has an amino acid sequence that comprises a sequence selected from the group consisting of: - (i) SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74;
- (ii) the amino acid sequence encoded by a cDNA of a clone deposited as one of ATCC® 207219, 207184, 207228, 207185, 207220, and 207221;
- (iii) at least 15 amino acid residues of the amino acid sequence of any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74;
- (iv) an amino acid sequence which is at least 95% identical to the amino acid sequence of any of SEQ ID NOs: 3-8, 11-16, 19-24, 27-32, 35-44, 47-52, 55-66, 69, and 74, wherein the percent identity is determined using the ALIGN program of the GCG software package with a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4; and
- (v) an amino acid sequence which is encoded by a nucleic acid molecule which hybridizes with a nucleic acid having a sequence selected from the group consisting of SEQ ID NOs: 1, 2, 9, 10, 17, 18, 25, 26, 33, 34, 45, 46, 53, 54, 67, 68, 72, and 73 under conditions of hybridization of 6× SSC (standard saline citrate) at 45° C. and washing in 0.2× SSC, 0.1% SDS at 65° C.
- After immunization, a sample is collected from the vertebrate that contains an antibody that specifically recognizes the polypeptide with which the vertebrate was immunized. Preferably, the polypeptide is recombinantly produced using a non-human host cell. Optionally, an antibody substance can be further purified from the sample using techniques well known to those of skill in the art. The method can further comprise making a monoclonal antibody-producing cell from a cell of the vertebrate. Optionally, antibodies can be collected from the antibody-producing cell.
- Recombinant Expression Vectors and Host Cells
- Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding a polypeptide of the invention (or a portion thereof). As used herein, the term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a “plasmid”, which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors, expression vectors, are capable of directing the expression of genes to which they are operably linked. In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids (vectors). However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.
- The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell. This means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operably linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, “operably linked” is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell). The term “regulatory sequence” is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, and the like. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein.
- The recombinant expression vectors of the invention can be designed for expression of a polypeptide of the invention in prokaryotic (e.g.,E. coli) or eukaryotic cells (e.g., insect cells (using baculovirus expression vectors), yeast cells or mammalian cells). Suitable host cells are discussed further in Goeddel, supra. Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.
- Expression of proteins in prokaryotes is most often carried out inE. coli with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson (1988) Gene 67:31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Phannacia, Piscataway, N.J.) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.
- Examples of suitable inducible non-fusionE. coli expression vectors include pTrc (Amann et al., (1988) Gene 69:301-315) and
pET 1 Id (Studier et al., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990) 60-89). Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pET 11d vector relies on transcription from a T7 gn10-lac fusion promoter mediated by a co-expressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident lambda prophage harboring a T7 gn1 gene under the transcriptional control of thelacUV 5 promoter. - One strategy to maximize recombinant protein expression inE. coli is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990) 119-128). Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in E. coli (Wada et al. (1992) Nucleic Acids Res. 20:2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.
- In another embodiment, the expression vector is a yeast expression vector. Examples of vectors for expression in yeastS. cerevisiae include pYepSec1 (Baldari et al. (1987) EMBO J. 6:229-234), pMFa (Kurjan and Herskowitz, (1982) Cell 30:933-943), pJRY88 (Schultz et al. (1987) Gene 54:113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and pPicZ (Invitrogen Corp, San Diego, Calif.).
- Alternatively, the expression vector is a baculovirus expression vector. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith et al. (1983) Mol. Cell Biol. 3:2156-2165) and the pVL series (Lucklow and Summers (1989) Virology 170:31-39).
- In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed (1987) Nature 329:840) and pMT2PC (Kaufman et al. (1987) EMBO J. 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and
Simian Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook et al., supra. - In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert et al. (1987) Genes Dev. 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) Adv. Immunol. 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) EMBO J. 8:729-733) and immunoglobulins (Banerji et al. (1983) Cell 33:729-740; Queen and Baltimore (1983) Cell 33:741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle (1989) Proc. Natl. Acad. Sci. USA 86:5473-5477), pancreas-specific promoters (Edlund et al. (1985) Science 230:912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, for example the murine hox promoters (Kessel and Gruss (1990) Science 249:374-379) and the α-fetoprotein promoter (Campes and Tilghman (1989) Genes Dev. 3:537-546).
- The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operably linked to a regulatory sequence in a manner which allows for expression (by transcription of the DNA molecule) of an RNA molecule which is antisense to the mRNA encoding a polypeptide of the invention. Regulatory sequences operably linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid, or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see Weintraub et al. (Reviews—Trends in Genetics, Vol. 1(1) 1986).
- Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms “host cell” and “recombinant host cell” are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.
- A host cell can be any prokaryotic (e.g.,E. coli) or eukaryotic cell (e.g., insect cells, yeast or mammalian cells).
- Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms “transformation” and “transfection” are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (supra), and other laboratory manuals.
- For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., for resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).
- In another embodiment, the expression characteristics of an endogenous nucleic acid within a cell, cell line, or microorganism (e.g., a
TANGO 202, TANGO 234, TANGO 265,TANGO 273,TANGO 286,TANGO 294, or INTERCEPT 296 nucleic acid, as described herein) can be modified by inserting a heterologous DNA regulatory element (i.e., one that is heterologous with respect to the endogenous gene) into the genome of the cell, stable cell line, or cloned microorganism. The inserted regulatory element can be operatively linked with the endogenous gene (e.g.,TANGO 202, TANGO 234, TANGO 265,TANGO 273,TANGO 286,TANGO 294, or INTERCEPT 296) and thereby control, modulate, or activate the endogenous gene. For example, anendogenous TANGO 202, TANGO 234, TANGO 265,TANGO 273,TANGO 286,TANGO 294, or INTERCEPT 296 gene which is normally “transcriptionally silent” (i.e., aTANGO 202, TANGO 234, TANGO 265,TANGO 273,TANGO 286,TANGO 294, or INTERCEPT 296 gene which is normally not expressed, or is normally expressed only at only a very low level) can be activated by inserting a regulatory element which is capable of promoting expression of the gene in the cell, cell line, or microorganism. Alternatively, a transcriptionally silent,endogenous TANGO 202, TANGO 234, TANGO 265,TANGO 273,TANGO 286,TANGO 294, or INTERCEPT 296 gene can be activated by inserting a promiscuous regulatory element that works across cell types. - A heterologous regulatory element can be inserted into a stable cell line or cloned microorganism such that it is operatively linked with and activates expression of an
endogenous TANGO 202, TANGO 234, TANGO 265,TANGO 273,TANGO 286,TANGO 294, or INTERCEPT 296 gene, using techniques, such as targeted homologous recombination, which are well known to those of skill in the art (described e.g., in Chappel, U.S. Pat. No. 5,272,071; PCT publication No. WO 91/06667, published May 16, 1991). - A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce a polypeptide of the invention. Accordingly, the invention further provides methods for producing a polypeptide of the invention using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding a polypeptide of the invention has been introduced) in a suitable medium such that the polypeptide is produced. In another embodiment, the method further comprises isolating the polypeptide from the medium or the host cell.
- The host cells of the invention can also be used to produce non-human transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which a sequences encoding a polypeptide of the invention have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous sequences encoding a polypeptide of the invention have been introduced into their genome or homologous recombinant animals in which endogenous encoding a polypeptide of the invention sequences have been altered. Such animals are useful for studying the function and/or activity of the polypeptide and for identifying and/or evaluating modulators of polypeptide activity. As used herein, a “transgenic animal” is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, an “homologous recombinant animal” is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.
- A transgenic animal of the invention can be created by introducing nucleic acid encoding a polypeptide of the invention (or a homologue thereof) into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably linked to the transgene to direct expression of the polypeptide of the invention to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Pat. Nos. 4,736,866 and 4,870,009, U.S. Pat. No. 4,873,191, in Hogan, Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986, and in Wakayama et al., 1999, Proc. Natl. Acad. Sci. USA 96:14984-14989. Similar methods can be used to produce other transgenic animals. A transgenic founder animal can be identified based upon the presence of the transgene in its genome and/or expression of mRNA encoding the transgene in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying the transgene can further be bred to other transgenic animals carrying other transgenes.
- To create a homologous recombinant animal, a vector is prepared which contains at least a portion of a gene encoding a polypeptide of the invention into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the gene. In a preferred embodiment, the vector is designed such that, upon homologous recombination, the endogenous gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a “knock out” vector). Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous protein). In the homologous recombination vector, the altered portion of the gene is flanked at its 5′ and 3′ ends by additional nucleic acid of the gene to allow for homologous recombination to occur between the exogenous gene carried by the vector and an endogenous gene in an embryonic stem cell. The additional flanking nucleic acid sequences are of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5′ and 3′ ends) are included in the vector (see, e.g., Thomas and Capecchi (1987) Cell 51:503 for a description of homologous recombination vectors). The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced gene has homologously recombined with the endogenous gene are selected (see, e.g., Li et al. (1992) Cell 69:915). The selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras (see, e.g., Bradley in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, Robertson, ed. (IRL, Oxford, 1987) pp. 113-152). A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley (1991) Current Opinion in Bio/Technology 2:823-829 and in PCT Publication Nos. WO 90/11354, WO 91/01140, WO 92/0968, and WO 93/04169.
- In another embodiment, transgenic non-human animals can be produced which contain selected systems which allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, see, e.g., Lakso et al. (1992) Proc. Natl. Acad. Sci. USA 89:6232-6236. Another example of a recombinase system is the FLP recombinase system ofSaccharomyces cerevisiae (O'Gorman et al. (1991) Science 251:1351-1355. If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of “double” transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.
- Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut et al. (1997) Nature 385:810-813 and PCT Publication Nos. WO 97/07668 and WO 97/07669.
- Pharmaceutical Compositions
- The nucleic acid molecules, polypeptides, and antibodies (also referred to herein as “active compounds”) of the invention can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein the language “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
- The invention includes methods for preparing pharmaceutical compositions for modulating the expression or activity of a polypeptide or nucleic acid of the invention. Such methods comprise formulating a pharmaceutically acceptable carrier with an agent which modulates expression or activity of a polypeptide or nucleic acid of the invention. Such compositions can further include additional active agents. Thus, the invention further includes methods for preparing a pharmaceutical composition by formulating a pharmaceutically acceptable carrier with an agent which modulates expression or activity of a polypeptide or nucleic acid of the invention and one or more additional active compounds.
- The agent which modulates expression or activity can, for example, be a small molecule other than a nucleic acid, polypeptide, or antibody of the invention. For example, such small molecules include peptides, peptidomimetics, amino acids, amino acid analogs, polynucleotides, polynucleotide analogs, nucleotides, nucleotide analogs, organic or inorganic compounds (i.e., including heteroorganic and organometallic compounds) having a molecular weight less than about 10,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 5,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 1,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 500 grams per mole, and salts, esters, and other pharmaceutically acceptable forms of such compounds.
- It is understood that appropriate doses of small molecule agents and protein or polypeptide agents depends upon a number of factors within the ken of the ordinarily skilled physician, veterinarian, or researcher. The dose(s) of these agents will vary, for example, depending upon the identity, size, and condition of the subject or sample being treated, further depending upon the route by which the composition is to be administered, if applicable, and the effect which the practitioner desires the agent to have upon the nucleic acid or polypeptide of the invention. Exemplary doses of a small molecule include milligram or microgram amounts per kilogram of subject or sample weight (e.g., about 1 microgram per kilogram to about 500 milligrams per kilogram, about 100 micrograms per kilogram to about 5 milligrams per kilogram, or about 1 microgram per kilogram to about 50 micrograms per kilogram). Exemplary doses of a protein or polypeptide include gram, milligram or microgram amounts per kilogram of subject or sample weight (e.g., about 1 microgram per kilogram to about 5 grams per kilogram, about 100 micrograms per kilogram to about 500 milligrams per kilogram, or about 1 milligram per kilogram to about 50 milligrams per kilogram). It is furthermore understood that appropriate doses of one of these agents depend upon the potency of the agent with respect to the expression or activity to be modulated. Such appropriate doses can be determined using the assays described herein. When one or more of these agents is to be administered to an animal (e.g., a human) in order to modulate expression or activity of a polypeptide or nucleic acid of the invention, a physician, veterinarian, or researcher can, for example, prescribe a relatively low dose at first, subsequently increasing the dose until an appropriate response is obtained. In addition, it is understood that the specific dose level for any particular animal subject will depend upon a variety of factors including the activity of the specific agent employed, the age, body weight, general health, gender, and diet of the subject, the time of administration, the route of administration, the rate of excretion, any drug combination, and the degree of expression or activity to be modulated.
- A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediamine-tetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose vials made of glass or plastic.
- Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL (BASF; Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a polypeptide or antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium, and then incorporating the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed.
- Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches, and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
- For administration by inhalation, the compounds are delivered in the form of an aerosol spray from a pressurized container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
- Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
- The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
- In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes which can be targeted to bind with virus-infected cells using a monoclonal antibody which binds specifically with a viral antigen) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.
- It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.
- For antibodies, the preferred dosage is 0.1 mg/kg to 100 mg/kg of body weight (generally 10 mg/kg to 20 mg/kg). If the antibody is to act in the brain, a dosage of 50 mg/kg to 100 mg/kg is usually appropriate. Generally, partially human antibodies and fully human antibodies have a longer half-life within the human body than other antibodies. Accordingly, lower dosages and less frequent administration is often possible. Modifications such as lipidation can be used to stabilize antibodies and to enhance uptake and tissue penetration (e.g., into the brain). A method for lipidation of antibodies is described by Cruikshank et al. ((1997) J. Acquired Immune Deficiency Syndromes and Human Retrovirology 14:193).
- The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (U.S. Pat. No. 5,328,470), or by stereotactic injection (see, e.g., Chen et al. (1994) Proc. Natl. Acad. Sci. USA 91:3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g. retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.
- The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.
- Uses and Methods of the Invention
- The nucleic acid molecules, proteins, protein homologs, and antibodies described herein can be used in one or more of the following methods: a) screening assays; b) detection assays (e.g., chromosomal mapping, tissue typing, forensic biology); c) predictive medicine (e.g., diagnostic assays, prognostic assays, monitoring clinical trials, and pharmacogenomics); and d) methods of treatment (e.g., therapeutic and prophylactic). For example, polypeptides of the invention can to used for all of the purposes identified herein in portions of the disclosure relating to individual types of protein of the invention (e.g.,
TANGO 202 proteins, TANGO 234 proteins, TANGO 265 proteins,TANGO 273 proteins,TANGO 286 proteins,TANGO 294 proteins, and INTERCEPT 296 proteins). Polypeptides of the invention can also be used to modulate cellular proliferation, cellular differentiation, cellular adhesion, or some combination of these. The isolated nucleic acid molecules of the invention can be used to express proteins (e.g., via a recombinant expression vector in a host cell in gene therapy applications), to detect mRNA (e.g., in a biological sample) or a genetic lesion, and to modulate activity of a polypeptide of the invention. In addition, the polypeptides of the invention can be used to screen drugs or compounds which modulate activity or expression of a polypeptide of the invention as well as to treat disorders characterized by insufficient or excessive production of a protein of the invention or production of a form of a protein of the invention which has decreased or aberrant activity compared to the wild type protein. In addition, the antibodies of the invention can be used to detect and isolate a protein of the and modulate activity of a protein of the invention. - This invention further pertains to novel agents identified by the above-described screening assays and uses thereof for treatments as described herein.
- Screening Assays
- The invention provides a method (also referred to herein as a “screening assay”) for identifying modulators, i.e., candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules or other drugs) which bind to polypeptide of the invention or have a stimulatory or inhibitory effect on, for example, expression or activity of a polypeptide of the invention.
- In one embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of the membrane-bound form of a polypeptide of the invention or biologically active portion thereof. The test compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the “one-bead one-compound” library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam (1997) Anticancer Drug Des. 12:145).
- Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt et al. (1993) Proc. Natl. Acad. Sci. USA 90:6909; Erb et al. (1994) Proc. Natl. Acad. Sci. USA 91:11422; Zuckermann et al. (1994). J. Med. Chem. 37:2678; Cho et al. (1993) Science 261:1303; Carrell et al. (1994) Angew. Chem. Int. Ed. Engl. 33:2059; Carell et al. (1994) Angew. Chem. Int. Ed. Engl. 33:2061; and Gallop et al. (1994) J. Med. Chem. 37:1233.
- Libraries of compounds can be presented in solution (e.g., Houghten (1992) Bio/Techniques 13:412-421), or on beads (Lam (1991) Nature 354:82-84), chips (Fodor (1993) Nature 364:555-556), bacteria (U.S. Pat. No. 5,223,409), spores (U.S. Pat. Nos. 5,571,698; 5,403,484; and 5,223,409), plasmids (Cull et al. (1992) Proc. Natl. Acad. Sci. USA 89:1865-1869) or phage (Scott and Smith (1990) Science 249:386-390; Devlin (1990) Science 249:404-406; Cwirla et al. (1990) Proc. Natl. Acad. Sci. USA 87:6378-6382; and Felici (1991) J. Mol. Biol. 222:301-310).
- In one embodiment, an assay is a cell-based assay in which a cell which expresses a membrane-bound form of a polypeptide of the invention, or a biologically active portion thereof, on the cell surface is contacted with a test compound and the ability of the test compound to bind to the polypeptide determined. The cell, for example, can be a yeast cell or a cell of mammalian origin. Determining the ability of the test compound to bind to the polypeptide can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that binding of the test compound to the polypeptide or biologically active portion thereof can be determined by detecting the labeled compound in a complex. For example, test compounds can be labeled with125I, 35S, 14C, or 3H, either directly or indirectly, and the radioisotope detected by direct counting of radio-emission or by scintillation counting. Alternatively, test compounds can be enzymatically labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product. In a preferred embodiment, the assay comprises contacting a cell which expresses a membrane-bound form of a polypeptide of the invention, or a biologically active portion thereof, on the cell surface with a known compound which binds the polypeptide to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with the polypeptide, wherein determining the ability of the test compound to interact with the polypeptide comprises determining the ability of the test compound to preferentially bind to the polypeptide or a biologically active portion thereof as compared to the known compound.
- In another embodiment, the assay involves assessment of an activity characteristic of the polypeptide, wherein binding of the test compound with the polypeptide or a biologically active portion thereof alters (i.e., increases or decreases) the activity of the polypeptide.
- In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of a polypeptide of the invention, or a biologically active portion thereof, on the cell surface with a test compound and determining the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the polypeptide or biologically active portion thereof. Determining the ability of the test compound to modulate the activity of the polypeptide or a biologically active portion thereof can be accomplished, for example, by determining the ability of the polypeptide to bind to or interact with a target molecule or to transport molecules across the cytoplasmic membrane.
- Determining the ability of a polypeptide of the invention to bind to or interact with a target molecule can be accomplished by one of the methods described above for determining direct binding. As used herein, a “target molecule” is a molecule with which a selected polypeptide (e.g., a polypeptide of the invention binds or interacts with in nature, for example, a molecule on the surface of a cell which expresses the selected protein, a molecule on the surface of a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule. A target molecule can be a polypeptide of the invention or some other polypeptide or protein. For example, a target molecule can be a component of a signal transduction pathway which facilitates transduction of an extracellular signal (e.g., a signal generated by binding of a compound to a polypeptide of the invention) through the cell membrane and into the cell or a second intercellular protein which has catalytic activity or a protein which facilitates the association of downstream signaling molecules with a polypeptide of the invention. Determining the ability of a polypeptide of the invention to bind to or interact with a target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (e.g., an mRNA, intracellular Ca2+, diacylglycerol, IP3, and the like), detecting catalytic/enzymatic activity of the target on an appropriate substrate, detecting the induction of a reporter gene (e.g., a regulatory element that is responsive to a polypeptide of the invention operably linked to a nucleic acid encoding a detectable marker, e.g. luciferase), or detecting a cellular response, for example, cellular differentiation, or cell proliferation.
- In yet another embodiment, an assay of the present invention is a cell-free assay comprising contacting a polypeptide of the invention or biologically active portion thereof with a test compound and determining the ability of the test compound to bind to the polypeptide or biologically active portion thereof. Binding of the test compound to the polypeptide can be determined either directly or indirectly as described above. In a preferred embodiment, the assay includes contacting the polypeptide of the invention or biologically active portion thereof with a known compound which binds the polypeptide to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with the polypeptide, wherein determining the ability of the test compound to interact with the polypeptide comprises determining the ability of the test compound to preferentially bind to the polypeptide or biologically active portion thereof as compared to the known compound.
- In another embodiment, an assay is a cell-free assay comprising contacting a polypeptide of the invention or biologically active portion thereof with a test compound and determining the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the polypeptide or biologically active portion thereof. Determining the ability of the test compound to modulate the activity of the polypeptide can be accomplished, for example, by determining the ability of the polypeptide to bind to a target molecule by one of the methods described above for determining direct binding. In an alternative embodiment, determining the ability of the test compound to modulate the activity of the polypeptide can be accomplished by determining the ability of the polypeptide of the invention to further modulate the target molecule For example, the catalytic activity, the enzymatic activity, or both, of the target molecule on an appropriate substrate can be determined as previously described.
- In yet another embodiment, the cell-free assay comprises contacting a polypeptide of the invention or biologically active portion thereof with a known compound which binds the polypeptide to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with the polypeptide, wherein determining the ability of the test compound to interact with the polypeptide comprises determining the ability of the polypeptide to preferentially bind to or modulate the activity of a target molecule.
- The cell-free assays of the present invention are amenable to use of both a soluble form or the membrane-bound form of a polypeptide of the invention. In the case of cell-free assays comprising the membrane-bound form of the polypeptide, it can be desirable to utilize a solubilizing agent such that the membrane-bound form of the polypeptide is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-octylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton X-100, Triton X-114, Thesit, Isotridecypoly(ethylene glycol ether)n, 3-[(3-cholamidopropyl)dimethylamminio]-1-propane sulfonate (CHAPS), 3-[(3-cholamidopropyl)dimethylamminio]-2-hydroxy-1-propane sulfonate (CHAP S O), or N-dodecyl-N,N-dimethyl-3-ammonio-1-propane sulfonate.
- In one or more embodiments of the above assay methods of the present invention, it can be desirable to immobilize either the polypeptide of the invention or its target molecule to facilitate separation of complexed from non-complexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to the polypeptide, or interaction of the polypeptide with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided which adds a domain that allows one or both of the proteins to be bound to a matrix. For example, glutathione-S-transferase fusion proteins or glutathione-S-transferase fusion proteins can be adsorbed onto glutathione SEPHAROSE™ beads (Sigma Chemical; St. Louis, Mo.) or glutathione derivatized microtiter plates, which are then combined with the test compound or the test compound and either the non-adsorbed target protein or A polypeptide of the invention, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components and complex formation is measured either directly or indirectly, for example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of binding or activity of the polypeptide of the invention can be determined using standard techniques.
- Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either the polypeptide of the invention or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated polypeptide of the invention or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well known in the art (e.g., biotinylation kit, Pierce Chemicals; Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with the polypeptide of the invention or target molecules but which do not interfere with binding of the polypeptide of the invention to its target molecule can be derivatized to the wells of the plate, and unbound target or polypeptide of the invention trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the polypeptide of the invention or target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the polypeptide of the invention or target molecule.
- In another embodiment, modulators of expression of a polypeptide of the invention are identified in a method in which a cell is contacted with a candidate compound and the expression of the selected mRNA or protein (i.e., the mRNA or protein corresponding to a polypeptide or nucleic acid of the invention) in the cell is determined. The level of expression of the selected mRNA or protein in the presence of the candidate compound is compared to the level of expression of the selected mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of expression of the polypeptide of the invention based on this comparison. For example, when expression of the selected mRNA or protein is greater (i.e., statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of the selected mRNA or protein expression. Alternatively, when expression of the selected mRNA or protein is less (i.e., statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of the selected mRNA or protein expression. The level of the selected mRNA or protein expression in the cells can be determined by methods described herein.
- In yet another aspect of the invention, a polypeptide of the inventions can be used as “bait proteins” in a two-hybrid assay or three hybrid assay (see, e.g., U.S. Pat. No. 5,283,317; Zervos et al. (1993) Cell 72:223-232; Madura et al. (1993) J. Biol. Chem. 268:12046-12054; Bartel et al. (1993) Bio/Techniques 14:920-924; Iwabuchi et al. (1993) Oncogene 8:1693-1696; and PCT Publication No. WO 94/10300), to identify other proteins, which bind to or interact with the polypeptide of the invention and modulate activity of the polypeptide of the invention. Such binding proteins are also likely to be involved in the propagation of signals by the polypeptide of the inventions as, for example, upstream or downstream elements of a signaling pathway involving the polypeptide of the invention.
- This invention further pertains to novel agents identified by the above-described screening assays and uses thereof for treatments as described herein.
- Detection Assays
- Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. For example, these sequences can be used to: (i) map their respective genes on a chromosome and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. These applications are described in the subsections below.
- Chromosome Mapping
- Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. Accordingly, nucleic acid molecules described herein or fragments thereof, can be used to map the location of the corresponding genes on a chromosome. The mapping of the sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.
- Briefly, genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 base pairs in length) from the sequence of a gene of the invention. Computer analysis of the sequence of a gene of the invention can be used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the gene sequences will yield an amplified fragment. For a review of this technique, see D'Eustachio et al. ((1983) Science 220:919-924).
- PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the nucleic acid sequences of the invention to design oligonucleotide primers, sub-localization can be achieved with panels of fragments from specific chromosomes. Other mapping strategies which can similarly be used to map a gene to its chromosome include in situ hybridization (described in Fan et al. (1990) Proc. Natl. Acad. Sci. USA 87:6223-27), pre-screening with labeled flow-sorted chromosomes, and pre-selection by hybridization to chromosome specific cDNA libraries. Fluorescence in situ hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one step. For a review of this technique, see Verma et al. (Human Chromosomes: A Manual of Basic Techniques (Pergamon Press, New York, 1988)).
- Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to non-coding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.
- Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. (Such data are found, for example, in V. McKusick, Mendelian Inheritance in Man, available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, e.g., Egeland et al. (1987) Nature 325:783-787.
- Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with a gene of the invention can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.
- Furthermore, the nucleic acid sequences disclosed herein can be used to perform searches against “mapping databases”, e.g., BLAST-type search, such that the chromosome position of the gene is identified by sequence homology or identity with known sequence fragments which have been mapped to chromosomes.
- In the instant case, the human gene for TANGO 265 is located on
chromosome 1 between markers D1 S305 and D1S2635, and the human gene forTANGO 273 is located on chromosome 7 between markers D7S2467 and D7S2552. - In the instant case, the human gene for
TANGO 286 exhibits significant amino acid homology with a region of the human chromosome region 22q12-13 genomic nucleotide sequence having GenBank Accession number AL021937. Alignment of a 45 kilobase nucleotidesequence encoding TANGO 286 with AL021937, however, indicated the presence inTANGO 286 of exons which differ from those disclosed in L021937 (pam120.mat scoring matrix; gap penalties −12/−4). This region ofchromosome 22 comprises an immunoglobulin lambda chain C (IGLC) pseudogene, the Ret finger protein-like 3 (RFPL3) and Ret finger protein-like 3 antisense (RFPL3S) genes, a gene encoding a novel immunoglobulin lambda chain V family protein, a novel gene encoding a protein similar both to mouse RGDS protein (RALGDS, RALGEF, guanine nucleotide dissociation stimulator A) and to rabbit oncogene RSC, a novel gene encoding the human orthologue of worm F16A11.2 protein, a novel gene encoding a protein similar both to BPI and to rabbit liposaccharide-binding protein, and a 5′-portion of a novel gene. This region also comprises various ESTs, STSs, GSSs, genomic marker D22S1175, a ca repeat polymorphism and putative CpG islands. - A polypeptide and fragments and sequences thereof and antibodies which bind specifically with such polypeptides/fragments can be used to map the location of the gene encoding the polypeptide on a chromosome. This mapping can be performed by specifically detecting the presence of the polypeptide/fragments in members of a panel of somatic cell hybrids between cells obtained from a first species of animal from which the protein originates and cells obtained from a second species of animal, determining which somatic cell hybrid(s) expresses the polypeptide, and noting the chromosome(s) of the first species of animal that it contains. For examples of this technique (see Pajunen et al., 1988, Cytogenet. Cell Genet. 47:37-41 and Van Keuren et al., 1986, Hum. Genet. 74:34-40). Alternatively, the presence of the polypeptide in the somatic cell hybrids can be determined by assaying an activity or property of the polypeptide (e.g., enzymatic activity, as described in Bordelon-Riser et al., 1979, Som. Cell Genet. 5:597-613 and Owerbach et al., 1978, Proc. Natl. Acad. Sci. USA 75:5640-5644).
- In the instant case, the human gene for TANGO 234 protein indicated that the gene is located at chromosomal location h12p13. Flanking chromosomal markers include WI-6980 and GATA8A09.43. Nearby human loci include IBD2 (inflammatory bowel disease 2), FPF (familial periodic fever), and HPDR2 (hypophosphatemia vitamin D resistant rickets 2). Nearby genes are KLRC (killer cell receptor cluster), DRPLA (dentatorubro-pallidoluysian atrophy), GAPD (glyceraldehyde-3-phosphate) dehydrogenase, and PXR1 peroxisome receptor 1). This region is syntenic to mouse chromosome mo6. Murine chromosomal mapping indicated that the murine orthologue is located near the scr (scruffy) locus. Nearby mouse genes include drpla (dentatorubral phillidoluysian atrophy), prp (proline rich protein), and kap (kidney androgen regulated protein).
- Tissue Typing
- The nucleic acid sequences of the present invention can also be used to identify individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification. This method does not suffer from the current limitations of “Dog Tags” which can be lost, switched, or stolen, making positive identification difficult. The sequences of the present invention are useful as additional DNA markers for RFLP (described in U.S. Pat. No. 5,272,057).
- Furthermore, the sequences of the present invention can be used to provide an alternative technique which determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the nucleic acid sequences described herein can be used to prepare two PCR primers from the 5′ and 3′ ends of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.
- Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the present invention can be used to obtain such identification sequences from individuals and from tissue. The nucleic acid sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the non-coding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the non-coding regions, fewer sequences are necessary to differentiate individuals. The non-coding sequences of any of SEQ ID NOs: 1, 9, 17, 25, 33, 45, and 53 can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers which each yield a non-coding amplified sequence of 100 bases. If predicted coding sequences, such as those in any of SEQ ID NOs: 2, 10, 18, 26, 34, 46, and 54 are used, a more appropriate number of primers for positive individual identification would be 500-2,000.
- If a panel of reagents from the nucleic acid sequences described herein is used to generate a unique identification database for an individual, those same reagents can later be used to identify tissue from that individual. Using the unique identification database, positive identification of the individual, living or dead, can be made from extremely small tissue samples.
- Use of Partial Gene Sequences in Forensic Biology
- DNA-based identification techniques can also be used in forensic biology. Forensic biology is a scientific field employing genetic typing of biological evidence found at a crime scene as a means for positively identifying, for example, a perpetrator of a crime. To make such an identification, PCR technology can be used to amplify DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, or semen found at a crime scene. The amplified sequence can then be compared to a standard, thereby allowing identification of the origin of the biological sample.
- The sequences of the present invention can be used to provide polynucleotide reagents, e.g., PCR primers, targeted to specific loci in the human genome, which can enhance the reliability of DNA-based forensic identifications by, for example, providing another “identification marker” (i.e., another DNA sequence that is unique to a particular individual). As mentioned above, actual base sequence information can be used for identification as an accurate alternative to patterns formed by restriction enzyme generated fragments. Sequences targeted to non-coding regions are particularly appropriate for this use as greater numbers of polymorphisms occur in the non-coding regions, making it easier to differentiate individuals using this technique. Examples of polynucleotide reagents include the nucleic acid sequences of the invention or portions thereof, e.g., fragments derived from non-coding regions having a length of at least 20 or 30 bases.
- The nucleic acid sequences described herein can further be used to provide polynucleotide reagents, e.g., labeled or labelable probes which can be used in, for example, an in situ hybridization technique, to identify a specific tissue, e.g., brain tissue. This can be very useful in cases where a forensic pathologist is presented with a tissue of unknown origin. Panels of such probes can be used to identify tissue by species and/or by organ type.
- Predictive Medicine
- The present invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the present invention relates to diagnostic assays for determining expression of a polypeptide or nucleic acid of the invention and/or activity of a polypeptide of the invention (e.g., expression or activity of one of
TANGO 202, TANGO 234, TANGO 265,TANGO 273,TANGO 286,TANGO 294, or INTERCEPT 296 genes or proteins), in the context of a biological sample (e.g., blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant expression or activity of a polypeptide of the invention. The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with aberrant expression or activity of a polypeptide of the invention. For example, mutations in a gene of the invention can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with aberrant expression or activity of a polypeptide of the invention. - As an alternative to making determinations based on the absolute expression level of a selected gene, determinations can be based on normalized expression levels of the gene. A gene expression level is normalized by correcting the absolute expression level of the gene (e.g., a
TANGO 202, TANGO 234, TANGO 265,TANGO 273,TANGO 286,TANGO 294, or INTERCEPT 296 gene as described herein) by comparing its expression to expression of a gene for which expression is not believed to be co-regulated with the gene of interest, e.g., a housekeeping gene that is constitutively expressed. Suitable genes for normalization include housekeeping genes such as the actin gene. Such normalization allows comparison of the expression level in one sample, e.g., a patient sample, with the expression level in another sample, e.g., a sample obtained from a patient known not to be afflicted with a disease or condition, or between samples obtained from different sources. - Alternatively, the expression level can be assessed as a relative expression level. To assess a relative expression level for a gene (e.g., a
TANGO 202, TANGO 234, TANGO 265,TANGO 273,TANGO 286,TANGO 294, or INTERCEPT 296 gene, as described herein), the level of expression of the gene is determined for 10 or more samples (preferably 50 or more samples) of different isolates of cells in which the gene is believed to be expressed, prior to assessing the level of expression of the gene in the sample of interest. The mean expression level of the gene detected in the large number of samples is determined, and this value is used as a baseline expression level for the gene. The expression level of the gene assessed in the test sample (i.e., its absolute level of expression) is divided by the mean expression value to yield a relative expression level. Such a method can identify tissues or individuals which are afflicted with a disorder associated with aberrant expression of a gene of the invention. - Preferably, the samples used in the baseline determination are generated either using cells obtained from a tissue or individual known to be afflicted with a disorder (e.g., a disorder associated with aberrant expression of one of the
TANGO 202, TANGO 234, TANGO 265,TANGO 273,TANGO 286,TANGO 294, or INTERCEPT 296 genes) or using cells obtained from a tissue or individual known not to be afflicted with the disorder. Alternatively, levels of expression of these genes in tissues or individuals known to be or not to be afflicted with the disorder can be used to assess whether the aberrant expression of the gene is associated with the disorder (e.g., with onset of the disorder, or as a symptom of the disorder over time). - Another aspect of the invention pertains to monitoring the influence of agents (e.g., drugs or other compounds) on the expression or activity of one or more of
TANGO 202, TANGO 234, TANGO 265,TANGO 273,TANGO 286,TANGO 294, andINTERCEPT 296 in clinical trials. These and other agents are described in further detail in the following sections. - Diagnostic Assays
- An exemplary method for detecting the presence or absence of a polypeptide or nucleic acid of the invention in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting a polypeptide or nucleic acid (e.g., mRNA, genomic DNA) of the invention such that the presence of a polypeptide or nucleic acid of the invention is detected in the biological sample. A preferred agent for detecting mRNA or genomic DNA encoding a polypeptide of the invention is a labeled nucleic acid probe capable of hybridizing to mRNA or genomic DNA encoding a polypeptide of the invention. The nucleic acid probe can be, for example, a full-length cDNA, such as the nucleic acid of any of SEQ ID NOs: 1, 9, 17, 25, 33, 45, 53, 67, and 72, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to a mRNA or genomic DNA encoding a polypeptide of the invention. Other suitable probes for use in the diagnostic assays of the invention are described herein.
- A preferred agent for detecting a polypeptide of the invention is an antibody capable of binding to a polypeptide of the invention, preferably an antibody with a detectable label Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab′)2) can be used. The term “labeled”, with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin. The term “biological sample” is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of a polypeptide of the invention include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. In vitro techniques for detection of genomic DNA include Southern hybridizations. Furthermore, in vivo techniques for detection of a polypeptide of the invention include introducing into a subject a labeled antibody directed against the polypeptide. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.
- In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.
- In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting a polypeptide of the invention or mRNA or genomic DNA encoding a polypeptide of the invention, such that the presence of the polypeptide or mRNA or genomic DNA encoding the polypeptide is detected in the biological sample, and comparing the presence of the polypeptide or mRNA or genomic DNA encoding the polypeptide in the control sample with the presence of the polypeptide or mRNA or genomic DNA encoding the polypeptide in the test sample.
- The invention also encompasses kits for detecting the presence of a polypeptide or nucleic acid of the invention in a biological sample (a test sample). Such kits can be used to determine if a subject is suffering from or is at increased risk of developing a disorder associated with aberrant expression of a polypeptide of the invention (e.g., one of the disorders described in the section of this disclosure wherein the individual polypeptide of the invention is discussed). For example, the kit can comprise a labeled compound or agent capable of detecting the polypeptide or mRNA encoding the polypeptide in a biological sample and means for determining the amount of the polypeptide or mRNA in the sample (e.g., an antibody which binds the polypeptide or an oligonucleotide probe which binds to DNA or mRNA encoding the polypeptide). Kits can also include instructions for observing that the tested subject is suffering from or is at risk of developing a disorder associated with aberrant expression of the polypeptide if the amount of the polypeptide or mRNA encoding the polypeptide is above or below a normal level.
- For antibody-based kits, the kit can comprise, for example: (1) a first antibody (e.g., attached to a solid support) which binds to a polypeptide of the invention; and, optionally, (2) a second, different antibody which binds to either the polypeptide or the first antibody and is conjugated to a detectable agent.
- For oligonucleotide-based kits, the kit can comprise, for example: (1) an oligonucleotide, e.g., a detectably labeled oligonucleotide, which hybridizes to a nucleic acid sequence encoding a polypeptide of the invention or (2) a pair of primers useful for amplifying a nucleic acid molecule encoding a polypeptide of the invention. The kit can also comprise, e.g., a buffering agent, a preservative, or a protein stabilizing agent. The kit can also comprise components necessary for detecting the detectable agent (e.g., an enzyme or a substrate). The kit can also contain a control sample or a series of control samples which can be assayed and compared to the test sample contained. Each component of the kit is usually enclosed within an individual container and all of the various containers are within a single package along with instructions for observing whether the tested subject is suffering from or is at risk of developing a disorder associated with aberrant expression of the polypeptide.
- Prognostic Assays
- The methods described herein can furthermore be utilized as diagnostic or prognostic assays to identify subjects having or at risk of developing a disease or disorder associated with aberrant expression or activity of a polypeptide of the invention. For example, the assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with aberrant expression or activity of a polypeptide of the invention (e.g., one of the disorders described in the section of this disclosure wherein the individual polypeptide of the invention is discussed). Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing such a disease or disorder. Thus, the present invention provides a method in which a test sample is obtained from a subject and a polypeptide or nucleic acid (e.g., mRNA, genomic DNA) of the invention is detected, wherein the presence of the polypeptide or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant expression or activity of the polypeptide. As used herein, a “test sample” refers to a biological sample obtained from a subject of interest. For example, a test sample can be a biological fluid (e.g., serum), cell sample, or tissue.
- Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant expression or activity of a polypeptide of the invention. For example, such methods can be used to determine whether a subject can be effectively treated with a specific agent or class of agents (e.g., agents of a type which decrease activity of the polypeptide). Thus, the present invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant expression or activity of a polypeptide of the invention in which a test sample is obtained and the polypeptide or nucleic acid encoding the polypeptide is detected (e.g., wherein the presence of the polypeptide or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant expression or activity of the polypeptide).
- The methods of the invention can also be used to detect genetic lesions or mutations in a gene of the invention, thereby determining if a subject with the lesioned gene is at risk for a disorder characterized aberrant expression or activity of a polypeptide of the invention. In preferred embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion or mutation characterized by at least one of an alteration affecting the integrity of a gene encoding the polypeptide of the invention, or the mis-expression of the gene encoding the polypeptide of the invention. For example, such genetic lesions or mutations can be detected by ascertaining the existence of at least one of: 1) a deletion of one or more nucleotides from the gene; 2) an addition of one or more nucleotides to the gene; 3) a substitution of one or more nucleotides of the gene; 4) a chromosomal rearrangement of the gene; 5) an alteration in the level of a messenger RNA transcript of the gene; 6) an aberrant modification of the gene, such as of the methylation pattern of the genomic DNA; 7) the presence of a non-wild type splicing pattern of a messenger RNA transcript of the gene; 8) a non-wild type level of the protein encoded by the gene; 9) an allelic loss of the gene; and 10) an inappropriate post-translational modification of the protein encoded by the gene. As described herein, there are a large number of assay techniques known in the art which can be used for detecting lesions in a gene.
- In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g., U.S. Pat. Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran et al. (1988) Science 241:1077-1080; and Nakazawa et al. (1994) Proc. Natl. Acad. Sci. USA 91:360-364), the latter of which can be particularly useful for detecting point mutations in a gene (see, e.g., Abravaya et al. (1995) Nucleic Acids Res. 23:675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to the selected gene under conditions such that hybridization and amplification of the gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. PCR and/or LCR can be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.
- Alternative amplification methods include: self-sustained sequence replication (Guatelli et al. (1990) Proc. Natl. Acad. Sci. USA 87:1874-1878), transcriptional amplification system (Kwoh, et al. (1989) Proc. Natl. Acad. Sci. USA 86:1173-1177), Q-Beta Replicase (Lizardi et al. (1988) Bio/Technology 6:1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.
- In an alternative embodiment, mutations in a selected gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, (optionally) amplified, digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (see, e.g., U.S. Pat. No. 5,498,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.
- In other embodiments, genetic mutations can be identified by hybridizing a sample and control nucleic acids, e.g., DNA or RNA, to high density arrays containing hundreds or thousands of oligonucleotides probes (Cronin et al. (1996) Human Mutation 7:244-255; Kozal et al. (1996) Nature Medicine 2:753-759). For example, genetic mutations can be identified in two-dimensional arrays containing light-generated DNA probes as described in Cronin et al., supra. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This step is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.
- In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the selected gene and detect mutations by comparing the sequence of the sample nucleic acids with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert ((1977) Proc. Natl. Acad. Sci. USA 74:560) or Sanger ((1977) Proc. Natl. Acad. Sci. USA 74:5463). It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays ((1995) Bio/Techniques 19:448), including sequencing by mass spectrometry (see, e.g., PCT Publication No. WO 94/16101; Cohen et al. (1996) Adv. Chromatogr. 36:127-162; and Griffin et al. (1993) Appl. Biochem. Biotechnol. 38:147-159).
- Other methods for detecting mutations in a selected gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes (Myers et al. (1985) Science 230:1242). In general, the technique of mismatch cleavage entails providing heteroduplexes formed by hybridizing (labeled) RNA or DNA containing the wild-type sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent which cleaves single-stranded regions of the duplex such as which will exist due to base pair mismatches between the control and sample strands. RNA/DNA duplexes can be treated with RNase to digest mismatched regions, and DNA/DNA hybrids can be treated with S1 nuclease to digest mismatched regions.
- In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. See, e.g., Cotton et al. (1988) Proc. Natl. Acad. Sci. USA 85:4397; Saleeba et al. (1992) Methods Enzymol. 217:286-295. In a preferred embodiment, the control DNA or RNA can be labeled for detection.
- In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called DNA mismatch repair enzymes) in defined systems for detecting and mapping point mutations in cDNAs obtained from samples of cells. For example, the mutY enzyme ofE. coli cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches (Hsu et al. (1994) Carcinogenesis 15:1657-1662). According to an exemplary embodiment, a probe based on a selected sequence, e.g., a wild-type sequence, is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, e.g., U.S. Pat. No. 5,459,039.
- In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in genes. For example, single strand conformation polymorphism (SSCP) can be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids (Orita et al. (1989) Proc. Natl. Acad. Sci. USA 86:2766; see also Cotton (1993) Mutat. Res. 285:125-144; Hayashi (1992) Genet. Anal. Tech. Appl. 9:73-79). Single-stranded DNA fragments of sample and control nucleic acids will be denatured and allowed to re-nature. The secondary structure of single-stranded nucleic acids varies according to sequence, and the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments can be labeled or detected with labeled probes. The sensitivity of the assay can be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In a preferred embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility (Keen et al. (1991) Trends Genet. 7:5).
- In yet another embodiment, the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE) (Myers et al. (1985) Nature 313:495). When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a ‘GC clamp’ of approximately 40 base pairs of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA (Rosenbaum and Reissner (1987) Biophys. Chem. 265:12753).
- Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers can be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions which permit hybridization only if a perfect match is found (Saiki et al. (1986) Nature 324:163); Saiki et al. (1989) Proc. Natl. Acad. Sci. USA 86:6230). Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.
- Alternatively, allele specific amplification technology which depends on selective PCR amplification can be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification can carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization; Gibbs et al. (1989) Nucleic Acids Res. 17:2437-2448) or at the extreme 3′ end of one primer where, under appropriate conditions, mismatching can prevent or reduce polymerase extension (Prossner (1993) Tibtech 11:238). In addition, it can be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection (Gasparini et al. (1992) Mol. Cell Probes 6:1). Amplification can also be performed using Taq ligase for amplification (Barany (1991) Proc. Natl. Acad. Sci. USA 88:189). In such cases, ligation will occur only if there is a perfect match at the 3′ end of the 5′ sequence making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.
- The methods described herein can be performed, for example, using pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which can be conveniently used, e.g., in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving a gene encoding a polypeptide of the invention. Furthermore, any cell type or tissue, preferably peripheral blood leukocytes, in which the polypeptide of the invention is expressed can be utilized in the prognostic assays described herein.
- Pharmacogenomics
- Agents, or modulators which have a stimulatory or inhibitory effect on activity or expression of a polypeptide of the invention as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) disorders associated with aberrant activity of the polypeptide. In conjunction with such treatment, the pharmacogenomics (i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) of the individual may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (e.g., drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of a polypeptide of the invention, expression of a nucleic acid of the invention, or mutation content of a gene of the invention in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.
- Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, e.g., Linder (1997) Clin. Chem. 43(2):254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body are referred to as “altered drug action.” Genetic conditions transmitted as single factors altering the way the body acts on drugs are referred to as “altered drug metabolism”. These pharmacogenetic conditions can occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzymopathy in which the main clinical complication is hemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.
- As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (e.g., N-acetyltransferase 2 (NAT 2) and cytochrome P450 enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, a PM will show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. The other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.
- Thus, the activity of a polypeptide of the invention, expression of a nucleic acid encoding the polypeptide, or mutation content of a gene encoding the polypeptide in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual. In addition, pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding drug-metabolizing enzymes to the identification of an individual's drug responsiveness phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with a modulator of activity or expression of the polypeptide, such as a modulator identified by one of the exemplary screening assays described herein.
- Monitoring of Effects During Clinical Trials
- Monitoring the influence of agents (e.g., drug compounds) on the expression or activity of a polypeptide of the invention (e.g., the ability to modulate aberrant cell proliferation chemotaxis, and/or differentiation) can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent, as determined by a screening assay as described herein, to increase gene expression, protein levels, or protein activity, can be monitored in clinical trials of subjects exhibiting decreased gene expression, protein levels, or protein activity. Alternatively, the effectiveness of an agent, as determined by a screening assay, to decrease gene expression, protein levels or protein activity, can be monitored in clinical trials of subjects exhibiting increased gene expression, protein levels, or protein activity. In such clinical trials, expression or activity of a polypeptide of the invention and preferably, that of other polypeptide that have been implicated in for example, a cellular proliferation disorder, can be used as a marker of the immune responsiveness of a particular cell.
- For example, and not by way of limitation, genes, including those of the invention, that are modulated in cells by treatment with an agent (e.g., compound, drug or small molecule) which modulates activity or expression of a polypeptide of the invention (e.g., as identified in a screening assay described herein) can be identified. Thus, to study the effect of agents on cellular proliferation disorders, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of a gene of the invention and other genes implicated in the disorder. The levels of gene expression (i.e., a gene expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of a gene of the invention or other genes. In this way, the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state can be determined before, and at various points during, treatment of the individual with the agent.
- In a preferred embodiment, the present invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of the polypeptide or nucleic acid of the invention in the pre-administration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level the of the polypeptide or nucleic acid of the invention in the post-administration samples; (v) comparing the level of the polypeptide or nucleic acid of the invention in the pre-administration sample with the level of the polypeptide or nucleic acid of the invention in the post-administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent can be desirable to increase the expression or activity of the polypeptide to higher levels than detected, i.e., to increase the effectiveness of the agent. Alternatively, decreased administration of the agent can be desirable to decrease expression or activity of the polypeptide to lower levels than detected, i.e., to decrease the effectiveness of the agent.
- Methods of Treatment
- The present invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant expression or activity of a polypeptide of the invention and/or in which the polypeptide of the invention is involved. Disorders characterized by aberrant expression or activity of the polypeptides of the invention are described elsewhere in this disclosure.
- Prophylactic Methods
- In one aspect, the invention provides a method for preventing in a subject, a disease or condition associated with an aberrant expression or activity of a polypeptide of the invention, by administering to the subject an agent which modulates expression or at least one activity of the polypeptide. Subjects at risk for a disease which is caused or contributed to by aberrant expression or activity of a polypeptide of the invention can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the aberrance, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending on the type of aberrance, for example, an agonist or antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein.
- Therapeutic Methods
- Another aspect of the invention pertains to methods of modulating expression or activity of a polypeptide of the invention for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of the polypeptide. An agent that modulates activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of the polypeptide, a peptide, a peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more of the biological activities of the polypeptide. Examples of such stimulatory agents include the active polypeptide of the invention and a nucleic acid molecule encoding the polypeptide of the invention that has been introduced into the cell. In another embodiment, the agent inhibits one or more of the biological activities of the polypeptide of the invention. Examples of such inhibitory agents include antisense nucleic acid molecules and antibodies. These modulatory methods can be performed in vitro (e.g., by culturing the cell with the agent) or, alternatively, in vivo (e.g., by administering the agent to a subject). As such, the present invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant expression or activity of a polypeptide of the invention. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., up-regulates or down-regulates) expression or activity. In another embodiment, the method involves administering a polypeptide of the invention or a nucleic acid molecule of the invention as therapy to compensate for reduced or aberrant expression or activity of the polypeptide.
- Stimulation of activity is desirable in situations in which activity or expression is abnormally low or down-regulated and/or in which increased activity is likely to have a beneficial effect. Conversely, inhibition of activity is desirable in situations in which activity or expression is abnormally high or up-regulated and/or in which decreased activity is likely to have a beneficial effect.
- The contents of all references, patents, and published patent applications cited throughout this application are hereby incorporated by reference.
- Deposit of Clones
- Each of these deposits was made merely as a convenience to those of skill in the art. These deposits are not an admission that a deposit is required under 35 U.S.C. §112.
- Clone EpT202, encoding
human TANGO 202 was deposited with the American Type Culture Collection (ATCC®, 10801 University Boulevard, Manassas, V. 20110-2209) on Apr. 21, 1999 and was assigned Accession Number 207219. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. Clone EpTm202, encodingmurine TANGO 202 was deposited with ATCC® on Apr. 21, 1999 and was assigned (composite) Accession Number 207221. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. - Clone EpT234, encoding human TANGO 234 was deposited with ATCC® on Apr. 2, 1999 and was assigned Accession Number 207184. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure.
- Clone EpT265, encoding human TANGO 265 was deposited with ATCC® on Apr. 28, 1999 and was assigned Accession Number 207228. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure.
- Clone EpT273, encoding
human TANGO 273 was deposited with ATCC® on Apr. 2, 1999 and was assigned Accession Number 207185. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. - Clone EpTm273, encoding
murine TANGO 273 was deposited with ATCC® on Apr. 2, 1999 and was assigned (composite) Accession Number 207221. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. - Clone EpT286, encoding
human TANGO 286 was deposited with ATCC® on Apr. 20, 1999 and was assigned (composite) Accession Number 207220. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. - Clone EpT294, encoding
human TANGO 294 was deposited with ATCC® on Apr. 20, 1999 and was assigned (composite) Accession Number 207220. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. - Clone EpT296, encoding
human INTERCEPT 296 was deposited with ATCC® on Apr. 20, 1999 and was assigned (composite) Accession Number 207220. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. - Clones containing cDNA molecules encoding
human TANGO 286,human TANGO 294, andINTERCEPT 296 were deposited with ATCC® on Apr. 21, 1999 as Accession Number 207220, as part of a composite deposit representing a mixture of five strains, each carrying one recombinant plasmid harboring a particular cDNA clone. - To distinguish the strains and isolate a strain harboring a particular cDNA clone, an aliquot of the mixture is streaked out to single colonies on nutrient medium (e.g., LB plates) supplemented with 100 mg/ml ampicillin, single colonies are grown, and then plasmid DNA is extracted using a standard mini-preparation procedure. Next, a sample of the DNA mini-preparation is digested with a combination of the restriction enzymes SalI, NotI, and DraII and the resulting products are resolved on a 0.8% agarose gel using standard DNA electrophoresis conditions. This digestion procedure liberates fragments as follows:
- 1. human TANGO 286 (clone EpT286): 1.85 kB and 0.1 kB (
human TANGO 286 has a DraII cut site at about base pair 1856). - 2. human TANGO 294 (clone EpT294): 1.4 kB and 0.6 kB (
human TANGO 294 has a DraII cut site at about base pair 1447). - 3. human INTERCEPT 296 (clone EpT296): 0.4 kB, 1.6 kB, and 0.1 kB (
human INTERCEPT 296 has DraII cut sites at aboutbase pair 410 and at about base pair 1933). The identity of the strains can be inferred from the fragments liberated. - Clones containing cDNA molecules encoding
mouse TANGO 202 andmouse TANGO 273 were deposited with ATCC® on Apr. 21, 1999 and were assigned Accession Number 207221, as part of a composite deposit representing a mixture of five strains, each carrying one recombinant plasmid harboring a particular cDNA clone. To distinguish the strains and isolate a strain harboring a particular cDNA clone, an aliquot of the mixture is streaked out to single colonies on nutrient medium (e.g., LB plates) supplemented with 100 mg/ml ampicillin, single colonies are grown, and then plasmid DNA is extracted using a standard mini-preparation procedure. Next, a sample of the DNA mini-preparation is digested with a combination of the restriction enzymes Sal I, Not I, and Apa I, and the resultant products are resolved on a 0.8% agarose gel using standard DNA electrophoresis conditions. This digestion procedure liberates fragments as follows: - 1. mouse TANGO 202 (clone EpTm202): 3.5 kB and 1.4 kB (
mouse TANGO 202 has a Apa I cut site at about base pair 3519). - 2. mouse TANGO 273 (clone EpTm273): 0.3 kB and 2.6 kB (
mouse TANGO 273 has a Apa I cut site at about base pair 298). - The identity of the strains can be inferred from the fragments liberated.
-
Human TANGO 202, human TANGO 234, human TANGO 265, andhuman TANGO 273 were each deposited as single deposits. Their clone names, deposit dates, and accession numbers are as follows: - 1. human TANGO 202: clone EpT202 was deposited with ATCC® on Apr. 21, 1999, and was assigned Accession Number 207219.
- 2. human TANGO 234: clone EpT234 was deposited with ATCC® on Apr. 2, 1999, and was assigned Accession Number 207184.
- 3. human TANGO 265: clone EpT265 was deposited with ATCC® on Apr. 28, 1999, and was assigned Accession Number 207228.
- 4. human TANGO 273: clone EpT273 was deposited with ATCC® on Apr. 2, 1999, and was assigned Accession Number 207185.
- All publications, patents, and patent applications referenced in this specification are incorporated by reference into the specification to the same extent as if each individual publication, patent, or patent application had been specifically and individually indicated to be incorporated herein by reference.
- Equivalents
- Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
-
1 79 1 1656 DNA Homo sapiens 1 gtcgacccac gcgtccgccc acgcgtccgg cccatggcgc cgcccgccgc ccgcctcgcc 60 ctgctctccg ccgcggcgct cacgctggcg gcccggcccg cgcctagccc cggcctcggc 120 cccggacccg agtgtttcac agccaatggt gcggattata ggggaacaca gaactggaca 180 gcactacaag gcgggaagcc atgtctgttt tggaacgaga ctttccagca tccatacaac 240 actctgaaat accccaacgg ggaggggggc ctgggtgagc acaactattg cagaaatcca 300 gatggagacg tgagcccctg gtgctatgtg gcagagcacg aggatggtgt ctactggaag 360 tactgtgaga tacctgcttg ccagatgcct ggaaaccttg gctgctacaa ggatcatgga 420 aacccacctc ctctaactgg caccagtaaa acgtccaaca aactcaccat acaaacttgc 480 atcagttttt gtcggagtca gaggttcaag tttgctggga tggagtcagg ctatgcttgc 540 ttctgtggaa acaatcctga ttactggaag tacggggagg cagccagtac cgaatgcaac 600 agcgtctgct tcggggatca cacccaaccc tgtggtggcg atggcaggat catcctcttt 660 gatactctcg tgggcgcctg cggtgggaac tactcagcca tgtcttctgt ggtctattcc 720 cctgacttcc ccgacaccta tgccacgggg agggtctgct actggaccat ccgggttccg 780 ggggcctccc acatccactt cagcttcccc ctatttgaca tcagggactc ggcggacatg 840 gtggagcttc tggatggcta cacccaccgt gtcctagccc gcttccacgg gaggagccgc 900 ccacctctgt ccttcaacgt ctctctggac ttcgtcatct tgtatttctt ctctgatcgc 960 atcaatcagg cccagggatt tgctgtttta taccaagccg tcaaggaaga actgccacag 1020 gagaggcccg ctgtcaacca gacggtggcc gaggtgatca cggagcaggc caacctcagt 1080 gtcagcgctg cccggtcctc caaagtcctc tatgtcatca ccaccagccc cagccaccca 1140 cctcagactg tcccaggtag caattcctgg gcgccaccca tgggggctgg aagccacaga 1200 gttgaaggat ggacagtcta tggtctggca actctcctca tcctcacagt cacagccatt 1260 gtagcaaaga tacttctgca cgtcacattc aaatcccatc gtgttcctgc ttcaggggac 1320 cttagggatt gtcatcaacc agggacttcg ggggaaatct ggagcatttt ttacaagcct 1380 tccacttcaa tttccatctt taagaagaaa ctcaagggtc agagtcaaca agatgaccgc 1440 aatccccttg tgagtgacta aaaaccccac tgtgcctagg acttgaggtc cctctttgag 1500 ctcaaggctg ccgtggtcaa cctctcctgt ggttcttctc tgacagactc ttccctcctc 1560 tccctctgcc tcggcctctt cggggaaacc ctcctcctac agactaggaa gaggcacctg 1620 ctgccagggc aggcagagcc tggattcctc ctgctt 1656 2 1425 DNA Homo sapiens 2 atggcgccgc ccgccgcccg cctcgccctg ctctccgccg cggcgctcac gctggcggcc 60 cggcccgcgc ctagccccgg cctcggcccc ggacccgagt gtttcacagc caatggtgcg 120 gattataggg gaacacagaa ctggacagca ctacaaggcg ggaagccatg tctgttttgg 180 aacgagactt tccagcatcc atacaacact ctgaaatacc ccaacgggga ggggggcctg 240 ggtgagcaca actattgcag aaatccagat ggagacgtga gcccctggtg ctatgtggca 300 gagcacgagg atggtgtcta ctggaagtac tgtgagatac ctgcttgcca gatgcctgga 360 aaccttggct gctacaagga tcatggaaac ccacctcctc taactggcac cagtaaaacg 420 tccaacaaac tcaccataca aacttgcatc agtttttgtc ggagtcagag gttcaagttt 480 gctgggatgg agtcaggcta tgcttgcttc tgtggaaaca atcctgatta ctggaagtac 540 ggggaggcag ccagtaccga atgcaacagc gtctgcttcg gggatcacac ccaaccctgt 600 ggtggcgatg gcaggatcat cctctttgat actctcgtgg gcgcctgcgg tgggaactac 660 tcagccatgt cttctgtggt ctattcccct gacttccccg acacctatgc cacggggagg 720 gtctgctact ggaccatccg ggttccgggg gcctcccaca tccacttcag cttcccccta 780 tttgacatca gggactcggc ggacatggtg gagcttctgg atggctacac ccaccgtgtc 840 ctagcccgct tccacgggag gagccgccca cctctgtcct tcaacgtctc tctggacttc 900 gtcatcttgt atttcttctc tgatcgcatc aatcaggccc agggatttgc tgttttatac 960 caagccgtca aggaagaact gccacaggag aggcccgctg tcaaccagac ggtggccgag 1020 gtgatcacgg agcaggccaa cctcagtgtc agcgctgccc ggtcctccaa agtcctctat 1080 gtcatcacca ccagccccag ccacccacct cagactgtcc caggtagcaa ttcctgggcg 1140 ccacccatgg gggctggaag ccacagagtt gaaggatgga cagtctatgg tctggcaact 1200 ctcctcatcc tcacagtcac agccattgta gcaaagatac ttctgcacgt cacattcaaa 1260 tcccatcgtg ttcctgcttc aggggacctt agggattgtc atcaaccagg gacttcgggg 1320 gaaatctgga gcatttttta caagccttcc acttcaattt ccatctttaa gaagaaactc 1380 aagggtcaga gtcaacaaga tgaccgcaat ccccttgtga gtgac 1425 3 475 PRT Homo sapiens 3 Met Ala Pro Pro Ala Ala Arg Leu Ala Leu Leu Ser Ala Ala Ala Leu 1 5 10 15 Thr Leu Ala Ala Arg Pro Ala Pro Ser Pro Gly Leu Gly Pro Gly Pro 20 25 30 Glu Cys Phe Thr Ala Asn Gly Ala Asp Tyr Arg Gly Thr Gln Asn Trp 35 40 45 Thr Ala Leu Gln Gly Gly Lys Pro Cys Leu Phe Trp Asn Glu Thr Phe 50 55 60 Gln His Pro Tyr Asn Thr Leu Lys Tyr Pro Asn Gly Glu Gly Gly Leu 65 70 75 80 Gly Glu His Asn Tyr Cys Arg Asn Pro Asp Gly Asp Val Ser Pro Trp 85 90 95 Cys Tyr Val Ala Glu His Glu Asp Gly Val Tyr Trp Lys Tyr Cys Glu 100 105 110 Ile Pro Ala Cys Gln Met Pro Gly Asn Leu Gly Cys Tyr Lys Asp His 115 120 125 Gly Asn Pro Pro Pro Leu Thr Gly Thr Ser Lys Thr Ser Asn Lys Leu 130 135 140 Thr Ile Gln Thr Cys Ile Ser Phe Cys Arg Ser Gln Arg Phe Lys Phe 145 150 155 160 Ala Gly Met Glu Ser Gly Tyr Ala Cys Phe Cys Gly Asn Asn Pro Asp 165 170 175 Tyr Trp Lys Tyr Gly Glu Ala Ala Ser Thr Glu Cys Asn Ser Val Cys 180 185 190 Phe Gly Asp His Thr Gln Pro Cys Gly Gly Asp Gly Arg Ile Ile Leu 195 200 205 Phe Asp Thr Leu Val Gly Ala Cys Gly Gly Asn Tyr Ser Ala Met Ser 210 215 220 Ser Val Val Tyr Ser Pro Asp Phe Pro Asp Thr Tyr Ala Thr Gly Arg 225 230 235 240 Val Cys Tyr Trp Thr Ile Arg Val Pro Gly Ala Ser His Ile His Phe 245 250 255 Ser Phe Pro Leu Phe Asp Ile Arg Asp Ser Ala Asp Met Val Glu Leu 260 265 270 Leu Asp Gly Tyr Thr His Arg Val Leu Ala Arg Phe His Gly Arg Ser 275 280 285 Arg Pro Pro Leu Ser Phe Asn Val Ser Leu Asp Phe Val Ile Leu Tyr 290 295 300 Phe Phe Ser Asp Arg Ile Asn Gln Ala Gln Gly Phe Ala Val Leu Tyr 305 310 315 320 Gln Ala Val Lys Glu Glu Leu Pro Gln Glu Arg Pro Ala Val Asn Gln 325 330 335 Thr Val Ala Glu Val Ile Thr Glu Gln Ala Asn Leu Ser Val Ser Ala 340 345 350 Ala Arg Ser Ser Lys Val Leu Tyr Val Ile Thr Thr Ser Pro Ser His 355 360 365 Pro Pro Gln Thr Val Pro Gly Ser Asn Ser Trp Ala Pro Pro Met Gly 370 375 380 Ala Gly Ser His Arg Val Glu Gly Trp Thr Val Tyr Gly Leu Ala Thr 385 390 395 400 Leu Leu Ile Leu Thr Val Thr Ala Ile Val Ala Lys Ile Leu Leu His 405 410 415 Val Thr Phe Lys Ser His Arg Val Pro Ala Ser Gly Asp Leu Arg Asp 420 425 430 Cys His Gln Pro Gly Thr Ser Gly Glu Ile Trp Ser Ile Phe Tyr Lys 435 440 445 Pro Ser Thr Ser Ile Ser Ile Phe Lys Lys Lys Leu Lys Gly Gln Ser 450 455 460 Gln Gln Asp Asp Arg Asn Pro Leu Val Ser Asp 465 470 475 4 19 PRT Homo sapiens 4 Met Ala Pro Pro Ala Ala Arg Leu Ala Leu Leu Ser Ala Ala Ala Leu 1 5 10 15 Thr Leu Ala 5 456 PRT Homo sapiens 5 Ala Arg Pro Ala Pro Ser Pro Gly Leu Gly Pro Gly Pro Glu Cys Phe 1 5 10 15 Thr Ala Asn Gly Ala Asp Tyr Arg Gly Thr Gln Asn Trp Thr Ala Leu 20 25 30 Gln Gly Gly Lys Pro Cys Leu Phe Trp Asn Glu Thr Phe Gln His Pro 35 40 45 Tyr Asn Thr Leu Lys Tyr Pro Asn Gly Glu Gly Gly Leu Gly Glu His 50 55 60 Asn Tyr Cys Arg Asn Pro Asp Gly Asp Val Ser Pro Trp Cys Tyr Val 65 70 75 80 Ala Glu His Glu Asp Gly Val Tyr Trp Lys Tyr Cys Glu Ile Pro Ala 85 90 95 Cys Gln Met Pro Gly Asn Leu Gly Cys Tyr Lys Asp His Gly Asn Pro 100 105 110 Pro Pro Leu Thr Gly Thr Ser Lys Thr Ser Asn Lys Leu Thr Ile Gln 115 120 125 Thr Cys Ile Ser Phe Cys Arg Ser Gln Arg Phe Lys Phe Ala Gly Met 130 135 140 Glu Ser Gly Tyr Ala Cys Phe Cys Gly Asn Asn Pro Asp Tyr Trp Lys 145 150 155 160 Tyr Gly Glu Ala Ala Ser Thr Glu Cys Asn Ser Val Cys Phe Gly Asp 165 170 175 His Thr Gln Pro Cys Gly Gly Asp Gly Arg Ile Ile Leu Phe Asp Thr 180 185 190 Leu Val Gly Ala Cys Gly Gly Asn Tyr Ser Ala Met Ser Ser Val Val 195 200 205 Tyr Ser Pro Asp Phe Pro Asp Thr Tyr Ala Thr Gly Arg Val Cys Tyr 210 215 220 Trp Thr Ile Arg Val Pro Gly Ala Ser His Ile His Phe Ser Phe Pro 225 230 235 240 Leu Phe Asp Ile Arg Asp Ser Ala Asp Met Val Glu Leu Leu Asp Gly 245 250 255 Tyr Thr His Arg Val Leu Ala Arg Phe His Gly Arg Ser Arg Pro Pro 260 265 270 Leu Ser Phe Asn Val Ser Leu Asp Phe Val Ile Leu Tyr Phe Phe Ser 275 280 285 Asp Arg Ile Asn Gln Ala Gln Gly Phe Ala Val Leu Tyr Gln Ala Val 290 295 300 Lys Glu Glu Leu Pro Gln Glu Arg Pro Ala Val Asn Gln Thr Val Ala 305 310 315 320 Glu Val Ile Thr Glu Gln Ala Asn Leu Ser Val Ser Ala Ala Arg Ser 325 330 335 Ser Lys Val Leu Tyr Val Ile Thr Thr Ser Pro Ser His Pro Pro Gln 340 345 350 Thr Val Pro Gly Ser Asn Ser Trp Ala Pro Pro Met Gly Ala Gly Ser 355 360 365 His Arg Val Glu Gly Trp Thr Val Tyr Gly Leu Ala Thr Leu Leu Ile 370 375 380 Leu Thr Val Thr Ala Ile Val Ala Lys Ile Leu Leu His Val Thr Phe 385 390 395 400 Lys Ser His Arg Val Pro Ala Ser Gly Asp Leu Arg Asp Cys His Gln 405 410 415 Pro Gly Thr Ser Gly Glu Ile Trp Ser Ile Phe Tyr Lys Pro Ser Thr 420 425 430 Ser Ile Ser Ile Phe Lys Lys Lys Leu Lys Gly Gln Ser Gln Gln Asp 435 440 445 Asp Arg Asn Pro Leu Val Ser Asp 450 455 6 373 PRT Homo sapiens 6 Ala Arg Pro Ala Pro Ser Pro Gly Leu Gly Pro Gly Pro Glu Cys Phe 1 5 10 15 Thr Ala Asn Gly Ala Asp Tyr Arg Gly Thr Gln Asn Trp Thr Ala Leu 20 25 30 Gln Gly Gly Lys Pro Cys Leu Phe Trp Asn Glu Thr Phe Gln His Pro 35 40 45 Tyr Asn Thr Leu Lys Tyr Pro Asn Gly Glu Gly Gly Leu Gly Glu His 50 55 60 Asn Tyr Cys Arg Asn Pro Asp Gly Asp Val Ser Pro Trp Cys Tyr Val 65 70 75 80 Ala Glu His Glu Asp Gly Val Tyr Trp Lys Tyr Cys Glu Ile Pro Ala 85 90 95 Cys Gln Met Pro Gly Asn Leu Gly Cys Tyr Lys Asp His Gly Asn Pro 100 105 110 Pro Pro Leu Thr Gly Thr Ser Lys Thr Ser Asn Lys Leu Thr Ile Gln 115 120 125 Thr Cys Ile Ser Phe Cys Arg Ser Gln Arg Phe Lys Phe Ala Gly Met 130 135 140 Glu Ser Gly Tyr Ala Cys Phe Cys Gly Asn Asn Pro Asp Tyr Trp Lys 145 150 155 160 Tyr Gly Glu Ala Ala Ser Thr Glu Cys Asn Ser Val Cys Phe Gly Asp 165 170 175 His Thr Gln Pro Cys Gly Gly Asp Gly Arg Ile Ile Leu Phe Asp Thr 180 185 190 Leu Val Gly Ala Cys Gly Gly Asn Tyr Ser Ala Met Ser Ser Val Val 195 200 205 Tyr Ser Pro Asp Phe Pro Asp Thr Tyr Ala Thr Gly Arg Val Cys Tyr 210 215 220 Trp Thr Ile Arg Val Pro Gly Ala Ser His Ile His Phe Ser Phe Pro 225 230 235 240 Leu Phe Asp Ile Arg Asp Ser Ala Asp Met Val Glu Leu Leu Asp Gly 245 250 255 Tyr Thr His Arg Val Leu Ala Arg Phe His Gly Arg Ser Arg Pro Pro 260 265 270 Leu Ser Phe Asn Val Ser Leu Asp Phe Val Ile Leu Tyr Phe Phe Ser 275 280 285 Asp Arg Ile Asn Gln Ala Gln Gly Phe Ala Val Leu Tyr Gln Ala Val 290 295 300 Lys Glu Glu Leu Pro Gln Glu Arg Pro Ala Val Asn Gln Thr Val Ala 305 310 315 320 Glu Val Ile Thr Glu Gln Ala Asn Leu Ser Val Ser Ala Ala Arg Ser 325 330 335 Ser Lys Val Leu Tyr Val Ile Thr Thr Ser Pro Ser His Pro Pro Gln 340 345 350 Thr Val Pro Gly Ser Asn Ser Trp Ala Pro Pro Met Gly Ala Gly Ser 355 360 365 His Arg Val Glu Gly 370 7 23 PRT Homo sapiens 7 Trp Thr Val Tyr Gly Leu Ala Thr Leu Leu Ile Leu Thr Val Thr Ala 1 5 10 15 Ile Val Ala Lys Ile Leu Leu 20 8 60 PRT Homo sapiens 8 His Val Thr Phe Lys Ser His Arg Val Pro Ala Ser Gly Asp Leu Arg 1 5 10 15 Asp Cys His Gln Pro Gly Thr Ser Gly Glu Ile Trp Ser Ile Phe Tyr 20 25 30 Lys Pro Ser Thr Ser Ile Ser Ile Phe Lys Lys Lys Leu Lys Gly Gln 35 40 45 Ser Gln Gln Asp Asp Arg Asn Pro Leu Val Ser Asp 50 55 60 9 4628 DNA Homo sapiens 9 gcggccgctc gcgatctaga actagtaatg atgctgcctc aaaactcgtg gcatattgat 60 tttggaagat gctgctgtca tcagaacctt ttctctgctg tggtaacttg catcctgctc 120 ctgaattcct gctttctcat cagcagtttt aatggaacag atttggagtt gaggctggtc 180 aatggagacg gtccctgctc tgggacagtg gaggtgaaat tccagggaca gtgggggact 240 gtgtgtgatg atgggtggaa cactactgcc tcaactgtcg tgtgcaaaca gcttggatgt 300 ccattttctt tcgccatgtt tcgttttgga caagccgtga ctagacatgg aaaaatttgg 360 cttgatgatg tttcctgtta tggaaatgag tcagctctct gggaatgtca acaccgggaa 420 tggggaagcc ataactgtta tcatggagaa gatgttggtg tgaactgtta tggtgaagcc 480 aatctgggtt tgaggctagt ggatggaaac aactcctgtt cagggagagt ggaggtgaaa 540 ttccaagaaa ggtgggggac tatatgtgat gatgggtgga acttgaatac tgctgccgtg 600 gtgtgcaggc aactaggatg tccatcttct tttatttctt ctggagttgt taatagccct 660 gctgtattgc gccccatttg gctggatgac attttatgcc aggggaatga gttggcactc 720 tggaattgca gacatcgtgg atggggaaat catgactgca gtcacaatga ggatgtcaca 780 ttaacttgtt atgatagtag tgatcttgaa ctaaggcttg taggtggaac taaccgctgt 840 atggggagag tagagctgaa aatccaagga aggtggggga ccgtatgcca ccataagtgg 900 aacaatgctg cagctgatgt cgtatgcaag cagttgggat gtggaaccgc acttcacttc 960 gctggcttgc ctcatttgca gtcagggtct gatgttgtat ggcttgatgg tgtctcctgc 1020 tccggtaatg aatcttttct ttgggactgc agacattccg gaaccgtcaa ttttgactgt 1080 cttcatcaaa acgatgtgtc tgtgatctgc tcagatggag cagatttgga actgcgacta 1140 gcagatggaa gtaacaattg ttcagggaga gtagaggtga gaattcatga acagtggtgg 1200 acaatatgtg accagaactg gaagaatgaa caagcccttg tggtttgtaa gcagctagga 1260 tgtccgttca gcgtctttgg cagtcgtcgt gctaaaccta gtaatgaagc tagagacatt 1320 tggataaaca gcatatcttg cactgggaat gagtcagctc tctgggactg cacatatgat 1380 ggaaaagcaa agcgaacatg cttccgaaga tcagatgctg gagtaatttg ttctgataag 1440 gcagatctgg acctaaggct tgtcggggct catagcccct gttatgggag attggaggtg 1500 aaataccaag gagagtgggg gactgtgtgt catgacagat ggagcacaag gaatgcagct 1560 gttgtgtgta aacaattggg atgtggaaag cctatgcatg tgtttggtat gacctatttt 1620 aaagaagcat caggacctat ttggctggat gacgtttctt gcattggaaa tgagtcaaat 1680 atctgggact gtgaacacag tggatgggga aagcataatt gtgtacacag agaggatgtg 1740 attgtaacct gctcaggtga tgcaacatgg ggcctgaggc tggtgggcgg cagcaaccgc 1800 tgctcgggaa gactggaggt gtactttcaa ggacggtggg gcacagtgtg tgatgacggc 1860 tggaacagta aagctgcagc tgtggtgtgt agccagctgg actgcccatc ttctatcatt 1920 ggcatgggtc tgggaaacgc ttctacagga tatggaaaaa tttggctcga tgatgtttcc 1980 tgtgatggag atgagtcaga tctctggtca tgcaggaaca gtgggtgggg aaataatgac 2040 tgcagtcaca gtgaagatgt tggagtgatc tgttctgatg catcggatat ggagctgagg 2100 cttgtgggtg gaagcagcag gtgtgctgga aaagttgagg tgaatgtcca gggtgccgtg 2160 ggaattctgt gtgctaatgg ctggggaatg aacattgctg aagttgtttg caggcaactt 2220 gaatgtgggt ctgcaatcag ggtctccaga gagcctcatt tcacagaaag aacattacac 2280 atcttaatgt cgaattctgg ctgcactgga ggggaagcct ctctctggga ttgtatacga 2340 tgggagtgga aacagactgc gtgtcattta aatatggaag caagtttgat ctgctcagcc 2400 cacaggcagc ccaggctggt tggagctgat atgccctgct ctggacgtgt tgaagtgaaa 2460 catgcagaca catggcgctc tgtctgtgat tctgatttct ctcttcatgc tgccaatgtg 2520 ctgtgcagag aattaaattg tggagatgcc atatctcttt ctgtgggaga tcactttgga 2580 aaagggaatg gtctaacttg ggccgaaaag ttccagtgtg aagggagtga aactcacctt 2640 gcattatgcc ccattgttca acatccggaa gacacttgta tccacagcag agaagttgga 2700 gttgtctgtt cccgatatac agatgtccga cttgtgaatg gcaaatccca gtgtgacggg 2760 caagtggaga tcaacgtgct tggacactgg ggctcactgt gtgacaccca ctgggaccca 2820 gaagatgccc gtgttctatg cagacagctc agctgtggga ctgctctctc aaccacagga 2880 ggaaaatata ttggagaaag aagtgttcgt gtgtggggac acaggtttca ttgcttaggg 2940 aatgagtcac ttctggataa ctgtcaaatg acagttcttg gagcacctcc ctgtatccat 3000 ggaaatactg tctctgtgat ctgcacagga agcctgaccc agccactgtt tccatgcctc 3060 gcaaatgtat ctgacccata tttgtctgca gttccagagg gcagtgcttt gatctgctta 3120 gaggacaaac ggctccgcct agtggatggg gacagccgct gtgccgggag agtagagatc 3180 tatcacgacg gcttctgggg caccatctgt gatgacggct gggacctgag cgatgcccac 3240 gtggtgtgtc aaaagctggg ctgtggagtg gccttcaatg ccacggtctc tgctcacttt 3300 ggggaggggt cagggcccat ctggctggat gacctgaact gcacaggaac ggagtcccac 3360 ttgtggcagt gcccttcccg cggctggggg cagcacgact gcaggcacaa ggaggacgca 3420 ggggtcatct gctcagaatt cacagccttg aggctctaca gtgaaactga aacagagagc 3480 tgtgctggga gattggaagt cttctataac gggacctggg gcagcgtcgg caggaggaac 3540 atcaccacag ccatagcagg cattgtgtgc aggcagctgg gctgtgggga gaatggagtt 3600 gtcagcctcg cccctttatc taagacaggc tctggtttca tgtgggtgga tgacattcag 3660 tgtcctaaaa cgcatatctc catatggcag tgcctgtctg ccccatggga gcgaagaatc 3720 tccagcccag cagaagagac ctggatcaca tgtgaagata gaataagagt gcgtggagga 3780 gacaccgagt gctctgggag agtggagatc tggcacgcag gctcctgggg cacagtgtgt 3840 gatgactcct gggacctggc cgaggcggaa gtggtgtgtc agcagctggg ctgtggctct 3900 gctctggctg ccctgaggga cgcttcgttt ggccagggaa ctggaaccat ctggttggat 3960 gacatgcggt gcaaaggaaa tgagtcattt ctatgggact gtcacgccaa accctgggga 4020 cagagtgact gtggacacaa ggaagatgct ggcgtgaggt gctctggaca gtcgctgaaa 4080 tcactgaatg cctcctcagg tcatttagca cttattttat ccagtatctt tgggctcctt 4140 ctcctggttc tgtttattct atttctcacg tggtgccgag ttcagaaaca aaaacatctg 4200 cccctcagag tttcaaccag aaggaggggt tctctcgagg agaatttatt ccatgagatg 4260 gagacctgcc tcaagagaga ggacccacat gggacaagaa cctcagatga cacccccaac 4320 catggttgtg aagatgctag cgacacatcg ctgttgggag ttcttcctgc ctctgaagcc 4380 acaaaatgac tttagacttc cagggctcac cagatcaacc tctaaatatc tttgaaggag 4440 acaacaactt ttaaatgaat aaagaggaag tcaagttgcc ctatggaaaa cttgtccaaa 4500 taacatttct tgaacaatag gagaacagct aaattgataa agactggtga taataaaaat 4560 tgaattatgt atatcactgt taaaaaaaaa aaaaaaaaaa aaaaaaaaaa acggacgcgt 4620 gggtcgac 4628 10 4359 DNA Homo sapiens 10 atgatgctgc ctcaaaactc gtggcatatt gattttggaa gatgctgctg tcatcagaac 60 cttttctctg ctgtggtaac ttgcatcctg ctcctgaatt cctgctttct catcagcagt 120 tttaatggaa cagatttgga gttgaggctg gtcaatggag acggtccctg ctctgggaca 180 gtggaggtga aattccaggg acagtggggg actgtgtgtg atgatgggtg gaacactact 240 gcctcaactg tcgtgtgcaa acagcttgga tgtccatttt ctttcgccat gtttcgtttt 300 ggacaagccg tgactagaca tggaaaaatt tggcttgatg atgtttcctg ttatggaaat 360 gagtcagctc tctgggaatg tcaacaccgg gaatggggaa gccataactg ttatcatgga 420 gaagatgttg gtgtgaactg ttatggtgaa gccaatctgg gtttgaggct agtggatgga 480 aacaactcct gttcagggag agtggaggtg aaattccaag aaaggtgggg gactatatgt 540 gatgatgggt ggaacttgaa tactgctgcc gtggtgtgca ggcaactagg atgtccatct 600 tcttttattt cttctggagt tgttaatagc cctgctgtat tgcgccccat ttggctggat 660 gacattttat gccaggggaa tgagttggca ctctggaatt gcagacatcg tggatgggga 720 aatcatgact gcagtcacaa tgaggatgtc acattaactt gttatgatag tagtgatctt 780 gaactaaggc ttgtaggtgg aactaaccgc tgtatgggga gagtagagct gaaaatccaa 840 ggaaggtggg ggaccgtatg ccaccataag tggaacaatg ctgcagctga tgtcgtatgc 900 aagcagttgg gatgtggaac cgcacttcac ttcgctggct tgcctcattt gcagtcaggg 960 tctgatgttg tatggcttga tggtgtctcc tgctccggta atgaatcttt tctttgggac 1020 tgcagacatt ccggaaccgt caattttgac tgtcttcatc aaaacgatgt gtctgtgatc 1080 tgctcagatg gagcagattt ggaactgcga ctagcagatg gaagtaacaa ttgttcaggg 1140 agagtagagg tgagaattca tgaacagtgg tggacaatat gtgaccagaa ctggaagaat 1200 gaacaagccc ttgtggtttg taagcagcta ggatgtccgt tcagcgtctt tggcagtcgt 1260 cgtgctaaac ctagtaatga agctagagac atttggataa acagcatatc ttgcactggg 1320 aatgagtcag ctctctggga ctgcacatat gatggaaaag caaagcgaac atgcttccga 1380 agatcagatg ctggagtaat ttgttctgat aaggcagatc tggacctaag gcttgtcggg 1440 gctcatagcc cctgttatgg gagattggag gtgaaatacc aaggagagtg ggggactgtg 1500 tgtcatgaca gatggagcac aaggaatgca gctgttgtgt gtaaacaatt gggatgtgga 1560 aagcctatgc atgtgtttgg tatgacctat tttaaagaag catcaggacc tatttggctg 1620 gatgacgttt cttgcattgg aaatgagtca aatatctggg actgtgaaca cagtggatgg 1680 ggaaagcata attgtgtaca cagagaggat gtgattgtaa cctgctcagg tgatgcaaca 1740 tggggcctga ggctggtggg cggcagcaac cgctgctcgg gaagactgga ggtgtacttt 1800 caaggacggt ggggcacagt gtgtgatgac ggctggaaca gtaaagctgc agctgtggtg 1860 tgtagccagc tggactgccc atcttctatc attggcatgg gtctgggaaa cgcttctaca 1920 ggatatggaa aaatttggct cgatgatgtt tcctgtgatg gagatgagtc agatctctgg 1980 tcatgcagga acagtgggtg gggaaataat gactgcagtc acagtgaaga tgttggagtg 2040 atctgttctg atgcatcgga tatggagctg aggcttgtgg gtggaagcag caggtgtgct 2100 ggaaaagttg aggtgaatgt ccagggtgcc gtgggaattc tgtgtgctaa tggctgggga 2160 atgaacattg ctgaagttgt ttgcaggcaa cttgaatgtg ggtctgcaat cagggtctcc 2220 agagagcctc atttcacaga aagaacatta cacatcttaa tgtcgaattc tggctgcact 2280 ggaggggaag cctctctctg ggattgtata cgatgggagt ggaaacagac tgcgtgtcat 2340 ttaaatatgg aagcaagttt gatctgctca gcccacaggc agcccaggct ggttggagct 2400 gatatgccct gctctggacg tgttgaagtg aaacatgcag acacatggcg ctctgtctgt 2460 gattctgatt tctctcttca tgctgccaat gtgctgtgca gagaattaaa ttgtggagat 2520 gccatatctc tttctgtggg agatcacttt ggaaaaggga atggtctaac ttgggccgaa 2580 aagttccagt gtgaagggag tgaaactcac cttgcattat gccccattgt tcaacatccg 2640 gaagacactt gtatccacag cagagaagtt ggagttgtct gttcccgata tacagatgtc 2700 cgacttgtga atggcaaatc ccagtgtgac gggcaagtgg agatcaacgt gcttggacac 2760 tggggctcac tgtgtgacac ccactgggac ccagaagatg cccgtgttct atgcagacag 2820 ctcagctgtg ggactgctct ctcaaccaca ggaggaaaat atattggaga aagaagtgtt 2880 cgtgtgtggg gacacaggtt tcattgctta gggaatgagt cacttctgga taactgtcaa 2940 atgacagttc ttggagcacc tccctgtatc catggaaata ctgtctctgt gatctgcaca 3000 ggaagcctga cccagccact gtttccatgc ctcgcaaatg tatctgaccc atatttgtct 3060 gcagttccag agggcagtgc tttgatctgc ttagaggaca aacggctccg cctagtggat 3120 ggggacagcc gctgtgccgg gagagtagag atctatcacg acggcttctg gggcaccatc 3180 tgtgatgacg gctgggacct gagcgatgcc cacgtggtgt gtcaaaagct gggctgtgga 3240 gtggccttca atgccacggt ctctgctcac tttggggagg ggtcagggcc catctggctg 3300 gatgacctga actgcacagg aacggagtcc cacttgtggc agtgcccttc ccgcggctgg 3360 gggcagcacg actgcaggca caaggaggac gcaggggtca tctgctcaga attcacagcc 3420 ttgaggctct acagtgaaac tgaaacagag agctgtgctg ggagattgga agtcttctat 3480 aacgggacct ggggcagcgt cggcaggagg aacatcacca cagccatagc aggcattgtg 3540 tgcaggcagc tgggctgtgg ggagaatgga gttgtcagcc tcgccccttt atctaagaca 3600 ggctctggtt tcatgtgggt ggatgacatt cagtgtccta aaacgcatat ctccatatgg 3660 cagtgcctgt ctgccccatg ggagcgaaga atctccagcc cagcagaaga gacctggatc 3720 acatgtgaag atagaataag agtgcgtgga ggagacaccg agtgctctgg gagagtggag 3780 atctggcacg caggctcctg gggcacagtg tgtgatgact cctgggacct ggccgaggcg 3840 gaagtggtgt gtcagcagct gggctgtggc tctgctctgg ctgccctgag ggacgcttcg 3900 tttggccagg gaactggaac catctggttg gatgacatgc ggtgcaaagg aaatgagtca 3960 tttctatggg actgtcacgc caaaccctgg ggacagagtg actgtggaca caaggaagat 4020 gctggcgtga ggtgctctgg acagtcgctg aaatcactga atgcctcctc aggtcattta 4080 gcacttattt tatccagtat ctttgggctc cttctcctgg ttctgtttat tctatttctc 4140 acgtggtgcc gagttcagaa acaaaaacat ctgcccctca gagtttcaac cagaaggagg 4200 ggttctctcg aggagaattt attccatgag atggagacct gcctcaagag agaggaccca 4260 catgggacaa gaacctcaga tgacaccccc aaccatggtt gtgaagatgc tagcgacaca 4320 tcgctgttgg gagttcttcc tgcctctgaa gccacaaaa 4359 11 1453 PRT Homo sapiens 11 Met Met Leu Pro Gln Asn Ser Trp His Ile Asp Phe Gly Arg Cys Cys 1 5 10 15 Cys His Gln Asn Leu Phe Ser Ala Val Val Thr Cys Ile Leu Leu Leu 20 25 30 Asn Ser Cys Phe Leu Ile Ser Ser Phe Asn Gly Thr Asp Leu Glu Leu 35 40 45 Arg Leu Val Asn Gly Asp Gly Pro Cys Ser Gly Thr Val Glu Val Lys 50 55 60 Phe Gln Gly Gln Trp Gly Thr Val Cys Asp Asp Gly Trp Asn Thr Thr 65 70 75 80 Ala Ser Thr Val Val Cys Lys Gln Leu Gly Cys Pro Phe Ser Phe Ala 85 90 95 Met Phe Arg Phe Gly Gln Ala Val Thr Arg His Gly Lys Ile Trp Leu 100 105 110 Asp Asp Val Ser Cys Tyr Gly Asn Glu Ser Ala Leu Trp Glu Cys Gln 115 120 125 His Arg Glu Trp Gly Ser His Asn Cys Tyr His Gly Glu Asp Val Gly 130 135 140 Val Asn Cys Tyr Gly Glu Ala Asn Leu Gly Leu Arg Leu Val Asp Gly 145 150 155 160 Asn Asn Ser Cys Ser Gly Arg Val Glu Val Lys Phe Gln Glu Arg Trp 165 170 175 Gly Thr Ile Cys Asp Asp Gly Trp Asn Leu Asn Thr Ala Ala Val Val 180 185 190 Cys Arg Gln Leu Gly Cys Pro Ser Ser Phe Ile Ser Ser Gly Val Val 195 200 205 Asn Ser Pro Ala Val Leu Arg Pro Ile Trp Leu Asp Asp Ile Leu Cys 210 215 220 Gln Gly Asn Glu Leu Ala Leu Trp Asn Cys Arg His Arg Gly Trp Gly 225 230 235 240 Asn His Asp Cys Ser His Asn Glu Asp Val Thr Leu Thr Cys Tyr Asp 245 250 255 Ser Ser Asp Leu Glu Leu Arg Leu Val Gly Gly Thr Asn Arg Cys Met 260 265 270 Gly Arg Val Glu Leu Lys Ile Gln Gly Arg Trp Gly Thr Val Cys His 275 280 285 His Lys Trp Asn Asn Ala Ala Ala Asp Val Val Cys Lys Gln Leu Gly 290 295 300 Cys Gly Thr Ala Leu His Phe Ala Gly Leu Pro His Leu Gln Ser Gly 305 310 315 320 Ser Asp Val Val Trp Leu Asp Gly Val Ser Cys Ser Gly Asn Glu Ser 325 330 335 Phe Leu Trp Asp Cys Arg His Ser Gly Thr Val Asn Phe Asp Cys Leu 340 345 350 His Gln Asn Asp Val Ser Val Ile Cys Ser Asp Gly Ala Asp Leu Glu 355 360 365 Leu Arg Leu Ala Asp Gly Ser Asn Asn Cys Ser Gly Arg Val Glu Val 370 375 380 Arg Ile His Glu Gln Trp Trp Thr Ile Cys Asp Gln Asn Trp Lys Asn 385 390 395 400 Glu Gln Ala Leu Val Val Cys Lys Gln Leu Gly Cys Pro Phe Ser Val 405 410 415 Phe Gly Ser Arg Arg Ala Lys Pro Ser Asn Glu Ala Arg Asp Ile Trp 420 425 430 Ile Asn Ser Ile Ser Cys Thr Gly Asn Glu Ser Ala Leu Trp Asp Cys 435 440 445 Thr Tyr Asp Gly Lys Ala Lys Arg Thr Cys Phe Arg Arg Ser Asp Ala 450 455 460 Gly Val Ile Cys Ser Asp Lys Ala Asp Leu Asp Leu Arg Leu Val Gly 465 470 475 480 Ala His Ser Pro Cys Tyr Gly Arg Leu Glu Val Lys Tyr Gln Gly Glu 485 490 495 Trp Gly Thr Val Cys His Asp Arg Trp Ser Thr Arg Asn Ala Ala Val 500 505 510 Val Cys Lys Gln Leu Gly Cys Gly Lys Pro Met His Val Phe Gly Met 515 520 525 Thr Tyr Phe Lys Glu Ala Ser Gly Pro Ile Trp Leu Asp Asp Val Ser 530 535 540 Cys Ile Gly Asn Glu Ser Asn Ile Trp Asp Cys Glu His Ser Gly Trp 545 550 555 560 Gly Lys His Asn Cys Val His Arg Glu Asp Val Ile Val Thr Cys Ser 565 570 575 Gly Asp Ala Thr Trp Gly Leu Arg Leu Val Gly Gly Ser Asn Arg Cys 580 585 590 Ser Gly Arg Leu Glu Val Tyr Phe Gln Gly Arg Trp Gly Thr Val Cys 595 600 605 Asp Asp Gly Trp Asn Ser Lys Ala Ala Ala Val Val Cys Ser Gln Leu 610 615 620 Asp Cys Pro Ser Ser Ile Ile Gly Met Gly Leu Gly Asn Ala Ser Thr 625 630 635 640 Gly Tyr Gly Lys Ile Trp Leu Asp Asp Val Ser Cys Asp Gly Asp Glu 645 650 655 Ser Asp Leu Trp Ser Cys Arg Asn Ser Gly Trp Gly Asn Asn Asp Cys 660 665 670 Ser His Ser Glu Asp Val Gly Val Ile Cys Ser Asp Ala Ser Asp Met 675 680 685 Glu Leu Arg Leu Val Gly Gly Ser Ser Arg Cys Ala Gly Lys Val Glu 690 695 700 Val Asn Val Gln Gly Ala Val Gly Ile Leu Cys Ala Asn Gly Trp Gly 705 710 715 720 Met Asn Ile Ala Glu Val Val Cys Arg Gln Leu Glu Cys Gly Ser Ala 725 730 735 Ile Arg Val Ser Arg Glu Pro His Phe Thr Glu Arg Thr Leu His Ile 740 745 750 Leu Met Ser Asn Ser Gly Cys Thr Gly Gly Glu Ala Ser Leu Trp Asp 755 760 765 Cys Ile Arg Trp Glu Trp Lys Gln Thr Ala Cys His Leu Asn Met Glu 770 775 780 Ala Ser Leu Ile Cys Ser Ala His Arg Gln Pro Arg Leu Val Gly Ala 785 790 795 800 Asp Met Pro Cys Ser Gly Arg Val Glu Val Lys His Ala Asp Thr Trp 805 810 815 Arg Ser Val Cys Asp Ser Asp Phe Ser Leu His Ala Ala Asn Val Leu 820 825 830 Cys Arg Glu Leu Asn Cys Gly Asp Ala Ile Ser Leu Ser Val Gly Asp 835 840 845 His Phe Gly Lys Gly Asn Gly Leu Thr Trp Ala Glu Lys Phe Gln Cys 850 855 860 Glu Gly Ser Glu Thr His Leu Ala Leu Cys Pro Ile Val Gln His Pro 865 870 875 880 Glu Asp Thr Cys Ile His Ser Arg Glu Val Gly Val Val Cys Ser Arg 885 890 895 Tyr Thr Asp Val Arg Leu Val Asn Gly Lys Ser Gln Cys Asp Gly Gln 900 905 910 Val Glu Ile Asn Val Leu Gly His Trp Gly Ser Leu Cys Asp Thr His 915 920 925 Trp Asp Pro Glu Asp Ala Arg Val Leu Cys Arg Gln Leu Ser Cys Gly 930 935 940 Thr Ala Leu Ser Thr Thr Gly Gly Lys Tyr Ile Gly Glu Arg Ser Val 945 950 955 960 Arg Val Trp Gly His Arg Phe His Cys Leu Gly Asn Glu Ser Leu Leu 965 970 975 Asp Asn Cys Gln Met Thr Val Leu Gly Ala Pro Pro Cys Ile His Gly 980 985 990 Asn Thr Val Ser Val Ile Cys Thr Gly Ser Leu Thr Gln Pro Leu Phe 995 1000 1005 Pro Cys Leu Ala Asn Val Ser Asp Pro Tyr Leu Ser Ala Val Pro Glu 1010 1015 1020 Gly Ser Ala Leu Ile Cys Leu Glu Asp Lys Arg Leu Arg Leu Val Asp 1025 1030 1035 1040 Gly Asp Ser Arg Cys Ala Gly Arg Val Glu Ile Tyr His Asp Gly Phe 1045 1050 1055 Trp Gly Thr Ile Cys Asp Asp Gly Trp Asp Leu Ser Asp Ala His Val 1060 1065 1070 Val Cys Gln Lys Leu Gly Cys Gly Val Ala Phe Asn Ala Thr Val Ser 1075 1080 1085 Ala His Phe Gly Glu Gly Ser Gly Pro Ile Trp Leu Asp Asp Leu Asn 1090 1095 1100 Cys Thr Gly Thr Glu Ser His Leu Trp Gln Cys Pro Ser Arg Gly Trp 1105 1110 1115 1120 Gly Gln His Asp Cys Arg His Lys Glu Asp Ala Gly Val Ile Cys Ser 1125 1130 1135 Glu Phe Thr Ala Leu Arg Leu Tyr Ser Glu Thr Glu Thr Glu Ser Cys 1140 1145 1150 Ala Gly Arg Leu Glu Val Phe Tyr Asn Gly Thr Trp Gly Ser Val Gly 1155 1160 1165 Arg Arg Asn Ile Thr Thr Ala Ile Ala Gly Ile Val Cys Arg Gln Leu 1170 1175 1180 Gly Cys Gly Glu Asn Gly Val Val Ser Leu Ala Pro Leu Ser Lys Thr 1185 1190 1195 1200 Gly Ser Gly Phe Met Trp Val Asp Asp Ile Gln Cys Pro Lys Thr His 1205 1210 1215 Ile Ser Ile Trp Gln Cys Leu Ser Ala Pro Trp Glu Arg Arg Ile Ser 1220 1225 1230 Ser Pro Ala Glu Glu Thr Trp Ile Thr Cys Glu Asp Arg Ile Arg Val 1235 1240 1245 Arg Gly Gly Asp Thr Glu Cys Ser Gly Arg Val Glu Ile Trp His Ala 1250 1255 1260 Gly Ser Trp Gly Thr Val Cys Asp Asp Ser Trp Asp Leu Ala Glu Ala 1265 1270 1275 1280 Glu Val Val Cys Gln Gln Leu Gly Cys Gly Ser Ala Leu Ala Ala Leu 1285 1290 1295 Arg Asp Ala Ser Phe Gly Gln Gly Thr Gly Thr Ile Trp Leu Asp Asp 1300 1305 1310 Met Arg Cys Lys Gly Asn Glu Ser Phe Leu Trp Asp Cys His Ala Lys 1315 1320 1325 Pro Trp Gly Gln Ser Asp Cys Gly His Lys Glu Asp Ala Gly Val Arg 1330 1335 1340 Cys Ser Gly Gln Ser Leu Lys Ser Leu Asn Ala Ser Ser Gly His Leu 1345 1350 1355 1360 Ala Leu Ile Leu Ser Ser Ile Phe Gly Leu Leu Leu Leu Val Leu Phe 1365 1370 1375 Ile Leu Phe Leu Thr Trp Cys Arg Val Gln Lys Gln Lys His Leu Pro 1380 1385 1390 Leu Arg Val Ser Thr Arg Arg Arg Gly Ser Leu Glu Glu Asn Leu Phe 1395 1400 1405 His Glu Met Glu Thr Cys Leu Lys Arg Glu Asp Pro His Gly Thr Arg 1410 1415 1420 Thr Ser Asp Asp Thr Pro Asn His Gly Cys Glu Asp Ala Ser Asp Thr 1425 1430 1435 1440 Ser Leu Leu Gly Val Leu Pro Ala Ser Glu Ala Thr Lys 1445 1450 12 40 PRT Homo sapiens 12 Met Met Leu Pro Gln Asn Ser Trp His Ile Asp Phe Gly Arg Cys Cys 1 5 10 15 Cys His Gln Asn Leu Phe Ser Ala Val Val Thr Cys Ile Leu Leu Leu 20 25 30 Asn Ser Cys Phe Leu Ile Ser Ser 35 40 13 1413 PRT Homo sapiens 13 Phe Asn Gly Thr Asp Leu Glu Leu Arg Leu Val Asn Gly Asp Gly Pro 1 5 10 15 Cys Ser Gly Thr Val Glu Val Lys Phe Gln Gly Gln Trp Gly Thr Val 20 25 30 Cys Asp Asp Gly Trp Asn Thr Thr Ala Ser Thr Val Val Cys Lys Gln 35 40 45 Leu Gly Cys Pro Phe Ser Phe Ala Met Phe Arg Phe Gly Gln Ala Val 50 55 60 Thr Arg His Gly Lys Ile Trp Leu Asp Asp Val Ser Cys Tyr Gly Asn 65 70 75 80 Glu Ser Ala Leu Trp Glu Cys Gln His Arg Glu Trp Gly Ser His Asn 85 90 95 Cys Tyr His Gly Glu Asp Val Gly Val Asn Cys Tyr Gly Glu Ala Asn 100 105 110 Leu Gly Leu Arg Leu Val Asp Gly Asn Asn Ser Cys Ser Gly Arg Val 115 120 125 Glu Val Lys Phe Gln Glu Arg Trp Gly Thr Ile Cys Asp Asp Gly Trp 130 135 140 Asn Leu Asn Thr Ala Ala Val Val Cys Arg Gln Leu Gly Cys Pro Ser 145 150 155 160 Ser Phe Ile Ser Ser Gly Val Val Asn Ser Pro Ala Val Leu Arg Pro 165 170 175 Ile Trp Leu Asp Asp Ile Leu Cys Gln Gly Asn Glu Leu Ala Leu Trp 180 185 190 Asn Cys Arg His Arg Gly Trp Gly Asn His Asp Cys Ser His Asn Glu 195 200 205 Asp Val Thr Leu Thr Cys Tyr Asp Ser Ser Asp Leu Glu Leu Arg Leu 210 215 220 Val Gly Gly Thr Asn Arg Cys Met Gly Arg Val Glu Leu Lys Ile Gln 225 230 235 240 Gly Arg Trp Gly Thr Val Cys His His Lys Trp Asn Asn Ala Ala Ala 245 250 255 Asp Val Val Cys Lys Gln Leu Gly Cys Gly Thr Ala Leu His Phe Ala 260 265 270 Gly Leu Pro His Leu Gln Ser Gly Ser Asp Val Val Trp Leu Asp Gly 275 280 285 Val Ser Cys Ser Gly Asn Glu Ser Phe Leu Trp Asp Cys Arg His Ser 290 295 300 Gly Thr Val Asn Phe Asp Cys Leu His Gln Asn Asp Val Ser Val Ile 305 310 315 320 Cys Ser Asp Gly Ala Asp Leu Glu Leu Arg Leu Ala Asp Gly Ser Asn 325 330 335 Asn Cys Ser Gly Arg Val Glu Val Arg Ile His Glu Gln Trp Trp Thr 340 345 350 Ile Cys Asp Gln Asn Trp Lys Asn Glu Gln Ala Leu Val Val Cys Lys 355 360 365 Gln Leu Gly Cys Pro Phe Ser Val Phe Gly Ser Arg Arg Ala Lys Pro 370 375 380 Ser Asn Glu Ala Arg Asp Ile Trp Ile Asn Ser Ile Ser Cys Thr Gly 385 390 395 400 Asn Glu Ser Ala Leu Trp Asp Cys Thr Tyr Asp Gly Lys Ala Lys Arg 405 410 415 Thr Cys Phe Arg Arg Ser Asp Ala Gly Val Ile Cys Ser Asp Lys Ala 420 425 430 Asp Leu Asp Leu Arg Leu Val Gly Ala His Ser Pro Cys Tyr Gly Arg 435 440 445 Leu Glu Val Lys Tyr Gln Gly Glu Trp Gly Thr Val Cys His Asp Arg 450 455 460 Trp Ser Thr Arg Asn Ala Ala Val Val Cys Lys Gln Leu Gly Cys Gly 465 470 475 480 Lys Pro Met His Val Phe Gly Met Thr Tyr Phe Lys Glu Ala Ser Gly 485 490 495 Pro Ile Trp Leu Asp Asp Val Ser Cys Ile Gly Asn Glu Ser Asn Ile 500 505 510 Trp Asp Cys Glu His Ser Gly Trp Gly Lys His Asn Cys Val His Arg 515 520 525 Glu Asp Val Ile Val Thr Cys Ser Gly Asp Ala Thr Trp Gly Leu Arg 530 535 540 Leu Val Gly Gly Ser Asn Arg Cys Ser Gly Arg Leu Glu Val Tyr Phe 545 550 555 560 Gln Gly Arg Trp Gly Thr Val Cys Asp Asp Gly Trp Asn Ser Lys Ala 565 570 575 Ala Ala Val Val Cys Ser Gln Leu Asp Cys Pro Ser Ser Ile Ile Gly 580 585 590 Met Gly Leu Gly Asn Ala Ser Thr Gly Tyr Gly Lys Ile Trp Leu Asp 595 600 605 Asp Val Ser Cys Asp Gly Asp Glu Ser Asp Leu Trp Ser Cys Arg Asn 610 615 620 Ser Gly Trp Gly Asn Asn Asp Cys Ser His Ser Glu Asp Val Gly Val 625 630 635 640 Ile Cys Ser Asp Ala Ser Asp Met Glu Leu Arg Leu Val Gly Gly Ser 645 650 655 Ser Arg Cys Ala Gly Lys Val Glu Val Asn Val Gln Gly Ala Val Gly 660 665 670 Ile Leu Cys Ala Asn Gly Trp Gly Met Asn Ile Ala Glu Val Val Cys 675 680 685 Arg Gln Leu Glu Cys Gly Ser Ala Ile Arg Val Ser Arg Glu Pro His 690 695 700 Phe Thr Glu Arg Thr Leu His Ile Leu Met Ser Asn Ser Gly Cys Thr 705 710 715 720 Gly Gly Glu Ala Ser Leu Trp Asp Cys Ile Arg Trp Glu Trp Lys Gln 725 730 735 Thr Ala Cys His Leu Asn Met Glu Ala Ser Leu Ile Cys Ser Ala His 740 745 750 Arg Gln Pro Arg Leu Val Gly Ala Asp Met Pro Cys Ser Gly Arg Val 755 760 765 Glu Val Lys His Ala Asp Thr Trp Arg Ser Val Cys Asp Ser Asp Phe 770 775 780 Ser Leu His Ala Ala Asn Val Leu Cys Arg Glu Leu Asn Cys Gly Asp 785 790 795 800 Ala Ile Ser Leu Ser Val Gly Asp His Phe Gly Lys Gly Asn Gly Leu 805 810 815 Thr Trp Ala Glu Lys Phe Gln Cys Glu Gly Ser Glu Thr His Leu Ala 820 825 830 Leu Cys Pro Ile Val Gln His Pro Glu Asp Thr Cys Ile His Ser Arg 835 840 845 Glu Val Gly Val Val Cys Ser Arg Tyr Thr Asp Val Arg Leu Val Asn 850 855 860 Gly Lys Ser Gln Cys Asp Gly Gln Val Glu Ile Asn Val Leu Gly His 865 870 875 880 Trp Gly Ser Leu Cys Asp Thr His Trp Asp Pro Glu Asp Ala Arg Val 885 890 895 Leu Cys Arg Gln Leu Ser Cys Gly Thr Ala Leu Ser Thr Thr Gly Gly 900 905 910 Lys Tyr Ile Gly Glu Arg Ser Val Arg Val Trp Gly His Arg Phe His 915 920 925 Cys Leu Gly Asn Glu Ser Leu Leu Asp Asn Cys Gln Met Thr Val Leu 930 935 940 Gly Ala Pro Pro Cys Ile His Gly Asn Thr Val Ser Val Ile Cys Thr 945 950 955 960 Gly Ser Leu Thr Gln Pro Leu Phe Pro Cys Leu Ala Asn Val Ser Asp 965 970 975 Pro Tyr Leu Ser Ala Val Pro Glu Gly Ser Ala Leu Ile Cys Leu Glu 980 985 990 Asp Lys Arg Leu Arg Leu Val Asp Gly Asp Ser Arg Cys Ala Gly Arg 995 1000 1005 Val Glu Ile Tyr His Asp Gly Phe Trp Gly Thr Ile Cys Asp Asp Gly 1010 1015 1020 Trp Asp Leu Ser Asp Ala His Val Val Cys Gln Lys Leu Gly Cys Gly 1025 1030 1035 1040 Val Ala Phe Asn Ala Thr Val Ser Ala His Phe Gly Glu Gly Ser Gly 1045 1050 1055 Pro Ile Trp Leu Asp Asp Leu Asn Cys Thr Gly Thr Glu Ser His Leu 1060 1065 1070 Trp Gln Cys Pro Ser Arg Gly Trp Gly Gln His Asp Cys Arg His Lys 1075 1080 1085 Glu Asp Ala Gly Val Ile Cys Ser Glu Phe Thr Ala Leu Arg Leu Tyr 1090 1095 1100 Ser Glu Thr Glu Thr Glu Ser Cys Ala Gly Arg Leu Glu Val Phe Tyr 1105 1110 1115 1120 Asn Gly Thr Trp Gly Ser Val Gly Arg Arg Asn Ile Thr Thr Ala Ile 1125 1130 1135 Ala Gly Ile Val Cys Arg Gln Leu Gly Cys Gly Glu Asn Gly Val Val 1140 1145 1150 Ser Leu Ala Pro Leu Ser Lys Thr Gly Ser Gly Phe Met Trp Val Asp 1155 1160 1165 Asp Ile Gln Cys Pro Lys Thr His Ile Ser Ile Trp Gln Cys Leu Ser 1170 1175 1180 Ala Pro Trp Glu Arg Arg Ile Ser Ser Pro Ala Glu Glu Thr Trp Ile 1185 1190 1195 1200 Thr Cys Glu Asp Arg Ile Arg Val Arg Gly Gly Asp Thr Glu Cys Ser 1205 1210 1215 Gly Arg Val Glu Ile Trp His Ala Gly Ser Trp Gly Thr Val Cys Asp 1220 1225 1230 Asp Ser Trp Asp Leu Ala Glu Ala Glu Val Val Cys Gln Gln Leu Gly 1235 1240 1245 Cys Gly Ser Ala Leu Ala Ala Leu Arg Asp Ala Ser Phe Gly Gln Gly 1250 1255 1260 Thr Gly Thr Ile Trp Leu Asp Asp Met Arg Cys Lys Gly Asn Glu Ser 1265 1270 1275 1280 Phe Leu Trp Asp Cys His Ala Lys Pro Trp Gly Gln Ser Asp Cys Gly 1285 1290 1295 His Lys Glu Asp Ala Gly Val Arg Cys Ser Gly Gln Ser Leu Lys Ser 1300 1305 1310 Leu Asn Ala Ser Ser Gly His Leu Ala Leu Ile Leu Ser Ser Ile Phe 1315 1320 1325 Gly Leu Leu Leu Leu Val Leu Phe Ile Leu Phe Leu Thr Trp Cys Arg 1330 1335 1340 Val Gln Lys Gln Lys His Leu Pro Leu Arg Val Ser Thr Arg Arg Arg 1345 1350 1355 1360 Gly Ser Leu Glu Glu Asn Leu Phe His Glu Met Glu Thr Cys Leu Lys 1365 1370 1375 Arg Glu Asp Pro His Gly Thr Arg Thr Ser Asp Asp Thr Pro Asn His 1380 1385 1390 Gly Cys Glu Asp Ala Ser Asp Thr Ser Leu Leu Gly Val Leu Pro Ala 1395 1400 1405 Ser Glu Ala Thr Lys 1410 14 1319 PRT Homo sapiens 14 Phe Asn Gly Thr Asp Leu Glu Leu Arg Leu Val Asn Gly Asp Gly Pro 1 5 10 15 Cys Ser Gly Thr Val Glu Val Lys Phe Gln Gly Gln Trp Gly Thr Val 20 25 30 Cys Asp Asp Gly Trp Asn Thr Thr Ala Ser Thr Val Val Cys Lys Gln 35 40 45 Leu Gly Cys Pro Phe Ser Phe Ala Met Phe Arg Phe Gly Gln Ala Val 50 55 60 Thr Arg His Gly Lys Ile Trp Leu Asp Asp Val Ser Cys Tyr Gly Asn 65 70 75 80 Glu Ser Ala Leu Trp Glu Cys Gln His Arg Glu Trp Gly Ser His Asn 85 90 95 Cys Tyr His Gly Glu Asp Val Gly Val Asn Cys Tyr Gly Glu Ala Asn 100 105 110 Leu Gly Leu Arg Leu Val Asp Gly Asn Asn Ser Cys Ser Gly Arg Val 115 120 125 Glu Val Lys Phe Gln Glu Arg Trp Gly Thr Ile Cys Asp Asp Gly Trp 130 135 140 Asn Leu Asn Thr Ala Ala Val Val Cys Arg Gln Leu Gly Cys Pro Ser 145 150 155 160 Ser Phe Ile Ser Ser Gly Val Val Asn Ser Pro Ala Val Leu Arg Pro 165 170 175 Ile Trp Leu Asp Asp Ile Leu Cys Gln Gly Asn Glu Leu Ala Leu Trp 180 185 190 Asn Cys Arg His Arg Gly Trp Gly Asn His Asp Cys Ser His Asn Glu 195 200 205 Asp Val Thr Leu Thr Cys Tyr Asp Ser Ser Asp Leu Glu Leu Arg Leu 210 215 220 Val Gly Gly Thr Asn Arg Cys Met Gly Arg Val Glu Leu Lys Ile Gln 225 230 235 240 Gly Arg Trp Gly Thr Val Cys His His Lys Trp Asn Asn Ala Ala Ala 245 250 255 Asp Val Val Cys Lys Gln Leu Gly Cys Gly Thr Ala Leu His Phe Ala 260 265 270 Gly Leu Pro His Leu Gln Ser Gly Ser Asp Val Val Trp Leu Asp Gly 275 280 285 Val Ser Cys Ser Gly Asn Glu Ser Phe Leu Trp Asp Cys Arg His Ser 290 295 300 Gly Thr Val Asn Phe Asp Cys Leu His Gln Asn Asp Val Ser Val Ile 305 310 315 320 Cys Ser Asp Gly Ala Asp Leu Glu Leu Arg Leu Ala Asp Gly Ser Asn 325 330 335 Asn Cys Ser Gly Arg Val Glu Val Arg Ile His Glu Gln Trp Trp Thr 340 345 350 Ile Cys Asp Gln Asn Trp Lys Asn Glu Gln Ala Leu Val Val Cys Lys 355 360 365 Gln Leu Gly Cys Pro Phe Ser Val Phe Gly Ser Arg Arg Ala Lys Pro 370 375 380 Ser Asn Glu Ala Arg Asp Ile Trp Ile Asn Ser Ile Ser Cys Thr Gly 385 390 395 400 Asn Glu Ser Ala Leu Trp Asp Cys Thr Tyr Asp Gly Lys Ala Lys Arg 405 410 415 Thr Cys Phe Arg Arg Ser Asp Ala Gly Val Ile Cys Ser Asp Lys Ala 420 425 430 Asp Leu Asp Leu Arg Leu Val Gly Ala His Ser Pro Cys Tyr Gly Arg 435 440 445 Leu Glu Val Lys Tyr Gln Gly Glu Trp Gly Thr Val Cys His Asp Arg 450 455 460 Trp Ser Thr Arg Asn Ala Ala Val Val Cys Lys Gln Leu Gly Cys Gly 465 470 475 480 Lys Pro Met His Val Phe Gly Met Thr Tyr Phe Lys Glu Ala Ser Gly 485 490 495 Pro Ile Trp Leu Asp Asp Val Ser Cys Ile Gly Asn Glu Ser Asn Ile 500 505 510 Trp Asp Cys Glu His Ser Gly Trp Gly Lys His Asn Cys Val His Arg 515 520 525 Glu Asp Val Ile Val Thr Cys Ser Gly Asp Ala Thr Trp Gly Leu Arg 530 535 540 Leu Val Gly Gly Ser Asn Arg Cys Ser Gly Arg Leu Glu Val Tyr Phe 545 550 555 560 Gln Gly Arg Trp Gly Thr Val Cys Asp Asp Gly Trp Asn Ser Lys Ala 565 570 575 Ala Ala Val Val Cys Ser Gln Leu Asp Cys Pro Ser Ser Ile Ile Gly 580 585 590 Met Gly Leu Gly Asn Ala Ser Thr Gly Tyr Gly Lys Ile Trp Leu Asp 595 600 605 Asp Val Ser Cys Asp Gly Asp Glu Ser Asp Leu Trp Ser Cys Arg Asn 610 615 620 Ser Gly Trp Gly Asn Asn Asp Cys Ser His Ser Glu Asp Val Gly Val 625 630 635 640 Ile Cys Ser Asp Ala Ser Asp Met Glu Leu Arg Leu Val Gly Gly Ser 645 650 655 Ser Arg Cys Ala Gly Lys Val Glu Val Asn Val Gln Gly Ala Val Gly 660 665 670 Ile Leu Cys Ala Asn Gly Trp Gly Met Asn Ile Ala Glu Val Val Cys 675 680 685 Arg Gln Leu Glu Cys Gly Ser Ala Ile Arg Val Ser Arg Glu Pro His 690 695 700 Phe Thr Glu Arg Thr Leu His Ile Leu Met Ser Asn Ser Gly Cys Thr 705 710 715 720 Gly Gly Glu Ala Ser Leu Trp Asp Cys Ile Arg Trp Glu Trp Lys Gln 725 730 735 Thr Ala Cys His Leu Asn Met Glu Ala Ser Leu Ile Cys Ser Ala His 740 745 750 Arg Gln Pro Arg Leu Val Gly Ala Asp Met Pro Cys Ser Gly Arg Val 755 760 765 Glu Val Lys His Ala Asp Thr Trp Arg Ser Val Cys Asp Ser Asp Phe 770 775 780 Ser Leu His Ala Ala Asn Val Leu Cys Arg Glu Leu Asn Cys Gly Asp 785 790 795 800 Ala Ile Ser Leu Ser Val Gly Asp His Phe Gly Lys Gly Asn Gly Leu 805 810 815 Thr Trp Ala Glu Lys Phe Gln Cys Glu Gly Ser Glu Thr His Leu Ala 820 825 830 Leu Cys Pro Ile Val Gln His Pro Glu Asp Thr Cys Ile His Ser Arg 835 840 845 Glu Val Gly Val Val Cys Ser Arg Tyr Thr Asp Val Arg Leu Val Asn 850 855 860 Gly Lys Ser Gln Cys Asp Gly Gln Val Glu Ile Asn Val Leu Gly His 865 870 875 880 Trp Gly Ser Leu Cys Asp Thr His Trp Asp Pro Glu Asp Ala Arg Val 885 890 895 Leu Cys Arg Gln Leu Ser Cys Gly Thr Ala Leu Ser Thr Thr Gly Gly 900 905 910 Lys Tyr Ile Gly Glu Arg Ser Val Arg Val Trp Gly His Arg Phe His 915 920 925 Cys Leu Gly Asn Glu Ser Leu Leu Asp Asn Cys Gln Met Thr Val Leu 930 935 940 Gly Ala Pro Pro Cys Ile His Gly Asn Thr Val Ser Val Ile Cys Thr 945 950 955 960 Gly Ser Leu Thr Gln Pro Leu Phe Pro Cys Leu Ala Asn Val Ser Asp 965 970 975 Pro Tyr Leu Ser Ala Val Pro Glu Gly Ser Ala Leu Ile Cys Leu Glu 980 985 990 Asp Lys Arg Leu Arg Leu Val Asp Gly Asp Ser Arg Cys Ala Gly Arg 995 1000 1005 Val Glu Ile Tyr His Asp Gly Phe Trp Gly Thr Ile Cys Asp Asp Gly 1010 1015 1020 Trp Asp Leu Ser Asp Ala His Val Val Cys Gln Lys Leu Gly Cys Gly 1025 1030 1035 1040 Val Ala Phe Asn Ala Thr Val Ser Ala His Phe Gly Glu Gly Ser Gly 1045 1050 1055 Pro Ile Trp Leu Asp Asp Leu Asn Cys Thr Gly Thr Glu Ser His Leu 1060 1065 1070 Trp Gln Cys Pro Ser Arg Gly Trp Gly Gln His Asp Cys Arg His Lys 1075 1080 1085 Glu Asp Ala Gly Val Ile Cys Ser Glu Phe Thr Ala Leu Arg Leu Tyr 1090 1095 1100 Ser Glu Thr Glu Thr Glu Ser Cys Ala Gly Arg Leu Glu Val Phe Tyr 1105 1110 1115 1120 Asn Gly Thr Trp Gly Ser Val Gly Arg Arg Asn Ile Thr Thr Ala Ile 1125 1130 1135 Ala Gly Ile Val Cys Arg Gln Leu Gly Cys Gly Glu Asn Gly Val Val 1140 1145 1150 Ser Leu Ala Pro Leu Ser Lys Thr Gly Ser Gly Phe Met Trp Val Asp 1155 1160 1165 Asp Ile Gln Cys Pro Lys Thr His Ile Ser Ile Trp Gln Cys Leu Ser 1170 1175 1180 Ala Pro Trp Glu Arg Arg Ile Ser Ser Pro Ala Glu Glu Thr Trp Ile 1185 1190 1195 1200 Thr Cys Glu Asp Arg Ile Arg Val Arg Gly Gly Asp Thr Glu Cys Ser 1205 1210 1215 Gly Arg Val Glu Ile Trp His Ala Gly Ser Trp Gly Thr Val Cys Asp 1220 1225 1230 Asp Ser Trp Asp Leu Ala Glu Ala Glu Val Val Cys Gln Gln Leu Gly 1235 1240 1245 Cys Gly Ser Ala Leu Ala Ala Leu Arg Asp Ala Ser Phe Gly Gln Gly 1250 1255 1260 Thr Gly Thr Ile Trp Leu Asp Asp Met Arg Cys Lys Gly Asn Glu Ser 1265 1270 1275 1280 Phe Leu Trp Asp Cys His Ala Lys Pro Trp Gly Gln Ser Asp Cys Gly 1285 1290 1295 His Lys Glu Asp Ala Gly Val Arg Cys Ser Gly Gln Ser Leu Lys Ser 1300 1305 1310 Leu Asn Ala Ser Ser Gly His 1315 15 24 PRT Homo sapiens 15 Leu Ala Leu Ile Leu Ser Ser Ile Phe Gly Leu Leu Leu Leu Val Leu 1 5 10 15 Phe Ile Leu Phe Leu Thr Trp Cys 20 16 70 PRT Homo sapiens 16 Arg Val Gln Lys Gln Lys His Leu Pro Leu Arg Val Ser Thr Arg Arg 1 5 10 15 Arg Gly Ser Leu Glu Glu Asn Leu Phe His Glu Met Glu Thr Cys Leu 20 25 30 Lys Arg Glu Asp Pro His Gly Thr Arg Thr Ser Asp Asp Thr Pro Asn 35 40 45 His Gly Cys Glu Asp Ala Ser Asp Thr Ser Leu Leu Gly Val Leu Pro 50 55 60 Ala Ser Glu Ala Thr Lys 65 70 17 3104 DNA Homo sapiens 17 gtcgacccac gcgtccggtc tgtggctgag catggccctc ccagccctgg gcctggaccc 60 ctggagcctc ctgggccttt tcctcttcca actgcttcag ctgctgctgc cgacgacgac 120 cgcgggggga ggcgggcagg ggcccatgcc cagggtcaga tactatgcag gggatgaacg 180 tagggcactt agcttcttcc accagaaggg cctccaggat tttgacactc tgctcctgag 240 tggtgatgga aatactctct acgtgggggc tcgagaagcc attctggcct tggatatcca 300 ggatccaggg gtccccaggc taaagaacat gataccgtgg ccagccagtg acagaaaaaa 360 gagtgaatgt gcctttaaga agaagagcaa tgagacacag tgtttcaact tcatccgtgt 420 cctggtttct tacaatgtca cccatctcta cacctgcggc accttcgcct tcagccctgc 480 ttgtaccttc attgaacttc aagattccta cctgttgccc atctcggagg acaaggtcat 540 ggagggaaaa ggccaaagcc cctttgaccc cgctcacaag catacggctg tcttggtgga 600 tgggatgctc tattctggta ctatgaacaa cttcctgggc agtgagccca tcctgatgcg 660 cacactggga tcccagcctg tcctcaagac cgacaacttc ctccgctggc tgcatcatga 720 cgcctccttt gtggcagcca tcccttcgac ccaggtcgtc tacttcttct tcgaggagac 780 agccagcgag tttgacttct ttgagaggct ccacacatcg cgggtggcta gagtctgcaa 840 gaatgacgtg ggcggcgaaa agctgctgca gaagaagtgg accaccttcc tgaaggccca 900 gctgctctgc acccagccgg ggcagctgcc cttcaacgtc atccgccacg cggtcctgct 960 ccccgccgat tctcccacag ctccccacat ctacgcagtc ttcacctccc agtggcaggt 1020 tggcgggacc aggagctctg cggtttgtgc cttctctctc ttggacattg aacgtgtctt 1080 taaggggaaa tacaaagagt tgaacaaaga aacttcacgc tggactactt ataggggccc 1140 tgagaccaac ccccggccag gcagttgctc agtgggcccc tcctctgata aggccctgac 1200 cttcatgaag gaccatttcc tgatggatga gcaagtggtg gggacgcccc tgctggtgaa 1260 atctggcgtg gagtatacac ggcttgcagt ggagacagcc cagggccttg atgggcacag 1320 ccatcttgtc atgtacctgg gaaccaccac agggtcgctc cacaaggctg tggtaagtgg 1380 ggacagcagt gctcatctgg tggaagagat tcagctgttc cctgaccctg aacctgttcg 1440 caacctgcag ctggccccca cccagggtgc agtgtttgta ggcttctcag gaggtgtctg 1500 gagggtgccc cgagccaact gtagtgtcta tgagagctgt gtggactgtg tccttgcccg 1560 ggacccccac tgtgcctggg accctgagtc ccgaacctgt tgcctcctgt ctgcccccaa 1620 cctgaactcc tggaagcagg acatggagcg ggggaaccca gagtgggcat gtgccagtgg 1680 ccccatgagc aggagccttc ggcctcagag ccgcccgcaa atcattaaag aagtcctggc 1740 tgtccccaac tccatcctgg agctcccctg cccccacctg tcagccttgg cctcttatta 1800 ttggagtcat ggcccagcag cagtcccaga agcctcttcc actgtctaca atggctccct 1860 cttgctgata gtgcaggatg gagttggggg tctctaccag tgctgggcaa ctgagaatgg 1920 cttttcatac cctgtgatct cctactgggt ggacagccag gaccagaccc tggccctgga 1980 tcctgaactg gcaggcatcc cccgggagca tgtgaaggtc ccgttgacca gggtcagtgg 2040 tggggccgcc ctggctgccc agcagtccta ctggccccac tttgtcactg tcactgtcct 2100 ctttgcctta gtgctttcag gagccctcat catcctcgtg gcctccccat tgagagcact 2160 ccgggctcgg ggcaaggttc agggctgtga gaccctgcgc cctggggaga aggccccgtt 2220 aagcagagag caacacctcc agtctcccaa ggaatgcagg acctctgcca gtgatgtgga 2280 cgctgacaac aactgcctag gcactgaggt agcttaaact ctaggcacag gccggggctg 2340 cggtgcaggc acctggccat gctggctggg cggcccaagc acagccctga ctaggatgac 2400 agcagcacaa aagaccacct ttctcccctg agaggagctt ctgctactct gcatcactga 2460 tgacactcag cagggtgatg cacagcagtc tgcctcccct atgggactcc cttctaccaa 2520 gcacatgagc tctctaacag ggtgggggct acccccagac ctgctcctac actgatattg 2580 aagaacctgg agaggatcct tcagttctgg ccattccagg gaccctccag aaacacagtg 2640 tttcaagaga tcctaaaaaa acctgcctgt cccaggaccc tatggtaatg aacaccaaac 2700 atctaaacaa tcatatgcta acatgccact cctggaaact ccactctgaa gctgccgctt 2760 tggacaccaa cactcccttc tcccagggtc atgcagggat ctgctccctc ctgcttccct 2820 taccagtcgt gcaccgctga ctcccaggaa gtctttcctg aagtctgacc acctttcttc 2880 ttgcttcagt tggggcagac tctgatccct tctgccctgg cagaatggca ggggtaatct 2940 gagccttctt cactccttta ccctagctga ccccttcacc tctccccctc ccttttcctt 3000 tgttttggga ttcagaaaac tgcttgtcag agactgttta ttttttatta aaaatataag 3060 gcttaaaaaa aaaaaaaaaa aaaaaaaaaa aaaagggcgg ccgc 3104 18 2283 DNA Homo sapiens 18 atggccctcc cagccctggg cctggacccc tggagcctcc tgggcctttt cctcttccaa 60 ctgcttcagc tgctgctgcc gacgacgacc gcggggggag gcgggcaggg gcccatgccc 120 agggtcagat actatgcagg ggatgaacgt agggcactta gcttcttcca ccagaagggc 180 ctccaggatt ttgacactct gctcctgagt ggtgatggaa atactctcta cgtgggggct 240 cgagaagcca ttctggcctt ggatatccag gatccagggg tccccaggct aaagaacatg 300 ataccgtggc cagccagtga cagaaaaaag agtgaatgtg cctttaagaa gaagagcaat 360 gagacacagt gtttcaactt catccgtgtc ctggtttctt acaatgtcac ccatctctac 420 acctgcggca ccttcgcctt cagccctgct tgtaccttca ttgaacttca agattcctac 480 ctgttgccca tctcggagga caaggtcatg gagggaaaag gccaaagccc ctttgacccc 540 gctcacaagc atacggctgt cttggtggat gggatgctct attctggtac tatgaacaac 600 ttcctgggca gtgagcccat cctgatgcgc acactgggat cccagcctgt cctcaagacc 660 gacaacttcc tccgctggct gcatcatgac gcctcctttg tggcagccat cccttcgacc 720 caggtcgtct acttcttctt cgaggagaca gccagcgagt ttgacttctt tgagaggctc 780 cacacatcgc gggtggctag agtctgcaag aatgacgtgg gcggcgaaaa gctgctgcag 840 aagaagtgga ccaccttcct gaaggcccag ctgctctgca cccagccggg gcagctgccc 900 ttcaacgtca tccgccacgc ggtcctgctc cccgccgatt ctcccacagc tccccacatc 960 tacgcagtct tcacctccca gtggcaggtt ggcgggacca ggagctctgc ggtttgtgcc 1020 ttctctctct tggacattga acgtgtcttt aaggggaaat acaaagagtt gaacaaagaa 1080 acttcacgct ggactactta taggggccct gagaccaacc cccggccagg cagttgctca 1140 gtgggcccct cctctgataa ggccctgacc ttcatgaagg accatttcct gatggatgag 1200 caagtggtgg ggacgcccct gctggtgaaa tctggcgtgg agtatacacg gcttgcagtg 1260 gagacagccc agggccttga tgggcacagc catcttgtca tgtacctggg aaccaccaca 1320 gggtcgctcc acaaggctgt ggtaagtggg gacagcagtg ctcatctggt ggaagagatt 1380 cagctgttcc ctgaccctga acctgttcgc aacctgcagc tggcccccac ccagggtgca 1440 gtgtttgtag gcttctcagg aggtgtctgg agggtgcccc gagccaactg tagtgtctat 1500 gagagctgtg tggactgtgt ccttgcccgg gacccccact gtgcctggga ccctgagtcc 1560 cgaacctgtt gcctcctgtc tgcccccaac ctgaactcct ggaagcagga catggagcgg 1620 gggaacccag agtgggcatg tgccagtggc cccatgagca ggagccttcg gcctcagagc 1680 cgcccgcaaa tcattaaaga agtcctggct gtccccaact ccatcctgga gctcccctgc 1740 ccccacctgt cagccttggc ctcttattat tggagtcatg gcccagcagc agtcccagaa 1800 gcctcttcca ctgtctacaa tggctccctc ttgctgatag tgcaggatgg agttgggggt 1860 ctctaccagt gctgggcaac tgagaatggc ttttcatacc ctgtgatctc ctactgggtg 1920 gacagccagg accagaccct ggccctggat cctgaactgg caggcatccc ccgggagcat 1980 gtgaaggtcc cgttgaccag ggtcagtggt ggggccgccc tggctgccca gcagtcctac 2040 tggccccact ttgtcactgt cactgtcctc tttgccttag tgctttcagg agccctcatc 2100 atcctcgtgg cctccccatt gagagcactc cgggctcggg gcaaggttca gggctgtgag 2160 accctgcgcc ctggggagaa ggccccgtta agcagagagc aacacctcca gtctcccaag 2220 gaatgcagga cctctgccag tgatgtggac gctgacaaca actgcctagg cactgaggta 2280 gct 2283 19 761 PRT Homo sapiens 19 Met Ala Leu Pro Ala Leu Gly Leu Asp Pro Trp Ser Leu Leu Gly Leu 1 5 10 15 Phe Leu Phe Gln Leu Leu Gln Leu Leu Leu Pro Thr Thr Thr Ala Gly 20 25 30 Gly Gly Gly Gln Gly Pro Met Pro Arg Val Arg Tyr Tyr Ala Gly Asp 35 40 45 Glu Arg Arg Ala Leu Ser Phe Phe His Gln Lys Gly Leu Gln Asp Phe 50 55 60 Asp Thr Leu Leu Leu Ser Gly Asp Gly Asn Thr Leu Tyr Val Gly Ala 65 70 75 80 Arg Glu Ala Ile Leu Ala Leu Asp Ile Gln Asp Pro Gly Val Pro Arg 85 90 95 Leu Lys Asn Met Ile Pro Trp Pro Ala Ser Asp Arg Lys Lys Ser Glu 100 105 110 Cys Ala Phe Lys Lys Lys Ser Asn Glu Thr Gln Cys Phe Asn Phe Ile 115 120 125 Arg Val Leu Val Ser Tyr Asn Val Thr His Leu Tyr Thr Cys Gly Thr 130 135 140 Phe Ala Phe Ser Pro Ala Cys Thr Phe Ile Glu Leu Gln Asp Ser Tyr 145 150 155 160 Leu Leu Pro Ile Ser Glu Asp Lys Val Met Glu Gly Lys Gly Gln Ser 165 170 175 Pro Phe Asp Pro Ala His Lys His Thr Ala Val Leu Val Asp Gly Met 180 185 190 Leu Tyr Ser Gly Thr Met Asn Asn Phe Leu Gly Ser Glu Pro Ile Leu 195 200 205 Met Arg Thr Leu Gly Ser Gln Pro Val Leu Lys Thr Asp Asn Phe Leu 210 215 220 Arg Trp Leu His His Asp Ala Ser Phe Val Ala Ala Ile Pro Ser Thr 225 230 235 240 Gln Val Val Tyr Phe Phe Phe Glu Glu Thr Ala Ser Glu Phe Asp Phe 245 250 255 Phe Glu Arg Leu His Thr Ser Arg Val Ala Arg Val Cys Lys Asn Asp 260 265 270 Val Gly Gly Glu Lys Leu Leu Gln Lys Lys Trp Thr Thr Phe Leu Lys 275 280 285 Ala Gln Leu Leu Cys Thr Gln Pro Gly Gln Leu Pro Phe Asn Val Ile 290 295 300 Arg His Ala Val Leu Leu Pro Ala Asp Ser Pro Thr Ala Pro His Ile 305 310 315 320 Tyr Ala Val Phe Thr Ser Gln Trp Gln Val Gly Gly Thr Arg Ser Ser 325 330 335 Ala Val Cys Ala Phe Ser Leu Leu Asp Ile Glu Arg Val Phe Lys Gly 340 345 350 Lys Tyr Lys Glu Leu Asn Lys Glu Thr Ser Arg Trp Thr Thr Tyr Arg 355 360 365 Gly Pro Glu Thr Asn Pro Arg Pro Gly Ser Cys Ser Val Gly Pro Ser 370 375 380 Ser Asp Lys Ala Leu Thr Phe Met Lys Asp His Phe Leu Met Asp Glu 385 390 395 400 Gln Val Val Gly Thr Pro Leu Leu Val Lys Ser Gly Val Glu Tyr Thr 405 410 415 Arg Leu Ala Val Glu Thr Ala Gln Gly Leu Asp Gly His Ser His Leu 420 425 430 Val Met Tyr Leu Gly Thr Thr Thr Gly Ser Leu His Lys Ala Val Val 435 440 445 Ser Gly Asp Ser Ser Ala His Leu Val Glu Glu Ile Gln Leu Phe Pro 450 455 460 Asp Pro Glu Pro Val Arg Asn Leu Gln Leu Ala Pro Thr Gln Gly Ala 465 470 475 480 Val Phe Val Gly Phe Ser Gly Gly Val Trp Arg Val Pro Arg Ala Asn 485 490 495 Cys Ser Val Tyr Glu Ser Cys Val Asp Cys Val Leu Ala Arg Asp Pro 500 505 510 His Cys Ala Trp Asp Pro Glu Ser Arg Thr Cys Cys Leu Leu Ser Ala 515 520 525 Pro Asn Leu Asn Ser Trp Lys Gln Asp Met Glu Arg Gly Asn Pro Glu 530 535 540 Trp Ala Cys Ala Ser Gly Pro Met Ser Arg Ser Leu Arg Pro Gln Ser 545 550 555 560 Arg Pro Gln Ile Ile Lys Glu Val Leu Ala Val Pro Asn Ser Ile Leu 565 570 575 Glu Leu Pro Cys Pro His Leu Ser Ala Leu Ala Ser Tyr Tyr Trp Ser 580 585 590 His Gly Pro Ala Ala Val Pro Glu Ala Ser Ser Thr Val Tyr Asn Gly 595 600 605 Ser Leu Leu Leu Ile Val Gln Asp Gly Val Gly Gly Leu Tyr Gln Cys 610 615 620 Trp Ala Thr Glu Asn Gly Phe Ser Tyr Pro Val Ile Ser Tyr Trp Val 625 630 635 640 Asp Ser Gln Asp Gln Thr Leu Ala Leu Asp Pro Glu Leu Ala Gly Ile 645 650 655 Pro Arg Glu His Val Lys Val Pro Leu Thr Arg Val Ser Gly Gly Ala 660 665 670 Ala Leu Ala Ala Gln Gln Ser Tyr Trp Pro His Phe Val Thr Val Thr 675 680 685 Val Leu Phe Ala Leu Val Leu Ser Gly Ala Leu Ile Ile Leu Val Ala 690 695 700 Ser Pro Leu Arg Ala Leu Arg Ala Arg Gly Lys Val Gln Gly Cys Glu 705 710 715 720 Thr Leu Arg Pro Gly Glu Lys Ala Pro Leu Ser Arg Glu Gln His Leu 725 730 735 Gln Ser Pro Lys Glu Cys Arg Thr Ser Ala Ser Asp Val Asp Ala Asp 740 745 750 Asn Asn Cys Leu Gly Thr Glu Val Ala 755 760 20 31 PRT Homo sapiens 20 Met Ala Leu Pro Ala Leu Gly Leu Asp Pro Trp Ser Leu Leu Gly Leu 1 5 10 15 Phe Leu Phe Gln Leu Leu Gln Leu Leu Leu Pro Thr Thr Thr Ala 20 25 30 21 730 PRT Homo sapiens 21 Gly Gly Gly Gly Gln Gly Pro Met Pro Arg Val Arg Tyr Tyr Ala Gly 1 5 10 15 Asp Glu Arg Arg Ala Leu Ser Phe Phe His Gln Lys Gly Leu Gln Asp 20 25 30 Phe Asp Thr Leu Leu Leu Ser Gly Asp Gly Asn Thr Leu Tyr Val Gly 35 40 45 Ala Arg Glu Ala Ile Leu Ala Leu Asp Ile Gln Asp Pro Gly Val Pro 50 55 60 Arg Leu Lys Asn Met Ile Pro Trp Pro Ala Ser Asp Arg Lys Lys Ser 65 70 75 80 Glu Cys Ala Phe Lys Lys Lys Ser Asn Glu Thr Gln Cys Phe Asn Phe 85 90 95 Ile Arg Val Leu Val Ser Tyr Asn Val Thr His Leu Tyr Thr Cys Gly 100 105 110 Thr Phe Ala Phe Ser Pro Ala Cys Thr Phe Ile Glu Leu Gln Asp Ser 115 120 125 Tyr Leu Leu Pro Ile Ser Glu Asp Lys Val Met Glu Gly Lys Gly Gln 130 135 140 Ser Pro Phe Asp Pro Ala His Lys His Thr Ala Val Leu Val Asp Gly 145 150 155 160 Met Leu Tyr Ser Gly Thr Met Asn Asn Phe Leu Gly Ser Glu Pro Ile 165 170 175 Leu Met Arg Thr Leu Gly Ser Gln Pro Val Leu Lys Thr Asp Asn Phe 180 185 190 Leu Arg Trp Leu His His Asp Ala Ser Phe Val Ala Ala Ile Pro Ser 195 200 205 Thr Gln Val Val Tyr Phe Phe Phe Glu Glu Thr Ala Ser Glu Phe Asp 210 215 220 Phe Phe Glu Arg Leu His Thr Ser Arg Val Ala Arg Val Cys Lys Asn 225 230 235 240 Asp Val Gly Gly Glu Lys Leu Leu Gln Lys Lys Trp Thr Thr Phe Leu 245 250 255 Lys Ala Gln Leu Leu Cys Thr Gln Pro Gly Gln Leu Pro Phe Asn Val 260 265 270 Ile Arg His Ala Val Leu Leu Pro Ala Asp Ser Pro Thr Ala Pro His 275 280 285 Ile Tyr Ala Val Phe Thr Ser Gln Trp Gln Val Gly Gly Thr Arg Ser 290 295 300 Ser Ala Val Cys Ala Phe Ser Leu Leu Asp Ile Glu Arg Val Phe Lys 305 310 315 320 Gly Lys Tyr Lys Glu Leu Asn Lys Glu Thr Ser Arg Trp Thr Thr Tyr 325 330 335 Arg Gly Pro Glu Thr Asn Pro Arg Pro Gly Ser Cys Ser Val Gly Pro 340 345 350 Ser Ser Asp Lys Ala Leu Thr Phe Met Lys Asp His Phe Leu Met Asp 355 360 365 Glu Gln Val Val Gly Thr Pro Leu Leu Val Lys Ser Gly Val Glu Tyr 370 375 380 Thr Arg Leu Ala Val Glu Thr Ala Gln Gly Leu Asp Gly His Ser His 385 390 395 400 Leu Val Met Tyr Leu Gly Thr Thr Thr Gly Ser Leu His Lys Ala Val 405 410 415 Val Ser Gly Asp Ser Ser Ala His Leu Val Glu Glu Ile Gln Leu Phe 420 425 430 Pro Asp Pro Glu Pro Val Arg Asn Leu Gln Leu Ala Pro Thr Gln Gly 435 440 445 Ala Val Phe Val Gly Phe Ser Gly Gly Val Trp Arg Val Pro Arg Ala 450 455 460 Asn Cys Ser Val Tyr Glu Ser Cys Val Asp Cys Val Leu Ala Arg Asp 465 470 475 480 Pro His Cys Ala Trp Asp Pro Glu Ser Arg Thr Cys Cys Leu Leu Ser 485 490 495 Ala Pro Asn Leu Asn Ser Trp Lys Gln Asp Met Glu Arg Gly Asn Pro 500 505 510 Glu Trp Ala Cys Ala Ser Gly Pro Met Ser Arg Ser Leu Arg Pro Gln 515 520 525 Ser Arg Pro Gln Ile Ile Lys Glu Val Leu Ala Val Pro Asn Ser Ile 530 535 540 Leu Glu Leu Pro Cys Pro His Leu Ser Ala Leu Ala Ser Tyr Tyr Trp 545 550 555 560 Ser His Gly Pro Ala Ala Val Pro Glu Ala Ser Ser Thr Val Tyr Asn 565 570 575 Gly Ser Leu Leu Leu Ile Val Gln Asp Gly Val Gly Gly Leu Tyr Gln 580 585 590 Cys Trp Ala Thr Glu Asn Gly Phe Ser Tyr Pro Val Ile Ser Tyr Trp 595 600 605 Val Asp Ser Gln Asp Gln Thr Leu Ala Leu Asp Pro Glu Leu Ala Gly 610 615 620 Ile Pro Arg Glu His Val Lys Val Pro Leu Thr Arg Val Ser Gly Gly 625 630 635 640 Ala Ala Leu Ala Ala Gln Gln Ser Tyr Trp Pro His Phe Val Thr Val 645 650 655 Thr Val Leu Phe Ala Leu Val Leu Ser Gly Ala Leu Ile Ile Leu Val 660 665 670 Ala Ser Pro Leu Arg Ala Leu Arg Ala Arg Gly Lys Val Gln Gly Cys 675 680 685 Glu Thr Leu Arg Pro Gly Glu Lys Ala Pro Leu Ser Arg Glu Gln His 690 695 700 Leu Gln Ser Pro Lys Glu Cys Arg Thr Ser Ala Ser Asp Val Asp Ala 705 710 715 720 Asp Asn Asn Cys Leu Gly Thr Glu Val Ala 725 730 22 652 PRT Homo sapiens 22 Gly Gly Gly Gly Gln Gly Pro Met Pro Arg Val Arg Tyr Tyr Ala Gly 1 5 10 15 Asp Glu Arg Arg Ala Leu Ser Phe Phe His Gln Lys Gly Leu Gln Asp 20 25 30 Phe Asp Thr Leu Leu Leu Ser Gly Asp Gly Asn Thr Leu Tyr Val Gly 35 40 45 Ala Arg Glu Ala Ile Leu Ala Leu Asp Ile Gln Asp Pro Gly Val Pro 50 55 60 Arg Leu Lys Asn Met Ile Pro Trp Pro Ala Ser Asp Arg Lys Lys Ser 65 70 75 80 Glu Cys Ala Phe Lys Lys Lys Ser Asn Glu Thr Gln Cys Phe Asn Phe 85 90 95 Ile Arg Val Leu Val Ser Tyr Asn Val Thr His Leu Tyr Thr Cys Gly 100 105 110 Thr Phe Ala Phe Ser Pro Ala Cys Thr Phe Ile Glu Leu Gln Asp Ser 115 120 125 Tyr Leu Leu Pro Ile Ser Glu Asp Lys Val Met Glu Gly Lys Gly Gln 130 135 140 Ser Pro Phe Asp Pro Ala His Lys His Thr Ala Val Leu Val Asp Gly 145 150 155 160 Met Leu Tyr Ser Gly Thr Met Asn Asn Phe Leu Gly Ser Glu Pro Ile 165 170 175 Leu Met Arg Thr Leu Gly Ser Gln Pro Val Leu Lys Thr Asp Asn Phe 180 185 190 Leu Arg Trp Leu His His Asp Ala Ser Phe Val Ala Ala Ile Pro Ser 195 200 205 Thr Gln Val Val Tyr Phe Phe Phe Glu Glu Thr Ala Ser Glu Phe Asp 210 215 220 Phe Phe Glu Arg Leu His Thr Ser Arg Val Ala Arg Val Cys Lys Asn 225 230 235 240 Asp Val Gly Gly Glu Lys Leu Leu Gln Lys Lys Trp Thr Thr Phe Leu 245 250 255 Lys Ala Gln Leu Leu Cys Thr Gln Pro Gly Gln Leu Pro Phe Asn Val 260 265 270 Ile Arg His Ala Val Leu Leu Pro Ala Asp Ser Pro Thr Ala Pro His 275 280 285 Ile Tyr Ala Val Phe Thr Ser Gln Trp Gln Val Gly Gly Thr Arg Ser 290 295 300 Ser Ala Val Cys Ala Phe Ser Leu Leu Asp Ile Glu Arg Val Phe Lys 305 310 315 320 Gly Lys Tyr Lys Glu Leu Asn Lys Glu Thr Ser Arg Trp Thr Thr Tyr 325 330 335 Arg Gly Pro Glu Thr Asn Pro Arg Pro Gly Ser Cys Ser Val Gly Pro 340 345 350 Ser Ser Asp Lys Ala Leu Thr Phe Met Lys Asp His Phe Leu Met Asp 355 360 365 Glu Gln Val Val Gly Thr Pro Leu Leu Val Lys Ser Gly Val Glu Tyr 370 375 380 Thr Arg Leu Ala Val Glu Thr Ala Gln Gly Leu Asp Gly His Ser His 385 390 395 400 Leu Val Met Tyr Leu Gly Thr Thr Thr Gly Ser Leu His Lys Ala Val 405 410 415 Val Ser Gly Asp Ser Ser Ala His Leu Val Glu Glu Ile Gln Leu Phe 420 425 430 Pro Asp Pro Glu Pro Val Arg Asn Leu Gln Leu Ala Pro Thr Gln Gly 435 440 445 Ala Val Phe Val Gly Phe Ser Gly Gly Val Trp Arg Val Pro Arg Ala 450 455 460 Asn Cys Ser Val Tyr Glu Ser Cys Val Asp Cys Val Leu Ala Arg Asp 465 470 475 480 Pro His Cys Ala Trp Asp Pro Glu Ser Arg Thr Cys Cys Leu Leu Ser 485 490 495 Ala Pro Asn Leu Asn Ser Trp Lys Gln Asp Met Glu Arg Gly Asn Pro 500 505 510 Glu Trp Ala Cys Ala Ser Gly Pro Met Ser Arg Ser Leu Arg Pro Gln 515 520 525 Ser Arg Pro Gln Ile Ile Lys Glu Val Leu Ala Val Pro Asn Ser Ile 530 535 540 Leu Glu Leu Pro Cys Pro His Leu Ser Ala Leu Ala Ser Tyr Tyr Trp 545 550 555 560 Ser His Gly Pro Ala Ala Val Pro Glu Ala Ser Ser Thr Val Tyr Asn 565 570 575 Gly Ser Leu Leu Leu Ile Val Gln Asp Gly Val Gly Gly Leu Tyr Gln 580 585 590 Cys Trp Ala Thr Glu Asn Gly Phe Ser Tyr Pro Val Ile Ser Tyr Trp 595 600 605 Val Asp Ser Gln Asp Gln Thr Leu Ala Leu Asp Pro Glu Leu Ala Gly 610 615 620 Ile Pro Arg Glu His Val Lys Val Pro Leu Thr Arg Val Ser Gly Gly 625 630 635 640 Ala Ala Leu Ala Ala Gln Gln Ser Tyr Trp Pro His 645 65023 21 PRT Homo sapiens 23 Phe Val Thr Val Thr Val Leu Phe Ala Leu Val Leu Ser Gly Ala Leu 1 5 10 15 Ile Ile Leu Val Ala 20 24 57 PRT Homo sapiens 24 Ser Pro Leu Arg Ala Leu Arg Ala Arg Gly Lys Val Gln Gly Cys Glu 1 5 10 15 Thr Leu Arg Pro Gly Glu Lys Ala Pro Leu Ser Arg Glu Gln His Leu 20 25 30 Gln Ser Pro Lys Glu Cys Arg Thr Ser Ala Ser Asp Val Asp Ala Asp 35 40 45 Asn Asn Cys Leu Gly Thr Glu Val Ala 50 55 25 2964 DNA Homo sapiens 25 gtcgacccac gcgtccgcgg acgcgtgggg acggctcccg gctgcagtct gcccgcccgc 60 cccgcgcggg ggccgagtcg cgaagcgcgc ctgcgacccg gcgtccgggc gcgctggaga 120 ggacgcgagg agccatgagg cgccagcctg cgaaggtggcggcgctgctg ctcgggctgc 180 tcttggagtg cacagaagcc aaaaagcatt gctggtattt cgaaggactc tatccaacct 240 attatatatg ccgctcctac gaggactgct gtggctccag gtgctgtgtg cgggccctct 300 ccatacagag gctgtggtac ttctggttcc ttctgatgat gggcgtgctt ttctgctgcg 360 gagccggctt cttcatccgg aggcgcatgt accccccgcc gctgatcgag gagccagcct 420 tcaatgtgtc ctacaccagg cagcccccaa atcccggccc aggagcccag cagccggggc 480 cgccctatta cactgaccca ggaggaccgg ggatgaaccc tgtcgggaat tccatggcaa 540 tggctttcca ggtcccaccc aactcacccc aggggagtgt ggcctgcccg ccccctccag 600 cctactgcaa cacgcctccg cccccgtacg aacaggtagt gaaggccaag tagtggggtg 660 cccacgtgca agaggagaga caggagaggg cctttccctg gcctttctgt cttcgttgat 720 gttcacttcc aggaacggtc tcgtgggctg ctaagggcag ttcctctgat atcctcacag 780 caagcacagc tctctttcag gctttccatggagtacaata tatgaactca cactttgtct 840 cctctgttgc ttctgtttct gacgcagtct gtgctctcac atggtagtgtggtgacagtc 900 cccgagggct gacgtcctta cggtggcgtg accagatcta caggagagag actgagagga 960 agaaggcagt gctggaggtg caggtggcat gtagaggggc caggccgagc atcccaggca 1020 agcatccttc tgcccgggta ttaataggaa gccccatgcc gggcggctca gccgatgaag 1080 cagcagccga ctgagctgag cccagcaggt catctgctcc agcctgtcctctcgtcagcc 1140 ttcctcttcc agaagctgtt ggagagacat tcaggagaga gcaagcccct tgtcatgttt 1200 ctgtctctgt tcatatccta aagatagact tctcctgcac cgccagggaa gggtagcacg 1260 tgcagctctc accgcaggat ggggcctaga atcaggcttg ccttggaggc ctgacagtga 1320 tctgacatcc actaagcaaa tttatttaaa ttcatgggaa atcacttcct gccccaaact 1380 gagacattgc attttgtgag ctcttggtct gatttggaga aaggactgtt acccattttt 1440 ttggtgtgtt tatggaagtg catgtagagc gtcctgccct ttgaaatcagactgggtgtg 1500 tgtcttccct ggacatcact gcctctccag ggcattctca ggcccgggggtctccttccc 1560 tcaggcagct ccagtggtgg gttctgaagg gtgctttcaa aacggggcac atctggctgg 1620 gaagtcacat ggactcttcc agggagagag accagctgag gcgtctctct ctgaggttgt 1680 gttgggtcta agcgggtgtg tgctgggctccaaggaggag gagcttgctg ggaaaagaca 1740 ggagaagtac tgactcaact gcactgacca tgttgtcata attagaataa agaagaagtg 1800 gtcggaaatg cacattcctg gataggaatc acagctcacc ccaggatctc acaggtagtc 1860 tcctgagtag ttgacggcta gcggggagct agttccgccg catagttata gtgttgatgt 1920 gtgaacgctg acctgtcctg tgtgctaaga gctatgcagc ttagctgagg cgcctagatt 1980 actagatgtg ctgtatcacg gggaatgagg tgggggtgct tattttttaatgaactaatc 2040 agagcctctt gagaaattgt tactcattga actggagcat caagacatct catggaagtg 2100 gatacggagt gatttggtgt ccatgctttt cactctgagg acatttaatcggagaacctc 2160 ctggggaatt ttgtgggaga cacttgggaa caaaacagac accctgggaa tgcagttgca 2220 agcacagatg ctgccaccag tgtctctgac caccctggtg tgactgctgactgccagcgt 2280 ggtacctccc atgctgcagg cctccatcta aatgagacaa caaagcacaa tgttcactgt 2340 ttacaaccaa gacaactgcg tgggtccaaa cactcctctt cctccaggtc atttgttttg 2400 catttttaat gtctttattt tttgtaatga aaaagcacac taagctgccc ctggaatcgg 2460 gtgcagctga ataggcaccc aaaagtccgt gactaaatttcgtttgtctt tttgatagca 2520 aattatgtta agagacagtg atggctaggg ctcaacaatt ttgtattccc atgtttgtgt 2580 gagacagagt ttgttttccc ttgaacttgg ttagaattgt gctactgtga acgctgatcc 2640 tgcatatgga agtcccactt tggtgacatt tcctggccat tcttgtttcc attgtgtgga 2700 tggtgggttg tgcccacttc ctggagtgag acagctcctg gtgtgtagaa ttcccggagc 2760 gtccgtggtt cagagtaaac ttgaagcaga tctgtgcatg cttttcctctgcaacaattg 2820 gctcgtttct cttttttgtt ctcttttgat aggatcctgt ttcctatgtgtgcaaaataa 2880 aaataaattt gggcaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2940 aaaaaaaaaa aaaagggcggccgc 296426 516 DNA Homo sapiens 26 atgaggcgcc agcctgcgaa ggtggcggcg ctgctgctcg ggctgctctt ggagtgcaca 60 gaagccaaaa agcattgctg gtatttcgaa ggactctatc caacctatta tatatgccgc 120 tcctacgagg actgctgtgg ctccaggtgc tgtgtgcggg ccctctccat acagaggctg 180 tggtacttct ggttccttct gatgatgggc gtgcttttct gctgcggagc cggcttcttc 240 atccggaggc gcatgtaccc cccgccgctg atcgaggagc cagccttcaa tgtgtcctac 300 accaggcagc ccccaaatcc cggcccagga gcccagcagc cggggccgcc ctattacact 360 gacccaggag gaccggggat gaaccctgtc gggaattcca tggcaatggc tttccaggtc 420 ccacccaact caccccaggg gagtgtggcc tgcccgcccc ctccagcctactgcaacacg 480 cctccgcccc cgtacgaaca ggtagtgaag gccaag 51627 172 PRT Homo sapiens 27 Met Arg Arg Gln Pro Ala Lys Val Ala Ala Leu Leu Leu Gly Leu Leu 1 5 10 15 Leu Glu Cys Thr Glu Ala Lys Lys His Cys Trp Tyr Phe Glu Gly Leu 20 25 30 Tyr Pro Thr Tyr Tyr Ile Cys Arg Ser Tyr Glu Asp Cys Cys Gly Ser 35 40 45 Arg Cys Cys Val Arg Ala Leu Ser Ile Gln Arg Leu Trp Tyr Phe Trp 50 55 60 Phe Leu Leu Met Met Gly Val Leu Phe Cys Cys Gly Ala Gly Phe Phe 65 70 75 80 Ile Arg Arg Arg Met Tyr Pro Pro Pro Leu Ile Glu Glu Pro Ala Phe 85 90 95 Asn Val Ser Tyr Thr Arg Gln Pro Pro Asn Pro Gly Pro Gly Ala Gln 100 105 110 Gln Pro Gly Pro Pro Tyr Tyr Thr Asp Pro Gly Gly Pro Gly Met Asn 115 120 125 Pro Val Gly Asn Ser Met Ala Met Ala Phe Gln Val Pro Pro Asn Ser 130 135 140 Pro Gln Gly Ser Val Ala Cys Pro Pro Pro Pro Ala Tyr Cys Asn Thr 145 150 155 160 Pro Pro Pro Pro Tyr Glu Gln Val Val Lys Ala Lys 165 170 28 22 PRT Homo sapiens 28 Met Arg Arg Gln Pro Ala Lys Val Ala Ala Leu Leu Leu Gly Leu Leu 1 5 10 15 Leu Glu Cys Thr Glu Ala 20 29 150 PRT Homo sapiens 29 Lys Lys His Cys Trp Tyr Phe Glu Gly Leu Tyr Pro Thr Tyr Tyr Ile 1 5 10 15 Cys Arg Ser Tyr Glu Asp Cys Cys Gly Ser Arg Cys Cys Val Arg Ala 20 25 30 Leu Ser Ile Gln Arg Leu Trp Tyr Phe Trp Phe Leu Leu Met Met Gly 35 40 45 Val Leu Phe Cys Cys Gly Ala Gly Phe Phe Ile Arg Arg Arg Met Tyr 50 55 60 Pro Pro Pro Leu Ile Glu Glu Pro Ala Phe Asn Val Ser Tyr Thr Arg 65 70 75 80 Gln Pro Pro Asn Pro Gly Pro Gly Ala Gln Gln Pro Gly Pro Pro Tyr 85 90 95 Tyr Thr Asp Pro Gly Gly Pro Gly Met Asn Pro Val Gly Asn Ser Met 100 105 110 Ala Met Ala Phe Gln Val Pro Pro Asn Ser Pro Gln Gly Ser Val Ala 115 120 125 Cys Pro Pro Pro Pro Ala Tyr Cys Asn Thr Pro Pro Pro Pro Tyr Glu 130 135 140 Gln Val Val Lys Ala Lys 145 150 30 38 PRT Homo sapiens 30 Lys Lys His Cys Trp Tyr Phe Glu Gly Leu Tyr Pro Thr Tyr Tyr Ile 1 5 10 15 Cys Arg Ser Tyr Glu Asp Cys Cys Gly Ser Arg Cys Cys Val Arg Ala 20 25 30 Leu Ser Ile Gln Arg Leu 35 31 21 PRT Homo sapiens 31 Trp Tyr Phe Trp Phe Leu Leu Met Met Gly Val Leu Phe Cys Cys Gly 1 5 10 15 Ala Gly Phe Phe Ile 20 32 91 PRT Homo sapiens 32 Arg Arg Arg Met Tyr Pro Pro Pro Leu Ile Glu Glu Pro Ala Phe Asn 1 5 10 15 Val Ser Tyr Thr Arg Gln Pro Pro Asn Pro Gly Pro Gly Ala Gln Gln 20 25 30 Pro Gly Pro Pro Tyr Tyr Thr Asp Pro Gly Gly Pro Gly Met Asn Pro 35 40 45 Val Gly Asn Ser Met Ala Met Ala Phe Gln Val Pro Pro Asn Ser Pro 50 55 60 Gln Gly Ser Val Ala Cys Pro Pro Pro Pro Ala Tyr Cys Asn Thr Pro 65 70 75 80 Pro Pro Pro Tyr Glu Gln Val Val Lys Ala Lys 85 90 33 1980 DNA Homo sapiens 33 gtcgacccac gcgtccgcag ctttggacac ttcctctgct tgaggacacc ttgactaacc 60 tccaagggca actaaaggat caagaaaggc ccagcacagc agaagatcag ctggatctag 120 ctcctgcagg agatgtgtac aaagacaatc ccagtcctct ggggatgttt cctcctgtgg 180 aatctctatg tctcatcctc tcagaccatt taccctggaa tcaaggcaag gattactcag 240 agggcacttg actatggtgt tcaagctgga atgaagatga ttgagcaaatgctaaaagaa 300 aagaaactcc cagatttaag cggttctgag tctcttgaat ttctaaaagt tgattatgta 360 aactacaatt tttcaaatat aaaaatcagt gccttttcat ttccaaatac ctcattggct 420 tttgtgcctg gagtgggaat caaagcgctaaccaaccatg gcactgccaa catcagcaca 480 gactgggggt tcgagtctcc actttttgtt ctgtataact cctttgctga gcccatggag 540 aaacccattt taaagaactt aaatgaaatg ctctgtccca ttattgcaag tgaagtcaaa 600 gcgctaaatg ccaacctcag cacactggag gttttaacca agattgacaactacactctg 660 ctggattact ccctaatcag ttctccagaa attactgaga actaccttga cctgaacttg 720 aagggtgtat tctacccact ggaaaacctc accgaccccc ccttctcacc agttcctttt 780 gtgctcccag aacgcagcaa ctccatgctc tacattggaa tcgccgagta tttctttaaa 840 tctgcgtcct ttgctcattt cacagctggg gttttcaatc tcactctctc caccgaagag 900 atttccaacc attttgttca aaactctcaa ggccttggca acgtgctctc ccggattgca 960 gagatctaca tcttgtccca gcccttcatg gtgaggatca tggccacaga gcctcccata 1020 atcaatctac aaccaggcaa tttcaccctg gacatccctg cctccatcat gatgctcacc 1080 caacccaaga actccacagt tgaaaccatc gtttccatgg acttcgttgc tagtaccagt 1140 gttggcctgg ttattttggg acaaagactg gtctgctcct tgtctctgaa cagattccgc 1200 cttgctttgc cagagtccaa tcgcagcaac attgaggtct tgaggtttga aaatattcta 1260 tcgtccattc ttcactttgg agtcctccca ctggccaatg caaaattgca gcaaggattt 1320 cctctgccca atccacacaa attcttattc gtcaattcag atattgaagt tcttgagggt 1380 ttccttttga tttccaccga cctgaagtat gaaacatcct caaagcagca gccaagtttc 1440 cacgtatggg aaggtctgaa cctgataagc agacagtgga gggggaagtc agccccttga 1500 ttgccggttt gcaattcacc ccaggaagta aatggtcctt aatcctacaactactgtaaa 1560 cccagaaggg aaagacagta cacactggaa ttgtaaagcc cttgtgaattgcttaggcag 1620 aaagttttct ttcttaagcc ttcaggaacc cagaataagg cagactctgt taaagggata 1680 aatagaggtg tctgaatgtg agtgtatgca tgctgcgtgt gtctgtgttt atgtttgttt 1740 gtttgtttgg ggcaagaaag attctaggac aagagctagg catgtacttc tgaccaggtg 1800 ggtaagcaac tctaagtctg tatttgtatt ggtcattctc agtggaaatc ccttaggccc 1860 tctagtggtt ttcccctacc tgcatattgg ttttcatgttttatattcac tgttactatc 1920 ttctgtgttt aattaaaatt gttttctatc aaaaaaaaaa aaaaaaaaaagggcggccgc 198034 1365 DNA Homo sapiens 34 atgtgtacaa agacaatccc agtcctctgg ggatgtttcc tcctgtggaa tctctatgtc 60 tcatcctctc agaccattta ccctggaatc aaggcaagga ttactcagag ggcacttgac 120 tatggtgttc aagctggaat gaagatgatt gagcaaatgc taaaagaaaa gaaactccca 180 gatttaagcg gttctgagtc tcttgaattt ctaaaagttg attatgtaaa ctacaatttt 240 tcaaatataa aaatcagtgc cttttcattt ccaaatacct cattggcttt tgtgcctgga 300 gtgggaatca aagcgctaac caaccatggc actgccaaca tcagcacagactgggggttc 360 gagtctccac tttttgttct gtataactcc tttgctgagc ccatggagaa acccatttta 420 aagaacttaa atgaaatgct ctgtcccatt attgcaagtgaagtcaaagc gctaaatgcc 480 aacctcagca cactggaggt tttaaccaag attgacaact acactctgct ggattactcc 540 ctaatcagtt ctccagaaat tactgagaac taccttgacc tgaacttgaa gggtgtattc 600 tacccactgg aaaacctcac cgaccccccc ttctcaccag ttccttttgt gctcccagaa 660 cgcagcaact ccatgctcta cattggaatc gccgagtatt tctttaaatc tgcgtccttt 720 gctcatttca cagctggggt tttcaatctc actctctcca ccgaagagat ttccaaccat 780 tttgttcaaa actctcaagg ccttggcaac gtgctctccc ggattgcagagatctacatc 840 ttgtcccagc ccttcatggt gaggatcatg gccacagagc ctcccataatcaatctacaa 900 ccaggcaatt tcaccctgga catccctgcc tccatcatga tgctcaccca acccaagaac 960 tccacagttg aaaccatcgt ttccatggac ttcgttgcta gtaccagtgt tggcctggtt 1020 attttgggac aaagactggt ctgctccttg tctctgaaca gattccgcct tgctttgcca 1080 gagtccaatc gcagcaacat tgaggtcttg aggtttgaaa atattctatc gtccattctt 1140 cactttggag tcctcccact ggccaatgca aaattgcagc aaggatttcc tctgcccaat 1200 ccacacaaat tcttattcgt caattcagat attgaagttc ttgagggttt ccttttgatt 1260 tccaccgacc tgaagtatga aacatcctca aagcagcagc caagtttccacgtatgggaa 1320 ggtctgaacc tgataagcag acagtggagg gggaagtcag cccct 136535 455 PRT Homo sapiens 35 Met Cys Thr Lys Thr Ile Pro Val Leu Trp Gly Cys Phe Leu Leu Trp 1 5 10 15 Asn Leu Tyr Val Ser Ser Ser Gln Thr Ile Tyr Pro Gly Ile Lys Ala 20 25 30 Arg Ile Thr Gln Arg Ala Leu Asp Tyr Gly Val Gln Ala Gly Met Lys 35 40 45 Met Ile Glu Gln Met Leu Lys Glu Lys Lys Leu Pro Asp Leu Ser Gly 50 55 60 Ser Glu Ser Leu Glu Phe Leu Lys Val Asp Tyr Val Asn Tyr Asn Phe 65 70 75 80 Ser Asn Ile Lys Ile Ser Ala Phe Ser Phe Pro Asn Thr Ser Leu Ala 85 90 95 Phe Val Pro Gly Val Gly Ile Lys Ala Leu Thr Asn His Gly Thr Ala 100 105 110 Asn Ile Ser Thr Asp Trp Gly Phe Glu Ser Pro Leu Phe Val Leu Tyr 115 120 125 Asn Ser Phe Ala Glu Pro Met Glu Lys Pro Ile Leu Lys Asn Leu Asn 130 135 140 Glu Met Leu Cys Pro Ile Ile Ala Ser Glu Val Lys Ala Leu Asn Ala 145 150 155 160 Asn Leu Ser Thr Leu Glu Val Leu Thr Lys Ile Asp Asn Tyr Thr Leu 165 170 175 Leu Asp Tyr Ser Leu Ile Ser Ser Pro Glu Ile Thr Glu Asn Tyr Leu 180 185 190 Asp Leu Asn Leu Lys Gly Val Phe Tyr Pro Leu Glu Asn Leu Thr Asp 195 200 205 Pro Pro Phe Ser Pro Val Pro Phe Val Leu Pro Glu Arg Ser Asn Ser 210 215 220 Met Leu Tyr Ile Gly Ile Ala Glu Tyr Phe Phe Lys Ser Ala Ser Phe 225 230 235 240 Ala His Phe Thr Ala Gly Val Phe Asn Leu Thr Leu Ser Thr Glu Glu 245 250 255 Ile Ser Asn His Phe Val Gln Asn Ser Gln Gly Leu Gly Asn Val Leu 260 265 270 Ser Arg Ile Ala Glu Ile Tyr Ile Leu Ser Gln Pro Phe Met Val Arg 275 280 285 Ile Met Ala Thr Glu Pro Pro Ile Ile Asn Leu Gln Pro Gly Asn Phe 290 295 300 Thr Leu Asp Ile Pro Ala Ser Ile Met Met Leu Thr Gln Pro Lys Asn 305 310 315 320 Ser Thr Val Glu Thr Ile Val Ser Met Asp Phe Val Ala Ser Thr Ser 325 330 335 Val Gly Leu Val Ile Leu Gly Gln Arg Leu Val Cys Ser Leu Ser Leu 340 345 350 Asn Arg Phe Arg Leu Ala Leu Pro Glu Ser Asn Arg Ser Asn Ile Glu 355 360 365 Val Leu Arg Phe Glu Asn Ile Leu Ser Ser Ile Leu His Phe Gly Val 370 375 380 Leu Pro Leu Ala Asn Ala Lys Leu Gln Gln Gly Phe Pro Leu Pro Asn 385 390 395 400 Pro His Lys Phe Leu Phe Val Asn Ser Asp Ile Glu Val Leu Glu Gly 405 410 415 Phe Leu Leu Ile Ser Thr Asp Leu Lys Tyr Glu Thr Ser Ser Lys Gln 420 425 430 Gln Pro Ser Phe His Val Trp Glu Gly Leu Asn Leu Ile Ser Arg Gln 435 440 445 Trp Arg Gly Lys Ser Ala Pro 450 45536 23 PRT Homo sapiens 36 Met Cys Thr Lys Thr Ile Pro Val Leu Trp Gly Cys Phe Leu Leu Trp 1 5 10 15 Asn Leu Tyr Val Ser Ser Ser 20 37 432 PRT Homo sapiens 37 Gln Thr Ile Tyr Pro Gly Ile Lys Ala Arg Ile Thr Gln Arg Ala Leu 1 5 10 15 Asp Tyr Gly Val Gln Ala Gly Met Lys Met Ile Glu Gln Met Leu Lys 20 25 30 Glu Lys Lys Leu Pro Asp Leu Ser Gly Ser Glu Ser Leu Glu Phe Leu 35 40 45 Lys Val Asp Tyr Val Asn Tyr Asn Phe Ser Asn Ile Lys Ile Ser Ala 50 55 60 Phe Ser Phe Pro Asn Thr Ser Leu Ala Phe Val Pro Gly Val Gly Ile 65 70 75 80 Lys Ala Leu Thr Asn His Gly Thr Ala Asn Ile Ser Thr Asp Trp Gly 85 90 95 Phe Glu Ser Pro Leu Phe Val Leu Tyr Asn Ser Phe Ala Glu Pro Met 100 105 110 Glu Lys Pro Ile Leu Lys Asn Leu Asn Glu Met Leu Cys Pro Ile Ile 115 120 125 Ala Ser Glu Val Lys Ala Leu Asn Ala Asn Leu Ser Thr Leu Glu Val 130 135 140 Leu Thr Lys Ile Asp Asn Tyr Thr Leu Leu Asp Tyr Ser Leu Ile Ser 145 150 155 160 Ser Pro Glu Ile Thr Glu Asn Tyr Leu Asp Leu Asn Leu Lys Gly Val 165 170 175 Phe Tyr Pro Leu Glu Asn Leu Thr Asp Pro Pro Phe Ser Pro Val Pro 180 185 190 Phe Val Leu Pro Glu Arg Ser Asn Ser Met Leu Tyr Ile Gly Ile Ala 195 200 205 Glu Tyr Phe Phe Lys Ser Ala Ser Phe Ala His Phe Thr Ala Gly Val 210 215 220 Phe Asn Leu Thr Leu Ser Thr Glu Glu Ile Ser Asn His Phe Val Gln 225 230 235 240 Asn Ser Gln Gly Leu Gly Asn Val Leu Ser Arg Ile Ala Glu Ile Tyr 245 250 255 Ile Leu Ser Gln Pro Phe Met Val Arg Ile Met Ala Thr Glu Pro Pro 260 265 270 Ile Ile Asn Leu Gln Pro Gly Asn Phe Thr Leu Asp Ile Pro Ala Ser 275 280 285 Ile Met Met Leu Thr Gln Pro Lys Asn Ser Thr Val Glu Thr Ile Val 290 295 300 Ser Met Asp Phe Val Ala Ser Thr Ser Val Gly Leu Val Ile Leu Gly 305 310 315 320 Gln Arg Leu Val Cys Ser Leu Ser Leu Asn Arg Phe Arg Leu Ala Leu 325 330 335 Pro Glu Ser Asn Arg Ser Asn Ile Glu Val Leu Arg Phe Glu Asn Ile 340 345 350 Leu Ser Ser Ile Leu His Phe Gly Val Leu Pro Leu Ala Asn Ala Lys 355 360 365 Leu Gln Gln Gly Phe Pro Leu Pro Asn Pro His Lys Phe Leu Phe Val 370 375 380 Asn Ser Asp Ile Glu Val Leu Glu Gly Phe Leu Leu Ile Ser Thr Asp 385 390 395 400 Leu Lys Tyr Glu Thr Ser Ser Lys Gln Gln Pro Ser Phe His Val Trp 405 410 415 Glu Gly Leu Asn Leu Ile Ser Arg Gln Trp Arg Gly Lys Ser Ala Pro 420 425 430 38 483 PRT Homo sapiens 38 Met Ala Arg Gly Pro Cys Asn Ala Pro Arg Trp Val Ser Leu Met Val 1 5 10 15 Leu Val Ala Ile Gly Thr Ala Val Thr Ala Ala Val Asn Pro Gly Val 20 25 30 Val Val Arg Ile Ser Gln Lys Gly Leu Asp Tyr Ala Ser Gln Gln Gly 35 40 45 Thr Ala Ala Leu Gln Lys Glu Leu Lys Arg Ile Lys Ile Pro Asp Tyr 50 55 60 Ser Asp Ser Phe Lys Ile Lys His Leu Gly Lys Gly His Tyr Ser Phe 65 70 75 80 Tyr Ser Met Asp Ile Arg Glu Phe Gln Leu Pro Ser Ser Gln Ile Ser 85 90 95 Met Val Pro Asn Val Gly Leu Lys Phe Ser Ile Ser Asn Ala Asn Ile 100 105 110 Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys Met Ser 115 120 125 Gly Asn Phe Asp Leu Ser Ile Glu Gly Met Ser Ile Ser Ala Asp Leu 130 135 140 Lys Leu Gly Ser Asn Pro Thr Ser Gly Lys Pro Thr Ile Thr Cys Ser 145 150 155 160 Ser Cys Ser Ser His Ile Asn Ser Val His Val His Ile Ser Lys Ser 165 170 175 Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys Ile Glu Ser Ala 180 185 190 Leu Arg Asn Lys Met Asn Ser Gln Val Cys Glu Lys Val Thr Asn Ser 195 200 205 Val Ser Ser Lys Leu Gln Pro Tyr Phe Gln Thr Leu Pro Val Met Thr 210 215 220 Lys Ile Asp Ser Val Ala Gly Ile Asn Tyr Gly Leu Val Ala Pro Pro 225 230 235 240 Ala Thr Thr Ala Glu Thr Leu Asp Val Gln Met Lys Gly Glu Phe Tyr 245 250 255 Ser Glu Asn His His Asn Pro Pro Pro Phe Ala Pro Pro Val Met Glu 260 265 270 Phe Pro Ala Ala His Asp Arg Met Val Tyr Leu Gly Leu Ser Asp Tyr 275 280 285 Phe Phe Asn Thr Ala Gly Leu Val Tyr Gln Glu Ala Gly Val Leu Lys 290 295 300 Met Thr Leu Arg Asp Asp Met Ile Pro Lys Glu Ser Lys Phe Arg Leu 305 310 315 320 Thr Thr Lys Phe Phe Gly Thr Phe Leu Pro Glu Val Ala Lys Lys Phe 325 330 335 Pro Asn Met Lys Ile Gln Ile His Val Ser Ala Ser Thr Pro Pro His 340 345 350 Leu Ser Val Gln Pro Thr Gly Leu Thr Phe Tyr Pro Ala Val Asp Val 355 360 365 Gln Ala Phe Ala Val Leu Pro Asn Ser Ser Leu Ala Ser Leu Phe Leu 370 375 380 Ile Gly Met His Thr Thr Gly Ser Met Glu Val Ser Ala Glu Ser Asn 385 390 395 400 Arg Leu Val Gly Glu Leu Lys Leu Asp Arg Leu Leu Leu Glu Leu Lys 405 410 415 His Ser Asn Ile Gly Pro Phe Pro Val Glu Leu Leu Gln Asp Ile Met 420 425 430 Asn Tyr Ile Val Pro Ile Leu Val Leu Pro Arg Val Asn Glu Lys Leu 435 440 445 Gln Lys Gly Phe Pro Leu Pro Thr Pro Ala Arg Val Gln Leu Tyr Asn 450 455 460 Val Val Leu Gln Pro His Gln Asn Phe Leu Leu Phe Gly Ala Asp Val 465 470 475 480 Val Tyr Lys 39 481 PRT Homo sapiens 39 Met Gly Ala Leu Ala Arg Ala Leu Pro Ser Ile Leu Leu Ala Leu Leu 1 5 10 15 Leu Thr Ser Thr Pro Glu Ala Leu Gly Ala Asn Pro Gly Leu Val Ala 20 25 30 Arg Ile Thr Asp Lys Gly Leu Gln Tyr Ala Ala Gln Glu Gly Leu Leu 35 40 45 Ala Leu Gln Ser Glu Leu Leu Arg Ile Thr Leu Pro Asp Phe Thr Gly 50 55 60 Asp Leu Arg Ile Pro His Val Gly Arg Gly Arg Tyr Glu Phe His Ser 65 70 75 80 Leu Asn Ile His Glu Phe Gln Leu Pro Ser Ser Gln Ile Ser Met Val 85 90 95 Pro Asn Val Gly Leu Lys Phe Ser Ile Ser Asn Ala Asn Ile Lys Ile 100 105 110 Ser Gly Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys Met Ser Gly Asn 115 120 125 Phe Asp Leu Ser Ile Glu Gly Met Ser Ile Ser Ala Asp Leu Lys Leu 130 135 140 Gly Ser Asn Pro Thr Ser Gly Lys Pro Thr Ile Thr Cys Ser Ser Cys 145 150 155 160 Ser Ser His Ile Asn Ser Val His Val His Ile Ser Lys Ser Lys Val 165 170 175 Gly Trp Leu Ile Gln Leu Phe His Lys Lys Ile Glu Ser Ala Leu Arg 180 185 190 Asn Lys Met Asn Ser Gln Val Cys Glu Lys Val Thr Asn Ser Val Ser 195 200 205 Ser Lys Leu Gln Pro Tyr Phe Gln Thr Leu Pro Val Met Thr Lys Ile 210 215 220 Asp Ser Val Ala Gly Ile Asn Tyr Gly Leu Val Ala Pro Pro Ala Thr 225 230 235 240 Thr Ala Glu Thr Leu Asp Val Gln Met Lys Gly Glu Phe Tyr Ser Glu 245 250 255 Asn His His Asn Pro Pro Pro Phe Ala Pro Pro Val Met Glu Phe Pro 260 265 270 Ala Ala His Asp Arg Met Val Tyr Leu Gly Leu Ser Asp Tyr Phe Phe 275 280 285 Asn Thr Ala Gly Leu Val Tyr Gln Glu Ala Gly Val Leu Lys Met Thr 290 295 300 Leu Arg Asp Asp Met Ile Pro Lys Glu Ser Lys Phe Arg Leu Thr Thr 305 310 315 320 Lys Phe Phe Gly Thr Phe Leu Pro Glu Val Ala Lys Lys Phe Pro Asn 325 330 335 Met Lys Ile Gln Ile His Val Ser Ala Ser Thr Pro Pro His Leu Ser 340 345 350 Val Gln Pro Thr Gly Leu Thr Phe Tyr Pro Ala Val Asp Val Gln Ala 355 360 365 Leu Ala Val Leu Pro Asn Ser Ser Leu Ala Ser Leu Phe Leu Ile Gly 370 375 380 Met His Thr Thr Gly Ser Met Glu Val Ser Ala Glu Ser Asn Arg Leu 385 390 395 400 Val Gly Glu Leu Lys Leu Asp Arg Leu Leu Leu Glu Leu Lys His Ser 405 410 415 Asn Ile Gly Pro Phe Pro Val Glu Leu Leu Gln Asp Ile Met Asn Tyr 420 425 430 Ile Val Pro Ile Leu Val Leu Pro Arg Val Asn Glu Lys Leu Gln Lys 435 440 445 Gly Phe Pro Leu Pro Thr Pro Ala Arg Val Gln Leu Tyr Asn Val Val 450 455 460 Leu Gln Pro His Gln Asn Phe Leu Leu Phe Gly Ala Asp Val Val Tyr 465 470 475 480 Lys40 383 PRT Caenorhabditis elegans 40 Met Arg Ile Ala His Ala Ser Ser Arg Gly Asn Ile Ser Ile Phe Ser 1 5 10 15 Val Phe Leu Ile Pro Leu Ile Ala Tyr Ile Leu Ile Leu Pro Gly Val 20 25 30 Arg Arg Lys Arg Val Val Thr Thr Val Thr Tyr Val Leu Met Leu Ala 35 40 45 Val Gly Gly Ala Leu Ile Ala Ser Leu Ile Tyr Pro Cys Trp Ala Ser 50 55 60 Gly Ser Gln Met Ile Tyr Thr Gln Phe Arg Gly His Ser Asn Glu Arg 65 70 75 80 Ile Leu Ala Lys Ile Gly Val Glu Ile Gly Leu Gln Lys Val Asn Val 85 90 95 Thr Leu Lys Phe Glu Arg Leu Leu Ser Ser Asn Asp Val Leu Pro Gly 100 105 110 Ser Asp Met Thr Glu Leu Tyr Tyr Asn Glu Gly Phe Asp Ile Ser Gly 115 120 125 Ile Ser Ser Met Ala Glu Ala Leu His His Gly Leu Glu Asn Gly Leu 130 135 140 Pro Tyr Pro Met Leu Ser Val Leu Glu Tyr Phe Ser Leu Asn Gln Asp 145 150 155 160 Ser Phe Asp Trp Gly Arg His Tyr Arg Val Ala Gly His Tyr Thr His 165 170 175 Ala Ala Ile Trp Phe Ala Phe Ala Cys Trp Cys Leu Ser Val Val Leu 180 185 190 Met Leu Phe Leu Pro His Asn Ala Tyr Lys Ser Ile Leu Ala Thr Gly 195 200 205 Ile Ser Cys Leu Ile Ala Cys Leu Val Tyr Leu Leu Leu Ser Pro Cys 210 215 220 Glu Leu Arg Ile Ala Phe Thr Gly Glu Asn Phe Glu Arg Val Asp Leu 225 230 235 240 Thr Ala Thr Phe Ser Phe Cys Phe Tyr Leu Ile Phe Ala Ile Gly Ile 245 250 255 Leu Cys Val Leu Cys Gly Leu Gly Leu Gly Ile Cys Glu His Trp Arg 260 265 270 Ile Tyr Thr Leu Ser Thr Phe Leu Asp Ala Ser Leu Asp Glu His Val 275 280 285 Gly Pro Lys Trp Lys Lys Leu Pro Thr Gly Gly Pro Ala Leu Gln Gly 290 295 300 Val Gln Ile Gly Ala Tyr Gly Thr Asn Thr Thr Asn Ser Ser Arg Asp 305 310 315 320 Lys Asn Asp Ile Ser Ser Asp Lys Thr Ala Gly Ser Ser Gly Phe Gln 325 330 335 Ser Arg Thr Ser Thr Cys Gln Ser Ser Ala Ser Ser Ala Ser Leu Arg 340 345 350 Ser Gln Ser Ser Ile Glu Thr Val His Asp Glu Ala Glu Leu Glu Arg 355 360 365 Thr His Val His Phe Leu Gln Glu Pro Cys Ser Ser Ser Ser Thr 370 375 380 41 399 PRT Homo sapiens 41 Met Lys Met Arg Phe Leu Gly Leu Val Val Cys Leu Val Leu Trp Pro 1 5 10 15 Leu His Ser Glu Gly Ser Gly Gly Lys Leu Thr Ala Val Asp Pro Glu 20 25 30 Thr Asn Met Asn Val Ser Glu Ile Ile Ser Tyr Trp Gly Phe Pro Ser 35 40 45 Glu Glu Tyr Leu Val Glu Thr Glu Asp Gly Tyr Ile Leu Cys Leu Asn 50 55 60 Arg Ile Pro His Gly Arg Lys Asn His Ser Asp Lys Gly Pro Lys Pro 65 70 75 80 Val Val Phe Leu Gln His Gly Leu Leu Ala Asp Ser Ser Asn Trp Val 85 90 95 Thr Asn Leu Ala Asn Ser Ser Leu Gly Phe Ile Leu Ala Asp Ala Gly 100 105 110 Phe Asp Val Trp Met Gly Asn Ser Arg Gly Asn Thr Trp Ser Arg Lys 115 120 125 His Lys Thr Leu Ser Val Ser Gln Asp Glu Phe Trp Ala Phe Ser Tyr 130 135 140 Asp Glu Met Ala Lys Tyr Asp Leu Pro Ala Ser Ile Asn Phe Ile Leu 145 150 155 160 Asn Lys Thr Gly Gln Glu Gln Val Tyr Tyr Val Gly His Ser Gln Gly 165 170 175 Thr Thr Ile Gly Phe Ile Ala Phe Ser Gln Ile Pro Glu Leu Ala Lys 180 185 190 Arg Ile Lys Met Phe Phe Ala Leu Gly Pro Val Ala Ser Val Ala Phe 195 200 205 Cys Thr Ser Pro Met Ala Lys Leu Gly Arg Leu Pro Asp His Leu Ile 210 215 220 Lys Asp Leu Phe Gly Asp Lys Glu Phe Leu Pro Gln Ser Ala Phe Leu 225 230 235 240 Lys Trp Leu Gly Thr His Val Cys Thr His Val Ile Leu Lys Glu Leu 245 250 255 Cys Gly Asn Leu Cys Phe Leu Leu Cys Gly Phe Asn Glu Arg Asn Leu 260 265 270 Asn Met Ser Arg Val Asp Val Tyr Thr Thr His Ser Pro Ala Gly Thr 275 280 285 Ser Val Gln Asn Met Leu His Trp Ser Gln Ala Val Lys Phe Gln Lys 290 295 300 Phe Gln Ala Phe Asp Trp Gly Ser Ser Ala Lys Asn Tyr Phe His Tyr 305 310 315 320 Asn Gln Ser Tyr Pro Pro Thr Tyr Asn Val Lys Asp Met Leu Val Pro 325 330 335 Thr Ala Val Trp Ser Gly Gly His Asp Trp Leu Ala Asp Val Tyr Asp 340 345 350 Val Asn Ile Leu Leu Thr Gln Ile Thr Asn Leu Val Phe His Glu Ser 355 360 365 Ile Pro Glu Trp Glu His Leu Asp Phe Ile Trp Gly Leu Asp Ala Pro 370 375 380 Trp Arg Leu Tyr Asn Lys Ile Ile Asn Leu Met Arg Lys Tyr Gln 385 390 395 42 19 PRT Mus sp. 42 Met Ala Pro Pro Ala Ala Arg Leu Ala Leu Leu Ser Ala Ala Ala Leu 1 5 10 15 Thr Leu Ala 43 451 PRT Mus sp. 43 Ala Arg Pro Ala Pro Gly Pro Arg Ser Gly Pro Glu Cys Phe Thr Ala 1 5 10 15 Asn Gly Ala Asp Tyr Arg Gly Thr Gln Ser Trp Thr Ala Leu Gln Gly 20 25 30 Gly Lys Pro Cys Leu Phe Trp Asn Glu Thr Phe Gln His Pro Tyr Asn 35 40 45 Thr Leu Lys Tyr Pro Asn Gly Glu Gly Gly Leu Gly Glu His Asn Tyr 50 55 60 Cys Arg Asn Pro Asp Gly Asp Val Ser Pro Trp Cys Tyr Val Ala Glu 65 70 75 80 His Glu Asp Gly Val Tyr Trp Lys Tyr Cys Glu Ile Pro Ala Cys Gln 85 90 95 Met Pro Gly Asn Leu Gly Cys Tyr Lys Asp His Gly Asn Pro Pro Pro 100 105 110 Leu Thr Gly Thr Ser Lys Thr Ser Asn Lys Leu Thr Ile Gln Thr Cys 115 120 125 Ile Ser Phe Cys Arg Ser Gln Arg Phe Lys Phe Ala Gly Met Glu Ser 130 135 140 Gly Tyr Ala Cys Phe Cys Gly Asn Asn Pro Asp Tyr Trp Lys His Gly 145 150 155 160 Glu Ala Ala Ser Thr Glu Cys Asn Ser Val Cys Phe Gly Asp His Thr 165 170 175 Gln Pro Cys Gly Gly Asp Gly Arg Ile Ile Leu Phe Asp Thr Leu Val 180 185 190 Gly Ala Cys Gly Gly Asn Tyr Ser Ala Met Ala Ala Val Val Tyr Ser 195 200 205 Pro Asp Phe Pro Asp Thr Tyr Ala Thr Gly Arg Val Cys Tyr Trp Thr 210 215 220 Ile Arg Val Pro Gly Ala Ser Arg Ile His Phe Asn Phe Thr Leu Phe 225 230 235 240 Asp Ile Arg Asp Ser Ala Asp Met Val Glu Leu Leu Asp Gly Tyr Thr 245 250 255 His Arg Val Leu Val Arg Leu Ser Gly Arg Ser Arg Pro Pro Leu Ser 260 265 270 Phe Asn Val Ser Leu Asp Phe Val Ile Leu Tyr Phe Phe Ser Asp Arg 275 280 285 Ile Asn Gln Ala Gln Gly Phe Ala Val Leu Tyr Gln Ala Thr Lys Glu 290 295 300 Glu Pro Pro Gln Glu Arg Pro Ala Val Asn Gln Thr Leu Ala Glu Val 305 310 315 320 Ile Thr Glu Gln Ala Asn Leu Ser Val Ser Ala Ala His Ser Ser Lys 325 330 335 Val Leu Tyr Val Ile Thr Pro Ser Pro Ser His Pro Pro Gln Thr Ala 340 345 350 Gln Val Ala Ile Pro Gly His Arg Gln Leu Gly Pro Thr Ala Thr Glu 355 360 365 Trp Lys Asp Gly Leu Cys Thr Ala Trp Arg Pro Ser Ser Ser Ser Gln 370 375 380 Ser Gln Gln Leu Ser Gln Arg Phe Phe Cys Met Ser His Leu Asn Leu 385 390 395 400 Ile Glu Ser Leu His Gln Glu Thr Leu Gly Thr Val Val Ser Leu Gly 405 410 415 Leu Leu Glu Ile Ser Gly Pro Phe Ser Met Asn Leu Pro Leu Gln Ser 420 425 430 Pro Ser Leu Arg Arg Ser Ser Arg Val Arg Val Asn Lys Met Thr Ala 435 440 445 Ile Pro Ser 450 44 150 PRT Mus sp. 44 Lys Lys His Cys Trp Tyr Phe Glu Gly Leu Tyr Pro Thr Tyr Tyr Ile 1 5 10 15 Cys Arg Ser Tyr Glu Asp Cys Cys Gly Ser Arg Cys Cys Val Arg Ala 20 25 30 Leu Ser Ile Gln Arg Leu Trp Tyr Phe Trp Phe Leu Leu Met Met Gly 35 40 45 Val Leu Phe Cys Cys Gly Ala Gly Phe Phe Ile Arg Arg Arg Met Tyr 50 55 60 Pro Pro Pro Leu Ile Glu Glu Pro Thr Phe Asn Val Ser Tyr Thr Arg 65 70 75 80 Gln Pro Pro Asn Pro Ala Pro Gly Ala Gln Gln Met Gly Pro Pro Tyr 85 90 95 Tyr Thr Asp Pro Gly Gly Pro Gly Met Asn Pro Val Gly Asn Thr Met 100 105 110 Ala Met Ala Phe Gln Val Gln Pro Asn Ser Pro His Gly Gly Thr Thr 115 120 125 Tyr Pro Pro Pro Pro Ser Tyr Cys Asn Thr Pro Pro Pro Pro Tyr Glu 130 135 140 Gln Val Val Lys Asp Lys 145 150 45 2044 DNA Homo sapiens 45 gtcgacccac gcgtccgggg aattgcagca ggaaaatatg tgaagagttt ttaaacccac 60 aaattcttct tactttagaa ttagttgtta cattggcagg aaaaaataaa tgcagatgtt 120 ggaccatgtt ggaaaccttg tcaagacagt ggattgtctc acacagaatg gaaatgtggc 180 ttctgattct ggtggcgtat atgttccaga gaaatgtgaa ttcagtacatatgccaacta 240 aagctgtgga cccagaagca ttcatgaata ttagtgaaat catccaacat caaggctatc 300 cctgtgagga atatgaagtc gcaactgaag atgggtatat cctttctgtt aacaggattc 360 ctcgaggcct agtgcaacct aagaagacag gttccaggcc tgtggtgtta ctgcagcatg 420 gcctagttgg aggtgctagc aactggattt ccaacctgcccaacaatagc ctgggcttca 480 ttctggcaga tgctggtttt gacgtgtgga tggggaacag caggggaaac gcctggtctc 540 gaaaacacaa gacactctcc atagaccaag atgagttctg ggctttcagt tatgatgaga 600 tggctaggtt tgaccttcct gcagtgataa actttatttt gcagaaaacg ggccaggaaa 660 agatctatta tgtcggctat tcacagggca ccaccatggg ctttattgca ttttccacca 720 tgccagagct ggctcagaaa atcaaaatgt attttgcttt agcacccatagccactgtta 780 agcatgcaaa aagccccggg accaaatttt tgttgctgcc agatatgatg atcaagggat 840 tgtttggcaa aaaagaattt ctgtatcaga ccagatttct cagacaactt gttatttacc 900 tttgtggcca ggtgattctt gatcagattt gtagtaatat catgttactt ctgggtggat 960 tcaacaccaa caatatgaac atgagccgag caagtgtatatgctgcccac actcttgctg 1020 gaacatctgt gcaaaatatt ctacactgga gccaggcagt gaattctggt gaactccggg 1080 catttgactg ggggagtgag accaaaaatc tggaaaaatg caatcagcca actcctgtaa 1140 ggtacagagt cagagatatg acggtcccta cagcaatgtg gacaggaggtcaggactggc 1200 tttcaaatcc agaagacgtg aaaatgctgc tctctgaggtgaccaacctc atctaccata 1260 agaatattcc tgaatgggct cacgtggatt tcatctgggg tttggatgct cctcaccgta 1320 tgtacaatga aatcatccat ctgatgcagc aggaggagac caacctttcc cagggacggt 1380 gtgaggccgt attgtgaagc atctgacact gacgatctta ggacaacctc ctgagggatg 1440 gggctaggac ccatgaaggc agaattacgg agagcagaga cctagtatac atttttcaga 1500 ttccctgcac ttggcactaa atccgacact tacatttaca ttttttttct gtaaattaaa 1560 gtacttatta ggtaaataga ggttttgtat gctattatat attctaccat cttgaagggt 1620 aggttttacc tgatagccag aaaatatcta gacattctctatatcattca ggtaaatctc 1680 tttaaaacac ctattgtttt ttctataagc catatttttggagcactaaa gtaaaatggc 1740 aaattgggac agatattgag gtctggagtc tgtggattat tgttgacttt gacaaaataa 1800 gctagacatt ttcaccttgt tgccacagag acataacact acctcaggaagctgagctgc 1860 tttaaggaca acaacaacaa aatcagtgtt acagtatgga tgaaatctatgttaagcatt 1920 ctcagaataa ggccaagttt tatagttgca tctcagggaa gaaaatttta taggatgttt 1980 atgagttctc caataaatgc attctgcatt acataaaaaa aaaaaaaaaa aaaagggcgg 2040ccgc 204446 1269 DNA Homo sapiens 46 atgttggaaa ccttgtcaag acagtggatt gtctcacaca gaatggaaat gtggcttctg 60 attctggtgg cgtatatgtt ccagagaaat gtgaattcag tacatatgccaactaaagct 120 gtggacccag aagcattcat gaatattagt gaaatcatcc aacatcaagg ctatccctgt 180 gaggaatatg aagtcgcaac tgaagatggg tatatccttt ctgttaacag gattcctcga 240 ggcctagtgc aacctaagaa gacaggttcc aggcctgtgg tgttactgca gcatggccta 300 gttggaggtg ctagcaactg gatttccaac ctgcccaaca atagcctgggcttcattctg 360 gcagatgctg gttttgacgt gtggatgggg aacagcaggg gaaacgcctggtctcgaaaa 420 cacaagacac tctccataga ccaagatgag ttctgggctt tcagttatga tgagatggct 480 aggtttgacc ttcctgcagt gataaacttt attttgcaga aaacgggcca ggaaaagatc 540 tattatgtcg gctattcaca gggcaccacc atgggcttta ttgcattttc caccatgcca 600 gagctggctc agaaaatcaa aatgtatttt gctttagcac ccatagccac tgttaagcat 660 gcaaaaagcc ccgggaccaa atttttgttg ctgccagata tgatgatcaa gggattgttt 720 ggcaaaaaag aatttctgta tcagaccaga tttctcagac aacttgttat ttacctttgt 780 ggccaggtga ttcttgatca gatttgtagt aatatcatgt tacttctggg tggattcaac 840 accaacaata tgaacatgag ccgagcaagt gtatatgctg cccacactct tgctggaaca 900 tctgtgcaaa atattctaca ctggagccag gcagtgaatt ctggtgaact ccgggcattt 960 gactggggga gtgagaccaa aaatctggaa aaatgcaatc agccaactcctgtaaggtac 1020 agagtcagag atatgacggt ccctacagca atgtggacag gaggtcaggactggctttca 1080 aatccagaag acgtgaaaat gctgctctct gaggtgacca acctcatcta ccataagaat 1140 attcctgaat gggctcacgt ggatttcatc tggggtttgg atgctcctcaccgtatgtac 1200 aatgaaatca tccatctgat gcagcaggag gagaccaacc tttcccaggg acggtgtgag 1260 gccgtattg 126947 423 PRT Homo sapiens 47 Met Leu Glu Thr Leu Ser Arg Gln Trp Ile Val Ser His Arg Met Glu 1 5 10 15 Met Trp Leu Leu Ile Leu Val Ala Tyr Met Phe Gln Arg Asn Val Asn 20 25 30 Ser Val His Met Pro Thr Lys Ala Val Asp Pro Glu Ala Phe Met Asn 35 40 45 Ile Ser Glu Ile Ile Gln His Gln Gly Tyr Pro Cys Glu Glu Tyr Glu 50 55 60 Val Ala Thr Glu Asp Gly Tyr Ile Leu Ser Val Asn Arg Ile Pro Arg 65 70 75 80 Gly Leu Val Gln Pro Lys Lys Thr Gly Ser Arg Pro Val Val Leu Leu 85 90 95 Gln His Gly Leu Val Gly Gly Ala Ser Asn Trp Ile Ser Asn Leu Pro 100 105 110 Asn Asn Ser Leu Gly Phe Ile Leu Ala Asp Ala Gly Phe Asp Val Trp 115 120 125 Met Gly Asn Ser Arg Gly Asn Ala Trp Ser Arg Lys His Lys Thr Leu 130 135 140 Ser Ile Asp Gln Asp Glu Phe Trp Ala Phe Ser Tyr Asp Glu Met Ala 145 150 155 160 Arg Phe Asp Leu Pro Ala Val Ile Asn Phe Ile Leu Gln Lys Thr Gly 165 170 175 Gln Glu Lys Ile Tyr Tyr Val Gly Tyr Ser Gln Gly Thr Thr Met Gly 180 185 190 Phe Ile Ala Phe Ser Thr Met Pro Glu Leu Ala Gln Lys Ile Lys Met 195 200 205 Tyr Phe Ala Leu Ala Pro Ile Ala Thr Val Lys His Ala Lys Ser Pro 210 215 220 Gly Thr Lys Phe Leu Leu Leu Pro Asp Met Met Ile Lys Gly Leu Phe 225 230 235 240 Gly Lys Lys Glu Phe Leu Tyr Gln Thr Arg Phe Leu Arg Gln Leu Val 245 250 255 Ile Tyr Leu Cys Gly Gln Val Ile Leu Asp Gln Ile Cys Ser Asn Ile 260 265 270 Met Leu Leu Leu Gly Gly Phe Asn Thr Asn Asn Met Asn Met Ser Arg 275 280 285 Ala Ser Val Tyr Ala Ala His Thr Leu Ala Gly Thr Ser Val Gln Asn 290 295 300 Ile Leu His Trp Ser Gln Ala Val Asn Ser Gly Glu Leu Arg Ala Phe 305 310 315 320 Asp Trp Gly Ser Glu Thr Lys Asn Leu Glu Lys Cys Asn Gln Pro Thr 325 330 335 Pro Val Arg Tyr Arg Val Arg Asp Met Thr Val Pro Thr Ala Met Trp 340 345 350 Thr Gly Gly Gln Asp Trp Leu Ser Asn Pro Glu Asp Val Lys Met Leu 355 360 365 Leu Ser Glu Val Thr Asn Leu Ile Tyr His Lys Asn Ile Pro GluTrp 370 375 380 Ala His Val Asp Phe Ile Trp Gly Leu Asp Ala Pro His Arg Met Tyr 385 390 395 400 Asn Glu Ile Ile His Leu Met Gln Gln Glu Glu Thr Asn Leu Ser Gln 405 410 415 Gly Arg Cys Glu Ala Val Leu 42048 33 PRT Homo sapiens 48 Met Leu Glu Thr Leu Ser Arg Gln Trp Ile Val Ser His Arg Met Glu 1 5 10 15 Met Trp Leu Leu Ile Leu Val Ala Tyr Met Phe Gln Arg Asn Val Asn 20 25 30 Ser 49 390 PRT Homo sapiens 49 Val His Met Pro Thr Lys Ala Val Asp Pro Glu Ala Phe Met Asn Ile 1 5 10 15 Ser Glu Ile Ile Gln His Gln Gly Tyr Pro Cys Glu Glu Tyr Glu Val 20 25 30 Ala Thr Glu Asp Gly Tyr Ile Leu Ser Val Asn Arg Ile Pro Arg Gly 35 40 45 Leu Val Gln Pro Lys Lys Thr Gly Ser Arg Pro Val Val Leu Leu Gln 50 55 60 His Gly Leu Val Gly Gly Ala Ser Asn Trp Ile Ser Asn Leu Pro Asn 65 70 75 80 Asn Ser Leu Gly Phe Ile Leu Ala Asp Ala Gly Phe Asp Val Trp Met 85 90 95 Gly Asn Ser Arg Gly Asn Ala Trp Ser Arg Lys His Lys Thr Leu Ser 100 105 110 Ile Asp Gln Asp Glu Phe Trp Ala Phe Ser Tyr Asp Glu Met Ala Arg 115 120 125 Phe Asp Leu Pro Ala Val Ile Asn Phe Ile Leu Gln Lys Thr Gly Gln 130 135 140 Glu Lys Ile Tyr Tyr Val Gly Tyr Ser Gln Gly Thr Thr Met Gly Phe 145 150 155 160 Ile Ala Phe Ser Thr Met Pro Glu Leu Ala Gln Lys Ile Lys Met Tyr 165 170 175 Phe Ala Leu Ala Pro Ile Ala Thr Val Lys His Ala Lys Ser Pro Gly 180 185 190 Thr Lys Phe Leu Leu Leu Pro Asp Met Met Ile Lys Gly Leu Phe Gly 195 200 205 Lys Lys Glu Phe Leu Tyr Gln Thr Arg Phe Leu Arg Gln Leu Val Ile 210 215 220 Tyr Leu Cys Gly Gln Val Ile Leu Asp Gln Ile Cys Ser Asn Ile Met 225 230 235 240 Leu Leu Leu Gly Gly Phe Asn Thr Asn Asn Met Asn Met Ser Arg Ala 245 250 255 Ser Val Tyr Ala Ala His Thr Leu Ala Gly Thr Ser Val Gln Asn Ile 260 265 270 Leu His Trp Ser Gln Ala Val Asn Ser Gly Glu Leu Arg Ala Phe Asp 275 280 285 Trp Gly Ser Glu Thr Lys Asn Leu Glu Lys Cys Asn Gln Pro Thr Pro 290 295 300 Val Arg Tyr Arg Val Arg Asp Met Thr Val Pro Thr Ala Met Trp Thr 305 310 315 320 Gly Gly Gln Asp Trp Leu Ser Asn Pro Glu Asp Val Lys Met Leu Leu 325 330 335 Ser Glu Val Thr Asn Leu Ile Tyr His Lys Asn Ile Pro Glu Trp Ala 340 345 350 His Val Asp Phe Ile Trp Gly Leu Asp Ala Pro His Arg Met Tyr Asn 355 360 365 Glu Ile Ile His Leu Met Gln Gln Glu Glu Thr Asn Leu Ser Gln Gly 370 375 380 Arg Cys Glu Ala Val Leu 385 390 50 221 PRT Homo sapiens 50 Val His Met Pro Thr Lys Ala Val Asp Pro Glu Ala Phe Met Asn Ile 1 5 10 15 Ser Glu Ile Ile Gln His Gln Gly Tyr Pro Cys Glu Glu Tyr Glu Val 20 25 30 Ala Thr Glu Asp Gly Tyr Ile Leu Ser Val Asn Arg Ile Pro Arg Gly 35 40 45 Leu Val Gln Pro Lys Lys Thr Gly Ser Arg Pro Val Val Leu Leu Gln 50 55 60 His Gly Leu Val Gly Gly Ala Ser Asn Trp Ile Ser Asn Leu Pro Asn 65 70 75 80 Asn Ser Leu Gly Phe Ile Leu Ala Asp Ala Gly Phe Asp Val Trp Met 85 90 95 Gly Asn Ser Arg Gly Asn Ala Trp Ser Arg Lys His Lys Thr Leu Ser 100 105 110 Ile Asp Gln Asp Glu Phe Trp Ala Phe Ser Tyr Asp Glu Met Ala Arg 115 120 125 Phe Asp Leu Pro Ala Val Ile Asn Phe Ile Leu Gln Lys Thr Gly Gln 130 135 140 Glu Lys Ile Tyr Tyr Val Gly Tyr Ser Gln Gly Thr Thr Met Gly Phe 145 150 155 160 Ile Ala Phe Ser Thr Met Pro Glu Leu Ala Gln Lys Ile Lys Met Tyr 165 170 175 Phe Ala Leu Ala Pro Ile Ala Thr Val Lys His Ala Lys Ser Pro Gly 180 185 190 Thr Lys Phe Leu Leu Leu Pro Asp Met Met Ile Lys Gly Leu Phe Gly 195 200 205 Lys Lys Glu Phe Leu Tyr Gln Thr Arg Phe Leu Arg Gln 210 215 220 51 25 PRT Homo sapiens 51 Leu Val Ile Tyr Leu Cys Gly Gln Val Ile Leu Asp Gln Ile Cys Ser 1 5 10 15 Asn Ile Met Leu Leu Leu Gly Gly Phe 20 25 52 144 PRT Homo sapiens 52 Asn Thr Asn Asn Met Asn Met Ser Arg Ala Ser Val Tyr Ala Ala His 1 5 10 15 Thr Leu Ala Gly Thr Ser Val Gln Asn Ile Leu His Trp Ser Gln Ala 20 25 30 Val Asn Ser Gly Glu Leu Arg Ala Phe Asp Trp Gly Ser Glu Thr Lys 35 40 45 Asn Leu Glu Lys Cys Asn Gln Pro Thr Pro Val Arg Tyr Arg Val Arg 50 55 60 Asp Met Thr Val Pro Thr Ala Met Trp Thr Gly Gly Gln Asp Trp Leu 65 70 75 80 Ser Asn Pro Glu Asp Val Lys Met Leu Leu Ser Glu Val Thr Asn Leu 85 90 95 Ile Tyr His Lys Asn Ile Pro Glu Trp Ala His Val Asp Phe Ile Trp 100 105 110 Gly Leu Asp Ala Pro His Arg Met Tyr Asn Glu Ile Ile His Leu Met 115 120 125 Gln Gln Glu Glu Thr Asn Leu Ser Gln Gly Arg Cys Glu Ala Val Leu 130 135 14053 2133 DNA Homo sapiens 53 gtcgacccac gcgtccacgg cgagggctcc cggggcgcag cattgccccc cctgcaccac 60 ctcaccaaga tggctacttt gggacacaca ttccccttct atgctggccccaagccaacc 120 ttcccgatgg acaccacttt ggccagcatc atcatgatct ttctgactgc actggccacg 180 ttcatcgtca tcctgcctgg cattcgggga aagacgaggc tgttctggctgcttcgggtg 240 gtgaccagct tattcatcgg ggctgcaatc ctggctgtga atttcagttc tgagtggtct 300 gtgggccagg tcagcaccaa cacatcatac aaggccttca gttctgagtg gatcagcgct 360 gatattgggc tgcaggtcgg gctgggtgga gtcaacatca cactcacagg gacccccgtg 420 cagcagctga atgagaccat caattacaac gaggagttca cctggcgcct gggtgagaac 480 tatgctgagg agtgtgcaaa ggctctggag aaggggctgc cagaccctgt gttgtaccta 540 gctgagaagt tcactccaag aagcccatgt ggcctatacc gccagtaccg cctggcggga 600 cactacacct cagccatgct atgggtggca ttcctctgctggctgctggc caatgtgatg 660 ctctccatgc ctgtgctggt atatggtggc tacatgctat tggccacgggcatcttccag 720 ctgttggctc tgctcttctt ctccatggcc acatcactca cctcaccctgtcccctgcac 780 ctgggcgctt ctgtgctgca tactcaccat gggcctgcct tctggatcac attgaccaca 840 ggactgctgt gtgtgctgct gggcctggct atggcggtgg cccacaggatgcagcctcac 900 aggctgaagg ctttcttcaa ccagagtgtg gatgaagacc ccatgctgga gtggagtcct 960 gaggaaggtg gactcctgag cccccgctac cggtccatgg ctgacagtcc caagtcccag 1020 gacattcccc tgtcagaggc ttcctccacc aaggcatact gtaaggaggc acaccccaaa 1080 gatcctgatt gtgctttata acattcctcc ccgtggaggc cacctggact tccagtctgg 1140 ctccaaacct cattggcgcc ccataaaacc agcagaactg ccctcagggtggctgttacc 1200 agacacccag caccaatcta cagacggagt agaaaaagga ggctctatatactgatgtta 1260 aaaaacaaaa caaaacaaaa agccctaagg gactgaagag atgctgggcc tgtccataaa 1320 gcctgttgcc atgataaggc caagcagggg ctagcttatc tgcacagcaa cccagccttt 1380 ccgtgctgcc ttgcctcttc aagatgctat tcactgaaac ctaacttcac ccccataaca 1440 ccagcagggt gggggttaca tatgattctc ctatggtttc ctctcatccc tcggcacctc 1500 ttgttttcct ttttcctggg ttccttttgt tcttccttta cttctccagc ttgtgtggcc 1560 ttttggtaca atgaaagaca gcactggaaa ggaggggaaa ccaaacttct catcctaggt 1620 ctaacattaa ccaactatgc cacattctct ttgagcttca gttcccaaat ttgctacata 1680 agattgcaag acttgccaag aatcttggga tttatctttc tatgccttgc tgacacctac 1740 cttggccctc aaacaccacc tcacaagaag ccaggtggga agttagggaa tcaactccaa 1800 aacgctattc cttcccaccc cactcagctg ggctagctga gtggcatcca ggacggggga 1860 gtgggtgacc tgcctcatca ctgccaccta acgtccccctggggtggttc agaaagatgc 1920 tagctctggt agggtccctc cggcctcact agagggcgcc cctattactctggagtcgac 1980 gcagagaatc aggtttcaca gcactgcgga gagtgtacta ggctgtctcc agcccagcga 2040 agctcatgag gacgtgcgac cccggcgcgg agaagccatgaaaattaatg ggaaaaacag 2100 tttttaaaaa aaaaaaaaaa aaagggcggc cgc 213354 1029 DNA Homo sapiens 54 atggctactt tgggacacac attccccttc tatgctggcc ccaagccaac cttcccgatg 60 gacaccactt tggccagcat catcatgatctttctgactg cactggccac gttcatcgtc 120 atcctgcctg gcattcgggg aaagacgagg ctgttctggc tgcttcgggtggtgaccagc 180 ttattcatcg gggctgcaat cctggctgtg aatttcagtt ctgagtggtc tgtgggccag 240 gtcagcacca acacatcata caaggccttc agttctgagt ggatcagcgc tgatattggg 300 ctgcaggtcg ggctgggtgg agtcaacatc acactcacag ggacccccgtgcagcagctg 360 aatgagacca tcaattacaa cgaggagttc acctggcgcc tgggtgagaa ctatgctgag 420 gagtgtgcaa aggctctgga gaaggggctg ccagaccctg tgttgtacct agctgagaag 480 ttcactccaa gaagcccatg tggcctatac cgccagtacc gcctggcggg acactacacc 540 tcagccatgc tatgggtggc attcctctgc tggctgctgg ccaatgtgat gctctccatg 600 cctgtgctgg tatatggtgg ctacatgcta ttggccacgg gcatcttcca gctgttggct 660 ctgctcttct tctccatggc cacatcactc acctcaccct gtcccctgcacctgggcgct 720 tctgtgctgc atactcacca tgggcctgcc ttctggatca cattgaccac aggactgctg 780 tgtgtgctgc tgggcctggc tatggcggtg gcccacagga tgcagcctca caggctgaag 840 gctttcttca accagagtgt ggatgaagac cccatgctgg agtggagtcc tgaggaaggt 900 ggactcctga gcccccgcta ccggtccatg gctgacagtc ccaagtcccaggacattccc 960 ctgtcagagg cttcctccac caaggcatac tgtaaggagg cacaccccaa agatcctgat 1020 tgtgcttta 102955 343 PRT Homo sapiens 55 Met Ala Thr Leu Gly His Thr Phe Pro Phe Tyr Ala Gly Pro Lys Pro 1 5 10 15 Thr Phe Pro Met Asp Thr Thr Leu Ala Ser Ile Ile Met Ile Phe Leu 20 25 30 Thr Ala Leu Ala Thr Phe Ile Val Ile Leu Pro Gly Ile Arg Gly Lys 35 40 45 Thr Arg Leu Phe Trp Leu Leu Arg Val Val Thr Ser Leu Phe Ile Gly 50 55 60 Ala Ala Ile Leu Ala Val Asn Phe Ser Ser Glu Trp Ser Val Gly Gln 65 70 75 80 Val Ser Thr Asn Thr Ser Tyr Lys Ala Phe Ser Ser Glu Trp Ile Ser 85 90 95 Ala Asp Ile Gly Leu Gln Val Gly Leu Gly Gly Val Asn Ile Thr Leu 100 105 110 Thr Gly Thr Pro Val Gln Gln Leu Asn Glu Thr Ile Asn Tyr Asn Glu 115 120 125 Glu Phe Thr Trp Arg Leu Gly Glu Asn Tyr Ala Glu Glu Cys Ala Lys 130 135 140 Ala Leu Glu Lys Gly Leu Pro Asp Pro Val Leu Tyr Leu Ala Glu Lys 145 150 155 160 Phe Thr Pro Arg Ser Pro Cys Gly Leu Tyr Arg Gln Tyr Arg Leu Ala 165 170 175 Gly His Tyr Thr Ser Ala Met Leu Trp Val Ala Phe Leu Cys Trp Leu 180 185 190 Leu Ala Asn Val Met Leu Ser Met Pro Val Leu Val Tyr Gly Gly Tyr 195 200 205 Met Leu Leu Ala Thr Gly Ile Phe Gln Leu Leu Ala Leu Leu Phe Phe 210 215 220 Ser Met Ala Thr Ser Leu Thr Ser Pro Cys Pro Leu His Leu Gly Ala 225 230 235 240 Ser Val Leu His Thr His His Gly Pro Ala Phe Trp Ile Thr Leu Thr 245 250 255 Thr Gly Leu Leu Cys Val Leu Leu Gly Leu Ala Met Ala Val Ala His 260 265 270 Arg Met Gln Pro His Arg Leu Lys Ala Phe Phe Asn Gln Ser Val Asp 275 280 285 Glu Asp Pro Met Leu Glu Trp Ser Pro Glu Glu Gly Gly Leu Leu Ser 290 295 300 Pro Arg Tyr Arg Ser Met Ala Asp Ser Pro Lys Ser Gln Asp Ile Pro 305 310 315 320 Leu Ser Glu Ala Ser Ser Thr Lys Ala Tyr Cys Lys Glu Ala His Pro 325 330 335 Lys Asp Pro Asp Cys Ala Leu 340 56 23 PRT Homo sapiens 56 Met Ala Thr Leu Gly His Thr Phe Pro Phe Tyr Ala Gly Pro Lys Pro 1 5 10 15 Thr Phe Pro Met Asp Thr Thr 20 57 112 PRT Homo sapiens 57 Asn Phe Ser Ser Glu Trp Ser Val Gly Gln Val Ser Thr Asn Thr Ser 1 5 10 15 Tyr Lys Ala Phe Ser Ser Glu Trp Ile Ser Ala Asp Ile Gly Leu Gln 20 25 30 Val Gly Leu Gly Gly Val Asn Ile Thr Leu Thr Gly Thr Pro Val Gln 35 40 45 Gln Leu Asn Glu Thr Ile Asn Tyr Asn Glu Glu Phe Thr Trp Arg Leu 50 55 60 Gly Glu Asn Tyr Ala Glu Glu Cys Ala Lys Ala Leu Glu Lys Gly Leu 65 70 75 80 Pro Asp Pro Val Leu Tyr Leu Ala Glu Lys Phe Thr Pro Arg Ser Pro 85 90 95 Cys Gly Leu Tyr Arg Gln Tyr Arg Leu Ala Gly His Tyr Thr Ser Ala 100 105 110 58 22 PRT Homo sapiens 58 Thr Ser Leu Thr Ser Pro Cys Pro Leu His Leu Gly Ala Ser Val Leu 1 5 10 15 His Thr His His Gly Pro 20 59 19 PRT Homo sapiens 59 Leu Ala Ser Ile Ile Met Ile Phe Leu Thr Ala Leu Ala Thr Phe Ile 1 5 10 15 Val Ile Leu 60 20 PRT Homo sapiens 60 Leu Phe Trp Leu Leu Arg Val Val Thr Ser Leu Phe Ile Gly Ala Ala 1 5 10 15 Ile Leu Ala Val 20 61 22 PRT Homo sapiens 61 Met Leu Trp Val Ala Phe Leu Cys Trp Leu Leu Ala Asn Val Met Leu 1 5 10 15 Ser Met Pro Val Leu Val 20 62 17 PRT Homo sapiens 62 Leu Ala Thr Gly Ile Phe Gln Leu Leu Ala Leu Leu Phe Phe Ser Met 1 5 10 15 Ala 63 22 PRT Homo sapiens 63 Ala Phe Trp Ile Thr Leu Thr Thr Gly Leu Leu Cys Val Leu Leu Gly 1 5 10 15 Leu Ala Met Ala Val Ala 20 64 8 PRT Homo sapiens 64 Pro Gly Ile Arg Gly Lys Thr Arg 1 5 65 6 PRT Homo sapiens 65 Tyr Gly Gly Tyr Met Leu 1 5 66 72 PRT Homo sapiens 66 His Arg Met Gln Pro His Arg Leu Lys Ala Phe Phe Asn Gln Ser Val 1 5 10 15 Asp Glu Asp Pro Met Leu Glu Trp Ser Pro Glu Glu Gly Gly Leu Leu 20 25 30 Ser Pro Arg Tyr Arg Ser Met Ala Asp Ser Pro Lys Ser Gln Asp Ile 35 40 45 Pro Leu Ser Glu Ala Ser Ser Thr Lys Ala Tyr Cys Lys Glu Ala His 50 55 60 Pro Lys Asp Pro Asp Cys Ala Leu 65 70 67 4928 DNA Mus sp. 67 gtcgacccac gcgtccgccc ggctcccggt gctgccccct ctgccccggg ccgcgcccgg 60 gggtcccgca ctgacggccc atggcgccgc ccgccgcccg tctcgcgctg ctctccgccg 120 ctgcgctcac tctggcggcc cggcccgcgc ccggtccccg ctccggccccgagtgcttca 180 cagccaacgg tgcagattac aggggaacac agagctggacagcgctgcaa ggtgggaagc 240 catgtctgtt ctggaacgag actttccagc atccgtacaa cacgctgaag taccccaacg 300 gggaaggagg actgggcgag cacaattatt gcagaaatcc agatggagac gtgagccctt 360 ggtgctacgt ggccgagcat gaggacggag tctactggaa gtactgtgaa attcctgcct 420 gccagatgcc tggaaacctt ggctgctaca aggatcatgg aaacccacct cctctcacgg 480 gcaccagtaa aacctctaac aagctcacca tacaaacctg tatcagcttc tgtcggagtc 540 agagattcaa gtttgctggg atggagtcag gctatgcctg cttctgtggg aacaatcctg 600 actactggaa gcacggggag gcggccagca ccgagtgcaa tagtgtctgc ttcggggacc 660 acacgcagcc ctgcggtggg gacggcagga ttatcctctttgacactctc gtgggcgcct 720 gcggtgggaa ctactcagcc atggcagccg tggtgtactc ccctgacttc cctgacacct 780 acgccactgg cagagtctgc tactggacca tccgggttcc aggagcctct cgcatccatt 840 tcaacttcac cctgtttgat atcagggact ctgcagacat ggtggagctg ctggacggct 900 acacccaccg cgtcctggtc cggctcagtg ggaggagccg cccgcctctg tctttcaatg 960 tctctctgga ttttgtcatt ttgtatttct tctctgatcg catcaatcag gcccagggat 1020 ttgctgtgtt gtaccaagcc accaaggagg aaccgccaca ggagagacctgctgtcaacc 1080 agaccctggc agaggtgatc accgagcaag ccaacctcag tgtcagcgct gcccactcct 1140 ccaaagtcct ctatgtcatc acccccagcc ccagccaccc tccgcagact gcccaggtag 1200 ccattcctgg gcaccgtcag ttggggccaa cagccacaga gtggaaggatggactgtgta 1260 cggcctggcg accctcctca tcctcacagt cacagcagtt gtcgcaaaga ttcttctgca 1320 tgtcacattt aaatctcatc gagtccctgc atcaggagac cttagggactgtcgtcagcc 1380 tggggcttct ggagatatct ggaccatttt ctatgaacct tccactacaa tctccatctt 1440 taagaagaag ctcaagggtc agagtcaaca agatgaccgc aatcccctcg tgagtgactg 1500 aagcccacgc ctgcatgaga ggctccgctc caagctcgag tttgctcccc tgagttctcc 1560 tctgatgagt tccctgcctt cccattcacc accatctctt ttgggagcac cctgctttag 1620 aggcagccca gcctgggatc ctccatcaca tgtaccagcc tggctgctct gctggggatg 1680 gtaagacagg cccaggctga caggacacag ctggacctgactccagaaga ctcttgggtg 1740 gtggggaggt atagtgtagg atgagttttc ttgcttcttc tctgttttgt ccacatacag 1800 atcggtttcc cctgtcttta cagtttgcaa tagagccaga ctgaaagaac tgtcaggttt 1860 tctaggctgg cctggttccc cactaagagtggcattggcg ccctagaggc ccagaggccc 1920 agtgtaggct tggagctttc tctgctgcca actaccatgt gtcatctagt ccgaggggac 1980 tgagagcagg gccacaccag atgtcatctt tctagagggt tctttttagtacccactgac 2040 caatggggca agcctgagga ttggtccatc tgtttgtcca tggaacagac acagtgaact 2100 tcctggatac tagacttaac tagcctagcc ctcaagtagt tgccaatcctgtggaatcag 2160 aattcagcct gtcttcctgt cctcagccca agcctgtagcctagagctgg ggctgtagcc 2220 tagagctggg gctgtagcct agagctgggg ctgtagcaca gagctggggc tgtagcctag 2280 agctggggct gtagcacaga gctggggctg tagcctagagctggggctgt agcacagagc 2340 tggggctgta gcacagagct ggggctgtag cctagagctg gggctgtagc acagagctgg 2400 ggctgtaact cagcgatcaa gagcttgctt tgtatacatc ggaccctagg ttctatccca 2460 gcactatcag aaggtgggag agaaaaagactgcaccatag catgcgggca gcatctgtgg 2520 ttcctacgtg aggtgtcatc attttaaaag cagatcaaaa ctaccgcgag ttttgtcctt 2580 tgtcccttat catgggagca gagtaggagt aagggctctg gtcttgctca ttgtccccca 2640 gacagggagg caggaaaagg tcaggcttgg gaactggaga tcctcccaggaaaagctgca 2700 agattgagag acccagctgc agttgggaga ggaagggcca tccccgactg agaagtcctg 2760 cagtctggaa gtggcctttg tcagcagcag ctgtgccctg aaggtagaccttggtcactc 2820 tcctgccagc ccttgagcct ctgctctcct gggtaccctc ctggaacaccatgctaacct 2880 tccccgagtc tctcagtcac tgccattgag gcctctcctc tagctgctgc tccccaggac 2940 tgtctggggc catctgggga tcagggagag gcagcaggag tactgacgag gcagtgacct 3000 gagctgatga gtcaaccaga ggacaccaga gtctacagtg ggctggctgc tggctcagct 3060 cctatgggag gcctacaggg gtactaagct agggggtcat catctcattt gatctgggaa 3120 aggctacagg ctcctggatg tgaagacagg cccactacataagaagacca ctggaaatag 3180 actgacagga gcaggttcca ctctaggctg tccatagcgt ttgcaggact cccctgagac 3240 caagtgttga gtcacagagt gccatgtgcg tagtgcataa aggatatggg ttcttaacca 3300 gggaaggctc atagcaggcc aggacatttt ttcagctcag agcactggcc ccaggcttcc 3360 tctaagccac cactcacctg tctcttccta tctcggacac aggaagcaagccccagtgtg 3420 gtggcagctg cggctcagca ttggtgtccc caggaagggc ggtggatgtgcccacgctcc 3480 ttttgctgtg ggcctggcac agcccaacac tgcagggccc accttctctc ttggggggta 3540 gggacacata aggaaaacta acccacctcc aacaacagca gaggacagtg ggaaggaagg 3600 gctgtaaatc acccaggcca gacctccaga aatgacaggc acagtctgtt agaacctgta 3660 ggcagccagt cacagagggc ctttgtgctg gtaacaccct gcctggagca taggggtaag 3720 ccgagggaga agagcagccc tcagagacat cagctaaaaa cataggtgcc ctatgtccct 3780 cccttcctgt cacactgctt acaaagcaga gacagagtag gaaagaggtc ttcatcctct 3840 cccacatcag caaggatagg gctgcggctg cctaaagtgagcaaggagaa cagagctctg 3900 gacttctcta aatgtgggct ctggcttcag actcctcagc caaaagctct tgaagatcaa 3960 agctctggcg ggtacagctg tcctggcctg tgggccagcc catgggatgt gcctgggcca 4020 ggtgccaccc cacggctcac tgtcatccca ggagggaccc cacctgatgc tcctcatcat 4080 ccgctggcct gacactatca gagctcgcgc cggctgttgc cagggacagactgactacac 4140 ttgaccttca agagcactta gaagtggatg gcctccagac tctgtcagcc tctgcagggg 4200 ccacacaagt ctcccgagcc aagtccacaa gcctccatgg ttccctggctcctctcctgt 4260 ggagtgtcct gtttgatgtc tgaggtctgc tttgggtacc gccctgggaactgctaacct 4320 ccgattggtc cctttgtgtc tctgtttact gtcctcttct acctccaggt cacttagctc 4380 tggctgctct ggctgggagt ggggggtggg gatgctggct gcacccccac cctggtctgc 4440 caacagaacc tgggggcctc acacgggctc ctgtcttgcc aagctggagc tgagcacact 4500 ggcccaggct gagtggggca gagcaaacaa gtggaagggg atctctctcc ttagagggag 4560 gtggccgaag gtgtagatcc agcgagggag ctgccatccc cgccaccttc atagcagcaa 4620 gaccttccca tttccaatct caccctccag cagggatatg actttggaca acaaggcttt 4680 atttgtaaat atgctcttaa tatgcaactt tgagaataag atagaaacat catgtatttt 4740 aaaatataaa atgaagtgtg acacactgta tacaatttaa tatatatttt taggattttg 4800 ttatttaaga aaatggaatg tgatggtact taacttttac aaaagagaga aaatgttatt 4860 tttactgttt gaagaaaata aatattctca ttgttgtaga aaaaaaaaaa aaaaaaaagg 4920gcggccgc 492868 1410 DNA Mus sp. 68 atggcgccgc ccgccgcccg tctcgcgctg ctctccgccg ctgcgctcac tctggcggcc 60 cggcccgcgc ccggtccccg ctccggcccc gagtgcttca cagccaacgg tgcagattac 120 aggggaacac agagctggac agcgctgcaa ggtgggaagc catgtctgtt ctggaacgag 180 actttccagc atccgtacaa cacgctgaag taccccaacg gggaaggagg actgggcgag 240 cacaattatt gcagaaatcc agatggagac gtgagccctt ggtgctacgt ggccgagcat 300 gaggacggag tctactggaa gtactgtgaa attcctgcct gccagatgcc tggaaacctt 360 ggctgctaca aggatcatgg aaacccacct cctctcacgg gcaccagtaa aacctctaac 420 aagctcacca tacaaacctg tatcagcttc tgtcggagtc agagattcaa gtttgctggg 480 atggagtcag gctatgcctg cttctgtggg aacaatcctg actactggaa gcacggggag 540 gcggccagca ccgagtgcaa tagtgtctgc ttcggggacc acacgcagccctgcggtggg 600 gacggcagga ttatcctctt tgacactctc gtgggcgcct gcggtgggaactactcagcc 660 atggcagccg tggtgtactc ccctgacttc cctgacacct acgccactggcagagtctgc 720 tactggacca tccgggttcc aggagcctct cgcatccatt tcaacttcac cctgtttgat 780 atcagggact ctgcagacat ggtggagctg ctggacggct acacccaccgcgtcctggtc 840 cggctcagtg ggaggagccg cccgcctctg tctttcaatg tctctctgga ttttgtcatt 900 ttgtatttct tctctgatcg catcaatcag gcccagggat ttgctgtgtt gtaccaagcc 960 accaaggagg aaccgccaca ggagagacct gctgtcaacc agaccctggc agaggtgatc 1020 accgagcaag ccaacctcag tgtcagcgct gcccactcct ccaaagtcctctatgtcatc 1080 acccccagcc ccagccaccc tccgcagact gcccaggtag ccattcctgg gcaccgtcag 1140 ttggggccaa cagccacaga gtggaaggat ggactgtgta cggcctggcg accctcctca 1200 tcctcacagt cacagcagtt gtcgcaaaga ttcttctgca tgtcacatttaaatctcatc 1260 gagtccctgc atcaggagac cttagggact gtcgtcagcc tggggcttct ggagatatct 1320 ggaccatttt ctatgaacct tccactacaa tctccatctt taagaagaagctcaagggtc 1380 agagtcaaca agatgaccgc aatcccctcg 141069 470 PRT Mus sp. 69 Met Ala Pro Pro Ala Ala Arg Leu Ala Leu Leu Ser Ala Ala Ala Leu 1 5 10 15 Thr Leu Ala Ala Arg Pro Ala Pro Gly Pro Arg Ser Gly Pro Glu Cys 20 25 30 Phe Thr Ala Asn Gly Ala Asp Tyr Arg Gly Thr Gln Ser Trp Thr Ala 35 40 45 Leu Gln Gly Gly Lys Pro Cys Leu Phe Trp Asn Glu Thr Phe Gln His 50 55 60 Pro Tyr Asn Thr Leu Lys Tyr Pro Asn Gly Glu Gly Gly Leu Gly Glu 65 70 75 80 His Asn Tyr Cys Arg Asn Pro Asp Gly Asp Val Ser Pro Trp Cys Tyr 85 90 95 Val Ala Glu His Glu Asp Gly Val Tyr Trp Lys Tyr Cys Glu Ile Pro 100 105 110 Ala Cys Gln Met Pro Gly Asn Leu Gly Cys Tyr Lys Asp His Gly Asn 115 120 125 Pro Pro Pro Leu Thr Gly Thr Ser Lys Thr Ser Asn Lys Leu Thr Ile 130 135 140 Gln Thr Cys Ile Ser Phe Cys Arg Ser Gln Arg Phe Lys Phe Ala Gly 145 150 155 160 Met Glu Ser Gly Tyr Ala Cys Phe Cys Gly Asn Asn Pro Asp Tyr Trp 165 170 175 Lys His Gly Glu Ala Ala Ser Thr Glu Cys Asn Ser Val Cys Phe Gly 180 185 190 Asp His Thr Gln Pro Cys Gly Gly Asp Gly Arg Ile Ile Leu Phe Asp 195 200 205 Thr Leu Val Gly Ala Cys Gly Gly Asn Tyr Ser Ala Met Ala Ala Val 210 215 220 Val Tyr Ser Pro Asp Phe Pro Asp Thr Tyr Ala Thr Gly Arg Val Cys 225 230 235 240 Tyr Trp Thr Ile Arg Val Pro Gly Ala Ser Arg Ile His Phe Asn Phe 245 250 255 Thr Leu Phe Asp Ile Arg Asp Ser Ala Asp Met Val Glu Leu Leu Asp 260 265 270 Gly Tyr Thr His Arg Val Leu Val Arg Leu Ser Gly Arg Ser Arg Pro 275 280 285 Pro Leu Ser Phe Asn Val Ser Leu Asp Phe Val Ile Leu Tyr Phe Phe 290 295 300 Ser Asp Arg Ile Asn Gln Ala Gln Gly Phe Ala Val Leu Tyr Gln Ala 305 310 315 320 Thr Lys Glu Glu Pro Pro Gln Glu Arg Pro Ala Val Asn Gln Thr Leu 325 330 335 Ala Glu Val Ile Thr Glu Gln Ala Asn Leu Ser Val Ser Ala Ala His 340 345 350 Ser Ser Lys Val Leu Tyr Val Ile Thr Pro Ser Pro Ser His Pro Pro 355 360 365 Gln Thr Ala Gln Val Ala Ile Pro Gly His Arg Gln Leu Gly Pro Thr 370 375 380 Ala Thr Glu Trp Lys Asp Gly Leu Cys Thr Ala Trp Arg Pro Ser Ser 385 390 395 400 Ser Ser Gln Ser Gln Gln Leu Ser Gln Arg Phe Phe Cys Met Ser His 405 410 415 Leu Asn Leu Ile Glu Ser Leu His Gln Glu Thr Leu Gly Thr Val Val 420 425 430 Ser Leu Gly Leu Leu Glu Ile Ser Gly Pro Phe Ser Met Asn Leu Pro 435 440 445 Leu Gln Ser Pro Ser Leu Arg Arg Ser Ser Arg Val Arg Val Asn Lys 450 455 460 Met Thr Ala Ile Pro Ser 465 47070 760 PRT Mus sp. 70 Met Ala Leu Pro Ser Leu Gly Gln Asp Ser Trp Ser Leu Leu Arg Val 1 5 10 15 Phe Phe Phe Gln Leu Phe Leu Leu Pro Ser Leu Pro Pro Ala Ser Gly 20 25 30 Thr Gly Gly Gln Gly Pro Met Pro Arg Val Lys Tyr His Ala Gly Asp 35 40 45 Gly His Arg Ala Leu Ser Phe Phe Gln Gln Lys Gly Leu Arg Asp Phe 50 55 60 Asp Thr Leu Leu Leu Ser Asp Asp Gly Asn Thr Leu Tyr Val Gly Ala 65 70 75 80 Arg Glu Thr Val Leu Ala Leu Asn Ile Gln Asn Pro Gly Ile Pro Arg 85 90 95 Leu Lys Asn Met Ile Pro Trp Pro Ala Ser Glu Arg Lys Lys Thr Glu 100 105 110 Cys Ala Phe Lys Lys Lys Ser Asn Glu Thr Gln Cys Phe Asn Phe Ile 115 120 125 Arg Val Leu Val Ser Tyr Asn Ala Thr His Leu Tyr Ala Cys Gly Thr 130 135 140 Phe Ala Phe Ser Pro Ala Cys Thr Phe Ile Glu Leu Gln Asp Ser Leu 145 150 155 160 Leu Leu Pro Ile Leu Ile Asp Lys Val Met Asp Gly Lys Gly Gln Ser 165 170 175 Pro Leu Thr Leu Phe Thr Ser Thr Gln Ala Val Leu Val Asp Gly Met 180 185 190 Leu Tyr Ser Gly Thr Met Asn Asn Phe Leu Gly Ser Glu Pro Ile Leu 195 200 205 Met Arg Thr Leu Gly Ser His Pro Val Leu Lys Thr Asp Ile Phe Leu 210 215 220 Arg Trp Leu His Ala Asp Ala Ser Phe Val Ala Ala Ile Pro Ser Thr 225 230 235 240 Gln Val Val Tyr Phe Phe Phe Glu Glu Thr Ala Ser Glu Phe Asp Phe 245 250 255 Phe Glu Glu Leu Tyr Ile Ser Arg Val Ala Gln Val Cys Lys Asn Asp 260 265 270 Val Gly Gly Glu Lys Leu Leu Gln Lys Lys Trp Thr Thr Phe Leu Lys 275 280 285 Ala Gln Leu Leu Cys Ala Gln Pro Gly Gln Leu Pro Phe Asn Ile Ile 290 295 300 Arg His Ala Val Leu Leu Pro Ala Asp Ser Pro Ser Val Ser Arg Ile 305 310 315 320 Tyr Ala Val Phe Thr Ser Gln Trp Gln Val Gly Gly Thr Arg Ser Ser 325 330 335 Ala Val Cys Ala Phe Ser Leu Thr Asp Ile Glu Arg Val Phe Lys Gly 340 345 350 Lys Tyr Lys Glu Leu Asn Lys Glu Thr Ser Arg Trp Thr Thr Tyr Arg 355 360 365 Gly Ser Glu Val Ser Pro Arg Pro Gly Ser Cys Ser Met Gly Pro Ser 370 375 380 Ser Asp Lys Ala Leu Thr Phe Met Lys Asp His Phe Leu Met Asp Glu 385 390 395 400 His Val Val Gly Thr Pro Leu Leu Val Lys Ser Gly Val Glu Tyr Thr 405 410 415 Arg Leu Ala Val Glu Ser Ala Arg Gly Leu Asp Gly Ser Ser His Val 420 425 430 Val Met Tyr Leu Gly Thr Ser Thr Gly Pro Leu His Lys Ala Val Val 435 440 445 Pro Gln Asp Ser Ser Ala Tyr Leu Val Glu Glu Ile Gln Leu Ser Pro 450 455 460 Asp Ser Glu Pro Val Arg Asn Leu Gln Leu Ala Pro Ala Gln Gly Ala 465 470 475 480 Val Phe Ala Gly Phe Ser Gly Gly Ile Trp Arg Val Pro Arg Ala Asn 485 490 495 Cys Ser Val Tyr Glu Ser Cys Val Asp Cys Val Leu Ala Arg Asp Pro 500 505 510 His Cys Ala Trp Asp Pro Glu Ser Arg Leu Cys Ser Leu Leu Ser Gly 515 520 525 Ser Thr Lys Pro Trp Lys Gln Asp Met Glu Arg Gly Asn Pro Glu Trp 530 535 540 Val Cys Thr Arg Gly Pro Met Ala Arg Ser Pro Arg Arg Gln Ser Pro 545 550 555 560 Pro Gln Leu Ile Lys Glu Val Leu Thr Val Pro Asn Ser Ile Leu Glu 565 570 575 Leu Arg Cys Pro His Leu Ser Ala Leu Ala Ser Tyr His Trp Ser His 580 585 590 Gly Arg Ala Lys Ile Ser Glu Ala Ser Ala Thr Val Tyr Asn Gly Ser 595 600 605 Leu Leu Leu Leu Pro Gln Asp Gly Val Gly Gly Leu Tyr Gln Cys Val 610 615 620 Ala Thr Glu Asn Gly Tyr Ser Tyr Pro Val Val Ser Tyr Trp Val Asp 625 630 635 640 Ser Gln Asp Gln Pro Leu Ala Leu Asp Pro Glu Leu Ala Gly Val Pro 645 650 655 Arg Glu Arg Val Gln Val Pro Leu Thr Arg Val Gly Gly Gly Ala Ser 660 665 670 Met Ala Ala Gln Arg Ser Tyr Trp Pro His Phe Leu Ile Val Thr Val 675 680 685 Leu Leu Ala Ile Val Leu Leu Gly Val Leu Thr Leu Leu Leu Ala Ser 690 695 700 Pro Leu Gly Ala Leu Arg Ala Arg Gly Lys Val Gln Gly Cys Gly Met 705 710 715 720 Leu Pro Pro Arg Glu Lys Ala Pro Leu Ser Arg Asp Gln His Leu Gln 725 730 735 Pro Ser Lys Asp His Arg Thr Ser Ala Ser Asp Val Asp Ala Asp Asn 740 745 750 Asn His Leu Gly Ala Glu Val Ala 755 76071 3046 DNA Mus sp. 71 ctcggacgcc tgggttaggg gtctgtactg ctggggaacc atctggtgac catctcaggc 60 tgaccatggc cctaccatcc ctgggccagg actcatggag tctcctgcgt gtttttttct 120 tccaactctt cctgctgcca tcactgccac ctgcttctgg gactggtggt caggggccca 180 tgcccagagt caaataccat gctggagacg ggcacagggc cctcagcttc ttccaacaaa 240 aaggcctccg agactttgac acgctgctcc tgagtgacga tggcaacact ctctatgtgg 300 gggctcgaga gaccgtcctg gccttgaata tccagaaccc aggaatcccaaggctaaaga 360 acatgatacc ctggccagcc agtgagagaa aaaagaccga atgtgccttt aagaagaaga 420 gcaatgagac acagtgtttc aacttcattc gagtcctggt ctcttacaat gctactcacc 480 tctatgcctg tgggaccttt gccttcagcc ctgcctgtac cttcattgaa ctccaagatt 540 ccctcctgtt gcccatcttg atagacaagg tcatggacgg gaagggccaa agccctttga 600 ccctgttcac aagcacacaa gctgtcttgg tcgatgggat gctttattcc ggcaccatga 660 acaacttcct gggcagcgag cccatcctga tgcggacact gggatcccatcctgttctca 720 agactgacat cttcttacgc tggctgcacg cggatgcctc cttcgtggca gccattccat 780 ccacccaggt cgtctatttc ttctttgagg agacagccag cgagtttgac ttctttgaag 840 agctgtatat atccagggtg gctcaagtct gcaagaacga cgtgggcggtgaaaagctgc 900 tgcagaagaa gtggaccacc ttcctcaaag cccagttgctctgcgctcag ccagggcagc 960 tgccattcaa catcatccgc cacgcggtcctgctgcccgc cgattctccc tctgtttccc 1020 gcatctacgc agtctttacc tcccagtggc aggttggcgg gaccaggagc tcagcagtct 1080 gtgccttctc tctcacggac attgagcgag tctttaaagg gaagtacaaggagctgaaca 1140 aggagacctc ccgctggacc acttaccggg gctcagaggt cagcccgagg ccaggcagtt 1200 gctccatggg cccctcctct gacaaagcct tgaccttcat gaaggaccat tttctgatgg 1260 atgagcacgt ggtaggaaca cccctgctgg tgaagtctgg tgtggagtac acacggcttg 1320 ctgtggagtc agctcggggc cttgatggga gcagccatgtggtcatgtat ctgggtacct 1380 ccacgggtcc cctgcacaag gctgtggtgc ctcaggacagcagtgcttat ctcgtggagg 1440 agattcagct gagccctgac tctgagcctg ttcgaaacct gcagctggcc cccgcccagg 1500 gtgcagtgtt tgcaggcttc tctggaggca tctggagagt tcccagggcc aattgcagtg 1560 tctacgagag ctgtgtggac tgtgtgcttg ccagggaccc tcactgtgcc tgggaccctg 1620 aatcaagact ctgcagcctt ctgtctggct ctaccaagcc ttggaagcag gacatggaac 1680 gcggcaaccc ggagtgggta tgcacccgtg gccccatggc caggagcccc cggcgtcaga 1740 gcccccctca actaattaaa gaagtcctga cagtccccaa ctccatcctg gagctgcgct 1800 gcccccacct gtcagcactg gcctcttacc actggagtca tggccgagccaaaatctcag 1860 aagcctctgc taccgtctac aatggctccc tcttgctgct gccgcaggatggtgtcgggg 1920 gcctctacca gtgtgtggcg actgagaacg gctactcata ccctgtggtc tcctattggg 1980 tagacagcca ggaccagccc ctggcgctgg accctgagct ggcgggcgtt ccccgtgagc 2040 gtgtgcaggt cccgctgacc agggtcggag gcggagcttc catggctgcc cagcggtcct 2100 actggcccca ttttctcatc gttaccgtcc tcctggccatcgtgctcctg ggagtgctca 2160 ctctcctcct cgcttcccca ctgggggcgc tgcgggctcg gggtaaggttcagggctgtg 2220 ggatgctgcc ccccagggaa aaggctccac tgagcaggga ccagcacctccagccctcca 2280 aggaccacag gacctctgcc agtgacgtag atgccgacaacaaccatctg ggcgccgaag 2340 tggcttaaac agggacacag atccgcagct gagcagagca agccactggc cttgttggct 2400 atgccaggca cagtgccact ctgaccaggg taggaggctc tcctgctaacgtgtgtcacc 2460 tacagcaccc agtaggtcct cccctgtgggactctcttct gcaagcacat tgggctgtct 2520 ccatacctgt acttgtgctg tgacaggaag agccagacag gtttctttga ttttgattga 2580 cccaagagcc ctgcctgtaa caaacgtgct ccaggagacc atgaaaggtgtggctgtctg 2640 ggattctgtg gtgacaaacc taagcatccg agcaagctgg ggctattcctgcaaactcca 2700 tcctgaacgc tgtcactcta gaagcagctg ctgctttgaa caccagccca ccctccttcc 2760 caagagtctc tatggagttg gccccttgtg tttcctttac cagtcgggcc atactgtttg 2820 ggaagtcatc tctgaagtct aaccaccttc cttcttggtt cagtttggac agattgttat 2880 tattgtctct gccctggcta gaatgggggc ataatctgag ccttgttccc ttgtccagtg 2940 tggctgaccc ttgacctctt ccttcctcct ccctttgttt tgggattcag aaaactgctt 3000 gtcacagaca atttattttt tattaaaaaa gatataagct ttaaag 304672 2915 DNA Mus sp. 72 gtcgacccac gcgtccggcc gcgcgtcctt ctgccggctt cagctcgtat ccccggagtc 60 cacccgcccg tcccggggtg cggactggcc ctgagctggc cgtacagccc ggcttcggac 120 ggtcctcgct ggagccatgg gccgccggctcggcagggtg gcggcgctgc tgctcgggct 180 gctagtggag tgcactgagg ccaaaaaaca ttgctggtat tttgaaggac tctatcccac 240 atactatata tgccgttcct atgaagactg ctgtggctcc aggtgctgtg tgagggccct 300 ttccatacag aggctgtggt atttttggttcctgctgatg atgggtgtgc tgttctgctg 360 tggtgccggt ttcttcattc gccggcgcat gtatccgcca ccactcattg aggagcccac 420 attcaatgtg tcctatacca ggcagccacc aaatcctgctccaggagcac agcaaatggg 480 accgccatat tacaccgacc ctggaggacc cgggatgaat cctgttggcaataccatggc 540 tatggctttc caggtccagc ccaattcacc tcacggaggc acaacttacc caccccctcc 600 ttcctactgc aacacgcctc caccccccta tgaacaggtg gtgaaggaca agtagcaaga 660 tgctacatca aaggcaaaga ggatggacag gcccttttgt ttaccttccc atcctcaccg 720 atacttgctg atagggtggt ccaagggaaa acttggatat tctcaaagca agcccagctc 780 tctttcaagt cttttgtgga ggacatttga atccacactg tctcctctgt tgcttctgtt 840 tctgatgtag tctgtgctct ctgagagagt gtggcaacag tccctgaggg ttgatattcc 900 tagggtgtcc agggtagatc ctcgggagag aggctaaggg gaaaggaagg catagcctgt 960 gtgttagggg gcagataaag tggtcaggct gagataagac tcacatgatgcagtagttgg 1020 cagtgaactt cgaagagaca ctatccacca tcccagccca ttctcctaat agaagctgtg 1080 gggctgtgtt gttgatgctc tttggtctcc actcacattt tgaaaatagg ctttcctctg 1140 caggaatagg aaagacccaa gtacatattt gcttccactt aaaaatgagg gtcagaacca 1200 ggcctcagtt ggacatctat agttaaataa aggccattag agaggggaaa tctttaagtt 1260 aggggaaatt ctctaaatgg agacattgcg ttttatgaat catcgtctgg cttttctttt 1320 agtgcatgta ttgaagtgag ggtgtccttt gagatcagat ggggagagtgaactctgcgg 1380 ggggtggggt gtctctactc agagggctcc aacacccttt tcttaggtag ttctggtgat 1440 gggttttatg ggcactatag agctgagggg cacattaggc cgggtagtta cattgaccct 1500 tggagaggaa gaggacagcc aaagaaactc agcaaagcaa gaccagcattgctgagttag 1560 agctagggtt gtatgtgatc ccaacagaga tgtgctggcc tcagaagagg ggacgtttgt 1620 ggatagagcc gtgaaaacct acttagttgcacagatgaca taatcaaaag tagagaaaga 1680 agtgtagtta gagatgccat ttcccaggtg agaatcagagctcatccata gatttacaag 1740 tagtggctgg agttaacagt atggagttct tttcccttgc gtagttagtc acgttgatgt 1800 gtatttaaac ccaggttgag accttgtgta ctaagagcaa ggaagtatagctaagatgtc 1860 tagattattt atatgtagta tggtggggag tggggctgca aggaaggggg ctgacattgt 1920 aaatgagaaa atcagagcca tttgataaac tgttacttgt tggatcaggc atccaaaagt 1980 gtctcttgag tggacattga gtattcttta ccacctacaagaccaggagg catggtgtca 2040 ttctccattg gggtatttat atgaggtaga ggttcaggaa tcgacagtagctgtgtgggc 2100 ttagtttaag gactgaaagc atagggactg gtagacagtt tcataggaaa ctgcggggaa 2160 ggaatggata cctttaaaga cagtttgtgg atgcagatgc tgccacccatcattgagcac 2220 ccttgtgtct ctggcttcct gtcactggat ccagtacccc tccatgcttg ggtccttgtt 2280 ttacataaga caacaaagca caatgtctgc tgtttacaat caagacgact acatggtcca 2340 aacatttctt ctctcttcta tcacttgtgg ctttaacttc catttcctcc gttccttttt 2400 aaaatcaaga agcacagtca gagctgcccc tgggattgca tcagggaacggctgatcaag 2460 gcattcagtg tccatgacta aatcttatct ttttgatagc aaatccttttaagaaactga 2520 acaattgcta aggctcagca attttatact ccaatgtctg tgtaaggtaa attttgtttg 2580 ccattgagcc cacattggaa ttccttctga cgtcaacact gacaatgcctatggaaattg 2640 cacttctggg tatatgtccc agcatccttg ttttcttatg tttggtgagt aaggctcacc 2700 ccttccagca gctctacttc tgtgtgctga ggtcctgtag agccggggct tgggcacaga 2760 catgaggcag acttgtgcat gctctttctt ggcaacactt ggctcatatttcttgttctc 2820 ttttgataga gtcctgtttc ctatgtattt aaaaaataat aaaagtgaat ttagtcaaaa 2880 aaaaaaaaaa aaaaaaaaaa aaaaagggcggccgc 291573 516 DNA Mus sp. 73 atgggccgcc ggctcggcag ggtggcggcg ctgctgctcg ggctgctagt ggagtgcact 60 gaggccaaaa aacattgctg gtattttgaa ggactctatc ccacatacta tatatgccgt 120 tcctatgaag actgctgtgg ctccaggtgc tgtgtgaggg ccctttccat acagaggctg 180 tggtattttt ggttcctgct gatgatgggtgtgctgttct gctgtggtgc cggtttcttc 240 attcgccggc gcatgtatcc gccaccactc attgaggagc ccacattcaa tgtgtcctat 300 accaggcagc caccaaatcc tgctccagga gcacagcaaa tgggaccgcc atattacacc 360 gaccctggag gacccgggat gaatcctgtt ggcaatacca tggctatggc tttccaggtc 420 cagcccaatt cacctcacgg aggcacaact tacccacccc ctccttcctactgcaacacg 480 cctccacccc cctatgaaca ggtggtgaag gacaag 51674 172 PRT Mus sp. 74 Met Gly Arg Arg Leu Gly Arg Val Ala Ala Leu Leu Leu Gly Leu Leu 1 5 10 15 Val Glu Cys Thr Glu Ala Lys Lys His Cys Trp Tyr Phe Glu Gly Leu 20 25 30 Tyr Pro Thr Tyr Tyr Ile Cys Arg Ser Tyr Glu Asp Cys Cys Gly Ser 35 40 45 Arg Cys Cys Val Arg Ala Leu Ser Ile Gln Arg Leu Trp Tyr Phe Trp 50 55 60 Phe Leu Leu Met Met Gly Val Leu Phe Cys Cys Gly Ala Gly Phe Phe 65 70 75 80 Ile Arg Arg Arg Met Tyr Pro Pro Pro Leu Ile Glu Glu Pro Thr Phe 85 90 95 Asn Val Ser Tyr Thr Arg Gln Pro Pro Asn Pro Ala Pro Gly Ala Gln 100 105 110 Gln Met Gly Pro Pro Tyr Tyr Thr Asp Pro Gly Gly Pro Gly Met Asn 115 120 125 Pro Val Gly Asn Thr Met Ala Met Ala Phe Gln Val Gln Pro Asn Ser 130 135 140 Pro His Gly Gly Thr Thr Tyr Pro Pro Pro Pro Ser Tyr Cys Asn Thr 145 150 155 160 Pro Pro Pro Pro Tyr Glu Gln Val Val Lys Asp Lys 165 170 75 398 PRT Homo sapiens 75 Met Trp Leu Leu Leu Thr Met Ala Ser Leu Ile Ser Val Leu Gly Thr 1 5 10 15 Thr His Gly Leu Phe Gly Lys Leu His Pro Gly Ser Pro Glu Val Thr 20 25 30 Met Asn Ile Ser Gln Met Ile Thr Tyr Trp Gly Tyr Pro Asn Glu Glu 35 40 45 Tyr Glu Val Val Thr Glu Asp Gly Tyr Ile Leu Glu Val Asn Arg Ile 50 55 60 Pro Tyr Gly Lys Lys Asn Ser Gly Asn Thr Gly Gln Arg Pro Val Val 65 70 75 80 Phe Leu Gln His Gly Leu Leu Ala Ser Ala Thr Asn Trp Ile Ser Asn 85 90 95 Leu Pro Asn Asn Ser Leu Ala Phe Ile Leu Ala Asp Ala Gly Tyr Asp 100 105 110 Val Trp Leu Gly Asn Ser Arg Gly Asn Thr Trp Ala Arg Arg Asn Leu 115 120 125 Tyr Tyr Ser Pro Asp Ser Val Glu Phe Trp Ala Phe Ser Phe Asp Glu 130 135 140 Met Ala Lys Tyr Asp Leu Pro Ala Thr Ile Asp Phe Ile Val Lys Lys 145 150 155 160 Thr Gly Gln Lys Gln Leu His Tyr Val Gly His Ser Gln Gly Thr Thr 165 170 175 Ile Gly Phe Ile Ala Phe Ser Thr Asn Pro Ser Leu Ala Lys Arg Ile 180 185 190 Lys Thr Phe Tyr Ala Leu Ala Pro Val Ala Thr Val Lys Tyr Thr Lys 195 200 205 Ser Leu Ile Asn Lys Leu Arg Phe Val Pro Gln Ser Leu Phe Lys Phe 210 215 220 Ile Phe Gly Asp Lys Ile Phe Tyr Pro His Asn Phe Phe Asp Gln Phe 225 230 235 240 Leu Ala Thr Glu Val Cys Ser Arg Glu Met Leu Asn Leu Leu Cys Ser 245 250 255 Asn Ala Leu Phe Ile Ile Cys Gly Phe Asp Ser Lys Asn Phe Asn Thr 260 265 270 Ser Arg Leu Asp Val Tyr Leu Ser His Asn Pro Ala Gly Thr Ser Val 275 280 285 Gln Asn Met Phe His Trp Thr Gln Ala Val Lys Ser Gly Lys Phe Gln 290 295 300 Ala Tyr Asp Trp Gly Ser Pro Val Gln Asn Arg Met His Tyr Asp Gln 305 310 315 320 Ser Gln Pro Pro Tyr Tyr Asn Val Thr Ala Met Asn Val Pro Ile Ala 325 330 335 Val Trp Asn Gly Gly Lys Asp Leu Leu Ala Asp Pro Gln Asp Val Gly 340 345 350 Leu Leu Leu Pro Lys Leu Pro Asn Leu Ile Tyr His Lys Glu Ile Pro 355 360 365 Phe Tyr Asn His Leu Asp Phe Ile Trp Ala Met Asp Ala Pro Gln Glu 370 375 380 Val Tyr Asn Asp Ile Val Ser Met Ile Ser Glu Asp Lys Lys 385 390 395 76 760 PRT Mus sp. 76 Met Ala Leu Pro Ser Leu Gly Gln Asp Ser Trp Ser Leu Leu Arg Val 1 5 10 15 Phe Phe Phe Gln Leu Phe Leu Leu Pro Ser Leu Pro Pro Ala Ser Gly 20 25 30 Thr Gly Gly Gln Gly Pro Met Pro Arg Val Lys Tyr His Ala Gly Asp 35 40 45 Gly His Arg Ala Leu Ser Phe Phe Gln Gln Lys Gly Leu Arg Asp Phe 50 55 60 Asp Thr Leu Leu Leu Ser Asp Asp Gly Asn Thr Leu Tyr Val Gly Ala 65 70 75 80 Arg Glu Thr Val Leu Ala Leu Asn Ile Gln Asn Pro Gly Ile Pro Arg 85 90 95 Leu Lys Asn Met Ile Pro Trp Pro Ala Ser Glu Arg Lys Lys Thr Glu 100 105 110 Cys Ala Phe Lys Lys Lys Ser Asn Glu Thr Gln Cys Phe Asn Phe Ile 115 120 125 Arg Val Leu Val Ser Tyr Asn Ala Thr His Leu Tyr Ala Cys Gly Thr 130 135 140 Phe Ala Phe Ser Pro Ala Cys Thr Phe Ile Glu Leu Gln Asp Ser Leu 145 150 155 160 Leu Leu Pro Ile Leu Ile Asp Lys Val Met Asp Gly Lys Gly Gln Ser 165 170 175 Pro Leu Thr Leu Phe Thr Ser Thr Gln Ala Val Leu Val Asp Gly Met 180 185 190 Leu Tyr Ser Gly Thr Met Asn Asn Phe Leu Gly Ser Glu Pro Ile Leu 195 200 205 Met Arg Thr Leu Gly Ser His Pro Val Leu Lys Thr Asp Ile Phe Leu 210 215 220 Arg Trp Leu His Ala Asp Ala Ser Phe Val Ala Ala Ile Pro Ser Thr 225 230 235 240 Gln Val Val Tyr Phe Phe Phe Glu Glu Thr Ala Ser Glu Phe Asp Phe 245 250 255 Phe Glu Glu Leu Tyr Ile Ser Arg Val Ala Gln Val Cys Lys Asn Asp 260 265 270 Val Gly Gly Glu Lys Leu Leu Gln Lys Lys Trp Thr Thr Phe Leu Lys 275 280 285 Ala Gln Leu Leu Cys Ala Gln Pro Gly Gln Leu Pro Phe Asn Ile Ile 290 295 300 Arg His Ala Val Leu Leu Pro Ala Asp Ser Pro Ser Val Ser Arg Ile 305 310 315 320 Tyr Ala Val Phe Thr Ser Gln Trp Gln Val Gly Gly Thr Arg Ser Ser 325 330 335 Ala Val Cys Ala Phe Ser Leu Thr Asp Ile Glu Arg Val Phe Lys Gly 340 345 350 Lys Tyr Lys Glu Leu Asn Lys Glu Thr Ser Arg Trp Thr Thr Tyr Arg 355 360 365 Gly Ser Glu Val Ser Pro Arg Pro Gly Ser Cys Ser Met Gly Pro Ser 370 375 380 Ser Asp Lys Ala Leu Thr Phe Met Lys Asp His Phe Leu Met Asp Glu 385 390 395 400 His Val Val Gly Thr Pro Leu Leu Val Lys Ser Gly Val Glu Tyr Thr 405 410 415 Arg Leu Ala Val Glu Ser Ala Arg Gly Leu Asp Gly Ser Ser His Val 420 425 430 Val Met Tyr Leu Gly Thr Ser Thr Gly Pro Leu His Lys Ala Val Val 435 440 445 Pro Gln Asp Ser Ser Ala Tyr Leu Val Glu Glu Ile Gln Leu Ser Pro 450 455 460 Asp Ser Glu Pro Val Arg Asn Leu Gln Leu Ala Pro Ala Gln Gly Ala 465 470 475 480 Val Phe Ala Gly Phe Ser Gly Gly Ile Trp Arg Val Pro Arg Ala Asn 485 490 495 Cys Ser Val Tyr Glu Ser Cys Val Asp Cys Val Leu Ala Arg Asp Pro 500 505 510 His Cys Ala Trp Asp Pro Glu Ser Arg Leu Cys Ser Leu Leu Ser Gly 515 520 525 Ser Thr Lys Pro Trp Lys Gln Asp Met Glu Arg Gly Asn Pro Glu Trp 530 535 540 Val Cys Thr Arg Gly Pro Met Ala Arg Ser Pro Arg Arg Gln Ser Pro 545 550 555 560 Pro Gln Leu Ile Lys Glu Val Leu Thr Val Pro Asn Ser Ile Leu Glu 565 570 575 Leu Arg Cys Pro His Leu Ser Ala Leu Ala Ser Tyr His Trp Ser His 580 585 590 Gly Arg Ala Lys Ile Ser Glu Ala Ser Ala Thr Val Tyr Asn Gly Ser 595 600 605 Leu Leu Leu Leu Pro Gln Asp Gly Val Gly Gly Leu Tyr Gln Cys Val 610 615 620 Ala Thr Glu Asn Gly Tyr Ser Tyr Pro Val Val Ser Tyr Trp Val Asp 625 630 635 640 Ser Gln Asp Gln Pro Leu Ala Leu Asp Pro Glu Leu Ala Gly Val Pro 645 650 655 Arg Glu Arg Val Gln Val Pro Leu Thr Arg Val Gly Gly Gly Ala Ser 660 665 670 Met Ala Ala Gln Arg Ser Tyr Trp Pro His Phe Leu Ile Val Thr Val 675 680 685 Leu Leu Ala Ile Val Leu Leu Gly Val Leu Thr Leu Leu Leu Ala Ser 690 695 700 Pro Leu Gly Ala Leu Arg Ala Arg Gly Lys Val Gln Gly Cys Gly Met 705 710 715 720 Leu Pro Pro Arg Glu Lys Ala Pro Leu Ser Arg Asp Gln His Leu Gln 725 730 735 Pro Ser Lys Asp His Arg Thr Ser Ala Ser Asp Val Asp Ala Asp Asn 740 745 750 Asn His Leu Gly Ala Glu Val Ala 755 760 77 3046 DNA Mus sp. 77 ctcggacgcc tgggttaggg gtctgtactg ctggggaacc atctggtgac catctcaggc 60 tgaccatggc cctaccatcc ctgggccagg actcatggag tctcctgcgt gtttttttct 120 tccaactctt cctgctgcca tcactgccac ctgcttctgg gactggtggt caggggccca 180 tgcccagagt caaataccat gctggagacg ggcacagggc cctcagcttc ttccaacaaa 240 aaggcctccg agactttgac acgctgctcc tgagtgacga tggcaacact ctctatgtgg 300 gggctcgaga gaccgtcctg gccttgaata tccagaaccc aggaatccca aggctaaaga 360 acatgatacc ctggccagcc agtgagagaa aaaagaccga atgtgccttt aagaagaaga 420 gcaatgagac acagtgtttc aacttcattc gagtcctggt ctcttacaat gctactcacc 480 tctatgcctg tgggaccttt gccttcagcc ctgcctgtac cttcattgaa ctccaagatt 540 ccctcctgtt gcccatcttg atagacaagg tcatggacgg gaagggccaa agccctttga 600 ccctgttcac aagcacacaa gctgtcttgg tcgatgggat gctttattcc ggcaccatga 660 acaacttcct gggcagcgag cccatcctga tgcggacact gggatcccatcctgttctca 720 agactgacat cttcttacgc tggctgcacg cggatgcctc cttcgtggca gccattccat 780 ccacccaggt cgtctatttc ttctttgagg agacagccag cgagtttgac ttctttgaag 840 agctgtatat atccagggtg gctcaagtct gcaagaacga cgtgggcggt gaaaagctgc 900 tgcagaagaa gtggaccacc ttcctcaaag cccagttgct ctgcgctcag ccagggcagc 960 tgccattcaa catcatccgc cacgcggtcctgctgcccgc cgattctccc tctgtttccc 1020 gcatctacgc agtctttacc tcccagtggc aggttggcgg gaccaggagc tcagcagtct 1080 gtgccttctc tctcacggac attgagcgag tctttaaagg gaagtacaag gagctgaaca 1140 aggagacctc ccgctggacc acttaccggg gctcagaggt cagcccgagg ccaggcagtt 1200 gctccatggg cccctcctct gacaaagcct tgaccttcat gaaggaccat tttctgatgg 1260 atgagcacgt ggtaggaaca cccctgctgg tgaagtctgg tgtggagtac acacggcttg 1320 ctgtggagtc agctcggggc cttgatggga gcagccatgtggtcatgtat ctgggtacct 1380 ccacgggtcc cctgcacaag gctgtggtgc ctcaggacagcagtgcttat ctcgtggagg 1440 agattcagct gagccctgac tctgagcctg ttcgaaacct gcagctggcc cccgcccagg 1500 gtgcagtgtt tgcaggcttc tctggaggca tctggagagt tcccagggccaattgcagtg 1560 tctacgagag ctgtgtggac tgtgtgcttg ccagggaccc tcactgtgcc tgggaccctg 1620 aatcaagact ctgcagcctt ctgtctggct ctaccaagcc ttggaagcaggacatggaac 1680 gcggcaaccc ggagtgggta tgcacccgtg gccccatggc caggagcccccggcgtcaga 1740 gcccccctca actaattaaa gaagtcctga cagtccccaa ctccatcctg gagctgcgct 1800 gcccccacct gtcagcactg gcctcttacc actggagtca tggccgagccaaaatctcag 1860 aagcctctgc taccgtctac aatggctccc tcttgctgct gccgcaggatggtgtcgggg 1920 gcctctacca gtgtgtggcg actgagaacg gctactcata ccctgtggtc tcctattggg 1980 tagacagcca ggaccagccc ctggcgctgg accctgagct ggcgggcgtt ccccgtgagc 2040 gtgtgcaggt cccgctgacc agggtcggag gcggagcttc catggctgcc cagcggtcct 2100 actggcccca ttttctcatc gttaccgtcc tcctggccatcgtgctcctg ggagtgctca 2160 ctctcctcct cgcttcccca ctgggggcgc tgcgggctcg gggtaaggttcagggctgtg 2220 ggatgctgcc ccccagggaa aaggctccac tgagcaggga ccagcacctc cagccctcca 2280 aggaccacag gacctctgcc agtgacgtag atgccgacaacaaccatctg ggcgccgaag 2340 tggcttaaac agggacacag atccgcagct gagcagagca agccactggc cttgttggct 2400 atgccaggca cagtgccact ctgaccaggg taggaggctc tcctgctaacgtgtgtcacc 2460 tacagcaccc agtaggtcct cccctgtgggactctcttct gcaagcacat tgggctgtct 2520 ccatacctgt acttgtgctg tgacaggaag agccagacag gtttctttga ttttgattga 2580 cccaagagcc ctgcctgtaa caaacgtgct ccaggagacc atgaaaggtgtggctgtctg 2640 ggattctgtg gtgacaaacc taagcatccg agcaagctgg ggctattcctgcaaactcca 2700 tcctgaacgc tgtcactcta gaagcagctg ctgctttgaa caccagccca ccctccttcc 2760 caagagtctc tatggagttg gccccttgtg tttcctttac cagtcgggcc atactgtttg 2820 ggaagtcatc tctgaagtct aaccaccttc cttcttggtt cagtttggac agattgttat 2880 tattgtctct gccctggcta gaatgggggc ataatctgagccttgttccc ttgtccagtg 2940 tggctgaccc ttgacctctt ccttcctcct ccctttgttt tgggattcag aaaactgctt 3000 gtcacagaca atttattttt tattaaaaaa gatataagct ttaaag 304678 1436 PRT Bos sp. 78 Met Ala Leu Gly Arg His Leu Ser Leu Arg Gly Leu Cys Val Leu Leu 1 5 10 15 Leu Gly Thr Met Val Gly Gly Gln Ala Leu Glu Leu Arg Leu Lys Asp 20 25 30 Gly Val His Arg Cys Glu Gly Arg Val Glu Val Lys His Gln Gly Glu 35 40 45 Trp Gly Thr Val Asp Gly Tyr Arg Trp Thr Leu Lys Asp Ala Ser Val 50 55 60 Val Cys Arg Gln Leu Gly Cys Gly Ala Ala Ile Gly Phe Pro Gly Gly 65 70 75 80 Ala Tyr Phe Gly Pro Gly Leu Gly Pro Ile Trp Leu Leu Tyr Thr Ser 85 90 95 Cys Glu Gly Thr Glu Ser Thr Val Ser Asp Cys Glu His Ser Asn Ile 100 105 110 Lys Asp Tyr Arg Asn Asp Gly Tyr Asn His Gly Arg Asp Ala Gly Val 115 120 125 Val Cys Ser Gly Phe Val Arg Leu Ala Gly Gly Asp Gly Pro Cys Ser 130 135 140 Gly Arg Val Glu Val His Ser Gly Glu Ala Trp Ile Pro Val Ser Asp 145 150 155 160 Gly Asn Phe Thr Leu Ala Thr Ala Gln Ile Ile Cys Ala Glu Leu Gly 165 170 175 Cys Gly Lys Ala Val Ser Val Leu Gly His Glu Leu Phe Arg Glu Ser 180 185 190 Ser Ala Gln Val Trp Ala Glu Glu Phe Arg Cys Glu Gly Glu Glu Pro 195 200 205 Glu Leu Trp Val Cys Pro Arg Val Pro Cys Pro Gly Gly Thr Cys His 210 215 220 His Ser Gly Ser Ala Gln Val Val Cys Ser Ala Tyr Ser Glu Val Arg 225 230 235 240 Leu Met Thr Asn Gly Ser Ser Gln Cys Glu Gly Gln Val Glu Met Asn 245 250 255 Ile Ser Gly Gln Trp Arg Ala Leu Cys Ala Ser His Trp Ser Leu Ala 260 265 270 Asn Ala Asn Val Ile Cys Arg Gln Leu Gly Cys Gly Val Ala Ile Ser 275 280 285 Thr Pro Gly Gly Pro His Leu Val Glu Glu Gly Asp Gln Ile Leu Thr 290 295 300 Ala Arg Phe His Cys Ser Gly Ala Glu Ser Phe Leu Trp Ser Cys Pro 305 310 315 320 Val Thr Ala Leu Gly Gly Pro Asp Cys Ser His Gly Asn Thr Ala Ser 325 330 335 Val Ile Cys Ser Gly Asn Gln Ile Gln Val Leu Pro Gln Cys Asn Asp 340 345 350 Ser Val Ser Gln Pro Thr Gly Ser Ala Ala Ser Glu Asp Ser Ala Pro 355 360 365 Tyr Cys Ser Asp Ser Arg Gln Leu Arg Leu Val Asp Gly Gly Gly Pro 370 375 380 Cys Ala Gly Arg Val Glu Ile Leu Asp Gln Gly Ser Trp Gly Thr Ile 385 390 395 400 Cys Asp Asp Gly Trp Asp Leu Asp Asp Ala Arg Val Val Cys Arg Gln 405 410 415 Leu Gly Cys Gly Glu Ala Leu Asn Ala Thr Gly Ser Ala His Phe Gly 420 425 430 Ala Gly Ser Gly Pro Ile Trp Leu Asp Asn Leu Asn Cys Thr Gly Lys 435 440 445 Glu Ser His Val Trp Arg Cys Pro Ser Arg Gly Trp Gly Gln HisAsn 450 455 460 Cys Arg His Lys Gln Asp Ala Gly Val Ile Cys Ser Glu Phe Leu Ala 465 470 475 480 Leu Arg Met Val Ser Glu Asp Gln Gln Cys Ala Gly Trp Leu Glu Val 485 490 495 Phe Tyr Asn Gly Thr Trp Gly Ser Val Cys Arg Asn Pro Met Glu Asp 500 505 510 Ile Thr Val Ser Thr Ile Cys Arg Gln Leu Gly Cys Gly Asp Ser Gly 515 520 525 Thr Leu Asn Ser Ser Val Ala Leu Arg Glu Gly Phe Arg Pro Gln Trp 530 535 540 Val Asp Arg Ile Gln Cys Arg Lys Thr Asp Thr Ser Leu Trp Gln Cys 545 550 555 560 Pro Ser Asp Pro Trp Asn Tyr Asn Ser Cys Ser Pro Lys Glu Glu Ala 565 570 575 Tyr Ile Trp Cys Ala Asp Ser Arg Gln Ile Arg Leu Val Asp Gly Gly 580 585 590 Gly Arg Cys Ser Gly Arg Val Glu Ile Leu Asp Gln Gly Ser Trp Gly 595 600 605 Thr Ile Cys Asp Asp Arg Trp Asp Leu Asp Asp Ala Arg Val Val Cys 610 615 620 Lys Gln Leu Gly Cys Gly Glu Ala Leu Asp Ala Thr Val Ser Ser Phe 625 630 635 640 Phe Gly Thr Gly Ser Gly Pro Ile Trp Leu Asp Glu Val Asn Cys Arg 645 650 655 Gly Glu Glu Ser Gln Val Trp Arg Cys Pro Ser Trp Gly Trp Arg Gln 660 665 670 His Asn Cys Asn His Gln Glu Asp Ala Gly Val Ile Cys Ser GlyPhe 675 680 685 Val Arg Leu Ala Gly Gly Asp Gly Pro Cys Ser Gly Arg Val Glu Val 690 695 700 His Ser Gly Glu Ala Trp Thr Pro Val Ser Asp Gly Asn Phe Thr Leu 705 710 715 720 Pro Thr Ala Gln Val Ile Cys Ala Glu Leu Gly Cys Gly Lys Ala Val 725 730 735 Ser Val Leu Gly His Met Pro Phe Arg Glu Ser Asp Gly Gln Val Trp 740 745 750 Ala Glu Glu Phe Arg Cys Asp Gly Gly Glu Pro Glu Leu Trp Ser Cys 755 760 765 Pro Arg Val Pro Cys Pro Gly Gly Thr Cys Leu His Ser Gly Ala Ala 770 775 780 Gln Val Val Cys Ser Val Tyr Thr Glu Val Gln Leu Met Lys Asn Gly 785 790 795 800 Thr Ser Gln Cys Glu Gly Gln Val Glu Met Lys Ile Ser Gly Arg Trp 805 810 815 Arg Ala Leu Cys Ala Ser His Trp Ser Leu Ala Asn Ala Asn Val Val 820 825 830 Cys Arg Gln Leu Gly Cys Gly Val Ala Ile Ser Thr Pro Arg Gly Pro 835 840 845 His Leu Val Glu Gly Gly Asp Gln Ile Ser Thr Ala Gln Phe HisCys 850 855 860 Ser Gly Ala Glu Ser Phe Leu Trp Ser Cys Pro Val Thr Ala Leu Gly 865 870 875 880 Gly Pro Asp Cys Ser His Gly Asn Thr Ala Ser Val Ile Cys Ser Gly 885 890 895 Asn His Thr Gln Val Leu Pro Gln Cys Asn Asp Phe Leu Ser Gln Pro 900 905 910 Ala Gly Ser Ala Ala Ser Glu Glu Ser Ser Pro Tyr Cys Ser Asp Ser 915 920 925 Arg Gln Leu Arg Leu Val Asp Gly Gly Gly Pro Cys Gly Gly Arg Val 930 935 940 Glu Ile Leu Asp Gln Gly Ser Trp Gly Thr Ile Cys Asp Asp Asp Trp 945 950 955 960 Asp Leu Asp Asp Ala Arg Val Val Cys Arg Gln Leu Gly Cys Gly Glu 965 970 975 Ala Leu Asn Ala Thr Gly Ser Ala His Phe Gly Ala Gly Ser Gly Pro 980 985 990 Ile Trp Leu Asp Asp Leu Asn Cys Thr Gly Lys Glu Ser His Val Trp 995 1000 1005 Arg Cys Pro Ser Arg Gly Trp Gly Arg His Asp Cys Arg His Lys Glu 1010 1015 1020 Asp Ala Gly Val Ile Cys Ser Glu Phe Leu Ala Leu Arg Met Val Ser 1025 1030 1035 1040 Glu Asp Gln Gln Cys Ala Gly Trp Leu Glu Val Phe Tyr Asn Gly Thr 1045 1050 1055 Trp Gly Ser Val Cys Arg Ser Pro Met Glu Asp Ile Thr Val Ser Val 1060 1065 1070 Ile Cys Arg Gln Leu Gly Cys Gly Asp Ser Gly Ser Leu Asn Thr Ser 1075 1080 1085 Val Gly Leu Arg Glu Gly Ser Arg Pro Arg Trp Val Asp Leu Ile Gln 1090 1095 1100 Cys Arg Lys Met Asp Thr Ser Leu Trp Gln Cys Pro Ser Gly Pro Trp 1105 1110 1115 1120 Lys Tyr Ser Ser Cys Ser Pro Lys Glu Glu Ala Tyr Ile Ser Cys Glu 1125 1130 1135 Gly Arg Arg Pro Lys Ser Cys Pro Thr Ala Ala Ala Cys Thr Asp Arg 1140 1145 1150 Glu Lys Leu Arg Leu Arg Gly Gly Asp Ser Glu Cys Ser Gly Arg Val 1155 1160 1165 Glu Val Trp His Asn Gly Ser Trp Gly Thr Val Cys Asp Asp Ser Trp 1170 1175 1180 Ser Leu Ala Glu Ala Glu Val Val Cys Gln Gln Leu Gly Cys Gly Gln 1185 1190 1195 1200 Ala Leu Glu Ala Val Arg Ser Ala Ala Phe Gly Pro Gly Asn Gly Ser 1205 1210 1215 Ile Trp Leu Asp Glu Val Gln Cys Gly Gly Arg Glu Ser Ser Leu Trp 1220 1225 1230 Asp Cys Val Ala Glu Pro Trp Gly Gln Ser Asp Cys Lys His Glu Glu 1235 1240 1245 Asp Ala Gly Val Arg Cys Ser Gly Val Arg Thr Thr Leu Pro Thr Thr 1250 1255 1260 Thr Ala Gly Thr Arg Thr Thr Ser Asn Ser Leu Pro Gly Ile Phe Ser 1265 1270 1275 1280 Leu Pro Gly Val Leu Cys Leu Ile Leu Gly Ser Leu Leu Phe Leu Val 1285 1290 1295 Leu Val Ile Leu Val Thr Gln Leu Leu Arg Trp Arg Ala Glu Arg Arg 1300 1305 1310 Ala Leu Ser Ser Tyr Glu Asp Ala Leu Ala Glu Ala Val Tyr Glu Glu 1315 1320 1325 Leu Asp Tyr Leu Leu Thr Gln Lys Glu Gly Leu Gly Ser Pro Asp Gln 1330 1335 1340 Met Thr Asp Val Pro Asp Glu Asn Tyr Asp Asp Ala Glu Glu Val Pro 1345 1350 1355 1360 Val Pro Gly Thr Pro Ser Pro Ser Gln Gly Asn Glu Glu Glu Val Pro 1365 1370 1375 Pro Glu Lys Glu Asp Gly Val Arg Ser Ser Gln Thr Gly Ser Phe Leu 1380 1385 1390 Asn Phe Ser Arg Glu Ala Ala Asn Pro Gly Glu Gly Glu Glu Ser Phe 1395 1400 1405 Trp Leu Leu Gln Gly Lys Lys Gly Asp Ala Gly Tyr Asp Asp Val Glu 1410 1415 1420 Leu Ser Ala Leu Gly Thr Ser Pro Val Thr Phe Ser 1425 1430 143579 4308 DNA Bos sp. 79 atggctctgg gcagacacct ctccctgcgg ggactctgtg tcctcctcct cggcaccatg 60 gtgggtggtc aagctctgga gctgaggttg aaggatggag tccatcgctg tgaggggaga 120 gtggaagtga agcaccaagg agaatggggc acagtggatg gttacaggtg gacattgaag 180 gatgcatctg tagtgtgcag acagctgggg tgtggagctg ccattggttt tcctggaggg 240 gcttattttg ggccaggact tggccccatt tggcttttgt atacttcatg tgaagggaca 300 gagtcaactg tcagtgactg tgagcattct aatattaaag actatcgtaa tgatggctat 360 aatcatggtc gggatgctgg agtagtctgc tcaggatttg tgcgtctggc tggaggggat 420 ggaccctgct cagggcgagt agaagtgcat tctggagaag cttggatccc agtgtctgat 480 gggaacttca cacttgccac tgcccagatc atctgtgcag agttgggttg tggcaaggct 540 gtgtctgtcc tgggacatga gctcttcaga gagtccagtg cccaggtctg ggctgaagag 600 ttcaggtgtg agggggagga gcctgagctc tgggtctgcc ccagagtgcc ctgtccaggg 660 ggcacgtgtc accacagtgg atctgctcag gttgtttgtt cagcatactc agaagtccgg 720 ctcatgacaa acggctcctc tcagtgtgaa gggcaggtgg agatgaacat ttctggacaa 780 tggagagcgc tctgtgcctc ccactggagt ctggccaatg ccaatgttatctgtcgtcag 840 ctcggctgtg gagttgccat ctccaccccc ggaggaccac acttggtgga agaaggtgat 900 cagatcctaa cagcccgatt tcactgctct ggggctgagt ccttcctgtg gagttgtcct 960 gtgactgccc tgggtggtcc tgactgttcc catggcaaca cagcctctgtgatctgctca 1020 ggaaaccaga tccaggtgct tccccagtgc aacgactccg tgtctcaacc tacaggctct 1080 gcggcctcag aggacagcgc cccctactgc tcagacagca ggcagctccg cctggtggac 1140 gggggcggtc cctgcgccgg gagagtggag atccttgacc agggctcctggggcaccatc 1200 tgtgatgacg gctgggacct ggacgatgcc cgcgtggtgtgcaggcagct gggctgtgga 1260 gaagccctca atgccacggg gtctgctcac ttcggggcag gatcagggcc catctggttg 1320 gacaacttga actgcacagg aaaggagtcc cacgtgtgga ggtgcccttc ccggggctgg 1380 gggcagcaca actgcagaca caagcaggac gcgggggtca tctgctcaga gttcctggcc 1440 ctcaggatgg tgagtgagga ccagcagtgt gctgggtggc tggaagttttctacaatggg 1500 acctggggca gtgtctgccg taaccccatg gaagacatca ctgtgtccac gatctgcaga 1560 cagcttggct gtggggacag tggaaccctc aactcttctg ttgctcttag agaaggtttt 1620 aggccacagt gggtggatag aatccagtgt cggaaaactg acacctctct ctggcagtgt 1680 ccttctgacc cttggaatta caactcatgc tctccaaagg aggaagccta tatctggtgt 1740 gcagacagca gacagatccg cctggtggat ggaggtggtc gctgctctgg gagagtggag 1800 atccttgacc agggctcctg gggcaccatc tgtgatgacc gctgggacct ggacgatgcc 1860 cgtgtggtgt gcaagcagct gggctgtgga gaagccctgg acgccactgtctcttccttc 1920 ttcgggacgg gatcagggcc catctggctg gatgaagtga actgcagagg agaggagtcc 1980 caagtatgga ggtgcccttc ctggggatgg cggcaacaca actgcaatca tcaagaagat 2040 gcaggagtca tctgctcagg atttgtgcgt ctggctggag gagatggaccctgctcaggg 2100 cgagtagaag tgcattctgg agaagcctgg accccagtgt ctgatggaaacttcacactc 2160 cccactgccc aggtcatctg tgcagagctg ggatgtggca aggctgtgtc tgtcctggga 2220 cacatgccat tcagagagtc cgatggccag gtctgggctg aagagttcag gtgtgatggg 2280 ggggagcctg agctctggtc ctgccccagagtgccctgtc caggaggcac atgtctccac 2340 agtggagctg ctcaggttgt ctgttcagtg tacacagaag tccagcttat gaaaaacggc 2400 acctctcaat gtgaggggca ggtggagatg aagatctctg gacgatggag agcgctctgt 2460 gcctcccact ggagtctggc caatgccaatgttgtctgtc gtcagctcgg ctgtggagtc 2520 gccatctcca cccccagagg accacacttg gtggaaggag gtgatcagat ctcaacagcc 2580 caatttcact gctcaggggc tgagtccttc ctgtggagtt gtcctgtgac tgccttgggt 2640 gggcctgact gttcccatgg caacacagcc tctgtgatct gctcaggaaa ccacacccag 2700 gtgctgcccc agtgcaacga cttcctgtctcaacctgcag gctctgcggc ctcagaggag 2760 agttctccct actgctcaga cagcaggcag ctccgcctgg tggacgggggcggtccctgc 2820 ggcgggagag tggagatcct tgaccagggc tcctggggca ccatctgtga tgatgactgg 2880 gacctggacg atgcccgtgt ggtgtgcagg cagctgggct gtggagaagc cctcaatgcc 2940 acggggtctg ctcacttcgg ggcaggatca gggcccatct ggctggacga cctgaactgc 3000 acaggaaagg agtcccacgt gtggaggtgc ccttcccggggctgggggcg gcacgactgc 3060 agacacaagg aggacgccgg ggtcatctgc tcagagttcc tggccctcag gatggtgagc 3120 gaggaccagc agtgtgctgg gtggctggag gttttctaca acgggacctggggcagtgtc 3180 tgccgcagcc ccatggaaga tatcactgtg tccgtgatct gcagacagct tggatgtggg 3240 gacagtggaa gtctcaacac ctctgttggt ctcagggaag gttctagacc ccggtgggta 3300 gatttaattc agtgtcggaa aatggatacc tctctctggc agtgtccttc tggcccatgg 3360 aaatacagtt catgctctcc aaaggaggaa gcctacatct catgtgaagg aagaagaccc 3420 aagagctgtc caactgctgc cgcctgcaca gacagagaga agctccgcct caggggagga 3480 gacagcgagt gctcagggcg ggtggaggtg tggcacaacg gctcctggggcaccgtgtgc 3540 gatgactcct ggagcctggc agaggctgag gtggtgtgtc agcagctggg ctgtggccag 3600 gccctggaag ccgtgcggtc tgcagcattt ggccctggaa atgggagcatctggctggac 3660 gaggtgcagt gcgggggccg ggagtcctcc ctgtgggactgtgttgcgga gccctggggg 3720 cagagcgact gcaagcacga ggaggatgct ggtgtgaggt gctctggtgtaaggacaaca 3780 ttgcccacga ccacagcagg gaccagaaca acctcaaattctctccctgg catcttctcc 3840 ctgcctgggg ttctctgcct tatcctgggg tcgcttctct tcctggtcctcgtcatcctg 3900 gtgactcagc tactcagatg gagagcagag cgcagagcct tatccagcta tgaagatgct 3960 cttgctgaag ctgtgtatga ggagctcgat taccttctgacacagaagga aggtctgggc 4020 agcccagatc agatgactga tgtccctgat gaaaattatg atgatgctga agaagtacca 4080 gtgcctggaa ctccttctcc ctctcagggg aatgaggagg aagtgccccc agagaaggag 4140 gacggggtga ggtcctctca gacaggctct ttcctgaact tctccagagaggcagctaat 4200 cctggggaag gagaagagag cttctggctg ctccagggga agaaagggga tgctgggtat 4260 gatgatgttg aactcagtgc cctgggaaca tccccagtga ctttctcg 4308
Claims (51)
1. An isolated nucleic acid molecule selected from the group consisting of:
a) a nucleic acid molecule having a nucleotide sequence which is at least 90% identical to the nucleotide sequence of any of SEQ ID NOs: 45, 46, the nucleotide sequence of a cDNA of a clone deposited as ATCC® 207220, or a complement thereof;
b) a nucleic acid molecule comprising at least 100 nucleotide residues and having a nucleotide sequence identical to at least 100 consecutive nucleotide residues of any of SEQ ID NOs: 45, 46, and the nucleotide sequence of a cDNA of a clone deposited as ATCC® 207220, or a complement thereof;
c) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of any of SEQ ID NOs: 47-52, and the amino acid sequence encoded by a cDNA of a clone deposited as ATCC® 207220, or a complement thereof;
d) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of any of SEQ ID NOs: 47-52 or the amino acid sequence encoded by a cDNA of a clone deposited as ATCC® 207220, wherein the fragment comprises at least 25 consecutive amino acid residues of any of SEQ ID NOs: 47-52 or the amino acid sequence encoded by a cDNA of a clone deposited as ATCC® 207220; and
e) a nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of any of SEQ ID NOs: 47-52, wherein the nucleic acid molecule hybridizes with a nucleic acid molecule consisting of the nucleotide sequence of any of SEQ ID NOs: 45, 46, and the nucleotide sequence of a cDNA of a clone deposited as ATCC® 207220, or a complement thereof under stringent conditions.
2. The isolated nucleic acid molecule of claim 1 , which is selected from the group consisting of:
a) a nucleic acid having the nucleotide sequence of any of SEQ ID NOs: 45, 46, and the nucleotide sequence of a cDNA of a clone deposited as ATCC® 207220, or a complement thereof; and
b) a nucleic acid molecule which encodes a polypeptide having the amino acid sequence of any of SEQ ID NOs: 47-52 or the amino acid sequence encoded by a cDNA of a clone deposited as ATCC® 207220, or a complement thereof.
3. The nucleic acid molecule of claim 1 , further comprising vector nucleic acid sequences.
4. The nucleic acid molecule of claim 1 further comprising nucleic acid sequences encoding a heterologous polypeptide.
5. A host cell which contains the nucleic acid molecule of claim 1 .
6. The host cell of claim 5 which is a mammalian host cell.
7. A non-human mammalian host cell containing the nucleic acid molecule of claim 1 .
8. An isolated polypeptide selected from the group consisting of:
a) a fragment of a polypeptide comprising the amino acid sequence of any of SEQ ID NOs: 47-52 or the amino acid sequence encoded by a cDNA of a clone deposited as ATCC® 207220, wherein the fragment comprises at least 25 contiguous amino acids of any of SEQ ID NOs: 47-52 or the amino acid sequence encoded by a cDNA of a clone deposited as ATCC® 207220;
b) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of any of SEQ ID NOs: 47-52 or the amino acid sequence encoded by a cDNA of a clone deposited as ATCC® 207220, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule consisting of the nucleotide sequence of any of SEQ ID NOs: 45, 46, and the nucleotide sequence of a cDNA of a clone deposited as ATCC® 207220, or a complement thereof under stringent conditions; and
c) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 90% identical to a nucleic acid consisting of the nucleotide sequence of any of SEQ ID NOs: 45, 46, and the nucleotide sequence of a cDNA of a clone deposited as ATCC® 207220, or a complement thereof.
9. The isolated polypeptide of claim 8 having the amino acid sequence of any of SEQ ID NOs: 47-52 or the amino acid sequence encoded by a cDNA of a clone deposited as ATCC® 207220, or a complement thereof.
10. The polypeptide of claim 8 , wherein the amino acid sequence of the polypeptide further comprises heterologous amino acid residues.
11. An antibody which selectively binds with the polypeptide of claim 8 .
12. A method for producing a polypeptide selected from the group consisting of:
a) a polypeptide having an amino acid sequence comprising any of SEQ ID NOs: 47-52 or the amino acid sequence encoded by a cDNA of a clone deposited as ATCC® 207220, or a complement thereof;
b) a polypeptide comprising a fragment of a protein having the amino acid sequence of any of SEQ ID NOs: 47-52 or the amino acid sequence encoded by a cDNA of a clone deposited as ATCC® 207220, or a complement thereof, wherein the fragment comprises at least 25 contiguous amino acid residues of any of SEQ ID NOs: 47-52 or the amino acid sequence encoded by a cDNA of a clone deposited as ATCC® 207220, or a complement thereof; and
c) a naturally occurring allelic variant of a polypeptide having an amino acid sequence comprising the sequence of any of SEQ ID NOs: 47-52 or the amino acid sequence encoded by a cDNA of a clone deposited as ATCC® 207220, or a complement thereof, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes with a nucleic acid molecule consisting of the nucleotide sequence of any of SEQ ID NOs: 45, 46, and the nucleotide sequence of a cDNA of a clone deposited as ATCC® 207220, or a complement thereof under stringent conditions,
the method comprising culturing the host cell of claim 5 under conditions in which the nucleic acid molecule is expressed.
13. A method for detecting the presence of a polypeptide of claim 8 in a sample, comprising:
a) contacting the sample with a compound which selectively binds with a polypeptide of claim 8; and
b) determining whether the compound binds with the polypeptide in the sample.
14. The method of claim 13 , wherein the compound which binds with the polypeptide is an antibody.
15. A kit comprising a compound which selectively binds with a polypeptide of claim 8 and instructions for use.
16. A method for detecting the presence of a nucleic acid molecule of claim 1 in a sample, comprising the steps of:
a) contacting the sample with a nucleic acid probe or primer which selectively hybridizes with the nucleic acid molecule; and
b) determining whether the nucleic acid probe or primer binds with a nucleic acid molecule in the sample.
17. The method of claim 16 , wherein the sample comprises mRNA molecules and is contacted with a nucleic acid probe.
18. A kit comprising a compound which selectively hybridizes with a nucleic acid molecule of claim 1 and instructions for use.
19. A method for identifying a compound which binds with a polypeptide of claim 8 , the method comprising the steps of:
a) contacting a polypeptide, or a cell expressing a polypeptide of claim 8 with a test compound; and
b) determining whether the polypeptide binds with the test compound.
20. The method of claim 19 , wherein the binding of the test compound with the polypeptide is detected by a method selected from the group consisting of:
a) detection of binding by direct detecting of test compound/polypeptide binding;
b) detection of binding using a competition binding assay; and
c) detection of binding using an assay for an activity characteristic of the polypeptide.
21. A method for modulating the activity of a polypeptide of claim 8 comprising contacting the polypeptide or a cell expressing the polypeptide with a compound which binds with the polypeptide in a sufficient concentration to modulate the activity of the polypeptide.
22. A method for identifying a compound which modulates the activity of a polypeptide of claim 8 , comprising:
a) contacting the polypeptide with a test compound; and
b) determining the effect of the test compound on the activity of the polypeptide to thereby identify a compound which modulates the activity of the polypeptide.
23. An antibody substance which selectively binds to the polypeptide of claim 8 , wherein the antibody substance is made by providing the polypeptide to an immunocompetent vertebrate and thereafter harvesting blood or serum from the vertebrate.
24. A method of assessing whether a first human patient is afflicted with an epithelial or endothelial tumor, the method comprising comparing:
a) occurrence of a nucleic acid molecule of claim 1 in a sample obtained from the first patient and
b) occurrence of the nucleic acid molecule in a control sample selected from the group consisting of
i) a control sample obtained from a tissue that is obtained from the first patient and that is known not to comprise the tumor; and
ii) a control sample obtained from a second patient who is known not to be afflicted with the tumor,
whereby a difference between the first sample and the control sample is an indication that the patient is afflicted with the tumor.
25. The method of claim 24 , wherein the tumor is selected from the group consisting of a colon tumor, a prostate tumor, a lung tumor, a pancreatic tumor, and a breast tumor.
26. The method of claim 25 , wherein the tumor is a colon tumor.
27. A method of assessing whether a first human patient is afflicted with an epithelial or endothelial tumor, the method comprising comparing
a) occurrence of a nucleic acid molecule of claim 1 in a sample obtained from the first patient and
b) occurrence of the nucleic acid molecule in a control sample selected from the group consisting of
i) a control sample obtained from a tissue that is obtained from the first patient and that is known to comprise the tumor; and
ii) a control sample obtained from a second patient who is known to be afflicted with the tumor,
whereby a difference between the first sample and the control sample is an indication that the patient is not afflicted with the tumor.
28. A method of screening for agents which decrease the activity of a TANGO-294-like lipase protein, the method comprising:
contacting a test compound with a TANGO 294-like lipase polypeptide encoded by an isolated nucleic acid molecule of claim 1 and
detecting binding between the test compound and the TANGO 294-like lipase polypeptide,
wherein binding between the test compound and the TANGO 294-like lipase polypeptide is an indication that the test compound is an agent which decreases the activity of the TANGO 294-like lipase protein.
29. A method of screening for agents which modulate the activity of a TANGO 294-like lipase protein, the method comprising:
contacting a test compound with a TANGO 294-like lipase polypeptide encoded by an isolated nucleic acid molecule of claim 1 and
detecting a TANGO 294-like lipase activity of the polypeptide,
wherein increased TANGO 294-like lipase activity in the presence of the test compound is an indication that the test compound is an agent useful for increasing the activity of the TANGO 294-like lipase protein, and decreased TANGO 294-like lipase activity in the presence of the test compound is an indication that the test compound is an agent useful for decreasing the activity of the TANGO 294-like lipase protein.
30. A method of screening for agents which decrease the activity of a TANGO 294-like lipase protein, the method comprising:
contacting a test compound with an isolated nucleic acid molecule of claim 1 and
detecting binding of the test compound with the isolated nucleic acid molecule,
wherein binding between the test compound and the isolated nucleic acid molecule is an indication that the test compound is a agent useful for decreasing the activity of the TANGO 294-like lipase protein.
31. A method of reducing the activity of a TANGO 294-like lipase protein of a cell, the method comprising contacting the cell with a reagent which specifically binds with an isolated nucleic acid molecule of claim 1 , whereby the activity of the TANGO 294-like lipase protein is reduced.
32. A method of reducing the activity of a TANGO 294-like lipase protein of a cell, the method comprising contacting the cell with a reagent which specifically binds with an isolated polypeptide of claim 8 , whereby the activity of the TANGO 294-like lipase protein is reduced.
33. A method of making a pharmaceutical composition, the method comprising identifying an agent according to the method of claim 28 and combining the agent and a pharmaceutically acceptable carrier to form the pharmaceutical composition.
34. A method of modulating the activity of a TANGO 294-like lipase protein in a TANGO 294-related disorder, the method comprising making the pharmaceutical composition according to claim 33 and administering the pharmaceutical composition to a human afflicted with the disorder.
35. The method of claim 34 , wherein the disorder is selected from the group consisting of a tumor, a disorder of fat absorption, a disorder of fat metabolism, a blood flow disorder, a blood pressure disorder, an inflammatory disorder, an immune disorder, a thrombotic disorder, and a disorder involving inappropriate platelet adherence.
36. The method of claim 35 , wherein the disorder is a tumor of endothelial or epithelial origin.
37. The method of claim 35 , wherein the disorder is a colon tumor.
38. The method of claim 35 , wherein the disorder is a pancreatic tumor.
39. The method of claim 35 , wherein the disorder is selected from the group consisting of inadequate expression of gastric lipase, inadequate expression of pancreatic lipase, cystic fibrosis, exocrine pancreatic insufficiency, and obesity.
40. The method of claim 35 , wherein the disorder is selected from the group consisting of arterial hypertension, renovascular hypertension, syncope, orthostatic hypotension, and shock.
41. The method of claim 35 , wherein the disorder is an inflammatory disorder selected from the group consisting of gastritis, gastric ulcer, colitis, irritable bowel syndrome, inflammatory bowel syndrome, dermatitis, and pancreatitis.
42. The method of claim 35 , wherein the disorder is an autoimmune disorder selected from the group consisting of rheumatoid arthritis, psoriasis, myasthenia gravis, an allergy, insulin resistance, systemic lupus erythematosus, scleroderma, and autoimmune diabetes mellitus.
43. The method of claim 35 , wherein the disorder is an infection of a human by an infectious agent.
44. The method of claim 43 , wherein the infectious agent is human immunodeficiency virus.
45. The method of claim 35 , wherein the disorder is selected from the group consisting of hemophilia, stroke, myocardial infarction, coronary artery disease, and atherosclerosis.
46. A method of making a pharmaceutical composition, the method comprising identifying an agent according to the method of claim 29 and combining the agent and a pharmaceutically acceptable carrier to form the pharmaceutical composition.
47. A method of modulating the activity of a TANGO 294-like lipase protein in a TANGO 294-related disorder, the method comprising making the pharmaceutical composition according to claim 46 and administering the pharmaceutical composition to a human afflicted with the disorder.
48. The method of claim 47 , wherein the disorder is selected from the group consisting of a tumor, a disorder of fat absorption, a disorder of fat metabolism, a blood flow disorder, a blood pressure disorder, an inflammatory disorder, an immune disorder, a thrombotic disorder, and a disorder involving inappropriate platelet adherence.
49. A method of making a pharmaceutical composition, the method comprising identifying an agent according to the method of claim 30 and combining the agent and a pharmaceutically acceptable carrier to form the pharmaceutical composition.
50. A method of modulating the activity of a TANGO 294-like lipase protein in a TANGO 294-related disorder, the method comprising making the pharmaceutical composition according to claim 49 and administering the pharmaceutical composition to a human afflicted with the disorder.
51. The method of claim 50, wherein the disorder is selected from the group consisting of a tumor, a disorder of fat absorption, a disorder of fat metabolism, a blood flow disorder, a blood pressure disorder, an inflammatory disorder, an immune disorder, a thrombotic disorder, and a disorder involving inappropriate platelet adherence.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/042,431 US20020182675A1 (en) | 1999-06-14 | 2001-10-25 | Novel genes encoding proteins having diagnostic, preventive, therapeutic and other uses |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/333,159 US7033780B1 (en) | 1999-06-14 | 1999-06-14 | Nucleic acids corresponding to TANGO 294 a gene encoding a lipase—like protein |
US09/578,063 US6764677B1 (en) | 1999-06-14 | 2000-05-24 | Tango 294, a lipase-like protein |
US10/042,431 US20020182675A1 (en) | 1999-06-14 | 2001-10-25 | Novel genes encoding proteins having diagnostic, preventive, therapeutic and other uses |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/578,063 Continuation-In-Part US6764677B1 (en) | 1999-06-14 | 2000-05-24 | Tango 294, a lipase-like protein |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020182675A1 true US20020182675A1 (en) | 2002-12-05 |
Family
ID=26988589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/042,431 Abandoned US20020182675A1 (en) | 1999-06-14 | 2001-10-25 | Novel genes encoding proteins having diagnostic, preventive, therapeutic and other uses |
Country Status (1)
Country | Link |
---|---|
US (1) | US20020182675A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160305944A1 (en) * | 2013-08-30 | 2016-10-20 | Nestec S.A. | Polyp recurrence |
-
2001
- 2001-10-25 US US10/042,431 patent/US20020182675A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160305944A1 (en) * | 2013-08-30 | 2016-10-20 | Nestec S.A. | Polyp recurrence |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8076086B2 (en) | Methods of modulating the activity of TANGO332 | |
US7459530B2 (en) | Tango 405 polypeptides and uses thereof | |
US6369196B1 (en) | Molecules of the card-related protein family and uses thereof | |
US20020055139A1 (en) | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses | |
US20020098540A1 (en) | Novel polypeptides, and nucleic acids encoding the same | |
US6482933B1 (en) | Molecules of the card-related protein family and uses thereof | |
US7160694B2 (en) | Nucleic acids encoding TANGO405 and functional fragments and uses thereof | |
EP1218392A1 (en) | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses | |
US20040147003A1 (en) | Novel polypeptides and nucleic acids encoding same | |
WO2000078808A1 (en) | Secreted proteins and uses thereof | |
US20020182675A1 (en) | Novel genes encoding proteins having diagnostic, preventive, therapeutic and other uses | |
EP1194534A2 (en) | Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses | |
US20050049399A1 (en) | Novel molecules of the card-related protein family and uses thereof | |
US6340576B1 (en) | Nucleic acid molecules related to card-4L and CARD-4S | |
US20050287612A1 (en) | CARD-4 molecules and uses thereof | |
US20030017983A1 (en) | Novel molecules of the pyrin/NBS/LRR protein family and uses thereof | |
WO2001000672A9 (en) | Secreted proteins and uses thereof | |
WO2000050442A2 (en) | Secreted proteins and uses thereof | |
US20050019810A1 (en) | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic and other uses | |
US20020086354A1 (en) | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic and other uses | |
WO2001029088A1 (en) | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses | |
US20030143632A1 (en) | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic and other uses | |
JP2006512045A (en) | CARD-4 molecule and use thereof | |
MXPA00007645A (en) | Novel molecules of the card-related protein family and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MILLENNIUM PHARMACEUTICALS, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MCCARTHY, SEAN A.;FRASER, CHRISTOPHER C.;SHARP, JOHN D.;AND OTHERS;REEL/FRAME:012839/0850;SIGNING DATES FROM 20011203 TO 20011217 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |